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• Purdue University’s School of Agriculture, for additional funding support
• The Interdepartmental Nutrition Program, for excellent training in nutrition
science and food chemistry
• The Purdue University Center on Aging and the Life Course and the Ingestive
Behavior Research Centers, who provided non-financial support for this project,
and excellent opportunities to expand my research interests
• My wonderful brother David, who always supported me




LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 Fetal Alcohol Spectrum Disorder . . . . . . . . . . . . . . . . . . . 1
1.2.1 An Overview of FASD . . . . . . . . . . . . . . . . . . . . . 1
1.2.2 Proposed Mechanisms . . . . . . . . . . . . . . . . . . . . . 5
1.2.3 Lack of Diagnostics . . . . . . . . . . . . . . . . . . . . . . . 6
1.3 Specific Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.3.1 Specific Aim #1: Investigate Mechanisms . . . . . . . . . . 7
1.3.2 Specific Aim #2: Compare Models . . . . . . . . . . . . . . 7
1.3.3 Specific Aim #3: Identify Biomarkers . . . . . . . . . . . . . 8
1.4 Introduction to chapters . . . . . . . . . . . . . . . . . . . . . . . . 9
2 Developing the Big Picture of Fetal Alcohol Spectrum Disorder: A Proposed
Mechanism of Metabolite Changes . . . . . . . . . . . . . . . . . . . . . . 10
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.2.1 Zebrafish Embryo Ethanol Exposure . . . . . . . . . . . . . 13
2.2.2 Metabolomics . . . . . . . . . . . . . . . . . . . . . . . . . . 13
2.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.3.1 Metabolite Clustering . . . . . . . . . . . . . . . . . . . . . 17
2.3.2 Ethanol Metabolites . . . . . . . . . . . . . . . . . . . . . . 17
2.3.3 Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
iv
Page
2.3.4 Protein-related Metabolites . . . . . . . . . . . . . . . . . . 59
2.3.5 Carbohydrates . . . . . . . . . . . . . . . . . . . . . . . . . 67
2.3.6 Other Metabolites . . . . . . . . . . . . . . . . . . . . . . . 69
2.3.7 Ingenuity Pathway Analysis® . . . . . . . . . . . . . . . . . 75
2.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.4.2 Ethanol Catabolism . . . . . . . . . . . . . . . . . . . . . . 78
2.4.3 Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . 81
2.4.4 Cardiovascular System . . . . . . . . . . . . . . . . . . . . . 108
2.4.5 Endocrine System . . . . . . . . . . . . . . . . . . . . . . . . 112
2.4.6 Renal System . . . . . . . . . . . . . . . . . . . . . . . . . . 116
2.4.7 Growth and Energy . . . . . . . . . . . . . . . . . . . . . . . 117
2.4.8 Morphology . . . . . . . . . . . . . . . . . . . . . . . . . . . 128
2.4.9 Cellular and Molecular Mechanisms . . . . . . . . . . . . . . 130
2.4.10 Disease Resistance . . . . . . . . . . . . . . . . . . . . . . . 141
2.4.11 Study Weaknesses . . . . . . . . . . . . . . . . . . . . . . . . 141
2.4.12 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . 145
2.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
3 Comparative Modeling of Fetal Alcohol Spectrum Disorder: More is Not
Just More . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.1 Abstract . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.2 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
3.2.1 FASD affects many, but alcohol is non-specific . . . . . . . . 148
3.2.2 Animal Modeling Considerations . . . . . . . . . . . . . . . 149
3.2.3 Utility of Zebrafish for FASD . . . . . . . . . . . . . . . . . 151
3.2.4 Comparative Modeling . . . . . . . . . . . . . . . . . . . . . 154
3.2.5 Comparison of PCA . . . . . . . . . . . . . . . . . . . . . . 155
3.2.6 Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
v
Page
3.2.7 Specific Aim and Study . . . . . . . . . . . . . . . . . . . . 157
3.3 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 157
3.3.1 Fatty Acids . . . . . . . . . . . . . . . . . . . . . . . . . . . 158
3.3.2 Glycerolipids . . . . . . . . . . . . . . . . . . . . . . . . . . 162
3.3.3 Glycerophospholipids . . . . . . . . . . . . . . . . . . . . . . 162
3.3.4 Prenol Lipids . . . . . . . . . . . . . . . . . . . . . . . . . . 165
3.3.5 Sphingolipids . . . . . . . . . . . . . . . . . . . . . . . . . . 167
3.3.6 Other Metabolites . . . . . . . . . . . . . . . . . . . . . . . 169
3.3.7 Common Metabolites . . . . . . . . . . . . . . . . . . . . . . 171
3.3.8 Pobabilistic Principal Component and Covariates Analysis . 173
3.4 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
3.4.1 Growth and Energy . . . . . . . . . . . . . . . . . . . . . . . 175
3.4.2 Nervous System . . . . . . . . . . . . . . . . . . . . . . . . . 179
3.4.3 Relativistic Inter-specific Development Model . . . . . . . . 181
3.5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 189
3.6 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 190
3.6.1 Animal Husbandry and Ethanol Exposure . . . . . . . . . . 190
3.6.2 Metabolomics . . . . . . . . . . . . . . . . . . . . . . . . . . 192
3.6.3 Data Processing . . . . . . . . . . . . . . . . . . . . . . . . . 192
3.6.4 Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . 193
3.6.5 Data Management Plan . . . . . . . . . . . . . . . . . . . . 195
3.7 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . 195
3.8 Competing Interests Statement . . . . . . . . . . . . . . . . . . . . 196
3.9 Funding . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
3.10 Supplementary Material . . . . . . . . . . . . . . . . . . . . . . . . 196
4 Biomarkers of Fetal Alcohol Spectrum Disorder: The Difference You Can’t
See . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 199
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 200
vi
Page
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 201
4.2.1 Mortality and Morphology . . . . . . . . . . . . . . . . . . . 201
4.2.2 IPA Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . 212
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 213
4.3.1 The Need for Biomarkers . . . . . . . . . . . . . . . . . . . . 213
4.3.2 Mortality and Morphology . . . . . . . . . . . . . . . . . . . 214
4.3.3 Existing Biomarkers . . . . . . . . . . . . . . . . . . . . . . 215
4.3.4 Biomarkers Suggestioned from Metabolomics . . . . . . . . . 220
4.4 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 222
4.5 Materials and Methods . . . . . . . . . . . . . . . . . . . . . . . . . 222
4.5.1 Study Design . . . . . . . . . . . . . . . . . . . . . . . . . . 222
4.5.2 Imaging and Morphometry . . . . . . . . . . . . . . . . . . . 224
4.5.3 Ingenuity Pathway Analysis ® . . . . . . . . . . . . . . . . 224
4.5.4 Statistical Analysis . . . . . . . . . . . . . . . . . . . . . . . 224
5 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
5.1 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 226
5.2 Major Findings . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 227
5.2.1 Developing the Big Picture of Fetal Alcohol Spectrum Disorder:
A Proposed Mechanism of Metabolite Changes (Chapter 2) . 227
5.2.2 Comparative Modeling of Fetal Alcohol Spectrum Disorder:
More is Not Just More (Chapter 3) . . . . . . . . . . . . . . 229
5.2.3 Biomarkers of Fetal Alcohol Spectrum Disorder: The Difference
You Can’t See (Chapter 4) . . . . . . . . . . . . . . . . . . . 230
5.3 Limitations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
5.3.1 Morphology . . . . . . . . . . . . . . . . . . . . . . . . . . . 231
5.3.2 Metabolomics . . . . . . . . . . . . . . . . . . . . . . . . . . 232
5.3.3 Mouse Study . . . . . . . . . . . . . . . . . . . . . . . . . . 233
5.3.4 Comparative Study . . . . . . . . . . . . . . . . . . . . . . . 234
5.4 Future Directions . . . . . . . . . . . . . . . . . . . . . . . . . . . . 234
vii
Page
REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 236




2.1 Ethanol catabolism associated metabolites were identified at several reten-
tion times within 10 ppm of their theoretical mass/charge from the polar
fractions. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
2.2 Palmitic acid was identified at several retention times within 3 ppm of its
theoretical mass/charge. . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.3 Stearic acid was identified at several retention times within 3 ppm of its
theoretical mass/charge. . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.4 Other fatty acids were identified in zebrafish embryos exposed from 2–24
hpf to 0–3% ethanol. Metabolites were within 3 ppm (non-polar) or 10
ppm (polar) of the theoretical m/z. . . . . . . . . . . . . . . . . . . . . 26
2.5 Many phosphatidic acids significantly changed in ethanol-exposed em-
bryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
2.6 Many phosphatidylserines were significantly changed in ethanol-exposed
embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.7 Many glycerophospholipids significantly changed in ethanol-exposed em-
bryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
2.8 Sphingolipids significantly changed in ethanol-exposed zebrafish embryos. 40
2.9 Hormones significantly changed in ethanol-exposed zebrafish embryos. . 44
2.10 Icosanoids significantly changed in ethanol-exposed zebrafish embryos. . 46
2.11 Vitamin A related metabolites were significantly changed in ethanol-exposed
zebrafish embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
2.12 Vitamin D metabolites were significantly changed in ethanol-exposed ze-
brafish embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 51
2.13 Several other vitamins were significantly changed in ethanol-exposed ze-
brafish embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
2.14 Steroids significantly changed in ethanol-exposed zebrafish embryos. . . 56
2.15 Histidine-related metabolites were identified from the polar fraction within
10 ppm of their theoretical m/z in zebrafish embryos exposed from 2–24
hpf to 0–1% ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
ix
Table Page
2.16 Tryptophan-related metabolites were identified in zebrafish embryos ex-
posed from 2–24 hpf to 0–1% ethanol. . . . . . . . . . . . . . . . . . . 61
2.17 Amino acid-related metabolites were identified from the polar fraction
within 10 ppm of their theoretical m/z in zebrafish embryos exposed from
2–24 hpf to 0–1% ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . 63
2.18 Peptide polar metabolites were identified within 10 ppm of their theoretical
m/z in zebrafish embryos exposed from 2–24 hpf to 0–1% ethanol. . . . 65
2.19 Other protein-related metabolites were identified within 10 ppm of their
theoretical m/z in zebrafish embryos exposed from 2–24 hpf to 0–1%
ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
2.20 Significantly changed carbohydrate-related metabolites were identified within
10 ppm of their theoretical m/z in zebrafish embryos exposed from 2–24
hpf to 0–1% ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 70
2.21 Other metabolites significantly changed in ethanol-exposed zebrafish em-
bryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
3.1 Fatty acid metabolites identified in the non-polar fraction of ethanol-
exposed mouse embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . 160
3.2 Glycerolipid metabolites identified in the non-polar fraction of ethanol-
exposed mouse embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . 162
3.3 Glycerophospholipid metabolites identified in the non-polar fraction of
ethanol-exposed mouse embryos. . . . . . . . . . . . . . . . . . . . . . 164
3.4 Prenol lipid metabolites identified in the non-polar fraction of ethanol-
exposed mouse embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . 166
3.5 Sphingolipid metabolites identified in the non-polar fraction of ethanol-
exposed mouse embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . 168
3.6 Other metabolites identified in the non-polar fraction of ethanol-exposed
mouse embryos. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 170
3.7 Significantly changed metabolites were common to both the Danio rerio
and Mus musculus non-polar metabolomes. . . . . . . . . . . . . . . . 172
4.1 Shapiro-Wilk Normality Test of Quantitative Measures of Zebrafish Em-




2.1 Clustering of non-polar metabolites from zebrafish embryos exposed to
ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
2.2 Clustering of polar metabolites from zebrafish embryos exposed to ethanol. 19
2.3 Ethanol is catabolized into several common metabolites observed in this
analysis. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
2.4 LC-MS/MS standards of stearic and palmitic acids. . . . . . . . . . . . 25
2.5 Developmental comparison of zebrafish FASD model versus humans. . . 78
2.6 Ethanol catabolism of metabolites isolated from extraction fractions of
whole zebrafish embryos exposed to ethanol from 2–24 in 0–3%ethanol.
Metabolite changes are indicated by sparklines. . . . . . . . . . . . . . 80
2.7 Metabolites isolated from extraction fractions of whole zebrafish embryos
exposed to ethanol from 2–24 in 0–3%ethanol that influence the nervous
system. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
2.8 Tryptophan-related pathway changes with metabolites isolated from ex-
traction fractions of whole zebrafish embryos exposed to ethanol from 2–24
in 0–3%ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
2.9 Two vitamin A metabolites, 9,13-cis-Retinoate and 1′-hydroxy-γ-carotene
glucoside, were identified in the polar fraction. . . . . . . . . . . . . . . 135
2.10 Several vitamin D metabolites were identified in the polar fraction. . . 140
3.1 Two of the vitamin A-related metabolites were identified, 9,13-cis-Retinoate
and 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one. . . . . . . . . 174
3.2 Principal component loadings barplots for the PPCCA model generated
from metabolites significantly changed in both the mouse and zebrafish
models of FASD, using species and ethanol exposure as covariates. . . . 183
3.3 PPCCA scores plot of the individuals in each treatment group with respect
to the PC loading, demonstrating the estimated score of each individual
within the reduced PrC space. . . . . . . . . . . . . . . . . . . . . . . . 184
xi
Figure Page
3.4 Scatterplot of the PPCCA model loadings generated from metabolites
significantly changed in both the mouse and zebrafish models of FASD,
using species as a covariate. . . . . . . . . . . . . . . . . . . . . . . . . 185
3.5 Barplot of the PPCCA model after Jackknife resampling, generated from
metabolites significantly changed in both the mouse and zebrafish models
of FASD, using species and ethanol exposure as covariates. . . . . . . . 186
3.6 Developmental comparison of zebrafish and mouse FASD models versus
humans. In our experiment, zebrafish were exposed from 2–24 hpf to
0–3% ethanol, indicated on the timeline as a blue horizontal bar. The
blue arrow indicates the time of zebrafish sacrifice. Mice were exposed
0, 1, or 2 times to 400 ng/dL of ethanol. Orange bars indicate mouse
ethanol exposure times. Orange arrow indicates the time when all mice
were sacrificed; Eye icon: lens vesicle complete; Open heart icon: begin-
ning of heart development; Filled and checked heart icon : completion of
heart development; A: initial development of arches; L: liver development
begins; M: beginning of meconium production; N: neural tube closure; N*:
neural rod cavitation completed; S: first somites appear
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
3.7 Experimental design for c57BL/6J Mus musculus embryos cultured in
ethanol. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 191
3.8 To adjust for the discontinuous ethanol exposure of the mouse model for
comparison to the continuous ethanol exposure of the zebrafish, a relative
ethanol exposure was calculated. . . . . . . . . . . . . . . . . . . . . . 194
3.9 Histogram of the p-values obtained from the ANOVA for the FASD mouse
model non-polar metabolome . . . . . . . . . . . . . . . . . . . . . . . 197
3.10 Bayesian Information Criterion plot for the PPCCA model. . . . . . . . 198
4.1 Kaplan-Meier survival curve demonstrating zebrafish embryos exposed to
increasing concentrations of ethanol were less likely to survive to hatch. 203
4.2 Significant morphological differences were seen only in the qualitative mea-
sures of body shape and yolk sack edema. . . . . . . . . . . . . . . . . 204
4.3 Q-Q Plot of Embryo Length at Different Ethanol Concentrations . . . 206
4.4 Q-Q Plots of Zebrafish Embryo Head Circumference with Ethanol Exposure 207
4.5 Q-Q Plots of Zebrafish Embryo Eye-to-Eye Distance with Ethanol Expo-
sure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 208
4.6 Q-Q Plot of Zebrafish Embryo Eye Area with Ethanol Exposure . . . . 209
xii
Figure Page
4.7 Q-Q Plot of Zebrafish Embryo Eye Area:Length with Ethanol Exposure 210
4.8 Ethanol treatment resulted in one or more individuals per group with
abnormal morphology, as qualitatively graded. Atypical tissue extending
from the eye (blue arrows) was seen in individuals in several treatment
groups (0.001, 0.01, 0.03, 0.3% lateral views). Abnormal tails were seen
in many individuals across treatment groups (0.003, 0.3, and 1% in lateral
views). Moderate pericardial edema was seen in 3/8 individuals in the
control group as well as in individuals in all ethanol exposure groups except
3%. Moderate yolk sack edema at was observed in a few individuals across
the treatment groups (0.003 and 0.1%). These individuals are shown in the
lateral view. Individuals with moderately abnormal head morphology were
present in several treatment groups, including 0.003 (2/6) and 0.3% (1/6),
appearing to have a shortened forebrain segment. Moderate narrowing of
the OOS was seen in a single individual in the control, 0.003, 0.03, and
0.1% groups.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212
xiii
ABSTRACT
Keller, Christine E.M. Ph.D., Purdue University, August 2016. Biochemical Changes
in Animal Models of Fetal Alcohol Spectrum Disorder . Major Professor: Paul B.
Brown.
Fetal alcohol spectrum disorder (FASD) is a completely preventable disease, that
has profound effects on life-long health and function of the affected individual. Preva-
lence estimates of FASD in the United States indicate 33.5 per 1,000 live births are
affected with this disorder [1]. FASD is caused by maternal ethanol intake during
pregnancy. However, recommendations of the amounts of alcohol safe to drink dur-
ing pregnancy are not established. Further, we lack a comprehensive understanding
of the biochemical pathways modified in prenatal ethanol exposure. Biomarkers are
also lacking. Our results demonstrate the vast array of biochemical pathways modified
in the chronic ethanol exposure zebrafish model of FASD. Many of these pathways
agree with existing literature, but the comprehensive nature of this study expands
upon several of them, and links branches that were previously considered in isolation
as mediators of FASD. In addition, examination of the non-polar excised embryonic
mouse demonstrates a significant difference between a single binge dose of ethanol and
a two binge doses. Similar metabolites to the zebrafish are identified in this model,
though the degree and direction of change is not always consistent. These findings
suggest that more ethanol does not necessarily result in an amplified, same-direction
response, and that longer duration exposures do not always change metabolites the
same way binge exposures do. In addition, a novel application of the probabilistic
principal component and covariate analysis (PPCCA) is used to examine latent vari-
ables suggested by the combined models. Lastly, we review biomarkers suggested
from the mouse and zebrafish model metabolomes, the PPCCA, and Ingenuity Path-
way Analysis® (Chapter 4). We consider these biomarkers with a morphometric
analysis of the zebrafish, where few significant differences are noted. Together, these
observations suggest that in spite of a lack of morphologic changes, biochemistry of




Fetal alcohol spectrum disorder (FASD) is a completely preventable disease, that
has profound effects on life-long health and function of the affected individual. Preva-
lence estimates of FASD in the United States indicate 33.5 per 1,000 live births are
affected with this disorder [1]. FASD is caused by maternal ethanol intake during
pregnancy. It is a difficult disease to study, for many reasons. It is difficult to deter-
mine the relationship between ethanol dose, consumption frequency, and the effects
on the offspring. These factors are altered by the woman’s health, fasted or non-
fasted state, and individual metabolism differences. Further, many women consume
alcohol in early pregnancy, before they know they are pregnant. The social stigma
surrounding alcohol consumption during pregnancy may make self-reporting less ac-
curate. Also, clinical definitions of FASD have been evolving in recent decades, which
make interpretation of older data difficult.
Because of the need for early intervention to minimize the effects of alcohol on the
offspring, especially until a consensus on recommended limits on alcohol are achieved,
early detection is key. In spite of a variety of proposed biomarkers, rapid and robust
clinical biomarkers are lacking. Further, ethanol’s polar protic nature makes it a
powerful molecule. To advance our understanding and ability to intervene in FASD,
a broader understanding of the mechanisms involved in this disease is needed. Ad-
ditionally, differences in models of ethanol dose and duration of exposure need to
be better characterized. This chapter summarizes the relevance of FASD investiga-
tion, difficulties in understanding FASD, the need for better biomarkers, and our
metabolomics studies investigating these problems.
1.2 Fetal Alcohol Spectrum Disorder
1.2.1 An Overview of FASD
For centuries, man has identified a link between maternal alcohol consumption
and abnormal offspring. The link between maternal alcohol consumption and fetal
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defects has been cited as far back as Greek and Roman mythology [2]. As early as
1971, scientists had begun to infer the effect of ethanol on offspring. Using chick
and rat embryos, researchers demonstrated the effect of ethanol on abnormal nervous
system morphology, somites, and growth in these models [3]. Through examina-
tion of case-studies of the children of two alcoholic mother and one other child that
appeared to have similar features, Jones made the association between maternal al-
cohol and infant malformations. In the two infants he studied, he noted that they
had respiratory deficiency, and biochemical abnormalities, including hypoglycemia,
hypocalcemia, and hyperbillirubinemia. Both infants had microopthalmia, cardiac
abnormalities, and a cleft soft palate. In autopsy of one of the children who died at 5
days of age, neural, glial structures were disoriented and brain structures were incom-
pletely formed [3]. Yet, we still lack a real understanding of this disease, preventing
the identification of successful therapies.
Fetal alcohol spectrum disorder (FASD), previously only recognized in its most
severe form, fetal alcohol syndrome (FAS), has been characterized for over 40 years
by its defects in craniofacial morphology, limb morphology, and heart defects [2].
FASD is a spectral disease, with variations in clinical features and severity defined
by the Institute of Medicine. The diagnosis of FASD severity is weighted heavily on
the abnormal morphology of the offspring, as well as neurologic or other physiology
deficits. Diagnostic morphologic features include short palpebral fissures, thin ver-
million border of the upper lip, smooth philtrum, and growth retardation. Based on
the morphology and mental faculties of a child, he or she may be classified as hav-
ing FASD. These classifications include alcohol-related neurodevelopmental disorder,
alcohol-related birth defects, partial FAS (pFAS) (with or without known maternal
drinking history), and FAS (with or without known maternal drinking history) [4].
Cognitive deficits are also present in FASD, with varying severity. The cognitive-
behavior phenotype has been described as “generalized deficit in processing complex
information” [5]. Verbal and non-verbal skills both appear to be diminished in FASD
[5]. Executive control function is also affected as well as complex task functioning [5].
In reports of FAS, some cite the average IQ to be as low as 68 [6].
Not included in the Institute of Medicine classification system is the contribution
of maternal alcohol consumption to early death, be it through spontaneous abortion,
pre-term labor, still births, or sudden infant death syndrome [2, 7–11]. In a study of
the National Danish Birth Cohort, women consuming seven of more drinks a week
had a relative very preterm delivery (fewer than 32 weeks) risk of 3.26 and 1.58 for
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moderate preterm labor (32–36 weeks) [7]. The association for drinkers for moderate
preterm labor was much lower for mothers consuming 4–7 drinks per week at only
1.15 [7]. This study controlled for variables including maternal history of preterm
labor, occupation, hypertension, education, age, child’s sex, and coffee and tobacco
intake [7].
The consideration of FASD as a spectral disorder in and of itself may skew the
data regarding the historical prevalence of this disease. Now that more phenotypes
are considered a part of FASD than those of FAS, it is possible that earlier FAS
diagnoses underestimate the count of those affected [12].
Understanding the physiological changes that occur in FASD is complicated by
the variation in maternal intake, timing of consumption, and the maternal and fetal
individual biological differences. All of these factors make the collection of relevant
human data and its interpretation difficult. For example, in a study of the association
between “light” and “moderate” maternal alcohol consumption pattern showed no
difference in the growth rate of children of some ethanol-consuming mothers. This
study examined a population cohort of over 7,300 pregnant women who were surveyed
in early, middle, and late pregnancy regarding the frequency and quantity of alcohol
they consumed. (This study defined “light-to-moderate” as equal to or less than 1
alcoholic beverage per day [13].) One study even reported women who were “mild
drinkers” (defined as 0.1–0.25 oz of absolute alcohol per day) statistically showed a
“protective” effect on intrauterine growth retardation, but preterm labor during the
seventh month of pregnancy was associated with nearly 3 times the odds for both
“light” and “mild-to-moderate” drinkers [10].
Timing of ethanol consumption during pregnancy is another major hurdle in
studying FASD. A study comparing quantities, patterns, and timing of alcohol con-
sumed by mothers showed a significant association between higher prenatal exposure
and a smooth philtrum. The thin vermilion border associated with exposure during
the second part of the first three months of pregnancy. Reduced length at birth was
associated with alcohol exposure at any time during pregnancy [14]. Growth and
development are rapidly changing in the developing offspring, and the response to
the teratogen is variable during gestation. Thus, another complication is that the
variability alcohol’s effects upon the constantly changing stage of development.
Differing consumption patterns contribute to the difficulty in finding consistent
outcomes of alcohol exposure. Some women drinking routinely, a glass or two of
wine nightly. Other women consume alcohol more in a weekend “binge” fashion.
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Another drinking pattern would include the chronic alcoholic. So, determining rele-
vant explanatory alcohol concentrations to study may be difficult in the laboratory.
Even within the field of alcohol research the broad categorization of “low-moderate”,
“moderate”, and “heavy”, for example, are not uniformly defined. Further, while
many researchers attempt to have mothers estimate alcohol consumed, dietary stud-
ies routinely show that recall of food and beverage intake and consumer estimates of
measurement are highly inaccurate. Further, mothers are often not willing or poten-
tially ashamed of having consumed alcohol while they are pregnant, making accurate
exposure history difficult to obtain.
Further, differences in the rates of metabolism differ from individual to individual,
stomach contents, and weight may contribute to the variety of outcomes in FASD-
related research. In addition, maternal tissues, fetal tissues, and the placenta all
vary in their contributions to ethanol metabolism. Further, amniotic recirculation
contributes to alcohol reentry in the fetus [15].
Socioeconomic status and lifestyle choices also influence fetal outcomes, making
human research of this disease further complicated. In the past, researchers largely
linked FASD to a lack of education among women. The result of this in the US was
the addition of an alcohol consumption label on bottles [6]. However, cross-sectional
study using the National Center or Health Statistics data, of the 45% of women who
report having consumed alcohol during the last 3 months, included in the highest risk
factors were being 25 years or older and college educated [16].
Genetics have also been implicated as a dispositional cause of FASD in some. Very
early investigations in FASD revealed the likely implication of genetic alterations. In
FAS, an irreversible growth deficit also occurs, even when children are placed in
foster home environments [2]. Twin studies have shown that in the occurrence of
monozygotic twins, both children are affected, whereas in dizygotic twins, one (or
both) may be affected [17, 18]. However, other twin studies have shown dizygotic
twins have reported only a single pair where both children presented with FAS [9,19].
In animal studies, polymorphisms of alcohol dehydrogenase (ADH1B) have been
identified that predisposes/protects individuals to FASD [18]. In a comparison of
different mice breeds, c57BL/6J, DBA/2J, and A/J mouse strains resulted in differing
levels of malformations and mortalities. These mice had been treated with the same
concentration and by the same route of administration, yet ended up with different
blood alcohol levels and different fetal outcomes [18, 20, 21]. Another study that
used excised mouse embryos demonstrated these effect were related to the difference
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in succeptibility of organs at different times to terratogenic ethanol in the different
mouse strains [22].
Due to variations in factors such as diagnostic criteria, sampling bias, and descent
(native or non-native), global estimates of the prevalence of FASD are limited [1].
A recent meta-analysis highlights the lack of global research of FASD, identifying
publications of only 10 countries with available prevalence data [1]. Pooled prevalence
statistics from general population studies vary widely between country and severity of
disease. South Africa, for instance, has a fetal alcohol syndrome prevalence of 55.42
per 1,000, and a point estimate of 113.22 for FASD [1]. In the United States, FAS
prevalence is estimated at 0.67 per 1,000 live births and FASD is estimated at 33.5
per 1,000 live births [1]. Survey of a nationally representative population of women
ages 15–44 in the United States suggest the rate of alcohol-exposed pregnancy risk is
7.3% [23].
FAS has an estimated annual cost in the United States of $3.6 billion [24]. The
mortality rate for fetal alcohol syndrome has been estimated to be 3.5 times that
expected of the general population [25]. Individuals with FASD have higher rates of
behavioral problems in school and with the law, inappropriate sexual behaviors, and
alcohol or drug problems [26].
1.2.2 Proposed Mechanisms
Understanding the nature of the mechanisms involved in FASD is essential to
prevention, diagnosis, and treatment of FASD. Because of the polar protic nature of
ethanol, this teratogen can interact with a wide variety of substances. Many differ-
ent pathways have been proposed as being key mediators in the abnormalities that
characterize FASD. Altered energy and nutrient metabolism that results in decreased
growth was an early proposed key mechanism [27–29]. Accumulation of FAEEs,
formed from the esterification by fatty acid ethyl ester synthase of ethanol and fatty
acids, has been hypothesized as a cause of FAS [30]. Other lipid and cholesterol
modifications are also altered in FASD [31,32]. Sphingolipid modifications have been
hypothesized as the cause of neuronal loss in FAS [33]. Another hypothesis is the
modified nuclear transcription factors. Vitamin A has been widely investigated as a
causative alteration and potential point of intervention in FASD [34–36]. Cell death,
beyond normal apoptosis, has been associated with FASD [37, 38]. Abnormal tryp-
tophan metabolism, particularly in the serotonin branch, has been well studied as a
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key mechanism altered in FASD. Alcohol deters the outgrowth, migration, and devel-
opment of serotonergic neurons [39–42]. Increased oxidative stress is also associated
with FASD [43–47]. Glycosylation, important for protein translocation, has been
proposed as well [48]. However, in spite of all of this work, there is still not a unified
theory of alcohol induced alterations in FASD.
1.2.3 Lack of Diagnostics
We currently lack sufficient tools to diagnose FASD, particularly ones that can
be used early pregnancy. Significant improvements in 3-D facial photography has
allowed diagnosis of children with a maternal history of drinking without classical
morphological features Prenatal ultrasounds provide some success as a diagnostic
tool in identifying a “hook”-shaped structure in the corpus collosum that was strongly
associated with ethanol exposure during pregnancy [49]. However, researchers were
successful in identifying only 12 of 23 ethanol-exposed infants and one false positive
among the 21 unexposed or “lightly” exposed controls [49].
Several biomarkers demonstrate a correlation with the maternal exposure to alco-
hol, including enzymes like cytochrome P450, γ-glutamyltransferase, aspartate amino-
transferase, and alanine aminotransferase [50, 51]. Large protein biomarkers, such as
carbohydrate deficient transferrine, have also been proposed for FASD biomarker
use [51]. Assessment of mean corpuscular volume of erythrocytes, is another pro-
posed FASD biomarker [51]. However, all of these are limited to chronic or long-term
alcohol use [51].
Fatty acid ethyl esters (FAEEs) have been proposed for decades as a biomarker of
prenatal ethanol exposure [30,52]. These molecules are formed from the esterification
of alcohol and fatty acids or acyl-CoA/fatty acids by fatty acid ethyl ester synthases,
and can be identified in a variety of tissues after ethanol ingestion [30]. FAEEs can
be detected in meconium, however it is unclear when meconium formation begins,
making correlation with gestational ethanol intake difficult [53]. False negatives for
some FAEE analytical methods are also a concern, as this could lead to sending a
child home to an at risk environment [53]. Importantly, meconial FAEEs have been
reported in children of non-ethanol consuming mothers, limiting their robustness
as population screening biomarkers [54–56]. FAEE detection in hair has also been
proposed, as hair will reflect historical alcohol consumption [57]. But, FAEEs have
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been shown to change based on the use of hair products, which is a tremendous
limitation [58,59].
With these limitations, a robust biomarker(s) is still needed. It needs to capture
both acute and chronic alcohol exposure, as well as correlate with quantity of alcohol
consumed and potentially the duration of exposure. Screening should be rapid and
robust, which has been a problem with many of the existing biomarkers proposed for
FASD. Ideally for interventions, screening for alcohol-exposed children should take
place in the womb. This would allow for interventions of the mother, so as to prevent
further alcohol-induced abnormalities in development. Further, an ideal biomarker
would reflect the effectiveness of FASD interventions, be they pharmacological or
otherwise.
1.3 Specific Aims
1.3.1 Specific Aim #1: Investigate Mechanisms
The first aim of this work is to investigate the mechanisms, as a whole, changed
in an animal model of FASD, through the use of metabolomics. Because a unified
theory of FASD is lacking, a generalized method to explore a variety of mechanistic
changes in FASD is essential. Metabolomics is an excellent tool, that allows for a
wide-spread scan of small molecule changes. This method removes the limits on the
number of mechanisms explored in a single study. Because of its “unbiased” nature,
metabolomics does not limit the researcher to the preconceived notions regarding the
pathways hypothesized in FASD. We will utilize a common zebrafish model for this
purpose, where zebrafish embryos are incubated in an ethanol solution from 2–24
hours post fertilization (hpf). We will utilize a wide range of ethanol concentrations
to mimic a variety of chronic drinking levels. While we anticipate we will confirm
observations of many of the proposed pathways modified in FASD, we also anticipate
identifying novel metabolites that will expand or alter some of the existing theories
of FASD.
1.3.2 Specific Aim #2: Compare Models
The second aim is to compare and contrast metabolite findings in two different,
well-established models of FASD. As is the case with most areas of biomedical re-
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search, FASD relies heavily on a few established animal models. More than ten years
ago, collaborators on this research project developed a model of prenatal ethanol ex-
posure that utilizes an excised mouse embryo (E8), which is then cultured [22]. This
offers the benefit of minimizing confounding maternal influence on the embryo, while
still generating observable developmental dysmorphology [22,60]. We will explore the
similarities and differences within this model of the non-polar metabolites changed
between control (untreated) animals and groups dosed with 400 mg/dL on one or two
consecutive days for six hours. As in our first specific aim, we anticipate confirming
many of the previously hypothesized pathways in FASD. But, we also anticipate iden-
tifying novel metabolites that extend or alter some of these theories. These findings
will be compared with those of the zebrafish models. In addition, a novel application
of a principal component analysis will be applied to examine the differences in the
non-polar metabolomes generated from the zebrafish and mouse models. A significant
overlap is expected between the metabolomes of these two models. This methodology
will allow examination of the universality of the metabolomics approach and validate
zebrafish model findings in a second model.
1.3.3 Specific Aim #3: Identify Biomarkers
The third specific aim is to identify and characterize potential biomarkers from
these models of FASD. Ethanol is a master solvent capable of acid-base modification,
ester formation, halogenation, haloform reactions, dehydration, oxidation, and chlo-
rination, and a great number of small molecules are altered by alcohol. Alteration of
these small metabolites may serve as biomarkers for the detection of alcohol exposure.
These biomarkers should be dose-responsive to ethanol, highly reproducible, and ide-
ally present in both of these established models of FASD. Based on the outcomes
anticipated from the second specific aim of similar metabolites from the zebrafish
and mouse models, we anticipate identifying several potential biomarkers relevant to
FASD. Some of these are anticipated to overlap with currently proposed (but insuffi-
ciently robust) biomarkers. In addition, these biomarkers will be compared with the
morphologic differences visibly identified in the zebrafish model.
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1.4 Introduction to chapters
This dissertation is a compilation of manuscripts prepared for submission to var-
ious journals.
Chapter 2 examines mechanisms highlighted by the metabolome changes identified
in the zebrafish model of chronic prenatal ethanol exposure. Unlike many other
metabolomics analyses, this presentation of a zebrafish FASD model metabolome
attempts to explore the actual mechanisms implicated by the whole of the metabolome
changes. Rather than simply presenting data, this work attempts to contextualize
that material within the proposed mechanisms of FASD. This analysis provides a
platform for the generation of new hypotheses of FASD as well as expanding upon
existing hypotheses.
Chapter 3 examines the non-polar metabolome changes in embryonic mice ex-
posed once or twice with 400 mg/dL ethanol for 6 hour binges, and compares these
findings relative their unexposed controls. We will also explore here the similarities
and differences in the zebrafish and mouse as models of FASD in humans, includ-
ing application of a novel probabilistic principal component and covariate analysis
(PPCCA).
Chapter 4 examines the biomarkers suggested by the metabolomics output and
PPCCA, including a secondary analysis with the biomarker filtering agent of Ingenu-
ity Pathway Analysis®. It also examines our findings relative the existing, commonly
proposed biomarkers. Results of a morphologic measurement of modifications of head
circumference, eye size, eye-to-eye distance, total length, and survival of ethanol ex-
posed zebrafish are presented, as are qualitative scoring of body shape, tail shape,
pericardial edema, yolk sack edema, head (brain) shape, and the otic-optic space. To-
gether, our biomarker findings in conjunction with our morphology results emphasize
the effect of ethanol, in spite of statistically significant morphology changes.
Chapter 5 summarizes the major findings of this dissertation. The limitations of
these studies are also briefly examined. This chapter also proposes future directions
for further investigation.
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2. DEVELOPING THE BIG PICTURE OF FETAL
ALCOHOL SPECTRUM DISORDER: A PROPOSED
MECHANISM OF METABOLITE CHANGES
Abstract
Although fetal alcohol spectrum disorder (FASD) has been clinically identifiable
by the medical community for decades, a comprehensive profile metabolic changes
has not been developed. To that end we characterized ethanol-induced metabolome
changes in the zebrafish model of FASD. Zebrafish embryos were exposed to ethanol
at concentrations of 0–3% from 2–24 hours post-fertilization. This was followed by
washing and further incubation with media for an additional 24 hours. At 48 hours
post fertilization whole-embryos were extracted and analyzed by liquid chromatog-
raphy using a Thermo Fisher Orbitrap mass spectrometer (non-polar fraction) or
liquid chromatography coupled with an Agilent Time of Flight mass spectrometer
(polar fraction). Data were aligned, normalized, and filtered followed by ANOVA.
Significant differences were detected in lipids, including short chain fatty acids, phos-
phatidic acid, phosphatidylserines, phosphatidylglycerols, ceramide, and sphingosine,
which support our existing understanding of neural abnormalities in FASD. We also
noted significant differences in metabolites related to essential enzymatic cofactors,
such as nicotinamide adenine dinucleotide, coenzyme A, pyridoxal phosphate biocytin
(biotin), and tetrahydrofolate. We also noted significant differences in metabolites
related to nuclear transcription factors, oxidative stress, and cardiovascular function.
Our work supports the work of many previous FASD mechanistic hypotheses, but
more importantly identifies novel metabolome changes that may alter our perception
of these previously proposed hypotheses.
2.1 Introduction
Though the relationship between maternal drinking and abnormal prenatal devel-
opment has been recognized for over a millennia, we still do not have a clear picture of
the widespread biochemical influences alcohol has on offspring. Fetal alcohol spectrum
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disorder (FASD) prevalence estimates vary widely due to the complex nature of this
disease. The nature of ethanol as a polar protic solvent means that it chemically mod-
ifies a vast array of molecular species, making the modeling of FASD a complicated
problem. (Polar protic, or proton donating, solvents, such as ethanol, are charac-
teristically capable of hydrogen bonding, are acidic (weakly, in the case of ethanol),
and dissolve salts through hydrogen bonding (for anions) or unshared free electron
pairs (for cations). They have a strong electric field strength in a vacuum, meaning a
high permittivity.) To address this issue, we pursued non-targeted metabolomics in
a widely used zebrafish model of FASD. Here we examine both established and new
mechanisms of FASD.
Significant contributions have been made to the understanding of FASD by ex-
ploring changes in many teratogenic pathways (nitric oxide and other reactive oxy-
gen species, glutamate, vitamin A, serotonin signaling, lipids, glucose regulation,
and adhesion molecules), which are altered after embryonic ethanol exposure. This
has resulted in a wide range of theoretical models as potential causative agents of
FASD [61,62]. Because of the technologies previously available, researchers have had
to limit the range of biochemical changes explored at one time, which has inhibited our
ability to create robust, reliable detection strategies, develop successful interventions,
and understand this complicated disease.
Metabolomics has become an excellent tool to determine the biochemical changes
occurring in a given condition. Through the use of liquid chromatography-mass spec-
trometry coupled with evolving metabolite databases, we were able to use a non-
targeted metabolomics approach to investigate the well-established zebrafish model
of FASD. This technique allows us to explore how the metabolome changes under
changing ethanol concentrations (dynamically), isolating systemic influences to in-
clude only that of ethanol, the embryo itself, and the maternally derived yolk sack. It
bolsters existing research as well as sheds light on possible new avenues for follow-up
research (hypothesis generating). With this approach, we seek a better understanding
of important biochemical changes that are occurring in the entire developing organ-
ism.
After exposing AB strain Danio rerio zebrafish to ethanol in concentrations from
0–3% from 2 - 24 hours after fertilization, whole embryo extracts were analyzed us-
ing liquid chromatography coupled with a mass spectrometer (MS) Agilent Orbitrap
(LC-MS/MS) technology (non-polar fraction) or Agilent 6220 Time of Flight (TOF)
LC-MS (polar fraction) detection. We compiled the significantly different metabo-
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lites, which we present here. Our results demonstrate embryonic ethanol exposure
often has a hormetic (J- or U-shaped) effect on the biochemical changes that occur.
In addition, our findings bolster the of the works of others on the impact of ethanol on
nervous system changes related to lipids; alterations in tryptophan-related metabo-
lites affecting serotonin, kynurenine, and growth; metabolome changes which alter
vitamin A and D regulatory functions; oxidative stress; PI3K changes which may
impact secondary messenger signaling and cardiovascular function; metabolites able
to alter the HPA axis; and hormone changes relevant to the sex differences noted in
FASD research. In addition, we noted many enzymatic cofactor-related metabolites,
which affect a vast array of biochemical processes.
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2.2 Materials and Methods
2.2.1 Zebrafish Embryo Ethanol Exposure
Animal experiments were performed in accordance with Purdue Animal Care and
Use policies at Purdue University, West Lafayette using approved protocol 1111000275.
Healthy AB strain zebrafish were housed in 15-gallon glass aquaria with approxi-
mately twenty-four individuals, mixed male and female, per tank. Pyrex dishes with
mesh tops were set in each tank at 0925 AM for spawning. Fertilized eggs were
collected shortly after spawning from six aquaria.
Embryos were examined microscopically to confirm fertilization and transferred
to E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM MgSO4 in
distilled water) [63]. At 2 hours post-fertilization (hpf), randomized embryos (n=8
per group) were exposed to ethanol at concentrations of 0, 0.001, 0.003, 0.01, 0.03,
0.1, 0.3, 1, or 3% v/v. Embryos were incubated in covered 6-well plates at 28 ◦C (18
hours light, 6 hours dark) until 24 hpf. After washing with E3 twice, zebrafish were
further incubated until 48 hpf. At that time, the larvae were flash frozen in liquid
nitrogen and stored at −80 ◦C.
2.2.2 Metabolomics
Sample Preparation
After thawing at 4 ◦C and removal of any visible water with a pipette, embryos
were extracted in 2:1 methanol:water, homogenized, extracted in ice-cold chloroform,
centrifuged and concentrated. The non-polar extract was dissolved in 50% ddiH2O,
25% methanol, 25% acetonitrile and analyzed with LC-MS/MS using Orbitrap (see
below). The polar extract was dissolved in 20% acetonitrile, 80% water with 0.1%
formic acid. Polar samples were then analyzed by LC-MS (Time of Flight).
Chromatography
Non-Polar Extract Chromatography A Thermo Fisher LTQ Orbitrap (Waltham,
MA USA) instrument was used for the non-polar sample analysis, where each sample
was analyzed once. It was coupled to an Agilent 1100 series Liquid Chromatography
(LC) (Agilent Technologies, Santa Clara, CA) equipped with a micro well plate auto
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sampler and binary pump. Reverse phase liquid chromatography was used to ana-
lyze the samples. An Eclipse XDB-C8 column (Agilent Technologies, Santa Clara,
CA) with 2.1x150 mm, 3.5 µm dimensions was used for the separation. Solvent A
consisted of water + 0.1% piperidine and Solvent B contained acetonitrile:methanol
(50:50 v/v) + 0.1% piperidine [64]. The flow rate was 300 µL/minute. A volume of
10 µL was loaded onto the column. The gradient was as follows: 0 minutes, 50% B;
25 minutes, 95% B; 45 minutes, 95% B; 50 minutes, 50% B; and 60 minutes, 50% B.
The mass spectrometry (MS) analysis used negative polarity electrospray ioniza-
tion with a source voltage of 3.0 kV, source current 100 µA, capillary voltage –45.50
V, and tube lens voltage –102.0 V. The capillary temperature was 275 ◦C, sheath gas
flow was 15, auxiliary gas was 30, and sweep gas was set to 0. Data were acquired
using data dependent scanning mode. Fourier transform mass spectrometry (FTMS)
resolution of 60,000 with a mass range of 100–1200 atomic mass units (based on the
limit of detection) was used for full scan analysis and the FTMS was used for MS/
MS data acquisition with a resolution of 7500. The top three most intense ions were
acquired with a minimum signal of 1000, isolation width of 2, normalized collision
energy of 35, default charge state of 1, activation Q of 0.250, and an activation time
of 30.0. The samples were evaluated with Thermo XCalibur software (v.2.1.0) and
downstream alignment done with an in-house data processing package (see below).
Standards for palmitic and stearic acids were analyzed using the same method.
Polar Extract Chromatography For the polar fraction, only the 0.01, 0.03, 0.1,
0.3, and 1% ethanol groups were analyzed, with each sample analyzed one time. An
Agilent 1100 series liquid chromatography (LC) instrument (Agilent Technologies,
Santa Clara, CA) equipped with a well plate auto sampler and binary pump coupled
to an Agilent 6220 TOF LC-MS instrument was used for the analysis of polar fraction
samples. Reverse phase liquid chromatography was used to separate the samples
before MS analysis. A Waters Atlantis T3 column (Waters Corporation, Milford,
MA) with 2.1 x 150 mm, 3.0 µM dimensions was used for the separation. Solvent A
consisted of water + 0.1 % formic acid. Solvent B consisted of acetonitrile + 0.1 %
formic acid. The flow rate was 300 µL/minute. A sample volume of 20 µL was loaded
onto the column. The linear gradient was as follows: time 0 minutes, 0 % B; time 1
minute, 0 % B; time 41 minutes, 95 % B; time 46 minutes, 95 % B; time 50 minutes,
0 % B; time 60 minutes, 0 % B.
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The MS analysis used positive polarity electrospray ionization (ESI). The source
conditions were as follows: capillary voltage 3.5 kV, gas temperature 325 ◦C, drying
gas 8 L/minute, nebulizer pressure 40 psi, fragmentor 120 V, and skimmer 65 V. Data
were acquired from 50–1000 m/z (based on the limit of detection) and the acquisition
rate was 0.99 spectra/second. An Agilent calibration mix (Agilent G1969–85001) was
used as an external mass correction for all samples. It was continuously infused into
the dual ESI source at a rate of 15 µL/minute throughout the run. The samples were
evaluated and preprocessed with Agilent Masshunter Qualitative Analysis software
(version B.03.01) followed by data filtering and analysis.
Data Filtering and Analysis
Using the Purdue Bindley Bioscience Center Omics Discovery Pipeline Software,
retention time, m/z, and peak intensity data from each data set were separately
deconvoluted with a m/z variation setting of 0.07, an LC peak width of 10, and
a minimum noise-to-signal ratio of 0.5 [65]. Alignment across non-polar samples
required an m/z variation of 0.015 and a retention time variation across samples of
less than 0.7 minutes. For the polar metabolites, alignment was required to be within
0.075 m/z with a retention variation of no more than 0.7 minutes. Due to poor
alignment, two samples from the 0.03 and one from the 0.1% treatment groups were
excluded from the polar analysis. In the non-polar samples, normalization required
the detected peak to occur in 60% of the samples of at least one treatment group
and 35% experiment-wide. For the polar samples, 70% and 35% were used for these
cut-offs, respectively.
Some metabolites with identical m/z appeared in the data. If the retention times
were within 1 minute, the metabolites were combined. For those that had a larger
difference in retention time, these molecules were retained as separate metabolites,
and are reported with their retention time ± standard deviation (SD). Metabolites
were identified and classified using the Kyoto Encyclopedia of Genes and Genomes
(KEGG) (Kanehisa Laboratories), the PubChem Substance and Compound database,
LipidMaps, the Human Metabolome Database, or METLIN [66–72]. Identified non-
polar metabolites were filtered based on being within 3 parts per million (ppm) dif-
ference of the exact mass of the metabolite, with ppm difference defined as
ppm difference ==
(observed mass − theoretical mass)
(theoretical mass)
× 1, 000, 000
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Polar metabolites were filtered based on being within 10 ppm of the theoretical mass.
Data was further filtered as noise if it failed to have a minimum signal intensity across
samples of e10 or greater or were likely misidentified (such as drug metabolites only
appearing in one sample concentration). Data for samples that were fractionated on
differently aligned peaks were manually combined for each species if entire groups were
split between metabolites identified as the same entity. Treatment groups for each
metabolite were compared using an ANOVA with metabolites considered significant





where ī is the average of the intensity values for the group of interest and c̄ is the
average of the intensity values for the control group.
Ingenuity Pathway Analysis ®
Ingenuity Pathway Analysis®(IPA) (Ingenuity Systems, Redwood, CA) was used
for additional metabolome network analysis. Metabolites were required to have at
least one concentration with a 0.001-fold or greater to be considered in the subsequent
IPA analysis. The P-value reported expresses the association between the identified
metabolite and a given pathway, based on the number of measured molecules that are
reported in the literature to participate in a function, and the number of all molecules
associated with that function in the Ingenuity Knowledge Base. These categories of
function can be prioritized by the IPA P (or P range for supersets) for each concentra-
tion tested. Reported here are the 0.03% ethanol treatment significantly associated
pathways, as the values from all ethanol doses provided similar P . Non-polar and
polar data sets were not combined for analysis due to the different chromatography




A total of 647 non-polar fraction metabolites were identified in the databases
queried. Of these, 94 were identified as molecules unique from each other with
less than a 3 ppm difference from the theoretical mass of their associated identi-
fied metabolite. Eighty-two metabolites significantly changed as a function of the
ethanol concentrations tested (P < 0.001, ANOVA). Metabolites clustered in three
main categories: fatty acids (9), glycerophospholipids (18), or sphingolipids (7). The
remainder of the identified metabolites were prenol lipids or exogenous/synthetics.
Hierarchical clustering resulted in samples within a treatment group appearing more
similar to each other than to samples of other treatment concentrations (Figure 2.1).
However, the groups did not always cluster in the order of ethanol concentration (0.03
and 1% groups were reversed).
The polar metabolome consisted of metabolites 219 identified by the databases
queried. The metabolites in each sample clustered more like the samples within the
same ethanol treatment group than to samples of other ethanol groups (Figure 2.2).
Fifty-one polar metabolites were identified as synthetic compounds or drugs. Other
classes of molecules included ethanol metabolites (15), proteins/amino acids (48),
carbohydrates (5), and lipids (57).
2.3.2 Ethanol Metabolites
Many metabolites related to ethanol catabolism were identified in the polar frac-
tions (Table 2.1, Structure 3-1). These included acetamide, butanal, dihydroxy-
acetone, acetoacetic acid, S -methylthioglycolate, and N -cyclohexylformamide. Ac-
etamide (Structure 3-2) is an amidated form of acetate. It was significant
higher at concentrations of 0.1, 0.3, and 1% ethanol at a retention time of 10.87±
0.08 minutes. It also occurred at a later retention time of 15.53 ±0.10 minutes, where
it was nearly two-fold higher than controls at concentrations of 0.3 and 1% ethanol.
Butanal (Structure 3-3) occurred with several different elution times. At
5.36±0.11 minutes, with was significantly elevated over controls at concentrations of
0.01, 0.03, and 0.1%. At the later retention times of 14.07±0.17 and 16.56 ±0.27
butanol was nearly 5.94-fold higher than controls. The metabolite dihydroxyacetone
(Structure 3-4) was identified as only slightly higher than control for
18
Fig. 2.1. Clustering of non-polar metabolites from zebrafish embryos ex-
posed to ethanol. Divisional clustering of the non-polar fraction sam-
ples demonstrates group members were more similar to other same group
members than to the members of another group. Clustering analysis is
a statistical tool used for grouping samples on the basis of similarity to
other samples. Clustering of the metabolite groups occurred in the reverse
order of what was expected for groups 0.03% and 1%, but samples within
each group were more like each other than samples of another group.
19
Fig. 2.2. Clustering of polar metabolites from zebrafish embryos exposed
to ethanol. Divisional clustering of the polar fraction samples demon-
strates group members were more similar to other same group members
than to the members of another group. Clustering analysis is a statistical
tool used for grouping samples on the basis of similarity to other samples.
Clustering of the metabolite groups occurred in the reverse order of what
was expected for groups 0.1% and 0.3%, as well as control and 0.01%.




























Fig. 2.3. Ethanol is catabolized into several common metabolites observed
in this analysis.
treatment groups of 0.01–0.3% ethanol, but dropped to –5.45-fold in the highest con-
centration treatment group. Acetoacetic acid (Structure 3-5) was higher
than controls at the lowest concentrations tested of 0.01 and 0.03% ethanol. The
metabolite S -methylthioglycolate (Structure 3-6) was elevated at all con-
centrations of ethanol higher than 0.01%. Lastly, N -cyclohexylformamide
(Structure 3-7) was approximately 6-fold higher than control in the 0.01 and 1%




Stearic and Palmitic Acids Lipids were identified in both the non-polar and polar
data sets, though were predominantly in the latter. The metabolites were broadly
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Table 2.1.
Ethanol catabolism associated metabolites were identified at several
retention times within 10 ppm of their theoretical mass/charge from the
polar fractions.
Metabolite Sparkline Fold
ID (Relative to 0% Ethanol)
Retention Time (min.) ppm 0.01 0.03 0.1 0.3 1
Acetamide
CID178
10.87 ± 0.08 6.520475 0.00 0.00 6.54 6.08 6.53
15.53 ± 0.10 3.070272 0.00 0.00 0.00 6.07 5.52
Butanal
CID261
5.36 ± 0.11 -3.273774 5.36 6.01 5.21 0.00 0.00
14.07 ± 0.17 -1.992159 0.00 0.00 5.94 5.44 5.76
16.56 ± 0.27 -1.043472 0.00 0.00 6.23 5.71 6.12
Dihydroxyacetone
CID670
2.83 ± 0.08 0.071753 0.77 1.03 1.02 0.96 -5.45
Acetoacetic acid
CID96
3.86 ± 0.17 1.95078 4.80 5.82 0.00 0.00 0.00
S -Methylthioglycolate
CID5179950
3.57 ± 0.13 1.95078 0.00 5.97 5.50 5.85 6.28
N -Cyclohexylformamide
CID13017
2.34 ± 0.23 -9.383972 5.43 0.00 0.00 0.00 5.90
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations from
0–1%. Metabolites were identified from polar extraction fractions using LC-MS
(TOF). The average retention time±SD are listed along with the PubChem
database ID (CID), followed by the ppm difference (ppm) between the theoretical
mass and the observed mass. Folds, relative to 0% controls, are listed for each
ethanol concentration. All metabolites listed are significantly changed from control,
P < 0.001, ANOV A.
classified as fatty acids, phospholipids, sphingolipids, and sterol metabolites. Of the
fatty acids identified, stearate and palmitate were predominant
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in the non-polar fraction. For both palmitic (HMDB00220, average molecular weight
256.4241 g/mol) and stearic acids (HMDB00827, average molecular weight 284.4772
g/mol), multiple metabolites were identified with similar mass/charge (m/z), but
different analyte retention times (Tables 2.2 and 2.3). Palmitic and stearic acid
standards were subsequently analyzed. Chromatograms and mass spectra are shown
in panels A and C of Figure 2.4 for palmitic acid (m/z 256.2370 [M + H]+ with a
retention time of 3.5 minutes). Panels B and D show the results for stearic acids (m/z
284.2682 [M +H]+ with a retention time of 6 minutes), respectively. The standards’
retention times suggest that the native palmitic acid eluted at 4.49±0.19 minutes.
At this retention time, palmitic acid is over 6-fold higher in ethanol concentrations
of 0.03, 1, and 3%. The later elution times of palmitic acid showed increases up
to 7.32-fold over that of the control embryos. The earliest metabolite identified as
stearic acid eluted at 14.20±0.17 minutes. Similar to the earliest eluting palmitic
acid, stearic acid eluting at this time was significantly lower, being –5.45-fold with
0.01% ethanol or greater, compared to control concentrations. The other metabolites
identified as stearic acid tended to be significantly lower as well, with the exception
of the 26.57±0.13 minute elution time, which was up to 7.08-fold greater than control
at 0.1% ethanol.
Other Fatty Acids Additional fatty acids were identified from both fractions.
Non-polar fraction fatty acids included caprolylglycine, tetradecanoic acid (myristic
acid), pentadecanoic acid, (9Z )-hexadecenoic acid, methyl hexadecanoate, 2-oxooc-
tadecanoic acid, monoacylglycerol (MAG), and (2S ,3S ,4S ,5R,6R)-6-(hexadecyloxy)-
-3,4,5-trihydroxyoxane-2-carboxylic acid (palmitoyl glucuronide) (Table 2.3.3). In
the polar fraction, fatty acids identified were 2-decene-4,6,8-triyn-1-al, 2-hexanami-
doacetic acid, (E )9-oxodec-2-enoic, trans-2-decenoyl-acyl-carrier protein (ACP), (4Z )-
decenedioc acid, 3(R)-hydroxy-dodecanoyl-ACP, 12(S )-hydroxy-16-heptadecynoic acid,
and 16-feruloxyloxypalmitate.
The non-polar fraction fatty acid metabolite 2-octanamidoacetic acid (capryloyl-
glycine) changed from control at all tested concentrations, however was
not significantly change (p = 0.035). It was –5.98-fold below controls at 1 and 3%
ethanol, but at the other tested concentrations changed little. Similarly, pentade-
canoic acid
was 6.09-fold below control in the non-polar fraction, but only in the 3% ethanol.
Methyl hexadecanoate was significantly lower by 6.33-fold in ethanol
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Table 2.2.
Palmitic acid was identified at several retention times within 3 ppm of
its theoretical mass/charge.
Retention ppm Fold (Relative to 0% Ethanol)
Time (min) 0.001 0.003 0.01 0.03 0.1 0.3 1 3
1.29 ± 0.08† 0.411333 0.00 0.00 0.00 6.87 0.00 0.00 0.00 0.00
4.49 ± 0.19† 2.002808 0.00 0.00 0.00 6.16 0.00 0.00 6.41 6.11
5.33 ± 0.09† 0.689587 7.13 7.32 6.63 0.00 0.00 0.00 0.00 0.00
5.70 ± 0.20 1.725334 5.48 5.86 5.46 5.83 6.60 6.83 7.08 6.59
7.60 ± 0.04 1.639477 0.00 0.02 -0.03 -0.04 -0.23 -0.05 -0.01 -0.70
7.71 ± 0.18 -2.088275 -0.91 -1.03 -0.89 -0.54 -0.93 -0.30 -0.23 -0.29
8.73 ± 0.25† 1.995393 0.00 0.00 0.00 5.48 5.53 6.27 6.74 6.72
21.65 ± 0.09† 1.846314 5.83 0.00 5.46 5.84 6.10 0.00 0.00 0.00
31.32 ± 0.24 0.807836 0.45 0.03 0.43 0.40 0.45 -5.36 0.72 0.36
44.64 ± 0.04† 1.817045 -6.64 -6.64 -6.64 -6.64 -1.36 -0.99 -1.40 -6.64
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations from
0–3%. Metabolites were identified from non-polar extraction fractions using
LC-MS/MS. The average retention time ± SD is listed, followed by the ppm
difference (ppm) between the theoretical mass and the observed mass. Folds, relative
to 0% controls, are listed for each ethanol concentration. † : P < 0.001, ANOV A.
treatments of 0.03% or greater. MAG and (2S ,3S ,4S ,5R,6R)-6-(hex-
adecyloxy)-3,4,5-trihydroxyoxane-2-carboxylic acid , also in the non-polar
fraction, were significantly lower (approximately 7-fold) at 0.3% ethanol on greater.
Conversely, tetradecanoic acid , was significantly higher than control
by as much as 7.19-fold in ethanol concentrations except 0.003%. 2-Oxooctadecanoic
acid was 6.23-fold higher than control, but only with the 0.03% ethanol
treatment. Lastly, (9Z )-hexadecenoic acid , also in the non-polar fraction,
was nearly 6.12-fold above control in the 3% ethanol treatment.
In the polar fraction, the unsaturated fatty acid 2-decene-4,6,8-triyn-1-al
was elevated more than 5.45-fold in the 0.03 and 0.1% ethanol treatment groups only.
The metabolite 2-hexanamidoacetic acid (hexanoylglycine) was different
from control only in the 0.01 and 0.03% ethanol treatment groups. It was 4.97-
and 5.72-fold higher in those two groups. (E )9-oxodec-2-enoic , increased
to 5.63-fold higher than controls in the 0.03% treatment group and 4.55-fold in the
24
Table 2.3.
Stearic acid was identified at several retention times within 3 ppm of its
theoretical mass/charge.
Retention ppm Fold (Relative to 0% Ethanol)
Time (min) 0.001 0.003 0.01 0.03 0.1 0.3 1 3
14.20 ± 0.17† 0.700387 0.02 0.02 -5.45 -5.45 -5.45 -5.45 -5.45 -5.45
19.10 ± 0.13† 1.223830 0.17 0.17 0.13 -0.03 -0.06 0.14 0.18 0.15
24.98 ± 0.06† 1.477812 0.19 0.38 -0.59 -6.89 -6.89 -6.89 -6.89 -6.89
25.28 ± 0.22 0.66943 -6.21 -6.21 -6.21 -6.21 -6.21 -6.21 -6.21 -6.21
26.57 ± 0.13 1.614302 0.00 0.00 5.77 7.02 7.08 7.05 6.81 6.51
29.43 ± 0.13† 0.490376 -0.08 -0.41 -6.28 -6.28 -6.28 -6.28 -6.28 -6.28
34.22 ± 0.09† 1.131313 0.28 0.64 -0.20 0.12 0.01 0.00 -5.55 0.66
Stearic acid was identified at several retention times within 3 ppm of its theoretical
mass/charge. Zebrafish embryos were exposed from 2–24 hpf to ethanol at
concentrations from 0–3%. Metabolites were identified from non-polar extraction
fractions using LC-MS/MS. The average retention times ± SD is listed, followed by
the ppm difference (ppm) between the theoretical mass and the observed mass.
Folds are listed for each ethanol concentration tested and are expressed relative to
0% controls. † : P < 0.001, ANOV A.
0.3% group. At all other ethanol concentrations, there was no difference relative to
controls. 2(E )-Decenoyl-ACP increased in the 0.01 and 0.1% ethanol
treatments to 5.55- and 4.75-fold greater than controls, but at the other tested con-
centrations was not different than controls. The metabolite (4Z )-decenedioc acid
was consistently higher than controls at 0.1% ethanol or greater, being maximally
different (5.94-fold) in the 0.1% treatment group. (3R)-Hydroxy-dodecanoyl-ACP
, was different than controls for the 0.01, 0.03, and 1% ethanol treatments.
It was as large as 5.72-fold greater than controls (0.03%). (12S )-Hydroxy-16-heptade-
cynoic acid in zebrafish embryos was unchanged from control at the lowest
and highest concentrations tested, but as much as 5.68-fold higher in the 0.03–0.1%
treatments. Similarly, 16-feruloyloxyhexadecanoic acid was higher than
controls in all ethanol treatment groups except 0.01%. This metabolite was approx-
imately 5.6-fold higher than controls until the 1% treatment group, where it was
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Fig. 2.4. LC-MS/MS standards of stearic and palmitic acids. Chro-
matograms of palmitic (panel A) and stearic acids (panel B) standards
generated using the same method as the metabolomics analysis. Mass
spectrogram of palmitic (panel C,m/z = 255.2363, mass = 256.2370)
and stearic acids (panel D, m/z = 283.2375, mass = 284.2382) for the
major peak(s) in panels A and B.
26
Table 2.4.: Other fatty acids were identified in zebrafish embryos exposed
from 2–24 hpf to 0–3% ethanol. Metabolites were within 3 ppm (non-polar)
or 10 ppm (polar) of the theoretical m/z.
Metabolite Sparkline Fold(Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
2-Decene-4,6,8-triyn-1-al†p
LMFA06000063 -2.215544 n/a n/a 0.00 5.45 5.60 0.00 0.00 n/a
2-Hexanamidoacetic acid†p
HMDB00701 -5.424447 n/a n/a 4.97 5.72 0.00 0.00 0.00 n/a
(E )9-Oxodec-2-enoic†p
CID1713086 -1.609908 n/a n/a 0.00 5.63 0.00 4.55 0.00 n/a
2(E )-Decenoyl-ACP†p
LMFA07060012 2.066991 n/a n/a 5.55 0.00 4.75 0.00 0.00 n/a
(4Z )-Decenedioc acid†p
HMDB00603 2.801531 n/a n/a 0.00 0.00 5.94 5.49 5.12 n/a
2-Octanamidoacetic acidn
HMDB00832 2.850303 -0.67 0.3 0.02 -0.29 -0.72 -0.01 -5.98 -5.98
Tetradecanoic acid†n
C06424 2.285625 6.56 0.00 6.19 7.00 7.19 6.75 6.47 6.46
3(R)-Hydroxy-
dodecanoyl-ACP†p
LMFA07060015 6.164180 n/a n/a 5.55 5.72 0.00 5.34 0.00 n/a
continued on next page
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Table 2.4.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Pentadecanoic acid†n
C16537 1.808239 0.30 0.71 -0.50 0.87 0.23 0.18 -0.13 -6.09
(9Z )-Hexadecenoic acid†n
C08362 1.631235 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.12
Methyl
hexadecanoate†n
C16995 0.980922 0.69 0.49 0.00 -6.33 -6.33 -6.33 -6.33 -6.33
(12S )-Hydroxy-
16-heptadecynoic acid†p
LMFA01050146 5.017726 n/a n/a 0.00 5.50 5.68 4.78 0.00 n/a
2-Oxooctadecanoic acid†n
C00869 0.335288 0.00 0.00 0.00 6.23 0.00 0.00 0.00 0.00
MG(18:0/0:0/0:0)†n
HMDB11131 0.913459 -0.95 -0.96 -0.95 -7.10 -7.10 -7.10 -7.10 -7.10
(2S ,3S ,4S ,5R,6R)-6-(hexadecyloxy)-
3,4,5-trihydroxyoxane-
2-carboxylic acid†n
HMDB10331 -0.099930 -0.64 -1.41 -1.39 -7.03 -7.03 -7.03 -7.03 -7.03
continued on next page
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Table 2.4.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
16-Feruloyloxy-
hexadecanoic acid†p
C18217 4.921450 n/a n/a 0.00 5.73 5.54 5.63 4.63 n/a
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations
from 0–3%. Metabolites were identified from non-polar (n) or the polar (p)
extraction fractions using LC-MS/MS (Orbitrap) or LC-MS (TOF), respec-
tively. The average retention time±SD is listed along with the matching
m/z database identifier (HMDB: Human Metabolome; C: KEGG; LMFA:
LipidMaps), followed by the ppm difference (ppm) between the theoretical
mass and the observed mass. Folds, relative to 0% controls, are listed for each
ethanol concentration. ACP: Acyl Carrier Protein; MG: Monoacylglycerde.
† : P < 0.001, ANOV A.
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Glycerophospholipids
Phosphatidic Acid Several glycerophospholipids were significantly different with
ethanol exposure. These included phosphatidic acid (PA), phosphatidylserine (PS),
phosphatidylcholine (PC), phosphatidylinositol (PI), phosphatidylethanolamine (PE),
phosphatidylglucose (PG), and glycerophosphoglucose (GP). Except as noted, PAs
were observed in the non-polar fractions (Table ??). The PA 14:1/22:2
was significantly lower, by 6.50-fold, in all concentrations of ethanol. The moiety
16:0/18:1 eluted at several retention times, and was always significantly
different. The direction of change, however, varied with retention time. The less sat-
urated 16:0/18:2 decreased nearly 6.50-fold, only at the lowest treatment
concentration. However, 18:0/18:1 was significantly higher at moderate
to high ethanol concentrations, including 0.03, 0.3, and 1%. The less saturated 18:0/
18:2 also had multiple retention times, all of which changed significantly.
Palmitoyl 3-carbacyclic PA was 6.36-fold lower in all ethanol treatment
groups greater than 0.003%. In the polar fraction, PA(13:0/0:0) was ele-
vated in ethanol concentrations of 0.03% and greater. It was 5.94-fold greater than
control at 0.1% ethanol, but dropped to 4.65-fold in 1% ethanol. Pyrophosphatidic
acid (PPA) 16:0/18:1 was higher by at least 5.75-fold greater than controls
in all ethanol treatments at 0.03% ethanol and higher.
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Table 2.5.: Many phosphatidic acids significantly changed in ethanol-exposed
embryos.
Metabolite Sparkline Fold(Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
PA(13:0/0:0)p
LMGP10050001 -0.944605 n/a n/a 0.00 5.65 5.94 5.43 4.65 n/a
PA(14:1/22:2)n
LMGP10010134 -0.864438 -6.50 -6.50 -6.50 -6.50 -6.50 -6.50 -6.50 -6.50
PA(16:0/18:1)n
M40905
32.84 ± 0.11 -0.680664 0.00 6.21 0.00 0.00 0.00 0.00 0.00 0.00
35.30 ± 0.17 -0.587705 -0.51 -0.45 -6.66 -0.15 -0.16 -0.17 0.25 0.17
36.51 ± 0.10 0.034396 0.00 0.00 0.00 6.51 6.50 6.49 6.91 6.83
PA(16:0/18:2)n
HMDB07860 0.000446 -6.58 -0.24 -0.84 -0.20 -0.43 -0.74 -0.18 -0.49
PA(18:0/18:1)n
M40933 -0.191027 0.00 0.00 0.00 6.00 0.00 5.29 5.24 0.00
PA(18:0/18:2)n
HMDB07861
30.74 ± 0.12 -0.880651 0.00 6.07 0.00 0.00 0.00 0.00 0.00 0.00
33.68 ± 0.13 -1.14075 -6.01 0.06 -6.01 0.56 0.10 0.09 0.75 0.29
continued on next page
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Table 2.5.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
37.45 ± 0.11 -0.200855 0.00 0.00 0.00 6.57 6.12 6.10 6.77 6.30
Palmitoyl 3-carba-
cyclic PAn
M44867 0.08866 -0.69 -0.71 -6.36 -6.36 -6.36 -6.36 -6.36 -6.36
PPA(16:0/18:1)p
LMGP11010001 1.028955 n/a n/a 0.00 6.12 6.19 6.21 5.75 n/a
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations
from 0 to 1 or 3%. Metabolites were identified from the database as indicated
by the ID below the name based on the matching the m/z (HMDB: Human
Metabolome; LMGP: LipidMaps; M: Metlin). Next listed is sparkline as well
as the parts per million difference (ppm) between the theoretical mass and the
observed mass. Folds are listed for each ethanol concentration tested and are
expressed relative to 0% controls. PA: Phosphatidic acid; PPA: Pyrophospa-
tidic Acid. n: Non-polar Fraction Metabolite;p:Polar Fraction Metabolite.
All metabolites were significantly changed, † : P < 0.001, ANOV A.
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Phosphatidylserines Many PS were present in both the polar and non-polar frac-
tions, reported here in order of length and saturation (Table ??). PS in the form of
15:0/22:0 was decreased (6.31-fold) at all but the 0.003 and 0.01% ethanol
concentrations. In the polar fraction, O -16:0/14:0 in the polar fraction
was increased only in the 0.1% ethanol treatment group. The metabolite O -16:0/17:1
was identified in the polar fraction and was approximately 5.8-fold control
in the 0.1 and 0.3% treatment groups. The PS 16:0/18:0 , also in the polar
fraction, was 5.13- and 5.93-fold higher than controls in the 0.1 and 0.3% treatment
groups. The non-polar 18:0/20:4 was lower than controls by 6.37 for all
concentrations tested. Less saturated 18:1/22:4 changed little through-
out the ethanol concentrations tested, while 18:2/22:2 was 6.25-fold lower
than control at all but 0.001% ethanol. However, the longer, unsaturated 19:1/22:4
, 20:0/22:4 , and 20:2/22:4 were all dramatically
lower approximately 6-fold in all but the lowest ethanol concentration groups. In
all ethanol treatments, O -20:0/20:3) from the polar fraction was elevated
at a minimum of 5.44-fold control. Conversely, 20:1/22:4 did not follow
this trend, decreasing to –6.56-fold for only the 0.001% treatment group. Lastly, the
longer, fully saturated 22:0/22:0 was present in the polar fractions of all
ethanol treatment groups as high as 6.18-fold control.
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Table 2.6.: Many phosphatidylserines were significantly changed in ethanol-
exposed embryos.
Metabolite Sparkline Fold(Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
15:0/22:0†n
LMGP03010156 -1.357278 -6.31 0.25 -0.99 -6.31 -6.31 -6.31 -6.31 -6.31
O-16:0/14:0†p
LMGP03020003 -4.166436 n/a n/a 5.45 0.00 6.21 6.43 0.00 n/a
O-16:0/17:1†p
LMGP03020008 2.747279 n/a n/a 0.00 0.00 5.90 5.74 0.00 n/a
16:0/18:0†p
HMDB12356 6.295313 n/a n/a 0.00 0.00 5.13 5.93 0.00 n/a
18:0/20:4†n
HMDB12383 -1.433454 -6.37 -6.37 -6.37 -6.37 -6.37 -6.37 -6.37 -6.37
18:1/22:4†n
LMGP03010339 -0.439376 -0.67 0.01 -0.07 -0.22 -0.68 -0.71 -0.02 -0.48
18:2/22:2†n
continued on next page
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Table 2.6.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
LMGP03010364 -0.628776 -0.94 -6.25 -6.25 -6.25 -6.25 -6.25 -6.25 -6.25
19:1/22:4†n
LMGP03010509 -0.587152 -0.49 -0.22 -6.62 -6.62 -6.62 -6.62 -6.62 -6.62
O-20:0/20:3†p
LMGP03020062 -6.709731 n/a n/a 6.24 6.43 5.95 6.04 5.44 n/a
20:0/22:4†n
LMGP03010527 -0.86918 -1.31 -0.26 -1.11 -6.86 -6.86 -6.86 -6.86 -6.86
20:1/22:4n
LMGP03010556 -0.729681 -6.56 -0.21 -0.84 -0.48 -0.79 -0.80 -0.48 -0.85
20:2/22:4†n
LMGP03010527 -0.714362 -1.18 -0.83 -6.60 -6.60 -6.60 -6.60 -6.60 -6.60
22:0/22:0†p
LMGP03010943 -8.050081 n/a n/a 4.78 6.18 5.96 6.00 5.96 n/a
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations from 0 to 1 or
3%. Metabolites were identified from non-polar (n) extraction fractions using LC-MS/MS
(Orbitrap) or the polar (p) fraction using LC-MS (TOF). The database ID below indicating
the reference matching the m/z (HMDB: Human Metabolome; LMGP: LipidMaps) is
listed, followed by the parts per million difference (ppm) between the theoretical mass
and the observed mass. Folds are listed for each ethanol concentration tested and are
expressed relative to 0% controls. † : P < 0.001, ANOV A.
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Other Phospholipids
Phosphatidylcholine In addition to the PA, both non- and polar metabolomes
contained several glycerophospholipids. The only PE identified was P -16:0/0:0
, which did not change more than 0.10-fold from the control group at any tested con-
centration (Table 2.3.3). Other identified phospholipids included PC, GP, PI, PS.
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Table 2.7.: Many glycerophospholipids significantly changed in ethanol-
exposed embryos. Zebrafish embryos were exposed from 2–24 hpf to ethanol
at concentrations from 0–3%. Metabolites were identified from non-polar
(n), using LC-MS/MS (Orbitrap), or polar (p), using LC-MS (TOF), extrac-
tion fractions, with the database ID below indicating the reference matching
the m/z (HMDB: Human Metabolome; C: KEGG; LMGP: LipidMaps; M:
Metlin). Next listed is the parts per million difference (ppm) between the
theoretical mass and the observed mass. Folds are listed for each ethanol
concentration tested, and are expressed relative to 0% controls. PC: phos-
phalidylcholine; PE: phosphatidylethanolamine; PG: Phosphatidylglucose;
PI: phosphatidylinositol. † : P < 0.001, ANOV A.
Metabolite Sparkline Fold(Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
PC(15:1/22:4)†p
LMGP01011460 -9.411992 n/a n/a 0.00 6.24 6.25 6.07 5.23 n/a
PC(P -16:0/20:5)†p
LMGP01030040 -8.396944 n/a n/a 0.00 6.08 5.86 4.96 0.00 n/a
PC(18:4/P -18:1)†p
M59706 0.903672 n/a n/a 5.41 0.00 5.92 6.39 0.00 n/a
LysoPC(10:0)†p
HMDB03752 -10.42851764 n/a n/a 0.00 0.00 5.38 0.00 5.74 n/a
PE(P -16:0/0:0)†n
continued on next page
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Table 2.7.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
HMDB11152 -0.089643 0.04 0.02 0.03 0.07 0.09 0.10 0.07 0.09
2-(α-d-Mannosyl)-
3-PG†p
C11516 1.50756 n/a n/a 4.81 6.24 6.28 5.59 6.00 n/a
PG(14:1/0:0)†p
LMGP04050035 1.379908 n/a n/a 4.83 5.59 0.00 0.00 0.00 n/a
PG(16:0/16:1)†p
HMDB10571 4.281506 n/a n/a 5.87 5.82 6.53 6.53 0.00 n/a
PG(O-18:0/22:6)n
LMGP04020083 2.764662 0.00 6.35 5.75 0.00 0.00 0.00 0.00 0.00
PI(16:1/22:2)†n
LMGP06010192 -2.188116 -6.03 0.34 -6.03 -6.03 -6.03 -6.03 -6.03 -6.03
PI(18:0/20:4)n
HMDB09815 -0.393944 -0.97 0.22 -0.65 0.15 -1.03 -0.63 0.15 -0.39
PI(22:0/12:0)†n
LMGP06010819 -2.774647 0.00 0.00 0.00 6.20 5.48 6.18 6.19 5.44
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PCs were identified in the polar fractions (Table 2.3.3). The glycerophospho-
choline lysoPC(10:0) was elevated in the 0.1 and 1% treatment groups
to 5.38- and 5.74-fold controls. Similarly, 15:1/22:4 was elevated in the
0.03, 0.1, 0.3, and 1% ethanol by 6.24-, 6.25-, 6.07-, and 5.23-fold higher than con-
trols. The PC P -16:0/20:5 in the polar fraction was significantly higher
than controls when treated with ethanol at 0.03 to 0.3% ethanol. It was maximally
elevated to 6.08-fold higher at 0.03% ethanol and fell to 4.96-fold at 0.3% ethanol.
Lastly, 18:4/P -18:1 , also in the polar fraction, was inconsistently increased
relative to the control treatments. It was 5.41-fold higher at 0.01%, 5.92-fold at 0.1%
ethanol, and 6.39-fold at 0.3% ethanol. It was not different from control at 0.03 and
1% ethanol.
Glycerophosphoglucose Several GP moieties were present in the metabolome
(Table 2.3.3). In the non-polar fraction, O -18:0/22:6 was different from
controls at only 0.003 and 0.01%. These were 6.35-fold and 5.75-fold, respectively,
however were not significantly different. The remaining GPs identified were in the
polar fraction. PG(14:1/0:0) was elevated for only the lowest two ethanol
concentrations tested. At 0.01% the it was at 4.83-fold and at 0.03% ethanol, it
was 5.59-fold elevated over controls. At all ethanol treatment concentrations except
the highest 1%, PG(16:0/16:1) was about 6-fold control levels. At 0.1
and 0.3% ethanol, it was 6.53-fold higher than controls. However, at 1% ethanol, it
was not different than controls. 2-(α-d-mannosyl)-3-phosphoglycerate was
elevated in all ethanol treatments. It was maximally 6.53-fold higher than controls in
the 0.1% ethanol treatment group.
Phosphatidylinositol PI, an important non-polar fraction secondary signaling
molecule, was present in the non-polar fraction (Table 2.3.3). It increased in all
ethanol concentrations greater than 0.01% for 22:0/12:0 , but the shorter,
less-saturated 16:1/22:2 was lower by 6.03-fold in all treatment groups




Sphingolipids were present in both the non-polar and polar extraction fractions.
In general, ethanol exposure tended to increase sphingolipids in the polar fractions,
but not in the non-polar fractions (Table 2.3.3). Ceramides, present in the non-polar
fractions, had an increasing trend at ethanol concentrations of 0.03% ethanol and
higher. Sulfatides in the non-polar fraction were found at lower levels than controls
when treated with ethanol.
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Table 2.8.: Many sphingolipids were also significantly changed in ethanol-
exposed zebrafish embryos.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
C16 Sphinganinep
LMSP01040001 -7.685164 n/a n/a 0.00 5.87 6.34 5.78 5.58 n/a
C17 Sphinganinen
LMSP01040003 1.024427 0.04 -0.73 0.47 -0.75 0.48 -0.05 -0.04 0.41
C17 Sphinganinep




M53980 8.742596 n/a n/a 0.00 5.92 5.77 5.54 0.00 n/a
(4E ,8E ,10E-d18:3 )-
Sphingosine†n
LMSP01080013 0.766805 5.44 5.86 6.72 6.74 6.96 6.50 5.91 5.88
Ceramide
(d18:1/24:1)†n
HMDB04953 0.388807 0.00 0.00 0.00 0.00 0.00 5.47 6.15 5.40
continued on next page
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Table 2.8.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Lignoceric
ceramide†n
HMDB00831 0.16717 0.00 0.00 0.00 6.10 5.42 5.86 6.39 5.75
Ceramide
(d18:1/25:0)†n
HMDB04957 0.005274 0.00 0.00 0.00 5.68 0.00 5.77 6.29 5.23
C20 Sulfatide†n
LMSP06020010 -0.349097 -1.23 -0.23 -0.75 -0.41 -1.12 -1.15 -0.74 -0.46
C22 Sulfatiden
HMDB12316
31.32 ± 0.01† -1.564932 -6.25 -6.25 -6.25 -0.57 -6.25 -0.48 0.04 -1.02
33.68 ± 0.13† -0.157014 -6.25 -6.25 -6.25 0.31 -0.15 -0.17 0.49 -0.22
PI-Cer
(d18:1/22:0)n
LMSP03030001 -1.699464 -6.46 0.01 -0.40 0.32 0.07 0.05 0.47 0.20
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations of
0–3%. Metabolites were identified using LC-MS/MS (Orbitrap) for non-polar
(n) or LC-MS (TOF) for polar (p). ID indicates the reference database entry
used to identify the metabolite (HMDB: Human Metabolome; C: KEGG; M:
Metlin). The ppm is the difference between the theoretical mass and the
observed mass. Folds are listed for each ethanol concentration tested and
are expressed relative to 0% controls. † : P < 0.001, ANOV A; PI-cer:
Inositol-1-phospho-ceramide.
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C16 sphinganine was present in the polar fraction and elevated with
ethanol treatments higher than 0.01%. It was in its highest concentration in the
0.1% treatment group at 6.34-fold above controls. C17 sphinganine was
also present in the polar fraction. In all ethanol treatments of 0.03% and higher,
this metabolite was approximately 7-fold that of controls. However, C17 sphinganine
, from the non-polar fraction, did not change more than 0.75-fold in either
direction for all treatments. Non-polar fraction sphingosine (d18:3) was
increased by as much as 6.96-fold over the concentrations tested.
N -Acetyl-sphingosine-1-phosphate increased at 0.03–0.3% ethanol, maximally 5.92-
fold at the low end of that range. Lignoceric ceramide increased up to
6.10-fold relative to controls in all treatment groups from 0.03% and higher. Ce-
ramide (d18:1/24:1) was significantly higher at treatment concentrations
of 0.3% and higher. Ceramide (d18:1/25:0) , by comparison, increased at
the 0.03% and at or above 0.3% ethanol, yet was not elevated at 0.1%. Inositol–1-
phosphate-ceramide (PI-cer) (d18:1/22:0) , a metabolite analogous to PI
fluctuated, lowering to 6.46-fold below controls at the lowest ethanol concentrations,
then returning to near control levels across all concentrations [73, 74]. C20 Sulfatide
differed little from controls. But, C22 Sulfatide was 6.25-fold
lower than controls at concentrations of 0.001, 0.01, and 0.1% ethanol. C20 sulfatide,
in contrast, was lower than the control by 1.23-fold at most.
Sterol Metabolites
Hormones Many sterol metabolites, including hormones, were identified in our
analysis (Table 2.9). These included hormones, such as estrogens, androgens, and
prostaglandins, as well as vitamins and other sterol lipids. Several different estro-
gens were significantly changed in ethanol-exposed embryos. 1α-Hydroxyesterone
was not different in the 1% ethanol treatment, but was increased in all
lower ethanol treatments tested, with the highest at 5.68-fold increased in the 0.03%
ethanol treatment. The steroid 16-dehydroprogesterone was increased
as much as 6.16-fold that of controls in all ethanol treatment groups except 0.3%.
13-Ethyl-16,17-dihydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one was
maximally increased in the 0.03% ethanol treatment only to 1.17-fold of control. In all
other treatments, it was decreased to –4.54-fold of control. In addition to estrogens,
an androgen, 13-hydroxy-3-oxo-13,17-secoandrost-4-en-17-oic acid was sig-
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nificantly different in the ethanol-exposed embryos, at 0.01 and 0.03% ethanol doses.
13-Hydroxy-3-oxo-13,17-secoandrost-4-en-17-oic acid was not different from control at
0.1% ethanol and higher but was increased in the lowest two ethanol treatments of
0.01 and 0.03% ethanol to 5.42- and 4.84-fold higher than controls.
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Table 2.9.
Many hormones, including several estrogens and an androgen, significantly changed in ethanol-exposed zebrafish
embryos.
Metabolite Fold Change
ID Structure Sparkline (Relative to 0% Ethanol)




































O 4.739243 5.42 4.84 0.00 0.0 0.00
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations of 0–1%. Metabolites were identified from the
polar fraction using LC-MS (TOF). Database ID indicates the reference database used to identify the molecule using the
m/z (HMDB: Human Metabolome; LMST: LipidMaps; M: Metlin), followed by the structure. Next listed is the ppm
difference (ppm) between the theoretical mass and the observed mass. Folds are listed for each ethanol concentration
tested and are expressed relative to 0% controls. All metabolites were significantly changed, P < 0.001, ANOV A.
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A variety of icosanoids were significantly different in embryos exposed to ethanol.
Anandamide was significantly lower (approximately 6.5-fold) at 0.01%
ethanol or greater. The 6-keto-prostaglandin F1α-d4 was not different from
control in the 0.01% ethanol treatment group, but was elevated in all higher ethanol
treatments tested. This metabolite is likely a misnomer, as we did not use deuterated
compounds in our study, and further clarification is needed. The maximum level was
5.68-fold higher than controls. The leukotriene 12-oxo-10,11-dihydro-20-COOH-LTB4
was increased in only the 0.01 and 0.03% ethanol treatment groups to 5.52-
and 5.29-fold, respectively. Similarly, prostaglandin G1 was increased to
5.55- and 4.93-fold higher than control at these concentrations. 9-Oxo-11α,(16R)-di-
hydroxy-17-cyclobutyl-5(Z ),13(E )-dien-1-oic acid was somewhat elevated
from controls in the 0.01 and 1% ethanol treatment groups, but decreased to –4.69-fold
control levels in the intermediate ethanol treatments. 17-Phenyl trinor-13,14-dihydro
prostaglandin A2 was elevated in the lowest three ethanol treatments to
5.64-fold control levels, at most. At the two highest ethanol treatments, it was not dif-
ferent than control. Lastly, 17-phenyl trinor prostaglandinE2 serinol amide
was increased in the lowest ethanol treatments to 5.74- and 4.95-fold for the 0.01 and
0.03% ethanol treatment groups.
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Table 2.10.: Many icosanoids significantly changed in ethanol-exposed ze-
brafish embryos.
Metabolite Sparkline Fold(Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Metabolite Sparklines Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Anandamide
(20:l, n-9)n




M45059 0.017299 n/a n/a 5.52 5.29 0.00 0.00 0.00 n/a
Prostaglandin G1
p




M45409 4.124907 n/a n/a 5.48 5.64 4.70 0.00 0.00 n/a
6-Keto-prostaglandin F1α-d4
p
LMFA03010037 2.076897 n/a n/a 0.00 5.59 5.41 5.49 5.68 n/a
continued on next page
47
Table 2.10.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
9-Oxo-11α,16R-dihydroxy-
17-cyclobutyl-
(5Z ,13E )-dien-1-oic acidp




M44884 7.974096 n/a n/a 5.74 4.95 0.00 0.00 0.00 n/a
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations
of 0–3%. Icosanoids were identified from the non-polar (n) fraction using
LC-MS/MS (Orbitrap) or the polar (p) fraction using LC-MS (TOF). ID in-
dicates the reference database used to identify the molecule using the m/z
(C: KEGG; HMDB: Human Metabolome Database; LMFA: LipidMaps; M:
Metlin; SID: PubChem). Next listed is the ppm difference (ppm) between
the theoretical mass and the observed mass. Folds are listed for each ethanol
concentration tested and are expressed relative to 0% controls. All metabo-
lites were significantly changed, P < 0.001, ANOV A.
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Vitamins A variety of vitamin-related metabolites were identified in our metabolome,
often significantly changing with ethanol exposure, including A, D, E, and K. Three
vitamin A metabolites were significantly different, including 9,13-cis-retinoate, 1′-hy-
droxy-γ-carotene glucoside, and 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one
(Table 2.11). 9,13-cis-Retinoate minimally altered from controls in the
0.03, 0.3, and 1% ethanol treatments. For the 0.01 and 0.1% treatments it dropped to
–4.67-fold controls. 1′-Hydroxy-γ-carotene glucoside at all ethanol treat-
ment concentrations was increased, to as much as 6.34-fold higher than controls. 1--
(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one , an isoprenoid, eluted
at four distinct times (17.19, 32.25, 33.32, and 34.49 minutes). At the early elution
time, there was little difference from the control as a result of the ethanol exposure.
For the later elution time, 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one was
significantly lowered at all concentrations above 0.01%.
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Table 2.11.
Several vitamin A related metabolites were significantly changed in ethanol-exposed zebrafish embryos.
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)





























17.19 ± 0.12†n 2.932932 0.02 0.02 -0.01 -0.01 -0.01 -0.04 -0.03 -0.07
32.25 ± 0.29n 3.092996 -0.71 0.11 0.40 -0.18 -6.20 0.34 0.33 0.04
33.32 ± 0.14†n 2.559449 0.16 -0.24 -6.89 -6.89 -6.89 -6.89 -6.89 -6.89
34.49 ± 0.07†n 1.793080 0.00 6.16 0.00 0.00 0.00 0.00 0.00 0.00
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations of 0–1%. Metabolites were identified from
non-polar (n) using LC-MS/MS (Orbitrap) and polar (p) fractions using LC-MS (TOF). ID indicates the reference
database used to identify the molecule using the m/z (HMDB: Human Metabolome; C: KEGG). Next listed is the
structure and ppm difference (ppm) between the theoretical mass. Folds are listed for each ethanol concentration tested
and are expressed relative to 0% controls. † : P < 0.001, ANOV A.
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Four forms of vitamin D were identified (Table 2.3.3). 1α-Hydroxy-24,25,26,27-
tetranorvitamin D3 23-carboxylic acid , calcitroic acid, was not different
than controls in 0.01, 0.03, and 0.3% ethanol treatments. It was elevated to 5.61-
and 5.27-fold control levels in the 0.1 and 1% treatment groups. This contrasts with
1α-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid , which, while
significantly higher than controls with ethanol treatment, was only 1.13-fold at most.
1α-Hydroxy-22-(3-methyl-phenyl)-23,24,25,26,27-Pentanorvitamin D3 in-
creased with all ethanol treatments, peaking to 6.28-fold higher than control in the
0.3% ethanol group. 1α,25-Dihydroxy-26,27-dimethyl-20,21-didehydro-23-oxavitamin
D3 increased to 6.69-fold higher than controls with ethanol treatments.
At 0.01 and 1% ethanol it was 5.71- and 5.58-fold higher than controls, respectively.
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Table 2.12.: Many vitamin D metabolites were significantly changed in
ethanol-exposed zebrafish embryos.
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.01 0.03 0.1 0.3 1
1α-Hydroxy-24,25,26,27-tetranor-







-7.136755 0.00 0.00 5.61 0.00 5.27
1α-Hydroxy-25,26,27-trinor-







-2.68685 1.05 1.10 1.12 1.13 1.11
continued on next page
52
Table 2.12.: continued
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)












LMST03020326 -7.101992 5.71 6.69 6.68 6.69 5.58
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations of
0–1%. Metabolites were identified from polar fraction using LC-MS (TOF).
ID indicates the reference database used to identify the molecule using the
m/z (LMST: LipidMaps). Next listed is the ppm difference (ppm) between
the theoretical mass and the observed mass. Folds are listed for each ethanol
concentration tested and are expressed relative to 0% controls. All metabo-
lites were significantly changed. P < 0.001, ANOV A.
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In addition, two vitamin E metabolites were observed (Table 2.13). The metabo-
lite 7′-carboxy-α-tocotrienol did not differ from controls in the 0.01 and
1% ethanol treatments, but was increased by as much as 5.73-fold higher than controls
in the intermediate ethanol concentrations. Contrastingly, 9′-carboxy-α-tocotrienol
was only higher than controls in the 0.1 and 1% ethanol-treated embryos
and –4.43 fold-lower than controls in the other tested concentrations. Vitamin K3
was irregularly increased with ethanol treatment. At the 0.1% ethanol
levels, embryos had 5.14- and 5.86-fold higher than controls. At all other ethanol
treatments, it was not different than controls. Dissimilarly, sulfated dihydrome-
naquinone-9 was significantly decreased at all ethanol doses. Lastly,
another non-vitamin antioxidant was identified as significantly different. Ethanol
treatment, at any of the tested doses, increased N,N ′-diphenyl-p-phenylenediamine




Several other vitamins were significantly changed in ethanol-exposed zebrafish embryos.
Vit. Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)



























4.694499 n/a n/a 0.00 0.00 5.14 0.00 5.86 n/a
Sulfated
Dihydromenaquinone-9n
LMPR02010038 O CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 CH3 O—SO OHOCH3
O








7.923689 n/a n/a 5.79 6.19 6.17 6.19 6.01 n/a
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations of 0–1%. Metabolites were identified using
LC-MS/MS (Orbitrap) for non-polar (n) and LC-MS (TOF) for polar (p) fractions. Database ID indicates the reference
database used to identify the molecule using the m/z (HMDB: Human Metabolome; LMPR: LipidMapsC: KEGG). Next
listed is the structure and ppm difference (ppm) between the theoretical mass and the observed mass. Folds are listed for
each ethanol concentration tested and are expressed relative to 0% controls. All metabolites were significantly changed.
P < 0.001, ANOV A.
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Other Steroid Lipids Several other steroid lipids were identified as significantly
different in our metabolome. These include 3α,7α,12α-trihydroxy-5α-cholan-24-yl sul-
fate, cortexolone, 6-hydroxymethasone, 3α,7α-dihydroxy-12-oxo-5β-cholanate, 3α-hy-
droxy-6-oxo-5β-cholan-24-oic acid, diginatigenin, and (25S )-3-oxo-12β-acetoxy-cholest-
1,4-dien-26-oic acid. 3α,7α,12α-Trihydroxy-5α-cholan-24-yl sulfate was
increased to 5.46- and 4.42-fold in the 0.1 and 1% ethanol treatment, but was not
different from controls in the other ethanol concentrations (Table 2.3.3). Cortex-
olone was not different in the 0.01–0.1% ethanol treatment groups, but
increased to 5.82- and 4.62-fold in the 0.3 and 1% ethanol treatments, respectively.
For 6-hydroxydexamethasone , the 0.01 and 0.03% treatments were ele-
vated to 5.56- and 5.35-fold controls, but was similar to controls in all of the higher
ethanol treatments. 3α,7α-Dihydroxy-12-oxo-5β-cholanate at all ethanol
concentrations was increased, by as much as 6.20-fold control levels. 3α,7α-Dihy-
droxy-12-oxo-5βcholanate
increased with all ethanol doses, approximately 6-fold. 3α-Hydroxy-
6-oxo-5β-cholan-24-oic acid eluted at three different times. At 2.04±0.06
it was elevated to 5.59-, 5.38-, and 5.96-fold higher than controls for 0.1, 0.3, and
1% ethanol treatments, respectively. At 10.70±0.22 it was only 1.21-fold higher than
control at these concentrations, but was decreased by –5.32 in the 0.01 and 0.03%
ethanol treatments. When eluting at 13.81±0.11 it was not different from controls at
0.03 and 0.3% ethanol, but was 4.99-, 6.42-, and 5.19-fold higher than controls at 0.01,
0.1, and 1% ethanol. Diginatigenin was minimally altered from controls
in most ethanol treatment groups, and dropped with the 0.3% ethanol to –4.46-fold
of controls. Finally,(25S )-3-oxo-12β-acetoxy-cholest-1,4-dien-26-oic acid
increased to as much as 6.44-fold control in the 0.03–0.3% ethanol treatment groups,
but was not different in the highest and lowest treatment groups.
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Table 2.14.: Many steroids significantly changed in ethanol-exposed ze-
brafish embryos.
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)














2.04±0.06 -4.116307 0.00 0.00 5.59 5.38 5.96



























-3.133862 5.92 6.11 6.15 6.20 5.95
continued on next page
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Table 2.14.: continued
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)













































3.315656 0.00 0.00 5.46 0.00 4.42
continued on next page
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Table 2.14.: continued
Metabolite Structure Sparkline Fold (Relative to 0% Ethanol)



























1.967824 1.06 1.19 0.95 -4.46 1.35
Goyaglycoside c









Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations
of 0–1%. Metabolites were identified from the polar fraction using LC-MS
(TOF). ID indicates the reference database used to identify the molecule us-
ing the m/z (HMDB: Human Metabolome; C: KEGG; LMST: LipidMaps;
M:Metlin). Next listed is the ppm difference (ppm) between the theoretical
mass and the observed mass. Folds are listed for each ethanol concentra-
tion tested and are expressed relative to 0% controls. All metabolites were
significantly changed, P < 0.001, ANOV A.
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2.3.4 Protein-related Metabolites
Proteins were another major class of metabolites identified in the ethanol-treated
zebrafish embryos. Several metabolites are associated with amino acid metabolism,
including some related to histidine, lysine, and tryptophan. Numerous oligopeptides
were identified as well, though by nature of our method, it is difficult to determine the
order of the component amino acids or their identity. Other protein-related metabo-
lites included urea, creatinine, crotono-betaine, aspidinol, ifosfamide, N -acetyl-leucyl-
leucyl-methioninal, and laserpitin.
Amino Acids
Histidine Metabolism Several metabolites associated with amino acid metabolism
were altered with ethanol treatment. Broadly, these included metabolites related to
histidine, lysine, and tryptophan metabolism, amongst others. Three metabolites
associated with histidine metabolism included N -ω-acetylhistamine, imidazol-5-yl-
pyruvate, and thiourocanic acid (Table 2.15). N -ω-Acetylhistamine was
not different than controls with the 0.01% ethanol treatment, but was increased at
all higher ethanol concentrations. It peaked at 6.24-fold higher than control in the
0.1% ethanol group. Imidazol-5-yl-pyruvate was not different than control
at most ethanol concentrations. However, at 0.03 and 1% ethanol it was 5.75 and
5.02-fold higher. Lastly, thiourocanic acid was not different than control
with low ethanol doses, but was 5.64-fold higher in the 0.1% treatment group. By
the 1% ethanol dose, it decreased to 5.42-fold control levels.
Tryptophan Metabolism Several tryptophan catabolism products were identified
in our analysis. The metabolite oxindole eluted with two separate reten-
tion times (Table 2.16). At 18.64±0.23 minutes it was irregularly elevated. With 0.03
and 0.3% ethanol treatments it was not different than control. With 0.01, 0.1, and 1%
ethanol treatments, it was increased by 4.64-, 6.01-, and 5.52-fold control. The later
eluting oxindole (24.64±0.10 minutes) it was unchanged from control in the lower
ethanol concentrations, but then peaked to 5.73-fold higher than controls in the 0.1%
dose. For higher concentrations, it decreased slightly to 5.49-fold higher than con-
trols at 1%. Kynurenic acid was different than controls only at the 0.03%
ethanol treatment, where it was 5.70-fold higher. (Note: this metabolite appeared
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Table 2.15.
Histidine-related metabolites were identified from the polar fraction within
10 ppm of their theoretical m/z in zebrafish embryos exposed from 2–24
hpf to 0–1% ethanol.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.01 0.03 0.1 0.3 1
N -ω-Acetylhistamine
M44795 6.60068 0.00 5.64 6.24 5.55 5.14
Imidazol-5-yl-pyruvate
C03277 -3.74064 0.00 5.75 0.00 0.00 5.02
Thiourocanic acid
M63494 -1.26930 0.00 0.00 5.64 5.49 5.42
Histidine-related metabolites were identified from polar extraction fractions by
LC-MS (TOF). ID indicates the database reference for the m/z (C: KEGG; M:
METLIN). Next, is the ppm difference (ppm) between the theoretical and observed
masses. Folds are expressed relative to 0% controls. All metabolites listed were
significantly changed from control, P < 0.001, ANOV A.
only in this ethanol concentration, and therefore was filtered out by our protocol
during data analysis. It is included here due to its potential mechanistic-relevance, as
discussed below.) Cotinine methonium ion was 4.63-, 5.72-, and 4.82-fold
higher than controls in 0.01–0.1% ethanol treatment and was not different from con-
trols at higher concentrations. 2,6-Dihydroxypseudooxynicotine , involved
in nicotinamate /nicotinamide metabolism, was nearly –5.67-fold lower than controls
at both 0.1 and 3% ethanol concentrations. The metabolite 7-chlorokynurenic acid
increased only with the 0.03% ethanol to 1.23-fold. At all other ethanol
concentrations, it decreased to –4.40-fold lower than controls. Nicotine glucuronide
was increased by at least 5.23-fold with all ethanol treatment concentra-
tions except 0.3%, where it was not different than controls. Uncaric acid A
was only different than control in the 1% ethanol treatment, where it was 5.66-fold
higher. Other significant tryptophan metabolites included oxindole, kynurenic acid,
and 7-chlorokynurenic acid. Mugineic acid increased to 1.14-fold higher
than controls in 0.03% ethanol. With all other ethanol treatments, it dropped to
–5.13-fold below that of controls.
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Table 2.16.
Tryptophan-related metabolites were identified in zebrafish embryos exposed from 2–24 hpf to 0–1% ethanol.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Oxindolep
M34541
18.64±0.23 -7.94497 n/a n/a 4.64 0.00 6.01 0.00 5.52 n/a
24.64±0.10 -3.79098 n/a n/a 0.00 0.00 5.73 5.21 5.49 n/a
Kynurenic acidp
HMDB00715 -7.888699 n/a n/a 0.00 5.70 0.00 0.00 0.00 n/a
Cotinine methonium ionp
HMDB01365 2.515717 n/a n/a 4.63 5.72 4.82 0.00 0.00 n/a
2,6-Dihydroxypseudo-
oxynicotinen
M63883 2.285098 0.62 0.82 0.61 0.07 -5.67 0.39 -0.35 -5.67
7-Chlorokynurenic acidp
M44301 -5.924567 n/a n/a -4.40 1.23 -4.40 -4.40 -4.40 n/a
Nicotine glucuronide
HMDB01272 -8.59683 n/a n/a 5.23 0.00 5.76 5.35 5.81 n/a
Uncaric acidp
C17874 -3.305022 n/a n/a 0.00 0.00 0.00 0.00 5.66 n/a
Mugineic acidp
C15500 1.724655 n/a n/a -5.13 1.14 -5.13 -5.13 -5.13 n/a
Tryptophan-related metabolites were identified from non-polar (n) extraction fractions using LC-MS/MS (Orbitrap) or
polar (p) fractions using LC-MS (TOF). ID indicates the database reference for the m/z (HMDB: Human Metabolome; C:
KEGG; LMFA: Lipidmaps; M: METLIN). Next, is the ppm difference (ppm) between the theoretical and observed masses.
Folds are expressed relative to 0% controls. All metabolites listed were significantly changed from control,
P < 0.001, ANOV A.
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Other Amino Acid-Related Metabolites Several additional amino acid-related
metabolites were identified, including 2-hydroxymethylserine, β-aminopropionitrile,
N -(3-oxo-octanyl)-homoserine lactone, purine, 2,6 dimethylheptanoyl carnitine, and
hydroxybutyrylcarnitine. 2-Hydroxymethylserine was identified in the
polar fractions (Table 2.17). At 0.1 and 0.3% ethanol treatments it was 6.44- and
5.44-fold higher than controls. With all other ethanol treatments, ethanol-treated
embryos were not different than controls. β-Aminopropionitrile was not
different than controls with low ethanol doses. However, at 0.01% and higher, it
was 4.90-fold or more that of control levels. N -(3-Oxo-octanoyl)-homoserine lactone
was similarly only increased in the 0.1% and higher ethanol treatments and
was 5.52-fold higher than controls at most. Purine increased in almost all
ethanol treatments by at most 6.34-fold controls. The exception the 1% concentration,
where it was not different than controls. Finally, two carnitine metabolites in the
polar analysis included 2,6 dimethylheptanoyl carnitine and hydroxybutyrylcarnitine.
The metabolite 2,6 dimethylheptanoyl carnitine increased at all ethanol
treatments of 0.03% ethanol and higher. It was at a minimum of 5.05-fold higher than
controls, peaking at 5.81- in the 0.1% treatment group. Hydroxybutyryrylcarnitine
eluted at two different retention times. At 18.62±0.13, it increased to
5.01- and 5.71-fold higher than controls in the 0.01 and 0.03% ethanol treatments,
respectively. For the later retention time, 29.29±0.21 it was increased in the 0.03,
0.1, and 1% ethanol treatments to 5.91-, 4.93-, and 5.44-fold higher than controls.
A lysine-associated molecule, l-pyrrolysine, was significantly higher in the ethanol-
treated embryos. With all ethanol treatments, L-pyrrolysine increased by
a minimum of 4.97-fold controls.
Peptides
Many peptides were identified in our analysis. However, due to the large number
of alternative peptide sequences for each m/z, consideration of functional character-
istics at all identified peptide masses is beyond the scope of this paper. α-Aspartyl
Lys was maximally 5.80-fold at 0.03% ethanol (Table 2.3.4). The pep-
tide His-Ile increased in all ethanol treatments to a maximum of 6.08-fold
higher than controls in the 0.03% ethanol treatments, but was not increased in the
1% treatment group. Pro-Ala-Pro was increased to 6.27-fold control lev-
els, only at 0.3% ethanol. Gly-Asp-Val similarly was increased with all
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Table 2.17.
Amino acid-related metabolites were identified from the polar fraction
within 10 ppm of their theoretical m/z in zebrafish embryos exposed from
2–24 hpf to 0–1% ethanol.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ppm 0.01 0.03 0.1 0.3 1
β-Aminopropionitrile
HMDB04101 4.68002 0.00 0.00 4.90 5.07 5.67
Purine
HMDB01366 -4.18015 6.22 6.00 5.78 6.34 0.00
2-Hydroxymethylserine
M65894 -1.06180 0.00 0.00 6.44 5.44 0.00
N -(3-Oxo-octanoyl)-
homoserine lactone
LMFA08030004 -9.57403 0.00 0.00 4.77 5.52 5.54
Hydroxybutyrylcarnitine
HMDB13127
18.62±0.13 -1.41902 5.01 5.71 0.00 0.00 0.00
29.29±0.21 3.19007 0.00 5.91 4.93 0.00 5.44
l-Pyrrolysine
C16138 5.26183 4.97 5.79 6.03 5.62 5.62
2,6 Dimethylheptanoyl
carnitine
HMDB06320 -3.76263 0.00 5.06 5.81 5.35 5.05
Amino acid-related metabolites were identified from polar extraction fractions by
LC-MS/MS. ID indicates the database reference for the m/z (C: KEGG; HMDB:
Human Metabolome; LMFA: Lipidmaps; M: Metlin). Next, is the ppm difference
(ppm) between the theoretical and observed masses. Folds are expressed relative to
0% controls. All metabolites listed were significantly changed from control,
P < 0.001, ANOV A.
ethanol treatments except 1% by a minimum of 4.87-higher than controls. Isoleucine-
tyrosine eluted with two different retention times. With a retention time
of 12.56±0.02 minutes it was increased to as much as 6.05-fold higher than control for
0.01–0.1% ethanol. For the later retention time 52.97±0.14 minutes it was increased
in all ethanol treatment groups except at 1%, also peaking in the 0.1% treatment
group to 5.75-fold higher than controls. Pro-Gln-Pro was inconsistently
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elevated. It was not different in the 0.01, 0.1, and 0.3% treatments, but was 5.72- and
4.56-fold higher than controls in the 0.03 and 1% treatments. Asp-Lys-Pro
was also only different form controls with 0.1 (5.40-fold higher) and 0.3% (4.91-fold
higher) ethanol. Glu-Thr-Leu was increased by 5.71-fold, only at the lowest ethanol
treatment concentration. (Ac)2-L-Lys-D-Ala-D-Ala was signif-
icantly different with all ethanol treatment levels, except 0.3% ethanol. It peaked with
0.03% ethanol treatment to 5.65-fold higher than controls. Leu-Phe-Pro
was not different from controls at higher ethanol concentrations. At low ethanol
concentrations (0.01–0.1%) it was 5.87-, 5.31-, and 5.09-fold higher than controls.
Val-Pro-Tyr increased with 0.01 and 0.03% ethanol, but was not different
from controls in higher ethanol treatments. Cys-Lys-Lys was not different
in 0.01 and 1% ethanol, but in intermediate concentrations it was increased by a mini-
mum to 5.27-fold higher than controls. The peptide Pro-His-Gln increased
to 5.24- and 5.69-fold higher than controls with 0.01 and 0.03% ethanol. Otherwise
it was similar to controls. Gly-Arg-Arg was not different from controls
at 0.1 and 1% ethanol treatment and was increased to 4.58-, 5.86-, and 5.05-fold
greater than controls for 0.01, 0.03, and 0.3% treatments, respectively. Lys-Ser-Arg
was 5.99-fold control levels, only at the 0.01% ethanol treatment. The
peptide Val-Lys-Phe was similarly inconsistently increased with ethanol
treatment. Only at 0.01% (5.79-fold) and 0.3% (4.67-fold) was it different than con-
trol. Ile-Lys-His increased to 5.95- and 4.71-fold higher than controls with
ethanol treatments of 0.01 and 0.3% and was otherwise not different than controls.
The tripeptide Lys-Lys-Lys increased at 0.1% ethanol and higher to a
maximum of 5.62-fold higher than controls. Pro-Arg-Arg increased at
those concentrations as well, but peaked at 1% ethanol (5.79-fold higher than con-
trols). Lys-Phe-Phe increased to 5.60- and 5.40-fold higher than controls
at 0.01 and 0.03% ethanol. Otherwise it was not different than controls. Ile-Arg-Arg
was increased in all ethanol treatments except 0.03%. It peaked to 5.88-
fold higher than control with 0.3% ethanol. The tripeptide Trp-Ile-Lys
was not different from controls at concentrations of 0.1% or higher. It was 5.59-fold
increased at 0.01% and 5.43-fold at 0.03% ethanol. Tyr-Leu-Arg was
higher than controls by 5.00-fold and 5.51-fold in only the 0.03 and 0.3% treatments.
Lastly, Leu-Pro-Glu-Ile increased with all ethanol treatments up to 0.3%.
It was highest at 0.01% ethanol, where it was 6.14-fold higher than controls.
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Table 2.18.: Peptide polar metabolites were identified within 10 ppm of their
theoretical m/z in zebrafish embryos exposed from 2–24 hpf to 0–1% ethanol.
Metabolite ppm Fold (Relative to 0% Ethanol)
ID Sparkline 0.01 0.03 0.1 0.3 1
α-Aspartyl Lys -2.423291 0.00 5.80 5.59 5.67 5.08
HMDB04987
His Ile 3.73033 5.06 6.08 5.86 5.39 0.00
M23749
Pro Ala Pro 2.074142 0.00 0.00 0.00 6.27 0.00
M17715




12.56 ± 0.02 -2.88145 5.57 5.97 6.05 0.00 0.00
52.97± 0.14 4.22664 5.59 5.39 5.75 4.63 0.00
Pro Gln Pro -8.82752 0.00 5.72 0.00 0.00 4.56
M17361
Asp Lys Pro 4.87625 0.00 0.00 5.40 4.91 0.00
M17409
Glu Thr Leu 4.443707 5.71 0.00 0.00 0.00 0.00
M16527
(Ac)2-l-Lys-d-Ala-d-Ala 3.54647 4.95 5.65 5.50 0.00 5.20
C03326
Leu Phe Pro -1.87545 5.87 5.31 5.09 0.00 0.00
M15721
Val Pro Tyr -5.12488 5.41 5.82 0.00 0.00 0.00
M16148
Cys Lys Lys -8.01093 0.00 5.27 5.77 5.27 0.00
M17941
Pro His Gln 0.15256 5.24 5.69 0.00 0.00 0.00
M16468
Gly Arg Arg -7.38519 4.58 5.86 0.00 5.05 0.00
continued on next page
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Table 2.18.: continued
Metabolite ppm Fold (Relative to 0% Ethanol)
ID Sparkline 0.01 0.03 0.1 0.3 1
M16729
Lys Ser Arg 9.498799 0.00 5.99 0.00 0.00 0.00
M16224
Val Lys Phe 0.77019 5.79 0.00 0.00 4.67 0.00
M16175
Ile Lys His -4.77302 5.95 0.00 0.00 4.71 0.00
M17418
Lys Lys Lys -9.67125 0.00 0.00 5.62 5.11 5.03
M18451
Pro Arg Arg 4.09535 0.00 0.00 5.43 4.85 5.79
M16005
Lys Phe Phe -2.49863 5.60 5.40 0.00 0.00 0.00
M17964
Ile Arg Arg 6.46339 5.04 0.00 4.83 5.88 5.68
M16035
Trp Ile Lys 0.16529 5.59 5.43 0.00 0.00 0.00
M16425
Tyr Leu Arg -5.43620 0.00 5.00 0.00 5.51 0.00
M16306
Leu Pro Glu Ile -8.944962 6.14 5.75 5.55 0.00 0.00
M180346
Peptide-related metabolites were identified from polar extraction fractions by
LC-MS (TOF). ID indicates the database reference for the m/z (C: KEGG;
HMDB: Human Metabolome; M: METLIN). Next, is the sparkline and the
ppm difference (ppm) between the theoretical and observed masses. Folds
are expressed relative to 0% controls. All metabolites listed were significantly
changed from control, P < 0.001, ANOV A.
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Other Proteins and Related Compounds
Several other proteins and related compounds were identified, including urea,
carnosine, creatinine, crotono-betaine, aspidinol, ifosfamide, N -acetylleucyl-leucyl-
methioninal, and laserptin. Urea increased in the 0.03 and 1% ethanol
treatments to 5.25- and 5.84-fold greater than controls (Table 2.19. Carnosine
increased in the 0.01, 0.1, and 0.3% ethanol treatments to a maximum of 1.13-fold
controls. In the other two ethanol treatment doses, it decreased to –4.70-fold be-
low controls. Creatinine was not different in all ethanol concentrations
except 0.1 and 0.3% ethanol. At those doses it was 6.09- and 5.57-fold higher than
controls, respectively. The polar metabolite crotono-betaine was slightly
elevated with low ethanol doses (maximum of 1.49-fold controls in 0.03% ethanol).
At higher ethanol concentrations, it dropped to –4.63-fold lower than control. As-
pidinol was elevated slightly in treatment groups of 0.01, 0.03, and 0.1%
ethanol. In the 1% treatment group, aspidinol dropped to –4.60-fold lower than con-
trols. Ifosfamide was significantly higher in all ethanol treatment groups.
It was maximally 1.40-fold higher than controls. N -Acetylleucyl-leucyl-methioninal
was increased in all ethanol treatment groups except the highest. It was at
the highest level of 5.69- that of controls. In the 0.3% ethanol group it was decreased
to 5.07-fold of controls. Lastly, laserpitin was significantly decreased to –
4.34 in all ethanol treatment groups except the highest (1%), where it rose to 1.14-fold
higher than controls.
2.3.5 Carbohydrates
The polar metabolites included several carbohydrates. These included 3-hydrox-
yglutarate, 2-oxosuberate, 5-methylthio-d-ribose, (R)-(homo)2-citrate, N -acetyl-d-
glucosamine, fructoselysine, bis-d-fructose 2′,1:2,1′-dianhydride, 8-oxo-deoxy guano-
sine monophosphate (dGMP), and minosaminomycin. 3-Hydroxyglutarate
was present in the polar fraction (Table 2.20). It was elevated to 5.59- and 5.05-fold
in the ethanol concentrations of 0.1 and 0.3% ethanol. The metabolite 2-oxosuber-
ate was elevated in intermediate ethanol treatment groups at 0.03% or
higher, not exceeding 5.58-fold above controls. 5-Methylthio-d-ribose was
nearly the same as controls in the 0.01 and 0.03% ethanol treatments. At 0.1% and
higher, it was –5.07-fold lower than controls. (R)-(Homo)2-citrate was
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Table 2.19.
Other protein-related metabolites were identified within 10 ppm of their
theoretical m/z in zebrafish embryos exposed from 2–24 hpf to 0–1%
ethanol.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.01 0.03 0.1 0.3 1
Urea
HMDB00294 -6.12370 0.00 5.25 0.00 0.00 5.84
Creatinine
HMDB00562 4.51092 0.00 0.00 6.09 5.57 0.00
Crotono-betaine
C04114 3.20426 0.80 1.49 -4.63 -4.63 -4.63
Aspidinol
C10673 -3.97091 0.99 1.40 0.89 0.01 -4.60
Carnosine
HMDB00033 7.845857 0.63 -4.70 1.13 0.65 -4.70
Ifosfamide
C07047 -1.23219 5.75 6.21 6.44 5.74 5.36
N -Acetyl-leucyl-
leucyl-methioninal
C11292 -5.72657 5.69 5.40 5.50 5.07 0.00
Laserpitin
C09697 5.01042 -4.34 -4.34 -4.34 -4.34 1.14
Amino acid and related metabolites were identified from polar fractions by LC-MS
(TOF). Metabolite ID indicates reference database for the m/z (C: KEGG; HMDB:
Human Metabolome). Next, is the sparkline and the ppm difference (ppm) between
the theoretical and observed masses. Fold changes are expressed relative to 0%
controls. All metabolites listed were significantly changed from controls,
P < 0.001, ANOV A.
at a minimum 5.47-fold higher than controls with ethanol treatment, excpet at the
highest ethanol concentration, where it was similar to controls. The metabolite N -
acetyl-d-glucosamine was significantly higher by 5.84-fold at 0.1% and
5.32-fold at 0.3% ethanol concentrations, but was otherwise not different than con-
trols. Fructoselysine was not different in the 0.03 and 1%, but increased
in the 0.01, 01, and 0.3% ethanol treatments. It was 4.75-, 4.83-, and 5.78-fold higher
for these treatments, respectively. At 0.03 and 0.1% ethanol treatment bis-d-fructose
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2′,1:2,1′-dianhydride was 1.67- or 5.5-fold higher than controls, depending
on the retention time. It was not different than controls at other ethanol treatments
tested. 8-Oxo-dGMP was increased in all ethanol treatment concentra-
tions, peaking at 6.42-fold or 6.14-fold with 0.1% ethanol. Lastly, the metabolite
minosaminomycin was elevated only at the intermediate concentrations
of 0.1 and 0.3% ethanol.
2.3.6 Other Metabolites
Several other metabolites were identified in both the non-polar and polar fractions
(Table 2.3.6). In the non-polar fraction, dethiobiotin , a precursor to biotin
and metabolite of caproic acid, eluted at two different retention times, increasing
up to 6.16-fold higher in some ethanol treatment groups. A metabolite known to
be a cereal constituent, identified as α-bergamotenol , was significantly
lower, by nearly –6.55-fold, at 0.03, 0.3, 1, and 3% ethanol by nearly –6.55-fold.
Epoxymurin-A , previously reported as a molecule from plant bark, was
lower by –6.44-fold at 0.03, and 0.1, and 3% ethanol [75]. Several other metabolites
identified that did not vary significantly from the control group, including dl-threo-
1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (dl-DPPD) .
In the polar fraction, sodium bicarbonate levels were elevated ap-
proximately 5.21-fold above controls at 0.1% ethanol and higher. Dimethyl trisulfide
was increased to 1.03- and 0.23-fold higher than control with 0.01 and
0.1% ethanol treatments. At the other tested concentrations, however, it dropped
to –4.60-fold below controls. Also, 4-sulfobenzoate was increased with
0.01–0.1%, but was not different with 0.3 and 1% ethanol treatments. 3-Amino-4,7-
dihydroxy-8-chlorocoumarin increased with all ethanol treatment doses
except 1%. It peaked with 0.03% ethanol, but did not drop below 4.85-fold in other
doses. Trinitrotoluene was not different from controls for some ethanol
treatments, but was 5.67- and 4.78-fold higher than controls with 0.1 and 1% ethanol.
Metyrapol was elevated by 5.54- and 4.96-fold in the 0.01 and 0.3% ethanol
treatments only. Thysanone , previously reported as a fungally derived an-
tibiotic, was not different than controls at low ethanol doses, but was nearly two-fold
higher than controls at 0.1% or greater ethanol concentrations [76]. Ethylenedi-
aminetetraacetic acid tetrasodium salt (EDTA) was elevated with 0.1%
(6.12-fold higher) and 1% (5.54-fold higher), but was not different than controls in the
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Table 2.20.
Significantly changed carbohydrate-related metabolites were identified
within 10 ppm of their theoretical m/z in zebrafish embryos exposed from
2–24 hpf to 0–1% ethanol.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.01 0.03 0.1 0.3 1
3-Hydroxyglutarate
HMDB00426 -5.43985 0.00 0.00 5.59 5.05 0.00
5-Methylthio-d-ribose
C03089 -2.204442 0.53 1.05 -5.07 -5.07 -5.07
2-Oxosuberate
C16589 7.056471 0.00 4.97 5.58 5.06 0.00
(R)-(Homo)2-citrate
M71244 4.987315 5.47 6.20 5.70 4.73 0.00
N -Acetyl-d-glucosamine
HMDB00215 7.943374 0.00 0.00 5.84 5.32 0.00
Fructoselysine




3.46 ± 0.04 3.727828 0.00 0.00 5.61 0.00 0.00
6.76 ± 0.25 -1.187884 0.00 5.54 5.56 0.00 0.00
8-Oxo-dGMP
M62410
7.21 ± 0.21 -6.413025 4.96 6.38 6.42 5.73 6.29
8.10 ± 0.06 -0.415912 5.07 5.84 6.14 5.11 0.00
Minosaminomycin
M71965 -2.677195 0.00 0.00 5.82 4.88 0.00
Carbohydrate-related metabolites were identified from polar fractions by LC-MS
(TOF). ID indicates reference database for the m/z (C: KEGG; HMDB: Human
Metabolome; M: METLIN). Next, is the ppm difference (ppm) between the
theoretical and observed masses. Fold changes are expressed relative to 0% controls.
All metabolites were significantly changed, P < 0.001, ANOV A.
other treatment groups. Pyochelin was not different in the lowest ethanol
treatment, and increased by as much as 6.37-fold higher than controls in the 0.1%
treatments. Inosine 5’-monophosphate (IMP) was increased to 5.80- and
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4.62-fold higher than controls with 0.1 and 0.3% ethanol treatment, but otherwise
was not different from controls. Aspidospermine increased with 0.1% or
greater ethanol treatment and was not different at lower doses. It peaked at 5.70-fold
in the 0.3% treatment group. 3′-Hydroxy-5,6,7,8,4′-pentamethoxyflavone
was not different than control for 0.01, 0.03, and 0.3% ethanol. It was increased to
5.55- and 5.39-fold higher than controls with 0.1 and 1% ethanol treatments. Also
in the polar fraction, a flavonoid 8-prenylafzelechin 5-methyl ether was
increased at ethanol concentrations of 0.03% and greater. The metabolite increased
up to 5.66-fold of the control group. At only the 0.1 and 1% ethanol treatment was
devapamil different than controls. It was 4.85- and 5.59-fold higher in
these, respectively. Lastly, 3-geranyl-4,2′,4′,6′-tetrahydroxy-5-prenyldihydrochalcone
increased only at the 0.1 and 0.3% ethanol treatment doses to 4.83- and
5.64-fold greater than controls.
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Table 2.21.: Other metabolites were significantly changed in ethanol-exposed
zebrafish embryos.
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Sodium bicarbonate†p
M69461 6.702719 n/a n/a 0.00 0.00 5.21 5.05 5.62 n/a
Dimethyl trisulfide†p
HMDB13780 -6.195462 n/a n/a 1.03 -4.60 0.23 -4.60 -4.60 n/a
4-Sulfobenzoate†p
C02236 5.799689 n/a n/a 4.60 5.43 5.68 0.00 0.00 n/a
Dethiobiotin
C01909
14.49 ± 0.23 †n 2.862257 0.00 0.00 5.33 0.00 6.08 6.08 5.74 5.31
18.03 ± 0.13†n 2.502198 0.00 0.00 5.40 6.16 0.00 0.00 0.00 0.00
α-Bergamotenol†n
HMDB36402 -1.3520387 0.19 -1.01 -0.97 -6.55 -1.00 -6.55 -6.55 -6.55
3-Amino-4,7-dihydroxy-
8-chlorocoumarin†p
C12469 1.515869 n/a n/a 4.85 5.97 5.44 5.56 0.00 n/a
Trinitrotoluene†p
C16391 -6.512265 n/a n/a 0.00 0.00 5.67 0.00 4.78 n/a
continued on next page
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Table 2.21.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
Metyrapol†p
CID161210 -3.402502 n/a n/a 5.54 0.00 0.00 4.96 0.00 n/a
Thysanone†p
LMPK13030001 7.282023 n/a n/a 0.00 0.00 6.46 6.26 6.41 n/a
Ethylenediamine-
tetraacetic acid†p
C00284 -4.42123 n/a n/a 0.00 0.00 6.12 0.00 5.54 n/a
Pyochelin†p
C12037 -8.825212 n/a n/a 0.00 5.38 6.37 5.33 4.92 n/a
Inosine 5′-
monophosphate†p
C00130 C00130 n/a n/a 0.00 0.00 5.80 4.62 0.00 n/a
Aspidospermine†p
C09042 7.090012 n/a n/a 0.00 0.00 5.41 5.70 4.92 n/a
8-Prenylafzelechin
5-methyl ether†p
LMPK12020136 3.029517 n/a n/a 0.00 5.38 5.66 5.56 5.01 n/a
continued on next page
74
Table 2.21.: continued
Metabolite Sparkline Fold (Relative to 0% Ethanol)
ID ppm 0.001 0.003 0.01 0.03 0.1 0.3 1 3
3′-Hydroxy-5,6,7,8,4′-
pentamethoxyflavone†p
LMPK12111478 3.361368 n/a n/a 0.00 0.00 5.55 0.00 5.39 n/a
Devapamil†p




LMPK12120523 -5.225479 n/a n/a 0.00 0.00 4.83 5.64 0.00 n/a
dl-PPMPn
CID49837889 2.808495 0.21 0.00 -0.04 -0.22 -0.25 -0.05 -0.05 -0.29
Epoxymurin-A†n
C08484 0.498426 -0.06 0.44 -0.06 -6.44 -6.44 0.02 -0.72 -6.44
Zebrafish embryos were exposed from 2–24 hpf to ethanol at concentrations
from 0–3%. Metabolites were identified from non-polar (n) extraction frac-
tions using LC-MS/MS (Orbitrap) or the polar (p) fraction using LC-MS
(TOF). ID indicates the reference database used to identify the molecule us-
ing the m/z (HMDB: Human Metabolome; C: KEGG; LMPK: LipidMaps;
M: Metlin; CID: PubChem). Next listed are the sparkline and the ppm dif-
ference (ppm) between the theoretical mass and the observed mass. Folds
are listed for each ethanol concentration tested and are expressed relative to
0% controls. dl-PPMP: dl-threo-1-Phenyl-2-palmitoylamino-3-morpholino-
1-propanol. † : P < 0.001, ANOV A.
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2.3.7 Ingenuity Pathway Analysis®
Ingenuity Pathway Analysis®(IPA) was utilized to identify relevant pathways
changed with the ethanol exposure. In the non-polar metabolome, due to the lev-
els of the non-polar metabolites tetradecanoic acid, palmitic, and stearic acids, lipid
metabolism was ranked highly in IPA. Relative to controls, the increases at 0.03%
ethanol treatment of palmitic, stearic, and tetradecanoic acids are associated with
the accumulation of diacylglycerol (DAG) (P < 0.001, where P-value reflects the
IPA generated association between the identified metabolite and a given pathway)
and synthesis of lipids ((P < 0.001)). The increases in palmitic and stearic acids
are also associated with accumulation and synthesis of ceramide, the conversion of
succinic and palmitic acids, the synthesis of d-erythro-C16-ceramide, localization of
triacylglycerides, and fat oxidation. Changes in the concentration of palmitic acid
were linked to toxicological functions, including renal and liver necrosis /cell death
as well as cardiac dysfunction. Increases in palmitic acid were associated with apop-
tosis of renal podocytes (P = 0.008) and proximal tubules (P = 0.008), as well as
dysfunction of cardiomyocytes(P = 0.011). Additional identified fatty acids asso-
ciated in IPA with other pathways. Increases in tetradecanoic, palmitic, pentade-
canoic, and stearic acids were all associated significantly with the quantity of Ca+2 in
cell signaling, vitamin and mineral metabolism, and molecular transport. Increased
stearic acid as well as decreased palmitic acid have been associated with apopto-
sis of hepatocytes (P = 0.003). Stearic and palmitic acids were also associated
with canonical stearate biosynthesis I pathway changes. Tetradecanoic, palmitic, and
stearic acids decreases were associated with the transport of d-glucose and the oxi-
dation of glucose–6-phosphate (P < 0.001); however tetradecanoic and palmitic acids
molecules were generally increased in our analysis studies (P < 0.001). Increases
in these molecules are associated with transport of d-glucose (P < 0.001). These
pathways were associated predominantly by tetradecanoic acid, palmitic, and stearic
acids.
Analysis of the polar metabolite data identified 221 metabolites, 45 of which were
mapped in IPA. The highest rank pathways identified were cell signaling, molecular
transport, and vitamin and mineral metabolism. This was due to the presence of
carnosine, dihydroxyacetone, kynurenic acid, purine, tretinoin, and urea. Carbohy-
drate and lipid metabolism as well as molecular transport was indicated by the in-
creases of dehydroxyacetone, kyurenenic acid, urea, tretinoin, and decreases in carno-
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sine (P=0.029, 0.047, 0.047, respectively). The increases in metabolite kynurenic acid,
treatinonin, and purine and the decrease in carnosine indicated cell-to-cell signaling
(P=0.042), nervous system development and function (P=0.047) as an important
pathway in the ethanol-exposed embryo. Due to the increases in urea, ifosamide,
and tretinoin, dermatological disease was indicated (P=0.003). Tissue development
was indicated with increases in tretinoin and kynurenic acid and the decrease in
carnosine (P=0.033). Decreased carnosine and increased tretinoin indicated toxico-
logic abnormalities in renal cell death of kidney and tubular cells (P=0.038). In-
creases in dihydroxyacetone, urea, and tretinoin, and decreases in carnosine were
associated with small molecule biochemistry (P=0.047), specifically synthesis of ni-
tric oxide (P=0.008). Hematological system development and function was indicated
by increases in N -Ac-leucyl-leucyl-methionial, tretinoin, and kynurenic acid as well
as decreases in carnosine (P=0.038). Increases in tretinoin, urea, and ifosfamide
combined with decreases in carnosine (P=0.043) resulted in inflammatory response
being indicated by IPA. Lastly, Free radical scavenging was indicated by increases in





To compare the effects of different ethanol treatment concentrations on a ze-
brafish model of FASD, we analyzed the changes in metabolome for zebrafish em-
bryos treated from 2–24 hpf with 0–3% ethanol. We used LC-MS/MS (Orbitrap) to
measure non-polar changes and LC-MS (TOF) to measure polar changes. Metabo-
lite classes that changed significantly in the non-polar zebrafish fractions included
fatty acids, glycerophospholipids, sphingolipids, and other metabolites. These find-
ings were anticipated, as our extraction method should isolate non-polar metabolites.
Lipid metabolism pathways were ranked highly in IPA due to higher levels of tetrade-
canoic, palmitic, and stearic acids. As these are the predominant fatty acids of fish
and other animal fats, these findings were not surprising [65,77]. In the polar fraction
where 219 metabolites were identified, many were identified as synthetic compounds
or drugs (51). The remaining metabolites were lipids (57), proteins or amino acids
(48), ethanol metabolites (15), and carbohydrates (5). Forty-five metabolites were
mapped in IPA, which highlighted pathways of cell signaling, molecular transport,
and vitamin and mineral metabolism.
In our data set, many metabolites lacked consistent linear dose-response trends
over the concentration curves. Often they were highly altered relative to controls at
0.03% ethanol, having a hormetic response (U- or J- shaped dose response curve).
Similar results have been demonstrated in the morphologic profiling of several strains
of ethanol-exposed zebrafish, as well as human embryonic stem cells differentiated to
neural cells in culture [78, 79]. This might be attributable to a shift from apoptosis
to necrosis occurring at some intermediate (i.e. 0.03 to 0.1%) ethanol concentra-
tion. Capturing the physiological changes at that switch-point may be essential to
determining the type of intervention required for ethanol-exposed children.
What mechanisms are demonstrated in our data?
Part of the devastating effect of ethanol is that it alters multiple tissue types and
organ systems. Here we highlight changes supported by our metabolomics data in
the neural, cardiovascular, endocrine, renal, and placental systems, as well as impacts
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on cell function, enzymatic cofactors, and the general disease resistance in ethanol-
exposed embryos.
Zebrafish as our model
Fig. 2.5. Developmental comparison of zebrafish FASD model versus hu-
mans. In our experiment, zebrafish were exposed from 2–24 hpf to 0–3%
ethanol, indicated on the timeline as a blue horizontal bar. The blue arrow
indicates the time of zebrafish sacrifice. Eye icon: lens vesicle complete;
Open heart icon: beginning of heart development; Filled and checked
heart icon : completion of heart development; A: initial development of
arches; L: liver development begins; M: beginning of meconium produc-
tion; N: neural tube closure; N*: neural rod cavitation completed; S: first
somites appear
2.4.2 Ethanol Catabolism
Ethanol may be metabolized several ways that may result in small metabolites.
These small metaboblites are not expected to be present in our metabolome, however,
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we did find several metabolites that are related to ethanol catabolism (Figure 2.6). In
response to ethanol, alcohol is oxidized to acetylaldehyde via alcohol dehydrogenase
(ADH). This enzyme, mediated by the ethanol-inducible cytochrome P450 enzyme
(Cyp) 2E1, oxidizes the alcohol to form acetylaldehyde [9, 15]. Acetylaldehyde is
known to be a teratogen and has a much greater catalytic efficiency with acetylalde-
hyde than for ethanol [80]. Thus, production of acetylaldehyde during the catabolism
of ethanol has been proposed by many to cause FASD [81–83]. In adults, hepatic
ethanol breakdown by ADH occurs in the cytosol [9]. This is followed by microso-
mal oxidation to acetate by aldehyde dehydrogenase [9]. The acetate is converted to
carbon dioxide and water [9].
Prenatally, Cyp is at a very low abundance, only 25–50% that of an adult [15].
CYP2E1 mRNA expression has been detected on placenta, including that of non-
drinkers [9]. Liver microsomes can also eliminate alcohol, but they only function
between 12 and 27% that of adults [15].
It is worth noting that there are differences in the ADH present in zebrafish
and mammals. Both lineages contain ADH3, though it is hypothesized that the
acquisition of ADH1 occurred independently in these two genetic lineages. Further,
teleosts underwent a whole-genome duplication event, including the genes encoding
ADH. The result of these changes created the ADH variants 1A1, 1A2, 3H, 3L, while
humans have 1A, 1B, 1C, 2, 3, 4, 5. Mice and rats have H1, H2, H3, H4, H6A, H6B,
with the variant H5ps being present in mice and H5 occurring in rats [84].
Several known inhibitors of ADH were identified in the polar metabolome. N -Cy-
clohexylformamide uncompetitively inhibits alcohol metabolism by the enzyme ADH
II activity in mice [85, 86]. N -Cyclohexylformamide is also a competitive inhibitor
against acetaldehyde [85]. ADH2 requires NADH as a coenzyme, and interestingly
was elevated at the lowest (0.01%) and highest (1%) ethanol concentrations tested,
but did not appear different than controls in intermediate concentrations. (We noted
several nicotine-related metabolites changed in our metabolome as well, discussed
below.) ADH2 causes a reversible oxidation of ethanol, but has fairly low activity
as compared to the other 5 endogenous classes of alcohol dehydrogenases [87]. Like
cyclohexylformamide, octanoic acid is an inhibitor of mammalian ADH2 activity, able
to competitively inhibit octanol [87].
We identified acetamide, which increased significantly at mid- and higher-dose
ethanol concentrations. Although N,N -dimethyl acetamide has been detected in ex-
halations from rat models of chronic renal failure, we have identified no reports of
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Fig. 2.6. Ethanol catabolism of metabolites isolated from extraction
fractions of whole zebrafish embryos exposed to ethanol from 2–24 in
0–3%ethanol. Metabolite changes are indicated by sparklines.
81
acetamide generated with ethanol exposure [88]. However, given the polar nature of
this metabolite (C2H5NO), and that of ethanol, in conjunction with the structural
similarity of these two molecules, understanding acetamide formation may be valu-
able. This may be especially true in the context of the alterations noted in peptides
and proteins.
Also identified was S -methylthioglycolate (significantly differed from controls in
0.3% ethanol and higher), a derivative of acetate. The higher levels of this metabolite
suggest increased reactant acetate, as commonly reported by others in investigations
of FASD. In addition, our metabolome demonstrated significant differences in ace-
toacetate, which can react with ethanol to reversibly form both butyric and caproic
acids [89–91]. 2-Octanamidoacetic acid (capryloylglycine) is a fatty acid metabolite,
which varied little until concentrations of 1 and 3% ethanol, where they were nearly
6-fold lower than controls. While acyl glycines, such as 2-octanamidoacetic acid, are
common metabolites of fatty acids, they are also associated with inborn errors of
metabolism [92].
2.4.3 Nervous System
It is widely understood that ethanol alters the developing nervous system and
subsequent function and behavior. Here we will explore metabolome changes related
to this system. In particular we will address the relationship between glycerophos-
pholipids, sphingolipids, and tryptophan-related metabolome changes and their asso-
ciation with FASD.
Glycerophospholipids
The membranes of all cells, including neurons, are complex structures with high
phospholipid content, including glycerophospholipids. Some of these function as sig-
naling molecules, such as PA. Glycerophospholipids, including PS, PA, PE, and PI,
are modified with ethanol exposure and showed a variety of changes in our model.
Previous investigators have demonstrated changes the concentrations of glycerophos-
pholipids, indicating a shift in the degree of saturation as well as the length of the
phospholipids. In the male Sprague Dawley® rat forebrain, the makeup of glyc-
erophospholipids changed in response to chronic (three week) 5% ethanol. These
changes included a decrease in the degree of unsaturation of PS, an increased unsat-
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uration of PC, but brain PI composition was not significantly changed [93]. These
observations are consistent with much of our data.
Multiple abnormalities have been associated with alteration of PLD function,
including changes in PA signaling targets, astrocyte mitogenesis, myelination, and
astroglial migration (Figure 2.7). An overview of phospholipase D (PLD) in the brain
during development is available [94]. Changes in downstream PA signaling have also
been hypothesized as a result of the lack of normal PLD conversion of PC to PA.
We detected a variety of PA moieties that responded differently at differing ethanol
concentrations. A shorter, unsaturated PA moiety was significantly lower with higher
ethanol doses, and more saturated and longer PA moieties were higher than controls
with ethanol exposure. The longer, mixed saturation PAs tended to be significantly
higher at mid and high ethanol concentrations. The variety of PA responses de-
noted are likely from multiple ethanol-induced causes. These may include altered
enzymatic activity, such as inducing PLD to generate more PA from PC or instead
make phosphatidylethanol from PC. Changes in conversion of diacylglycerol to PA
by diacylglyerol kinase may also contribute to the inconsistent PA response we ob-
served [95]. It also may be due to changed needs structural components that can
be accommodated by PA, increased dihydroxyacetone conversion via lysophospha-
tidic acid, or there may be changed requirements or utilization of PA as a second
messenger.
Ethanol affects PLD in cells such as astrocytes and astroglia, and is altered in our
zebrafish embryo model of FASD. Based on data from neonatal rat astrocytes, ethanol
binds to PC, preventing the conversion to PA by membrane bound enzyme PLD [96].
In permeabilized astrocytes, this can cause a decrease in DNA synthesis [97]. PA
can also cause an increase in DNA synthesis, which is not sensitive to ethanol [97].
Physiologically, PA deficit can cause significant developmental defects, as alteration
of this signaling pathway can also prevent astroglial proliferation [95,97,98]. In whole
larvae Drosophila melanogaster extract, dietary ingestion of ethanol has been shown
to increase activity of PC-induced PLD [99]. These experiments provide support that
changes in PA, PC, and PE in our model are induced by ethanol-induced alteration
of PLD function.
PLD has both transferase and hydrolysis activities that require an activator. Of
the fatty acids that have been shown to be strong activators of PLD, the strongest
fatty acid activators appear to be lauric, palmitoleic, oleic, linoleic, and arachidonic
acids [100]. In our analysis of ethanol-exposed embryos, only palmitoleic acid was
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Fig. 2.7. Metabolites isolated from extraction fractions of whole zebrafish
embryos exposed to ethanol from 2–24 in 0–3%ethanol that influence the
nervous system. Metabolite changes are indicated by sparklines.
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significantly changed. It was significantly higher than controls at the 3% ethanol
concentration, where it was 6.12-fold higher. It is possible that it was consumed in
PLD activation at lower ethanol concentrations, but by 3% ethanol normal enzymatic
functioning had been interrupted, leaving additional palmitoleic acid present.
PA has numerous downstream functions such as membrane trafficking, signal
transduction, intracellular signaling, and protein kinase C activation [97,101]. Others
have demonstrated that ethanol also appears to increase triglyceride, diacylglycerol,
and fatty acid ethyl esters generated from PC [99]. One difficulty in understanding
the ramifications of changes in PA is that no clear binding site has been established
for its targets. However, it is understood that PA is a lipase product in the cell
membrane [102].
Another PA function of note is the regulation effects on sphingosine kinase 1(SK1)
[102]. Upon formation of PA by PLD in the lipid bilayer, SK1 translocates from the
cytosol to the membrane [103]. Then, SK1 phosphorylates sphingosine forming sph-
ingosine 1-phosphate, a polar G-protein coupled receptor substrate. (These receptors
are conserved in zebrafish [104].) We noted a significant increase in sphingosine with
ethanol treatment. The product, sphingosine 1-phosphate was not identified as a
significantly changed metabolite in our analysis, but is known to be an intracellular
second messenger and extracellular mediator, important for functions such as cy-
toskeletal rearrangements, control of growth, calcium mobilization, and cell survival
pathways [105–107].
In addition to the effects of PA via sphingolipids and cell signaling, PA appears
to be an important player in neuronal development via cytoskeletal reorganization
and neuronal surface enlargement via exocytosis of cytoplasmic vesicles [101]. Due
to its small, negatively charged head group in the phospholipid membrane, PA pro-
vides membrane flexibility, to a greater degree than other phospholipids, and attracts
positively charged molecules [101]. Conversely, ethanol has also been shown to cause
increase membrane fluidity [96]. Thus, ethanol-induced interruptions in PA also alter
physical structure of neurons.
Dihydroxyacetone is a monosaccharide that eventually can be converted to PA
or interconvert to glyceraldehyde [108]. It was marginally decreased at all concen-
trations, but was 5.45-fold lower than controls at 1% ethanol. Dihydroxyacetone
can be phosphorylated by dihydroxyacetone kinase, which can eventually become
lysophosphatidic acid and then structural PA [101]. We found PA moieties to gen-
erally be significantly increased with high ethanol concentrations. In conjunction
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with significant decreases in dihydroxyacetone, this could indicate that dihydroxy-
acetone available to support structural PA are depleted at the highest ethanol dose.
In essence, ethanol’s attack of membrane structure can no longer be overcome with
dihydroxyacetone conversion to PA.
In addition to its structural role, PA, via PLD signaling, is associated with neurite
outgrowth, so alterations in PLD function discussed above also alter normal neurite
outgrowth [101]. We also identified significant lowering of palmitoyl 3-carbacyclic PA
(CPA) at 0.03% ethanol concentrations and higher. This cyclic PA has neurotrophin-
like activity and can inhibit DNA polymerase, fibroblast cell proliferation, and Cdc25
phosphatase [109–111]. Further, CPA is neuroprotective, promotes neurite devel-
opment, and has been shown to decrease cell death in the adult male Wistar rat
hippocampus (CA1) after ischemic injury [109]. Thus, the large decrease observed at
0.03% ethanol or more might indicate a point of no return for the damaged neuron
or possibly the the onset of neuronal cell death. CPA is discussed further below with
respect to the cardiovascular system.
Bile acids have also been shown to activate PLD [96, 100]. The bile acid deriva-
tives 3α-hydroxy-6-oxo-5β-cholan-24-oic acid, 3α,7α-dihydroxy-12-oxo-5β-cholanate,
and (25S )-3-oxo-12β-acetoxy-cholest-1,4-dien-26-oic acid were present in our data
set. (Addressing possible functional differences between these bile acids is beyond
the scope of this article, rather they will be considered as a single class of molecule.)
These metabolites generally were increased at mid-range ethanol concentrations rel-
ative to unexposed controls. However, at the highest ethanol treatment, levels had
returned control levels. It is possible these bile salts are activating PLD, resulting in
the increased PA present in our data set. However, the amount of PC substrate did
not differ over the dose response curve of ethanol in our analysis. Thus, the substrate
source is unclear.
Insulin-like growth factor–1 stimulates rat astroglial PLD activity and mitogenesis,
which can be inhibited by ethanol or 1-butanol [112]. Others have demonstrated that
1-butanol is a substrate for PLD transphosphatidylation activities [113]. 1-Butanol
decreases the amount of PA formed via transphosphatidylation [112]. 1-Butanol is the
reduced form of butanal, a marker for oxidative damage to lipids, proteins, and DNA.
We saw significantly higher butanal at all ethanol concentrations tested, which may
indicate both oxidative damage to lipids, proteins, and DNA, as well as an influence
on PA levels.
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It is possible the increase we detected in PA is of a protective nature, in spite of
ethanol-induced decreases in PLD activity. In the presence of alcohol, PA is increased,
perhaps through increased DAG kinase activity or another mechanism besides PLD.
Further investigation is needed to understand if there are alternative enzymatic source
(beyond PLD) of PA increases when exposed to ethanol, such as via lysophosphatidic
acid acylation or by DAG kinase. In addition, further characterization is needed
regarding the changes in PA-related secondary signaling and cytoskeletal changes that
are occurring in our model. Also, whether this bile acid-induced PLD stimulation
is physiologically relevant or simply an artifact of using whole-embryo extracts is
unclear.
We did not identify phosphatidylethanol in our analysis. Under normal conditions,
PC is converted by PLD to PA. However, with ethanol exposure, PLD instead shunts
PC towards phosphatidylethanol, which occurs in most organs [96, 97, 99, 114–116].
This was surprising as several have suggested phosphatidylethanol as a biomarker for
FASD.
In addition to its role in the coagulation cascade discussed below, changes to
plasminogen maintaining reactions may be relevant to altered neural structural de-
velopment. Conversion of plasminogen to plasmin is activated by tissue-plasminogen
activator (tPA). TPA is activated by plasminogen activator inhibitor–1 (PAI–1). In
addition to mediating fibrinolysis, tPA also is important for neuronal structure me-
diation [117]. Ethanol exposure in neonatal tPA null mice appear to be protected
from neuronal loss in the cortex and thalamus as well as cognitive deficits in adult-
hood. This appears to be mediated by preventing normal NMDA receptor subunit
B2 induced apoptosis [118].
In rat primary cortical astrocytes, ethanol treatment dose dependently increases
tPA mRNA, and increases cellular and released tPA [119]. Ethanol also decreases
DNA methyltransferase and DNA methylation in the promotor region of tPA [119].
Ethanol has been shown in vitro to dose dependently inhibit carbachol-induced (ac-
tivates PLD in astrocytes) hippocampal neurite outgrowth, an effect attributed to
inhibition of astrocyte PAI–1 [120]. The abnormal neurite extension effect has also
been demonstrated in tPA knock-out mouse neuroprogenitor cells [117]. This may
suggest that even if low levels of ethanol and acetate are converted to caproic acids,
conversion to the epsilon amino form, this can be devastating in the neurite outgrowth
in the neonate.
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Saturated PI in our experiments also increased with ethanol treatment, while
less saturated forms decreased. The formation of PI is derived from PA. Under
ethanol exposure in neurons, this is known to be inhibited due to the formation of
phosphatidylethanol instead. Also, PI (4,5)-bisphosphate and PI (3,4,5)-triphosphate
levels decrease, which are both involved in cytoskeleton organization and intracellular
trafficking [121]. In addition, PI changes may be relevant to activation of various
protein kinase C isoforms, discussed below.
PE, while significantly different, was unremarkable in its change from the control
group when compared to other glycerophospholipid changes. This is noteworthy be-
cause of PE’s structural role in the neuron cell body, axon, and myelin. PE composes
as much as 43% of myelin in some species [122]. So, this could indicate triaging of
PE levels in attempt to maintain neural structures.
Our results demonstrate a mixed response of PS moieties to increasing concen-
trations of ethanol. There were increases in longer, more saturated moieties, but
decreases in in shorter and less saturated PSs. Alcohol decreases more unsaturated
PS moieties in subcellular fractions of synaptosomes, mitochondria, and myelin, and
to a lesser extent liver homogenate [93]. However, in hippocampi from Sprague Daw-
ley® rat embryos exposed to maternally consumed ethanol (up to 35% energy from
ethanol) from E11 to E18 ethanol exposure decreased 13 of 14 moieties of PS reported
as well as total PS; only 18:0/22:5 PS was reported as increased with ethanol expo-
sure [123]. This inhibition of PS accumulation is associated with neuronal apoptosis,
potentially due to decreased caspase–3 inhibition [123].
Sphingolipids
Another important lipid class identified in our analysis was the sphingolipids, a
group of molecules that have a variety of biological functions of cells, including as part
of membranes, and regulating growth, differentiation, senescence, and apoptosis [124].
We will focus here on the relationship between sphingolipids and the nervous system,
which impact astroglial migration, neurite outgrowth, myelin structure, and cell mem-
branes. Depending on the sphingolipid moiety, metabolites in this class tended to be
significantly higher at either mid-range ethanol doses or with all concentrations tested.
These results are consistent with findings in neonatal (days 5, 15, 21, and 30) c57BL/
6J mouse brains after a single 1.5, 3.0, and 6.0 g/kg (15.8, 31.6, and 63.2% ethanol)
dose of ethanol was given to their mothers during the third trimester [33]. These
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authors proposed that maternal ethanol increases offspring ceramide concentrations
by increasing serine-palmitoyl transferase activity resulting in de novo synthesis of
ceramide, rather than conversion from sphingomyelin via sphingomyelinase [33]. vi-
tamin K3 , which was significantly increased in our metabolome, has also
been shown in bacteria to activate serine-palmitoyl transferase [125,126]. Others have
shown in rat cerebellar granule cells that ethanol increased the rate of ceramide sph-
ingosine recycling for use by gangliosides (composed of ceramide, oligosaccharide, and
sialic acids that function in cell communication), as opposed to de novo ganglioside
synthesis [127].
Likewise, we did not detect sphingomyelin as a significantly different metabolite,
but our results show that at 0.01 or 0.03% ethanol and higher, ceramides, sphin-
ganine, and sphingosine are elevated. Additionally, vitamin D3 has been shown to
induce conversion of sphingomyelin to ceramide via sphingomyelinase activity. Pro-
viding promyelocytic HL–60 cells with vitamin D3 increases sphingomyelin turnover.
Two hours after treatment, ceramide levels remain increased, but then return to
baseline [128]. We demonstrated significant difference in four vitamin D metabo-
lites. Whether the ceramide increase in our metabolome is a result of greater stearate
supply, abnormal conversion from increased sphingosine, deficient sphingomyelinase
resulting in less utilization of ceramide for sphingomyelin, abnormal vitamin D levels,
or increased recycling of damaged neurons is unclear.
In addition to the transcription regulation functions of vitamin D discussed below,
vitamin D is essential in many capacities in brain development and normal functioning
related to neurite growth and regulation of nerve growth factor. Vitamin D has the
capability to pass through the blood-brain barrier [129]. The brain possesses P450 en-
zymes capable of converting the active form 1,25-dihydroxy vitamin D3 and then the
inactive 24,25-dihydroxy vitamin D3 (CYP27B1 and CYP24B1, respectively) [129].
In neural development, vitamin D3 also is involved in inducing neurite formation and
upregulating nerve growth factor (NGF) [130]. Adding 1,25-dihydroxy vitamin D3 to
cultured primary hippocampal cells results in increases neurite outgrowth [129]. Sub-
sequent to the 1,25-dihydroxyvitamin D3 stimulation of NGF in the Sall2 transcription
factor mediated promotion of hippocampal neurite outgrowth, ceramide formation is
induced; then ceramide binds to the p75 neurotrophin receptor [131–133].
Increases in ceramide is of great importance as it can lead to an eventual increase in
activation of sphingomyelinase causing additional ceramide accumulation. Ceramide
has also been shown to inhibit PLD, which consequently may have contributed to
89
the decreased levels of PA observed relative to controls [116]. Ceramide accumulation
with ceramidase activity, can lead to increases in sphingosine, as demonstrated in our
results, and result in consequent toxicity to neurons [134]. Additionally, sphingosine
can inhibit protein kinase C (PKC), as can ceramide when activated with the ubiq-
uitously expressed caspase–3 substrate prostate apoptosis response 4 [33,135,136].
Accumulation of DAG is biphasic [137]. Initially PI, via PI–4,5-bisphosphate
specific phospholipase C-mediated hydrolysis, can form polyunsaturated 1,2-DAG
[137, 138]. Then mono-unsaturated and saturated DAGs are then generated from
PC, via PLD’s dephosphorylation of PA) [137–139]. In conjunction with DAG, PS
can activate “novel” PKC isoforms present in the central nervous system (such as ε
or θ) [?,140,141]. Signaling functionality of DAG may be dependent on its fatty acid
composition. Polyunsaturated DAGs (those from PI) appear to activate PKC more
efficiently than mono-unsaturated or saturated DAGs, perhaps due to its receptor
affinity or possibly a physical alteration generated in the phospholipid bilayer that
allows improved PKC access [138,139].
Saturated forms of PI increased, but polyunsaturated ones decreased, as a func-
tion of ethanol in our experiments. We did not detect mono-unsaturated PI. This
may suggest decreased production of mono-saturated DAG, resulting in decreased
efficiency of PKC activation. PI-Cer can result from a reaction between ceramide
and PI. In spite of increases in other ceramides with increased ethanol concentra-
tions, PI-Cer was significantly decreased at very low doses of ethanol. These results
show that PKC inhibition is relevant in FASD, due to the accumulation of inhibitors
sphingosine and ceramide and the increased in suboptimal saturated PI.
In a study of cultured cerebellar neurons from juvenile Sprague Dawley® rats,
incubation with 50 or 100 mM of ethanol for 48 hours followed by culture medium
resulted an apparent increase in the recycling of sphingosine [127]. This is inconsis-
tent with our results. Our data show that with increased ethanol dose sphingosine
was elevated, but we also saw its precursor/product ceramide increased. (Given that
the ceramide precursor sphinganine shows similar changes with ethanol exposure as
ceramide in our polar fraction samples, we are assuming the reaction between ce-
ramide and sphingosine favors sphingosine.) Thus, if increased ceramide contributed
to elevated sphingosine, the consistent, elevated levels of sphingosine would be a
result of the increased ceramide. However, at lower doses, sphingosine is elevated
when ceramide is not, which at that concentration may be consistent with increased
recycling.
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In SH-SY5Y neuroblastoma cell culture, neutral ceramidase, an enzyme critical for
control of ceramide turnover, has been shown to be downregulated (mRNA, protein,
and enzymatic activity) during all-transretinoic acid induced neuron differentiation
[142]. This occurs without a change in the level of sphingosine or sphingosine–1-
phosphate [142]. The significant increase in sphingosine in conjunction with the
biphasic dose response of retinoic acid may result in abnormal neuron differentiation.
Myelination
Sulfatides, a class of sulfoglycosphingolipid, play a role in a variety of immune
system responses, insulin secretion, hemostasis, and thrombosis [143]. They compose
∼4.4% of myelin lipids (Sprague Dawley® , dry weight) [143, 144], and function as
a negative regulator in oligodendrocyte differentiation [143, 145], as well as influence
myelin stability [143, 146]. Schwann cells appear to have myelin formation initiated
in part by sulfatide [143, 147]. Sulfatide is a myelin-associated neurite outgrowth in-
hibitor, which may contribute to axon regenerative failure [143, 148]. C22 sulfatide
was 6.25-fold lower than controls at both 0.001 and 0.003% ethanol levels, potentially
indicating a breakdown in myelin components. In addition, C20 sulfatide was re-
duced from controls in some treatments by 1.23-fold. These may represent important
alterations in metabolism, the nervous system, and cardiovascular system.
In addition to the effect of vitamin K on coagulation, discussed below, the el-
evation in vitamin K3 has important neural implications that remain
underexplored in FASD. Vitamin K plays essential roles in development, particularly
in the nervous system [126]. A case study of individuals with the congenital skeletal
dysplasia chondrodysplasia punctata were also associated fetal alcohol syndrome or
related vitamin K abnormalities [149]. In addition, vitamin K has been suggested to
provide an anti-oxidant benefit to Sprague Dawley® primary oligodendrocytes and
embryonic cortical neurons [150].
Lignoceric acid is converted to α-hydroxy fatty acids and ceramide in the brain
via α-hydroxylation, which is associated with myelination [151, 152]. The increases
we noted in lignoceric ceramide may suggest an increased myelin generation, poten-
tially as compensation for the decreased sulfatides. Our findings in sphingolipids and
sphingolipid-mediating metabolite levels suggest novel pathways in FASD that re-
quire further investigation. These include the relationship between myelin and other
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neural components, vitamins A and D, and newly associated sulfatides and lignoceric
ceramides.
Tryptophan
Tryptophan, the least abundant essential amino acid, is an important component
of proteins and normal functioning of cells, including neurons. It also is a precursor
of serotonin and nicotinamide adenine dinucleotide. Several tryptophan metabo-
lites significantly differed with ethanol treatment in our data set, including oxindole,
kynurenic acid, 7-chlorokynurenic acid, and uncaric acid (Figure 2.8). Additionally,
significant differences in vitamin D3 and glucocorticoid metabolites may also influence
the tryptophan related metabolites in ethanol-exposed individuals. Several studies
have suggested the increased conversion of tryptophan to nicotinic acid ribonucleo-
side is related to the changes occurring in response to pregnancy-related estrogen and
progesterone changes [153]. Therefore, related estrogen changes will be explored here
as well.
Serotonergic Changes Serotonin (5-hydroxytryptamine, 5-HT) is a tryptophan
metabolite recognized as being altered in FASD. Previously our colleagues have
demonstrated that mouse embryos from alcohol-exposed dams have decreased neu-
ronal migration or differentiation in 5-HT neurons originating in the midline raphe
of the brainstem and projecting to the dorsal and median raphe [41]. These effects
persist into adulthood of male offspring animals [40]. In addition, prenatal ethanol
exposure leads to persistent decreases in the number of serotonin immunoreactive
neurons in the brainstem of both males and females [154].
In a model of chronic, low dose ethanol exposure in pups of Wistar rat dams
fed 6.6% ethanol in drinking water, tryptophan hydroxylase immunoreactivity was
significantly increased in dorsal and median raphe nuclei. 5-HT was increased, but
not significantly in both nuclei [155]. While our metabolomics data does not address
specific alterations to serotonin synthesis or metabolism, our data does demonstrate
an ethanol induced effect. Tryptophan-related pathways outside of 5-HT are altered
in our metabolome, including indole and kynurenine metabolites. Increased synthesis
of these metabolites could explain the decrease in 5-HT related pathways, signaling,
and synthesis. In addition, changes noted in vitamin D related pathways also may
influence normal 5-HT function in ethanol-exposed individuals.
92
Fig. 2.8. Tryptophan-related pathway changes with metabolites iso-
lated from extraction fractions of whole zebrafish embryos exposed to
ethanol from 2–24 in 0–3%ethanol. Metabolite changes are indicated by
sparklines.
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Kim and coauthors showed that maternal ethanol consumption in Sprague Daw-
ley®rats leads to decreased 5-HT synthesis and expression of tryptophan hydroxy-
lase in the dorsal raphe, where cell bodies of most serotonergic neurons are and then
project to other parts of the brain. This result was more pronounced at 5 wks of age
compared to 3 wks [156]. Schneider and coauthors examined the effects of carrying
the gene (homozygous or heterozygous) for the short allele of 5-HT transporter pro-
motor region in rhesus monkeys exposed to alcohol during gestation. They found that
when mother rhesus monkeys were exposed to 0.6 g/kg/d during early (0–50 days)
or middle-late (50 to 135 days) gestation, these allelic carriers had lower levels of the
a 5-HT metabolite 5-hydroxyindoleacetic acid in cerebral spinal fluid when offspring
were 30 months of age. Homovanilic acid was also decreased at baseline in these test
groups as well [157].
Tryptophan hydroxylase gene transcription is activated by a vitamin D response
element (VDRE) [158]. The VDREs “on two different tryptophan hydroxylase genes
involved in serotonin synthesis . . . are functionally opposite to one another: one
of them induces transcriptional activation of tryptophan hydroxylase 2 (TPH2) by
vitamin D in the brain and the other induces repression of tryptophan hydroxylase
1 (TPH1) in tissues outside the blood-brain barrier or peripheral to the brain” [158].
Our metabolome demonstrates increases in vitamin D3 that occur with ethanol ex-
posure. Given the well-established links between serotonin system abnormalities and
behavioral and cognitive disruption, such as anxiety, aggression, impulsive behavior,
and learning and memory impairment, it is logical to associate serotonin malfunction
in FASD functional changes. “For example, polymorphisms in the serotonin trans-
porter gene have been linked to social behavioral defects including aggression, impul-
sivity, anxiety, psychopathology, and personality disorder. Experimentally lowering
brain serotonin levels in normal people has a wide range of behavioral consequences:
impulsive behavior, impaired learning and memory, poor long-term planning, inabil-
ity to resist short-term gratification, and social behavioral deficits characterized by
impulse aggression or lack of altruism” [159].
Patrick and Ames proposed a mechanism for the development of autism, empha-
sizing the relationship with fetal-maternal interactions influenced by vitamin D status
and how they impact changes associated with brain defects in autism spectrum dis-
order. While FASD and autism spectrum disorder are very different, both disorders
share some common features in presentation, such as diminished social and behav-
ioral function. The effect of a low vitamin D (<30 ng/mL) status in maternal blood
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causes increased activation of placental tryptophan hydroxylase 1, resulting in higher
concentrations of serotonin and lower amounts of indoleamine-derived kynurenine,
causing fewer Treg cells. The decreased Treg cells results in an autoimmune response
from maternal antibodies in the fetal brain and abnormal brain development [158].
In addition, Patrick and Ames hypothesize that diminished supplies of marine-
derived fats such as eicosapentanoic acid (EPA) and docosahexanoic acid (DHA), in
conjunction with low vitamin D, contribute to the abnormal regulation of serotonin
and thus associated behavioral abnormalities [159]. The association of DHA inad-
equacies in FASD has also been proposed by others [160]. Given the elevation in
vitamin D3 isoforms occuring with ethanol exposure in our experiment, it is possible
that the vitamin D synthesis from cholesterol has been upregulated in response to
alcohol. This could be an attempt to correct serotonin imbalance caused by increased
metabolism of tryptophan to the kynurenine pathway, rather than serotonin. This
hypothesis, on the surface, is contradicted by literature in rodents demonstrating
the vitamin D deficiency during gestation being causal for behavioral abnormalities
in later life as well as Kim’s findings of decreased tryptophan hydroxylase activity.
However, if one considers the Patrick and Ames hypothesis in the context of increased
levels of vitamin D in order to regulate the decreased level of serotonin induced by
ethanol, these ideas do not contradict each other, but rather suggests that there is
a feedback loop between the serotonin insufficiency and vitamin D regulation. Vi-
tamin D can activate tyrosine hydroxylase in the brain to stimulate the synthesis
of serotonin. EPA aids in the release of serotonin from the presynaptic membrane,
and DHA increases membrane permeability of the post-synaptic membrane of the
serotonin receptor [159].
In a dietary recall survey of South African mothers of children with FASD, DHA
and EPA consumption tended to be less than controls. Nearly all women consumed
less vitamin D, vitamin E, dietary fat, and cholesterol than the estimated average
requirement [161]. Additionally, zebrafish on a low vitamin E diet have reduced
polyunsaturated fatty acids [162]. We did not directly measure the effects of ethanol
on EPA or DHA in our zebrafish model, but that would be an important next step
in the examination of this hypothesis. We did, however observe significant decreases
in anandamide with increasing dosages of ethanol. DHA and EPA can be converted
to docosahexanoyl-ethanolamide and eicosapentanoyl-ethanolamide, respectively, and
these molecules as well as anandamide are endocannabinoids. Further details about
the relationship of endocannabinoids and FASD are beyond the scope of this article.
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Sex hormones also have an impact on 5-HT and ethanol’s effects. In studies
by Sliwowska, et al. in female rats, prenatal alcohol exposure (PAE) causes a de-
crease in the 5-HT immunoreactive brainstem neurons in the dorsal raphe (p=0.060).
Ovariectomization, which resulted in a significant decrease in the plasma estradiol and
progesterone levels, caused an even greater decrease of these neurons (p<0.018) [154].
In our dataset, 1α-hydroxyesterone, a metabolite of estradiol, was significantly higher
in mid-dose range levels followed by a return to baseline at the highest dose. Estra-
diol has relevant neuroprotective effects on 5-HT neurons, including promoting cell
survival, preventing cell death, and decreasing DNA fragmentation [163]. Exogenous
subcutaneous estrogen administration to ovariectomized control animals showed a
non-significant increase in the number of 5-HT neurons. But, PAE ovariectomized an-
imals that were estrogen-supplemented had a significant increase in dorsal (P<0.029)
and median (P<0.004) raphe 5-HT immunoreactive neurons, an effect that was ab-
lated by progesterone supplementation. However, alcohol exposed animals had no
difference in estrogen or progesterone levels without ovariectomization. Our results
contrast to Sliwowska’s findings in sham operated prenatal alcohol exposed rats. 16-
Dehydroprogesterone was also higher than control at most ethanol concentrations
tested as well. Our data showed similar responses, in that 16-dehydroprogesterone
was significantly higher in both mid- and highest-ethanol doses tested.
Previously, we have documented the disruption of the neural tube midline and
decreased brain size in mice whose mothers consumed alcohol. In addition, we have
shown that 5-HT production is disrupted in these offspring, which may be mediated
with activity-derived neurotrophic factor agonist peptide (Ser-Ala-Leu-Leu-Arg-Ser-
Ile-Pro-Ala) and to a lesser extent brain-derived neurotrophic factor (Asn-Ala-Pro-
Val-Ser-Ile-Pro-Gln) [164,165]. While our results in zebrafish embryos demonstrated
many peptide chains, those identified through our filtering and analysis process did
not align with fragments of these bioactive peptides. However, since we did not
attempt to examine all possible peptide sequences, it is possible we did not align our
peptide masses with correct amino acid sequences. It is possible that if these bioactive
peptides were endogenously produced in attempts to repair ethanol-induced damage,
the prolonged duration of our exposure would have caused the bioactive peptides to
be a limiting reagent in any such repair. Further investigation is needed to examine if
the peptide masses identified in our metabolome are important to the FASD etiology.
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Oxindole Oxindole, elevated approximately 5-fold or higher at most ethanol treat-
ment concentration, is a metabolite of tryptophan catabolism via indole production,
and may be produced in several tissues, including the brain [166, 167]. This is pro-
posed to occur in the intestine by bacterial tryptophanase and then oxidation of the
indole in mammalian tissues [167].
Oxindole contributes to a sedative effect, demonstrated both in animal models or
patients with acute or chronic hepatic impairment, correlating to declines in mental
and neuromuscular function in patients with hepatic encephalopathy [166,167]. It has
been shown to accumulate in the brains of rats with hepatotoxin thioacetamide or
galactosamine-induced liver failure, potentially relevant due to the associated neural
abnormalities [166]. In addition, plasma levels of the precursor indole have been shown
to be increased in the plasma of cirrhotic patients, especially those with associated
altered mentation (hepatic encephaly) [167]. And, oxindole has been shown to modify
the voltage-gated sodium channel function of neurons resulting in decreased excitation
[168]. In low doses, this metabolite can cause vasodilation, loss of muscular tone, and
decreased activity, but in higher doses it can cause coma or even death [168].
5-Hydroxyindole is also produced by tryptophanase’s catabolism of tryptophan
found in bacteria [169]. In rat pyramidal hippocampal neurons, addition of 5-hydroxyindole
causes modifications of both pre- and post-synaptic neurons’ potentials. On the presy-
naptic side, the time until the neuron fires after depolarization is reduced. At the
post-synaptic side, there is increased the amplitude of excitation potential and slowed
inhibition of the glutamate neuron [170]. The indole metabolite 5-hydroxyindole has
also been shown to cause release of glutamate via the selective activation of presynap-
tic α7 nicotinic acetylcholine receptors (α7nAchR), a process that can be negatively
modulated by kynurenine [171]. In addition, 5-hydroxyindole has an inhibitory ef-
fect on dopamine, noradrenaline, and acetylcholine receptors [171]. This change may
be relevant to the etiology of FASD, as increased oxidase activity generating oxin-
dole with ethanol treatment may indicate less indole available for 5-hydroxyindole
functioning.
Indoleacetylaldehyde The tryptophan metabolite (via indole-pyruvate) indoleacety-
laldehyde has been identified as a potential biomarker of prenatal alcohol exposure
in vitro. Ethanol-induced increases in indoleacetylaldehyde decrease tryptophan hy-
droxylase activity, thus may be the origination of increased kynurenine in neural
progenitor cells [79]. Palmer, et al. reported results of a metabolomics study using
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human embryonic stem cells, including embryoid bodies, neuronal progenitors, and
neurons at two ethanol doses (0.1 and 0.3% ethanol) [79]. Each cell type had a dif-
ferent metabolomic profile with “no significant features” common to the three cell
types; fifteen metabolites appeared to have a “dose response” [79]. They were able
to confirm four entities, including l-thyroxine, 5-methylthioadenosine, l-kynurenine,
and indoleacetaldehyde. Surprisingly, there was little overlap in the significantly dif-
ferent metabolites from their data and ours. This may be attributed to our analysis
covering such a wide range of alcohol doses as well as being whole-embryo extracts.
Additionally, they also reported significant differences from controls at both ethanol
treatments concentrations for methylated purine 7-methylinosine and succinyladeno-
sine, neither of which were present in our ethanol-altered metabolome. Unlike Palmer,
we did not identify a metabolite matching the tryptophan metabolite indoleacetalde-
hyde [79]. This is likely due to a limitation of the detection method used in the
non-polar fraction analysis, for which a 200 amu cut-off value was utilized.
Kynurenine Pathway Production of serotonin from ingested tryptophan accounts
for only 1% of the total tryptophan catabolism, with more than 95% catabolized in
the kynurenine pathway [153, 172, 173]. In our analysis, the kynurenine metabolite
kynurenic acid was identified in the 0.03% ethanol group, where it was elevated to
5.70-fold over control, but in other ethanol concentrations was not different from con-
trols. The significant difference in this metabolite with ethanol demonstrated in our
analysis supports the relevance of kynurenine-pathway changes to FASD biochemistry.
This increase in non-serotonin tryptophan catabolic products supports findings of
previous studies that demonstrated in 19- and 35-day old Sprague Dawley®offspring
of dams fed 6.6% (v/v) ethanol have decreased 5-HT motor neurons [174]. Similarly,
offspring of female Sprague Dawley® dams gavaged with 5.1 g/kg ethanol on E20
had decreased 5-HT neurons relative to dams dosed from E1–E20 [175]. E13 c57BL/
6 offspring of mice on a 4.49% (v/v) ethanol diet from E7 to E13 had significantly
reduced serotonin levels [176].
Enzymatic conversion via IDO Two enzymes are responsible for the rate-
limiting conversion of tryptophan to kynurenine. Indoleamine 2,3-dioxygenase (IDO)
converts indoles like tryptophan in the presence of oxide or superoxide to kynurenine,
functioning to open the indole ring of tryptophan [177–180]. IDO is expressed by
most organs, including the placenta [158, 179]. Tryptophan 2,3-dioxygenase (TDO)
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converts tryptophan (specifically) and oxide to kynurenine [181]. It is expressed in
the liver, but is absent or very low in the newborn [153].
IDO can be influenced by several factors, including nutrient levels and immune
system activation. In normal conditions, the rate of tryptophan degradation increases
due to immune-mediated activation of IDO with duration of pregnancy, with the
highest kynurenine/tryptophan ratio at birth [182]. IDO is “highly expressed in
the trophoblasts surrounding the developing fetus. This starves local immune cells,
conferring fetal immunotolerance and preventing rejection of the foreign fetus by the
immune system” [183]. This enzyme can also be stimulated by stress, high B 6, insulin
resistance or magnesium insufficiency [153, 184]. Lignans have been shown to limit
IDO activity and limit tryptophan catabolism, which has potential relevance due to
the lignans identified in our metabolome [177].
IDO plays an important role in the health of the cell. Outside of superoxide
dismutase, IDO is the only enzyme known to use superoxide as a substrate [180]. This
suggests that any alteration increasing the conversion of tryptophan to kynurenine
via IDO is limiting capabilities of the cell contributed by IDO.
Steroids and inflammatory cytokines such as interleukin-1β and interferon-γ are
also able to increase IDO, while TGF-β and IL-4 are able to decrease IDO in macrophage
or glial cells, thereby altering kynurenine products [180]. Increases in immune acti-
vation markers that occur concurrently with interferon-γ, tryptophan decreases, and
kynurenine increases, indicate the function of IDO, as opposed to TDO [182]. This
is considered by some to be an “anti-proliferative mechanism of monocyte-derived
macrophage and dendritic cells” [182].
IDO-activated tryptophan catabolism is a marker of several diseases, including in-
fection, malignant disease, autoimmune diseases, and neurodegenerative disease [182].
Diseases such as neurodegenerative diseases (Alzheimer’s, Huntington’s, and Parkin-
son’s), cardiovascular disease, and pregnancy can all cause tryptophan degradation
with immune system activation [182]. In addition, IDO is a useful biomarker of
several pregnancy or fetal problems, such as chorioamnionitis, spontaneous abortion,
and inborn errors of metabolism. Chorioamnionitis, an infection of the fetal-maternal
membrane, is associated with higher risk of preterm delivery, as is FASD. In an inves-
tigation of “sterile chorioamnionitis”, intra-amniotic interleukin–1 injection resulted
in a significant increase in immunomodulatory enzyme IDO [185]. In addition, in a
prospective study of healthy 5–9 week pregnant women undergoing elective abortions
or with a history of recurrent spontaneous abortion, levels of IDO normally found at
99
the placenta and decidua were significantly lower in women with a history of recur-
rent spontaneous abortions [186]. Lastly, in the inborn error of metabolism glutaric
aciduria type I, the deficiency of glutaryl-CoA dehydrogenase has been hypothesized
to increase IDO in macrophages and monocytes, resulting in an eventual increase
in quinolinic acid, resulting in antagonism of the NMDA glutamate receptors [187].
These examples of IDO as a biomarker support the importance of the kynurenine
pathway abnormalities in our metabolome.
Enzymatic conversion TDO Tryptophan 2,3-dioxygenase (TDO) is the heme-
containing enzyme that converts L-tryptophan to N-formyl-L-kynurenine. It exists
in low concentrations in the newborn and can be influenced by a variety of factors,
including several steroid structures [153,188].
TDO has been shown to be elevated in pregnant rats, but it is reportedly extremely
low in newborn animals and humans [153]. Thus, any changes in the kynurenine
pathway occurring via TDO would be maternally-derived alterations, initially, then
offspring. This may explain the increase and then sudden decrease in kynurenic acid
and 7-chlorokynurenic acid in our data, as our model system has finite ability to
provide resources. Stress due to lower concentrations may be handled by maternally
or the low amounts of embryonic enzyme. But, with higher enzymatic demands,
existing concentrations of the enzyme is exceeded. Because of the limitations of
TDO, there may be an increase in kynurenine 3-hydroxylase utilization, resulting in
the potential for 3-hydroxykynurenine and the resultant neuronal toxicity [179].
Steroids with glucocorticoid activity increase TDO, and TDO can be increased by
compounds containing the indole nucleus [153]. The opposite can be achieved with
injection of nicotinamide in rats, metabolites of which were significantly altered in our
model [153]. In assessment of human liver biopsy samples, hydrocortisone stimulation
caused an increase in TDO, leading Altman and Greengard to conclude “any form of
stress or treatment with a variety of drugs that act directly or indirectly to stimulate
the pituitary-adrenal system may also increase the level of [TDO]” [189]. Hydrocorti-
sone administered to normal male patients or benign prostatic hypertrophic subjects
also showed a significant increase in urinary excretion of kynurenine, kynurenic acid,
and other kynurenine pathway catabolites [153]. These studies support the notion
that stress, such as that which alcohol exposed zebrafish are subjected to, causes
additional catabolism of tryptophan via the kynurenine pathway.
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Due to the presence of a glucocorticoid response element on TDO [179, 190], the
metabolite 6-hydroxydexamethasone, present in our analysis, may be of particular
relevance. This metabolite was significantly higher at low concentrations of ethanol.
6-Hydroxydexamethasone is normally a metabolite of the synthetic glucocorticoid
dexamethasone, shown to be significantly more potent than endogenous cortisol, so
its presence in our analysis requires further investigation.
In addition to glucocorticoid-response changes, estrogens have been shown to in-
duce TDO in vivo [153,191]. In addition, peri- and post- menopausal women adminis-
tered estrogen in conjunction with tryptophan show no increase in urinary kynurenic
acid, suggesting that estrogens inhibit TDO [192]. In our metabolome, 1α-hydroxyes-
terone was significantly different, elevated at all ethanol concentrations tested until
the highest dose, suggesting TDO may be decreased by 1α-hydroxyesterone.
Kynurenic acid Once L-tryptophan has been converted by IDO or TDO to L-
kynurenine, kynurenine aminotransferase enzymes are able to convert it to kynurenic
acid. Kynurenic acid is an astrocyte-derived neuromodulator and neuroprotector
[193, 194]. Most brain kynurenine metabolism occurs in the glial cells [195]. It can
be formed by oxidation of tryptophan residues in close proximity to heme or copper
binding sites [196]. Kynurenine metabolism can also occur in astrocytes, converted
by kynurenine aminotransferases and vitamin B6 to kynurenic acid, which can then
be converted to quinolinic acid [195]. Kynurenine is actively transported into the
brain, but most kynurenine catabolites, such as kynurenic and quinolinic acids are
poor at crossing the blood brain barrier [197,198]. Because of this, it is hypothesized
that these catabolites must be made in the brain [198], and the regulation is largely
enzymatic [195].
Before birth, kynurenic acid levels increase, and then on the day of birth decrease,
changes which are suggested to reflect neuronal plasticity [172,199,200]. Fetal astro-
cytes contain most enzymes of kynurenine pathway, with the exception of kynurenine
3-hydroxylase, which is hypothesized to provide a protective mechanism in the devel-
oping brain from damaging quinolinic acid-induced NMDA synthesis [180].
Kynurenic acid acts as an antagonist of the nicotine cholinergic (α7nAchR), glu-
tamate receptors, as well as the glycineB site on N -methyl-d-aspartate (NMDA) re-
ceptors [179, 180, 194, 201]. Kynurenic acid has been shown to inhibit the permis-
sive effect of 5-hydroxyindole on the α7 nicotinic acetylcholine receptors discussed
above [171]. Kynurenine also attenuates NMDA- or ischemia-induced brain damage
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in neonates [179], a protective effect that may be reduced with the ethanol-induced
mid-range increase in kynurenic acid shown in our data.
In adult male Sprague Dawley® rats, kynurenic acid applied extracellularly re-
versibly decreases GABA concentrations in a dose-responsive manner. 7-Chlorokynurenic
acid, which also acts at the glycineB site of the NMDA receptor, has no effect on
GABA [193]. We demonstrated the kynurenic acid catabolite 7-chlorokynurenic acid,
significantly decreased with ethanol treatment at all concentrations except 0.03%.
Additionally, we demonstrate that higher ethanol concentrations resulted in in-
creased vitamin D, potentially suggesting activation of some sort of protective effect
from alcohol. The increases in oxindole, another tryptophan catabolite (via indole),
during ethanol treatment may indicate indole that would otherwise be used in the
formation of kynurenine is not available with ethanol exposure. It also suggests that
additional tryptophan utilization of for indole generation with ethanol exposure in
the embryo likely limits its availability for protein and NAD and serotonin synthesis.
Others previously demonstrated that mid-range ethanol concentrations are associ-
ated with an increase in kynurenic acid, possibly through modification of kynurenine
aminotransferase [202]. But, at higher ethanol concentrations, additional dysregula-
tion occurs preventing the activation of the Treg cells that prevent fetal rejection [203].
Furthermore, stress alone affects this pathway. Notably, in tryptophan-infused
sheep with late-term chronically diminished placental blood flow, kynurenine is in-
creased in the fetal plasma to a lesser degree than demonstrated with tryptophan-
infusion alone [204]. Fetal brain levels show higher levels of kynurenic and quinolinic
acids with tryptophan infusion, but embolized placenta offspring had a greater amount
of these metabolites [204]. In addition, explants of placental villi from normal mothers
and mothers of small for gestational age babies, cultured in hypoxic conditions caused
a significant decrease in kynurenine, relative normoxic samples. Likewise, culturing
in hyperoxic conditions resulted in a significant increase in kynurenine [205]. These
observations support the notion that kynurenine is in essence a marker of oxidation,
emphasizing the importance of the lack of ROS protection in the fetus discussed
above.
Another kynurenine, 7-chlorokynurenic acid, was present in our metabolome.
Though this metabolite has only been described as a synthetic molecule, its changes
mirror in a reduced fashion what is happening with kynurenic acid. 7-Chlorokynurenic
acid has been shown in rat cortical slices to act as in antagonist to NMDA by binding
at its glycine receptor site [206,207]. This inhibition of NMDA was not reversible by
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the addition of additional NMDA, but was reversible by the addition of glycine [206].
Further, in 10-week old Sprague Dawley® rats, activation of the NMDA receptor
glycine site by the addition of glycine in the dorsal vagal complex results in a de-
crease in glucose production in the liver [208]. The antagonist 7-chlorokynurenic
acid, decreased production of glucose [208]. 7-Chlorokynurenic acid is more potent
and selective to the glycine binding site on NMDA than kynurenic acid [197]. These
studies support the importance of 7-chlorokynurenic acid in our metabolome, and
support the need for further investigation.
Quinolinic acid, an indirect metabolite of kynurenine via kynurenic acid, can pro-
mote NMDA activation of select glutamate receptors that can eventually cause exci-
totoxic neuronal death [179,209]. Accumulation of quinolinic acid occurs in neuroin-
flammatory diseases such as Alzheimer’s, cerebral malaria, poliovirus brain infection,
and ischemic brain disease [173,210–212]. This increased level of quinolic acid had a
strong correlation with upregulation of IDO as well as the severity of injury [211]. The
tryptophan catabolites 3-hydroxykynurenine, 3-hydroxyanthranilic acid, anthranilic
acid, and quinolinic acid were not present in our data set, likely due to their small sizes
being beyond the limits of detection in our assay. However, their potential impact
should not be ignored in future investigations.
Vitamin B6 in the form pyridoxal phosphate, is a limiting coenzyme for kynuren-
inase and cofactor of kynurenine aminotransferases. It was not identified as a signif-
icantly different metabolite in our experiments [153]. However, chronic alcoholism is
associated with low pyridoxal phosphate. Our model of chronic embryonic exposure
may similarly be taxing the zebrafish embryo. In addition, pregnancy can often result
in decreased levels of B6. This can have a marked effect on kynureninase levels. Thus,
diminished levels of B6 can result in increased levels of 3-hydroxykynurenine as well
as the neurotoxin xanthanurenic acid [153]. In addition, this potential increase in
xanthanurenic acid has implications on energy metabolism. This compound forms a
chelate complex with insulin and reduces receptor sensitivity of insulin receptors [213].
Interestingly, we also identified uncaric acid A elevated in the 1% ethanol treat-
ment group. This alkaloid has been reported to act as a kynurenine-3-hydroxylase
inhibitor, which if inhibited, could cause an excessive amount of kynurenine to be
present or cause an increase of tryptophan conversion to oxindole [202,214,215]. Un-
caric acid can inhibit IDO, potentially inhibiting the protective IDO-induced maternal
T cell fetal tolerance [203].
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In conclusion, at the highest ethanol concentration, levels of inhibitory uncaric
acid are quite elevated, potentially causing the reduction IDO activity and a result-
ing decrease in kynurenic acid and 7-chlorokynurenic acid at the same concentration.
This also might explain the increase in oxindole at the highest ethanol concentra-
tion, as tryptophan would be shunted away from kynurenine production. This could
affect the activation of Treg cells that prevent fetal rejection [203]. The decrease in
kyurenine catabolites at the highest concentration, however, may be due to increased
production of 3-hydroxykyurenine, which is known to cause neuronal cytotoxicity and
oxidative stress [179]. Quinolinic acid, another metabolite of the kynurenine pathway,
can cause NMDA activation of glutamate neuroreceptors as well as act as an endoge-
nous excitotoxin [179]. Our evidence supports the work of others that demonstrate
kynurenine pathway modifications are important in the pathways involved in FASD.
Further work is needed to fully understand the ramifications and possible biomarkers
of the kynurenine pathway.
Oxidative Stress
One hypothesis as to why alcohol is such a potent teratogen is that its catabolism
results in the formation of reactive oxygen species (ROS) [9]. Denham Harman orig-
inally put the concept of oxidative stress forth in the 1950s. Advanced as a “free
radical theory”, he hypothesized that endogenous oxygen radicals generated within
cells caused a net result of damage to the tissues. This concept of oxidative stress
is now believed to be largely associated with generation of oxygen radicals by mi-
tochondrial metabolism within the cell. The presence of acetylaldehyde in elevated
concentrations can lead to oxidative damage and the consumption of glutathione [9].
Further, it is the change in the cellular responses to the free radicals that is a major
regulator in the aging process throughout the body [216]. The damage caused by
free radicals can dramatically alter the composition and function of macromolecules
in the cell. ROS have the capability to alter lipids, protein, and DNA by the very
presence of the unpaired electron, which is relevant to brain-related changes in FASD.
Recent evidence has shown that abnormalities in sphingosine kinase, discussed above,
are associated with increased risk of spontaneous abortion. This appears to be due
to an increase in neutrophils followed by oxidative damage to the decidua [217].
Free radical damage has been advocated by many as an important mechanism in
FASD. ROS are generated during alcohol metabolism. Due to the early developmental
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stage of the fetus, free radical scavengers that would normally mediate the effects of
ROS are absent or insufficient to counteract threats [218]. Changes in acetylaldehyde,
butanal, carnosine, aspidospermine, anandamide, and tryptophan may support the
oxidate stress hypothesis of FASD.
Acetylaldehyde Butanal can inhibit PLD-induced mitogenesis, as discussed above.
The lack of ROS protection makes butanal a greater threat to abnormal PA signal-
ing. We show butanal is significantly different with ethanol exposure, which is likely
related abnormalities noted in PA levels in the embryo, and therefore PA signaling
functions. Other direct catabolites of ethanol have also been shown to influence as-
troglial cells. Acetylaldehyde in the presence of astroglial cells inhibits their growth,
and in conjunction with ethanol can increase superoxide dismutase [218,219]. While
increased SOD would be protective, the oxidative stress noted in FASD suggests that
such an increase would be sufficient enough to ameliorate the alcohol-induced distress
demonstrated in our model.
Carnosine Carnosine was identified in our polar metabolites with a biphasic re-
sponse. Such a response is common amongst other members of the vitagene fam-
ily, important to neuroprotective mechanisms [220]. It is synthesized in the brain
(glial and neuron) by carnosine synthetase, as demonstrated in Sprague Dawley®
rat olfactory glial cells in culture [220, 221]. Importantly in our model, carnosine is
neuroprotective against nitrosative and oxidative stress [220,222,223], functioning as
a “proton buffer, metal chelator, antioxidant, antiglycating, immunostimulant, anti-
tumoral and wound-healing agent” [220], and alters neuronal excitability due to zinc
and copper induced neurotoxicity [220,224]. Carnosine has been proposed as a treat-
ment for neurodegenerative disorders [220]. But, to our knowledge, it has not been
reported on for its role in FASD since 1981, when it was proposed to be relevant to a
50% decrease in fetal free plasma histidine demonstrated after maternal ethanol ex-
posure [225]. Given the significant decrease at mid- and high- ethanol concentrations,
this metabolite requires further exploration in its role in FASD etiology as well as a
potential intervention.
Tryptophan and Aspidospermine Other metabolites possibly changed via FASD
oxidative stress include tryptophan and aspidospermine. Oxidative stress may also
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play a role in tryptophan catabolism, as tryptophan’s aromatic nature makes it sus-
ceptible to oxidation to N -formylkynurenine [226].
In spite of the increased aspidospermine with mid-range and high
ethanol doses, relevance of this metabolite in our system is unclear. Aspidosper-
mine is an alkaloid known to be an inhibitor of Trypanosoma cruzi trypanothione
reductase [227]. Trypanothione (di(glutathionyl)spermidine)reductase is a protazoic
“NADPH-dependent flavoenzyme that helps fight oxidative stress by maintaining
adequate levels of trypanothione T[SH]2” [227, 228] It functions as a “glutathione-
glutathione reductase system in these parasites and appears to be involved in defense
against oxidants and some heavy metals” [228].
Oxidative Stress Resistance
Vitamin E In addition to alterations in metabolites associated with oxidative
stress, we noted changes in metabolites associated with mediation of oxidative stress.
Vitamin E is believed to function largely in an antioxidant capacity. Supplementation
with α- or γ-tocopherols to ethanol-exposed chick eggs prevents fatty acid changes
of membrane composition, brain mass, and brain protein levels [229]. 7′-Carboxy-
α-tocotrienol , in our metabolome, increased at mid-range ethanol doses,
while 9′-carboxy-α-tocotrienol generally decreased with ethanol. Because
of the opposite effect of ethanol on these metabolites, it is possible that the data
merely reflects a conversion between the two products, favoring the more saturated
hydrocarbon chain with increased ethanol doses. The overall increase in vitamin E
may suggest an increase in mechanisms which preserve fatty acid membranes and
brain composition.
N,N ′-Diphenyl-p-phenylenediamine N,N ′-Diphenyl-p-phenylenediamine (dl-
DPPD) has antioxidant and anti-inflammatory capabilities, and was ele-
vated approximately 6.1-fold in all concentrations tested [230]. The endogenous origin
of this metabolite is unclear. This metabolite has been shown to be well-tolerated in
adults, but negatively impacts pregnant rats. Individuals suffered from hypothermia,
decreased litter size, significantly prolonged gestation, dystocia, and even death [231].
In neonatal rat cardiomyocytes dl-DPPD has also been shown to reduce lipid per-
oxidation caused by oxidative stress [232]. In cultured, serum-starved rat cortical
neurons, supplementation with dl-DPPD significantly decreased the production of
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reactive oxygen species [233]. And, in cultured hepatocytes, supplementation with
dl-DPPD prevents ferrous, vanadium, and copper ion-induced lipid peroxidation,
protecting even more that α-tocopherol [234]. Similarly, dl-DPPD inhibited the lipid
peroxidation of rat liver microsomes incubated with ascorbic acid and ferric sulfate, as
well as protect enzymes (aldehyde dehydrogenase), from activation [235]. When ad-
ministered to rats, dl-DPPD does not cause an increase in ubiquinone, but has been
describe as having a protective effect on the levels of vitamin A, which is known to
influence ubiquinone levels [236]. These functionalities of dl-DPPD may contribute
to difficulties in elucidating FASD mechanisms.
8-Oxo-dGMP The mutagenic 8-oxo-dGMP was in-
creased in all ethanol treatment concentrations. This metabolite can be generated
through MutT Homolog 1 by binding to the nucleotide and hydrolyzing 8-oxo-dGTP
to 8-oxo-dGMP [237]. This is a mechanism that protects DNA from damage from
oxygen free radicals generated by mitochondrial oxidation. The significant increase in
8-oxo-dGMP supports the commonly held belief that ethanol exposure is increasing
oxidative stress in FASD, and that the embryos is compensating for this.
Other
Anandamide Anandamide and PKC-related metabolites may also be releavant to
FASD nervous system changes. Astroglial cells are important support neurons in the
nervous system. Astroglial cells perform support functions to other neurons, including
providing nutrients, supporting biochemical reactions and homeostasis, and repair of
damaged neurons. They also direct synapse formation, maturation, and elimination
by the secretion of chemicals that induce relevant changes [238]. Importantly for
lipid alterations occurring in FASD, this process requires cholesterol, which has been
shown to increase excitatory synapse formation in retinal ganglion cells as well as
influence pre-synaptic neurotransmitter release [238,239].
We demonstrated a significant decrease in anandamide . Others have
demonstrated that under acute ethanol exposure (0.75, 2, or 4 g/kg), anandamide
in Wistar male rats decreases (not statistically significantly) in the cerebellum, nu-
cleus acumbens and hippocampus [240]. Anandamide has been demonstrated to have
many relevant neurophysiological properties, including the ability to induce PLD in
some cell types [139, 241], modulate ROS production [242], and modulates both L-
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and T-type calcium channels [243]. Anandamide modulates intracellular calcium lev-
els via interacting with the cytosolic domain of the transient vanilloid receptor type
1 (TRPV1) channel protein [244]. Additionally, at low concentrations anandamide
prepares the mammalian blastocyst for implantation, however at high concentra-
tions anandamide alters calcium concentrations [245]. Thus, ethanol’s alteration of
anandamide, which must be narrowly controlled for successful implantation, may
contribute to decreased rates of successful pregnancy in alcohol-consuming mothers.
In astroglial cells in particular, calcium signaling is important in signal trans-
mission. However, compared to the dramatic changes detectable in neuronal action
potentials, calcium signaling in astroglial cells appears to occur at a much slower
and more difficult to detect (smaller potential difference) than in other neurons [246].
This implies it would take low levels of alteration of calcium signaling capabilities
to disrupt normal astroglial function and therefore synaptogenesis. Therefore, cal-
cium signaling interruptions caused by changes such as the significant decrease in
anandamide we demonstrated, could be an important astroglial change in FASD.
Protein Kinase C Membrane bound PKC is present in neurons, and in conjunction
with calcium may be activated by DAG and possibly PI-ceramide . PKC
in turn phosphorylates other proteins in astrocytes and responds uniquely to alcohol,
as compared to neuronal stem cells. In human neuronal stem cells, 10 mM ethanol
activates membraneous, but not cytosolic, PKC [247]. Astrocytes, in contrast, do
not show activation of membranous nor cytosolic PKC [247]. Upon stimulation with
25–200 mM of ethanol in LRM55 astroglial cells, PKC appears to translocate from the
cytosol to the membrane [248]. This change may precede activation of apoptosis in
response to the cellular damage [247]. However, PKC translocation acutely decreases
in “neurons, astrocytes, keratinocytes, lymphocytes, and platelets” in response to
ethanol as reviewed by Carter and Kane [249]. PKC and one of its substrates, growth
and plasticity protein–43, expression have been shown to decrease in response to
ethanol exposure in rat hippocampus. Further, it has been proposed that this is due
to the deficiency in PKCβ2 and PKCε translocation from the membrane surface of
hippocampal cells PKC, an effect that was statistically significant in animals that
underwent contextual fear conditioning [250].
In addition, ethanol appears to alter activation of targets downstream from PKC.
In cultured cortical astrocytes, “ethanol raises the set-point for basal [mitogen acti-
vated protein kinase (MAPK)] activity, thereby changing [Platelet-Derived Growth
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Factor (PDGF)]-mediated increases in MAPK activity into an antiproliferative sig-
nal” [251]. In the brains of ethanol-exposed adult zebrafish, MAPK-related changes
in microRNA occur [252]. In lysates from cultured guinea pig airway smooth muscle
cells, sphingosine, which was significantly increased in our metabolome, prevented
activation of MAPK and PKC [253].
2.4.4 Cardiovascular System
Myocyte Contraction
PKC is activated by calcium in order to induce excitation-contraction in the L-
type cardiomyocyte. (This type of channel is long-lasting, and passes calcium inward
in to the cardiomyocyte; it couples excitation-contraction coupling.) It may also be
activated by DAG and PI-ceramide . The latter is present at decreased
levels when zebrafish embryos are exposed to ethanol. This may be due to alcohol-
associated shunting of ceramide to sphingosine in conjunction with decreased PI.
Ceramide is a known inhibitor of PKC [136]. Perhaps as compensation, PKC activity
is acutely increased by ethanol [249].
PKC activation of myocyte contraction is regulated by phosphoinositol-3 kinase
(PI3K) signaling [254]. Ethanol can interfere with excitation-contraction coupling
through calcium loading and apoptosis in neonatal myocytes [255,256]. Interruption
of this pathway might be associated with persistent cardiac abnormalities in FASD.
PI3K also plays an important role in the movement of cells during gastrulation. In
response to chemoattractant gradient signals, PI3K localizes directionally with respect
to migrating cell [257]. In the zebrafish, gastrulation has been established as 5.25–10
hpf, during the window of our model’s ethanol exposure [258].
In addition to the neural-related functions of anandamide discussed above, anan-
damide can inhibit L-type calcium ventricular myocyte signaling [259]. The significant
decrease in anandamide at mid- to high-doses of ethanol suggest abnormal modulation
as a result of these alterations.
Minosaminomycin , originally identified as a mycobacteria antibiotic,
was elevated at 0.1 and 0.3% ethanol. A major component of this molecule is l-myo-
inosamine-1, which may be synthesized from d-inositol [260]. It is unclear what the
relationship is to ethanol-induced changes in our model or how it might relate to the
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overall etiology of FASD. However, PI-cer also contains a similar structure
and was significantly changed in our model.
In addition, pathways downstream of PKC are associated with FASD cardiovas-
cular abnormalities. PKC activates sphingosine kinase, which phosphorylates sphin-
gosine to form sphingosine–1 phosphate. Morpholinos generated with sphingosine–1
phosphate receptor 1 demonstrated a phenotype with similarities to FASD, includ-
ing global and pericardial edema and vascular abnormalities [261, 262]. Knockdown
of sphingosine–1 phosphate receptor 2 in conjunction generated even more severe
vascular anomalies as well as earlier death [261].
Many changes noted in our model support the notion that in spite of alterations
induced by ethanol, surrounding molecules are being modified to compensate for
ethanol’s effects on PKC activity or more broadly bioactive lipid functions. Increases
in palmitate metabolites may be to maintain PKC signaling induced by DAG, to
maintain levels of sphingolipid de novo biosynthesis, or as a result from reduction
of phosphatidylethanolamine to eventually generate palmitate [263]. It may also be
compensating for decreases in anandamide, which induces calcium signaling for PKC
activation. DAG may also be contributing to the increases noted in PA via conversion
by DAG kinase [95]. Further, levels of these products are innately disproportional
to each other, so small changes in one reactant may have a large impact, making it
critical to understand precisely what metabolites are acting as signaling effectors in
FASD [263]. The complexity and variety of bioactive lipid changes are important to
explore to understand cardiovascular etiology.
Lastly, diginatigenin is a cardiac glycoside previously identified in Digitalis lantana
[264]. Though it is unclear how this metabolite was generated endogenously, we
identified a significant change with ethanol treatment. It was increased in many
concentrations, but decreased greatly in the 0.3% ethanol treated embryos. Cardiac
glycosides inhibit Na+/K+-ATPase increasing cardiac contractility, as demonstrated
in human-induced pluripotent stem cells [265].
Vasculature
Many metabolites identified are associated with the cardiovascular system. In ad-
dition to the neural-related effects ethanol has on PA discussed above, there is strong
evidence that PA has a role in normal angiogenesis and cardiovascular function. In
our model, at 0.03% or more ethanol we observed significant lowering of palmitoyl
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3-carbacyclic PA (CPA) . This cyclic PA, as discussed above with respects
to its neural impacts, is a product of PLD and can also be produced via transpho-
sphatidylation of lysophosphatidylcholine by autotaxin in human serum [111]. CPA
is also produced by autotaxin in blood, which has also been linked to vascular devel-
opment in zebrafish [111]. CPA has also been reported as a bioactive lipid bound to
human serum albumin [110]. This suggests the significant lowering of CPA at 0.03%
ethanol and higher may exacerbate cardiovascular and circulatory abnormalities [266].
We also noted a significant increase in β-aminopropionitrile, an irreversible in-
hibitor of lysyl oxidase (LOX). LOX is expressed in healthy coronary artery endothe-
lium and in the nucleus of vascular smooth muscle cells [267]. In mice, LOX mRNA
is highly expressed in the developing cardiovascular system [268, 269]. Low-density
lipoprotein as well as β-aminopropionitrile inhibit this enzyme and alter normal mem-
brane permeability [267]. The inhibition of collagen cross-linking by β-aminopropioni-
trile has also been linked to reduced aortic stiffness in young SPF Wistar rats [270].
LOX downregulation in the lab mimics the atherosclerotic process observed in en-
dothelial dysfunction in cardiovascular disease [267].
Coagulation
Several metabolites related to coagulation were identified in our metabolome. Vi-
tamin K3 was elevated, inconsistently, with ethanol treatment. In 0.1%
and 1% ethanol treatments, vitamin K was 5.14 and 5.86 fold higher than control
embryos, respectively. Intake of vitamin K below adequate intake has been noted
as a nutrition deficit in individuals with FASD. In Western Cape Provence, South
Africa, as indicated in a 24-hour recall survey of mothers of children with FASD, as
compared to mothers of children without FASD [271]. In an analysis of 31 children
with FASD using parental 24-hour dietary recall, most children did not receive an
adequate intake of vitamin K [272]. Similar findings were made in a 24-hour dietary
recall of school-aged children with heavy FAE [273].
Vitamin K3 is a synthetic chemical that can be converted to vitamin K1 or vitamin
K2 (menaquinone) in the liver. In addition, vitamin K exists in the brain as meaquni-
none (MK–4), which is converted by a cellular, rather than bacterial process [126].
Reduced vitamin K hydroquinone functions as a cofactor for γ-glutamylcarboxylase.
It posttranslationally modifies certain proteins, most of which are involved in coag-
ulation, γ-carboxylating at specific glutamic acid residues [126,274]. As summarized
111
by Tsaioun, “the highly negatively charged [product] appear[s] to be involved in Ca+-
[2]-dependent phospholipid binding, necessary for the biologic activity of all the blood
coagulation factor” [274]. Vitamin K is rarely used in treatment of deficiencies due
to hemorrhage in infants resulting from difficulties in dosing (it has been linked to
brain damage and even death, among other symptoms) [130,149].
Two coumarin compounds were identified in our metabolome. Coumarins are
known to be vitamin K antagonists and anticoagulator [275]. Laserpitin
is recognized as a coumarin extract from Angelic keiskei plants, thus it is unclear
why it was present in our metabolome. It was significantly decreased in all ethanol
doses, except the highest. Nonetheless, this metabolite change may reflect a cau-
sation for cardiovascular abnormalities induced in FASD. This metabolite has been
shown to effect lipid metabolism. Six-week old spontaneous hypertensive rats fed a
diet with 0.1% laserpitin for 7 weeks demonstrated significant increases in serum total
cholesterol, phospholipid, and apolipoprotein E in low- and high-density lipoproteins.
There was a significant increase in 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase
mRNA and a significant decrease in H-triglycerides and peroxisome proliferation-acti-
vated receptor α mRNA [276]. In addition, 3-amino-4,7-dihydroxy-8-chlorocoumarin
was increased with all ethanol doses. This metabolite is recognized in
novobiocin synthesis, an aminocoumarin antibiotic. It is unclear why the directional
change of these two metabolites appears in opposition.
However, coumarins have been shown to significantly reduced sulfatides in 16-day
old male Swiss mice (ICR), an effect that was rescuable with vitamin K treatment
[126,277]. This occurs via inhibition of sulfotransferase activity [278]. We noted that
C20 sulfatide changed little from controls, but C22 sulfatide
was increased significantly with ethanol. Our findings suggest that ethanol may be
inducing a compensatory effect on vitamin K, which in turn supports maintenance of
sulfatide levels. However, the functional difference between sulfatides C20 and C22
in this model remain unclear, and should be further explored in the context of FASD
—perhaps they are related to the opposing coumarin effects noted above.
The electron carrier sulfated dihydromenaquinone–9 , was also identi-
fied as a significantly changed metabolite, decreased marginally with ethanol treat-
ment. The inter-relationship between menaquinone and sulfated dihydromenaquinone–




Several important components of the endocrine system were modified in our
metabolome, including sex hormones, the hypothalamic-pituitary-adrenal (HPA) axis,
and icosanoids. Numerous studies have documented differences in male and female
offspring responses to prenatal alcohol exposure. While the design of our study
does not allow for examination of direct effects between sexes, many of the changes
noted in our metabolome are relevant to exploring the nature of these differences.
Changes upon ethanol exposure in steroids related to sex-hormones were noted in our
metabolome, including significant decreases in 13-ethyl-16,17-dihydroxy-18,19-dinor-
pregna-4,9,11-trien-20-yn-3-one as well as significant increases in 16-dehydroproges-
terone, 1α-hydroxyesterone, and 13-hydroxy-3-oxo-13,17-secoandrost-4-en-17-oic acid.
These changes are consistent with previous studies reporting that pre-natal ethanol
exposure alters sex hormones in offspring. In normal metabolism cholesterol can be
converted in to pregnenolone, which is then converted to progesterone. This is then
converted to downstream products such as cortisol, corticosterone (and then aldos-
terone), or testosterone (eventually converted to estradiol). Although the role in
normal metabolism of 13-ethyl-16,17-dihydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-
3-one is unclear, the significant decrease in may suggest an increase in conversion of
pregnenolone to progesterone. This is supported by the increase in 16-dehydroproges-
terone which occurred with ethanol treatment. Previous findings of transient nuclear
progesterone receptor expression in the brain of developing rodents suggest that pro-
gesterone plays a role in normal cortical development [280]. Adult zebrafish express
progesterone receptors in all regions of the brain, and strongly in radial glial cells [281].
Further, ethanol alters the ability of cultured placenta cytotrophoblast cells to gen-
erate progesterone, potentially by preventing cholesterol from entering organelles,
perhaps highlighting a compensatory mechanism of the increased 16-dehydroproges-
terone, if also true in placentates [31]. In addition, 1α-hydroxyesterone is significantly
increased, supporting the notion of increased conversion of pregnenolone to proges-
terone. Serum hormone analysis of young male rats fed a 35% isocalorically-controlled
ethanol diet from postnatal days 35–99 show a significant increase of estradiol and
leptin, decrease in IGF–1, and no change in testosterone levels. In females, proges-
terone, insulin, and IGF–1 are significantly reduced [282]. (In this study progesterone
levels in males and testosterone levels in females were not reported.) Dihydrotestos-
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terone is known to be significantly decreased in the brains of 1–2 postnatal day male
Sprague Dawley® rats from dams given 35% isocallorically-controlled ethanol diet
for gestational days ∼16 and on [283]. 13-Hydroxy-3-oxo-13,17-secoandrost-4-en-17-
oic acid, common name testolate, is an androgen derivative that was significantly
changed with ethanol exposure in our metabolome. The relevance of this metabolite
is also unclear, but it can be derived from steroid-lactonase conversion of testololac-
tone, a progesterone derivative and steroid estrogen synthase inhibitor. Testolactone
can be synthesized from phytosterols [284]. The significant increase in this metabolite
may indicate decreased levels of estrogen synthase inhibitor, which may be related
to the significant increases in estradiol noted in ethanol-exposed offspring. Further
research is needed to understand the implications of the sex-hormone related metabo-
lites demonstrated in this metabolome.
HPA Axis
The ethanol-induced alterations of the hypothalamic-pituitary-adrenal axis has
been extensively examined [285]. As reviewed by Smith, et. al, during normal
metabolism, the periventricular nucleus of the hypothalamus releases corticotrophin-
releasing factor (CRF), which signals to the pituitary. The pituitary gland responds
with activation of cAMP signaling, which induces adrenocorticotrophic hormone(ACTH)
release into circulation. ACTH binds to a melanocortin receptor, stimulating gluco-
corticoid synthesis (generally cortisol and corticosterone) and release, which acts in
a negative feedback loop [286]. Glucocorticoids are produced in the adrenal cortex
and largely regulate carbohydrate metabolism. Glucocorticoid receptor trafficking
proteins are altered in prenatally alcohol exposed c57BL/6J mice, linked to frontal
cortical learning deficits [287].
Adult animals with prenatal ethanol exposure are hyper-responsive to handling
and chronic stress. Female Sprague Dawley® rats prenatally exposed to ethanol have
increased plasma adrenocorticotropin when subjected to repeated handling restraint
stress [288]. This was a persistent effect in middle-aged adult animals as well, and
appears to be associated with the increase in the basal levels of hypothalamic CRF,
in spite of the actual levels of cortisol and adrenocorticotropin hormone having no
difference between sexes, whether ethanol teated, pair fed, or controls [289,290]. This
work also demonstrated a sex-specific effect of cold stress on the HPA axis, showing
the ethanol-exposed males had higher hormone responses to cold stress [289]. Ad-
114
ditionally, prenatally ethanol exposed Sprague Dawley® rats also exhibit enhanced
ACTH sensitivity to increased NO levels in the brain, particularly in males [291].
Corticosterone is known to be significantly increased in the brains and plasma of
1–2 postnatal day Sprague Dawley® rats from dams given 35% ethanol diet from
gestational days ∼16 and on [283]. 19-Hydroxydeoxycorticosterone , or
the same m/z entity cortexolone, was 5.82-fold higher than controls at 0.3% ethanol,
but was not different from controls at lower ethanol concentrations. Cortexolone is
a glucoocorticoid, which when oxygenated can form cortisol. In intact or regenerat-
ing rat adrenals, 19-hydroxydeoxycorticosterone can be produced from progesterone,
which was significantly increased in our metabolome, or alternatively deoxycorticos-
terone [292–294]. Elevations in this metabolite may therefore suggest that in re-
sponse to moderate or higher ethanol concentrations the adrenal gland function has
been altered. In adrenal adenomas in humans and canines with Cushing’s disease,
a decreased responsiveness to ACTH has been documented in the release of steroid
hormones, such as progesterone. This has been suggested to be due to a blockade
of 11β-hydroxylase, which hydroxylates steroids at the 18-position to generate al-
dosterone [295, 296]. Interestingly, decreased cortisol levels in premature infants in
response to illness is hypothesized to be due to an immature response of this en-
zyme [297]. Thus, further investigation may be useful to understand the role of
11β-hydroxylase in FASD.
It is worth noting that there is some maternally derived cortisol in the yolk of the
zebrafish, and offspring cortisol does not increase significantly until after the embryo
hatches [298]. Little, if any, maternally-derived steroid acute regulatory protein or
11β-hydroxylase are present, though the latter does significantly increase prior to
hatching between 0–15 hpf [298]. Further, Alsop hypothesizes that the only after
hatching is the corticosteroid axis fully developed [298]. As discussed by Tokarz
and reviews referenced within, steroid synthesis in teleosts is largely controlled by
the hypothalamus-pituitary-interrenal axis and hypothtlamic-pituitary-gonadal axis,
taking place primarily in the gonads, brain, and interrenal gland (similar to the
adrenal) [299].
In our work, very low levels of ethanol result in a significant increase in 6-hy-
droxydexamethasone , but it was not different at mid- or high-ethanol
concentrations. Normally a metabolite of the synthetic compound dexamethasone,
this metabolite functions like cortisol as an anti-inflammatory and an immunosuppres-
sant [71,300]. Dexamethasone has been shown to act primarily on the glucocorticoid
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receptors in the pituitary, resulting in suppression of adrenocorticotropin hormone,
thus preventing subsequent production and release of adrenal cortisol [301]. Thus,
6-hydroxydexamethasone being elevated with low ethanol concentrations may indi-
cate cortisol levels are lowered by ethanol. Dexamethasone suppresses both resting
and stress-altered levels of the glucocorticoid corticosterone and ACTH in prena-
tal ethanol exposure [302]. Although the mechanism of endogenous formation of
6-hydroxydexamethasone is unclear, the changes in 6-hydroxydexamethasone, in con-
junction with the increase in 19-hydroxydeoxycorticosterone may suggest
that at low- to mid-range doses of ethanol an endogenous suppression of the gluco-
corticoid response element by 6-hydroxydexamethasone acts to prevent stimulation of
the HPA. However, at mid- to high-range ethanol concentrations the system can no
longer suppress pathological induction of ACTH-induced glucocorticoid release. Al-
ternatively, the increase in cortexolone may indicate a failure of the negative feedback
loop responsible for suppressing further CRF release from the pituitary.
Icosanoids
We identified several icosanoid metabolites, including anandamide (discussed fur-
ther below), a leukotriene B4 (LTB4), and prostaglandins. Associations between alco-
hol induced pathogenesis, including FASD, has long been associated with altered es-
sential fatty acid and prostaglandin metabolism, including increases in prostaglandin
E [303, 304]. 12-Oxo-10,11-dihydro20-COOH-LTB4 was greatly increased
in low concentrations of ethanol, but was not different from controls at moderate to
high ethanol concentrations.
Consistent with previous reports in the literature, we found several prostaglandins
significantly changed with ethanol exposure. These include prostaglandin G1
, 17-phenyl trinor-13,14-dihydro A2 , and 17-phenyl trinor E2 serinol amide
. We also identified 6-keto-prostaglandin F1α-d4 was significantly elevated
at mid-range ethanol concentrations and higher. It is unclear what the identity of
this metabolite is, as we were not using deuterated chemicals. The presence of this
metabolite, however, is consistent with findings that infants with fetal alcohol effects
excrete higher levels of 6-keto-prostaglandin F1α and its metabolite 2,3-dinor-6-keto-
prostaglandin F1α [305]. 6-Keto-prostaglandin F1α was increased in fetal, but not
significantly changed on maternal or fetal aspects of ethanol perfused human pla-
cental cotyledon [306]. Each of these metabolites demonstrated a profile similar to
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the 12-oxo-10,11-dihydro20-COOH-LTB4 in response to ethanol treat-
ment. The metabolite 17-phenyl trinor prostaglandin E2 serinol amide
was significantly increased at low ethanol concentrations. Prostaglandin E2 has a
variety of important functions, including inducing uterine concentrations, participat-
ing in platelet aggregation, maintaining fetal patent arteriosus, mediating portions of
the stress response, and can act in both pro- and anti-inflammatory manners [307].
It is known to be increased in uterine-embryo tissue of c57BL/6 mice after 5.8 g/
kg ethanol treatment [308]. Fetal sheep exposed to ethanol microdialysis have no
change on preterm or near-term plasma PGE, but mixed effects on cerebral cortical
PGE [309]. It is believed that ethanol enhances conversion of dihommoγ-linoleic acid
to PGE and thromboxane B2 [303,310].
(12S )-Hydroxy-16 heptadecynoic acid, elevated at intermediate ethanol concentra-
tions, can inactivate pulmonary Cyp4A4, which catalyzes ω-hydroxylation of prostaglandin
[311]. This may explain prostaglandin increases with mid-range ethanol doses noted
in our metabolome.
Melatonin, a tryptophan derivative, and its kynuramine metabolites inhibit for-
mation of prostaglandins in a dose dependent manner [180, 312]. Kynuramines may
also be formed from kynurenine or indoleamines [313]. We noted ethanol-induced
changes in kynurenine metabolites, as discussed above, which showed kynurenic acid
increased at mid-range ethanol doses, but otherwise unchanged from controls. While
at first glance these notions may contradict each other, the alterations may be due to
altered pathway shunting prior to kynurenine’s conversion to kynurenic acid, resulting
in a reduction in tryptophan-pathway related inhibition of prostaglandin synthesis.
2.4.6 Renal System
(12S )-Hydroxy-16-heptadecynoic acid is a hydroxylated, saturated
fatty acid that was elevated at intermediate ethanol concentrations. It has been
reported to have the capability to inhibit renal vessel vasoconstriction by preventing
arachidonic acid ω-hydroxylation [311].
In zebrafish, pronephros nephron morphogenesis is identifiable at 32–33 hpf, but
the rudiments are present as early as the 3-somite stage and identifiable at the 8-
somite stage [258, 314, 315]. The primary function of the pronephros in zebrafish is
osmoregulation, and early on are functionally limited. In spite of this, the pronephros
is considered a relevant model for the human kidney [315]. The pronephros duct is
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apparent at the 14-somite stage [258]. Vascularization and glomerular filtration occurs
as early as 36–48 hpf [314]. Thus, during the time of our ethanol exposure, increases
in intermediate ethanol concentrations may inhibit vasoconstriction via an increase
in (12S )-hydroxy-16-heptadecynoic acid.
2.4.7 Growth and Energy
Prenatal ethanol exposure has been associated with later-life changes in energy
metabolism, including weight gain, insulin resistance, and body weight. FASD-related
growth deficits are not recovered after pregnancy. In a follow-up study of mother-
child pairs, the reported pregnancy alcohol consumption was a significant predictor of
size [316]. This included levels less than one drink per day. Some have suggested this
is due to ethanol-induced hypothalamic oxidative stress and altered melanocortin
[317]. Studies have shown that 80% of individuals with in utero ethanol exposure
have decreased subcutaneous fat, congruous with abnormalities in energy production
[318]. Kaminen-Ahola, et al., have investigated ethanol-mediated postnatal growth
reductions in FASD. Pregnant c57BL/6J dams were provided 10% ethanol solution
until E8.5, and were then cross-fostered by control dams. (It is important to note
that this study was not matched with an isocalorically-controlled group.) In the liver,
they noted significant change in genes that encode hepcidin. Genome-wide association
indicated enrichment of genes associated with lipid metabolism (Grb10) and growth
(Vldlr, Pparg, Scp2, Nr5a2, Ehhadh, and Abcg5), amongst others. We noted changes
relevant to many of these altered genes in our metabolome.
Glycolysis and Gluconeogensis
Glucose regulation, glycolysis, and gluconeogenesis are important for normal growth,
development, and metabolism. Abnormalities in glucose metabolism have been widely
suggested as a causation for the reduced growth demonstrated in FASD. For example,
glucose turnover is significantly reduced in term Sprague Dawley® rats fed a diet
with 30% calories derived from ethanol [319]. The use of radioactive 2-deoxyglucose
suggests that placental transport of glucose is likely inhibited [28]. In gluconeogen-
esis, bicarbonate combines with pyruvate and ATP to generate oxaloacetate, ADP,
and inorganic phosphate. We noted significant increases in sodium bicarbonate at
mid-range and higher ethanol doses, which may support increased utilization of ATP.
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3-Hydroxyglutaric acid is known to accumulate in glutaryl-CoA de-
hydrogenase deficiency, which contributes to altered brain energy metabolism [320].
It is hypothesized to act as an “endogenous uncoupler of mitochondrial respiration”
resulting in a blockade of lysine and tryptophan catabolism [321]. The increases in
3-hydroxyglutaric acid at mid- to high-doses of ethanol may account for a portion of
the tryptophan- and lysine-related abnormalities in this metabolome.
In addition to the functions of CPA in neural and cardiovascular as-
pects discussed above, it is an antagonist of peroxisome proliferator-activated recep-
tor-γ, which coordinates fatty acid storage and glucose regulation [322]. The signifi-
cant decrease of CPA, even at low ethanol concentrations, may also have implications
for energy regulation in FASD.
The disaccharide fructoselysine was elevated at several of the ethanol
doses tested. Human gut bacteria can convert fructoselysine to butyrate [323]. 2-Ox-
osuberate is a precursor to coenzyme B in redox reactions in methanogens,
so the relevance of this significantly changed methane metabolite is unclear in this
model. However, like 2-oxosuberate, (R)-(homo)2-citrate also participates in coen-
zyme B synthesis, and was elevated at all ethanol concentrations tested except the
highest dose.
bis-d-Fructose 2′,1:2,1′-dianhydride increased at intermediate ethanol
concentrations. Because of the anhydrous nature of this metabolite, it may simply
be a product of ethanol acting on fructose. It may also signify an inhibition in the
ability to convert fructose in the liver to glycogen for storage or triglyceride synthesis,
or disfunction in glycolysis, which could contribute to abnormal energy regulation.
Fatty Acid Metabolism
Fatty acid oxidation is altered in FASD. For example, consumption of ethanol by
adult Sprague Dawley® intact male and female testosterone-treated offspring of dams
who had consumed ethanol has been shown to result in a significant increase in fasting
serum triglyceride levels as well as diaphyseal bone marrow triglycerides [?, 324].
Triglycerides are then hydrolyzed, forming free fatty acids that can eventually be
oxidized in the mitochondria.
β-Oxidation The quaternary amino acid carnitine predominantly functions in trans-
port of long-chain fatty acids into the mitochondria for β-oxidation. It is derived
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from N -methylated lysine [325, 326]. Sbriccoli, et al., have stated that supplementa-
tion with acetyl-l-carnitine mediates fetal ethanol exposure in Wistar rats, however
do not present data to support this [327]. Acylcarnitine, the transport form of fatty
acids, is generated by carnitine palmitoyltransferase-1, which conjugates the activated
fatty acid with carnitine. This is then translocated across the mitochondrial mem-
brane. In the adult ethanol-exposed Caenorhabditis elegans, carnitine palmitoyltrans-
ferases mRNA is slightly higher [328]. We noted increases in hydroxybutyrylcarnitine
and 2,6-dimethylheptanoyl carnitine , an acylcarnitine, were in-
creased with ethanol treatment. In addition, crotono-betaine , which was
significantly decreased in moderate to high ethanol doses, has been shown to undergo
reversible hydrolysis to form l-carnitine in Escheria coli and Proteus sp. [329,330].
Several metabolites identified in our metabolome are known to be associated with
other types of β-oxidation abnormalities. The unsaturated dicarboxylic acid cis-4-
decenedioic acid was elevated by as much as 5.94-fold relative to controls.
This metabolite has been associated with abnormal fatty acid oxidation due to de-
ficiencies in medium chain acyl-CoA dehydrogenase [331]. In addition, excretion of
acetoacetic acid can occur in instances of fatty acid catabolism errors [90].
Acetoacetic acid was increased with low doses of ethanol. This metabolite is a product
of acetyl-coenzyme A mitochondrial fatty acid β-oxidation in the liver [325]. Although
ethanol treatment did not statistically significantly alter it, 2-octanamidoacetic acid
(capryloylglycine) , at high ethanol concentrations it did fall below con-
trols by 5.98-fold. 2-Octanamidoacetic acid is the acylated, glycine form of octanoic
(caprylic) acid. While normally present as a metabolite of fatty acids, its presence
in excretion also occurs in an inborn error of metabolism in the β-oxidation of fatty
acids [332].
Fatty Acid Synthesis In fatty acid synthesis fatty acids are covalently bound
to acyl-carrier protein (ACP). We noted significant change in two ACP-bound fatty
acids, including trans-2-decenoyl-ACP and (3R)-hydroxy-dodecanoyl-ACP.
However, the response was not consistent between doses. Our results suggest abnor-
mal fatty acid synthesis and β-oxidation in FASD. Additionally, the fatty aldehyde
2-decene-4,6,8-triyn-1-al was increased in mid-range ethanol doses in our
metabolome. Fatty aldehyde dehydrogenase functions to convert fatty aldehydes to
fatty acids, suggesting abnormal fatty acid generation in FASD.
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8-Prenylafzelechin 5-methyl ether increased with most ethanol doses.
This metabolite is a member of the polyketide class, which are biosynthesized in a
similar manner as fatty acids [333]. However, polyketides are not produced by all
organisms, so the relevance is unclear.
16-Feruloyloxyhexadecanoic acid , previously reported as a plant ex-
tract, increased in all but the lowest ethanol concentration. It is generated by feruloyl-
CoA and 16-hydroxyhexadecanoate and belongs to the plant acyltransferase family.
While it is unclear why this metabolite appears in this metabolome, it is possible that
this is involved with the aberrant fatty acid metabolism noted in FASD.
Energy and Bile Acids As noted above, several bile acids were increased in our
experiment at mid-ethanol concentrations relative to unexposed controls, but not
at the highest ethanol treatment. Bile acids are formed through the oxidation of
cholesterol, so it is possible that increases in bile acids indicate that there has been
an increase in the oxidation of cholesterol as the concentration of ethanol increases.
At 42 hpf the liver primordium has begun development in the zebrafish embryo. Since
there is a limited amount of liver functional capacity at that time, increased bile salts
generated from cholesterol oxidation is sourced from the maternally-derived yolk sac.
Secondary bile acids, such as cholanoic acids, are formed by bacterial metabolism.
The key is the function of bile acids, which is in the digestion and absorption of
fats. Thus, the increased levels of bile acids in the zebrafish embryo may be an
attempt to increase lipid and energy supply of the compromised zebrafish embryo.
Importantly, bile acids have been recognized to have important functional roles as
signaling factors in regulating energy expenditure via G protein-coupled receptors,
regulating farnesoid X receptor binding that controls cholesterol metabolism, and
mediating glucose regulation via both types of receptor [334–336]. Given the variety
and significant changes in bile acids noted in our experiments, further consideration
of bile acid modification in FASD is warranted.
Other Cholesterol Derivatives Two other cholesterol metabolites were identi-
fied. (25S )-3-Oxo-12β-acetoxy-cholest-1,4-dien-26-oic acid was increased at interme-
diate ethanol does, and is known to have antihepatotoxic effects [337]. Mid- and high-
concentrations of ethanol moderately increased 3α,7α,12α-trihydroxy-5α-cholan-24-yl
sulfate, a steroid sulfate oxoanion. The functional relevance of the latter is unclear.
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4-Sulfobenzoate is present in some microorganisms, and is known to be generated
in Comamonas testeosteroni T–2. C. Testeosteroni is capable of growing on steroids
which are reversibly converted by α- or β-hydroxysteroid dehydrogenase to the ke-
tosteroid [338, 339]. The enzymes responsible for conversion of sulfobenzyl- alcohol
and sulfobenzaldehyde to 4-sulfobenzoate are classified as members of the short-chain
dehydrogenases/reductases family of enzymes, of which ADH in some species is in-
cluded [340].
Our findings demonstrate a variety of cholesterol-derived steroids are modified.
We must consider if there is a common lineage to these modifications, to determine
if a common alteration exists among them. After cholesterol is synthesized, Cyp
side chain cleavage enzyme acts on it to generate pregnenolone [299]. The steroido-
genic acute regulatory protein transfers it across the mitochondrial membrane [299].
“Downstream of the synthesis pathway, several enzymes modify the steroid nucleus
including side chain cleavage, D5/D4-isomerization, hydrogenation, and aromatiza-
tion. Other enzymes add and modify functional groups by hydroxylation, reduction,
or oxidation” [299]. In addition, we identified many metabolite previously recognized
only in plants or microorganisms. However, several of them, such as mugineic acid
and coumarin compounds, have structures reminiscent of cholesterol. It is possible
that these unusual compounds reflect the remains of destroyed cholesterol units.
Anandamide
Anandamide, as well as other fatty acid ethanolamides (FAE), function in a va-
riety of conserved signaling mechanisms regulating uterine blastocyst implantation,
feeding behavior, energy metabolism, and immune function [341]. Anandamide also
modulates growth and lipid metabolism, as demonstrated in the zebrafish, via sterol
regulatory element binding protein and insulin-like growth factors [342]. We observed
a significant change in the amount of anandamide present with even low
concentrations of ethanol, which further decreased with higher ethanol doses. This
is consistent with previous research demonstrating that acute intraparitoneal ethanol
administration results in significant decreases in anandamide in the brain [240]. En-
dogenous synthesis of anandamide has been demonstrated. PE is combined with sn-1
arachidonoyl phosphate by the calcium mediated N -acyltransferase. The resulting N -
arachidonyl PE is subsequently converted to anandamide, with the loss of PA [343].
And, acute ethanol administration had been shown to not inhibit either of these en-
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zymes [240]. Phospholipase C and α,β-hydrolase 4 can generate intermediates that
generate anandamide [344]. Interestingly, we noted a general trend of increasing con-
centrations of PA with mid- to high-levels of ethanol, suggesting anandamide is not
the source of the increased PA, or alternatively that anandamide is being consumed at
a rate greater than it can be generated, contributing to the rise in PA. Also, fatty acid
ethanolamine signaling is initiated by the high-affinity, reversible binding of bile acids
to membranous N -acylphosphatidylethanolamine-hydrolyzing phospholipase D [345].
The erratic response of bile acids to differing ethanol concentrations demonstrated
with our metabolome, may indicate alterations in this arm of anandamide signaling
as well.
Amino Acid Metabolism
Histidine Metabolism Histidine is important in the metabolism of several amino
acids, as well as the pentose phosphate pathway, and purine synthesis. N -ω-Acetyl-
histamine is an imidazole intermediate in the metabolism of histidine. Histamine
has a potent impact on gastric secretions, bronchial smooth muscle cell constriction,
vasodilation, and as a neurotransmitter [346–350]. This metabolite is known to be
present at high concentrations only the brains of poikilothermic vertebrates, such
as zebrafish [351, 352]. However, it was only significantly changed at 0.03% ethanol
and higher. Further investigation is needed to understand which this metabolite is
significantly higher with higher doses of ethanol.
In rats, chronic maternal alcohol exposure during gestation is associated with
increased levels of cerebral histamine and free histidine in fetal plasma in the off-
spring [225, 353, 354]. Histamine, a metabolite of histidine decarboxylation, was not
present in our data set. But, using an in situ hybridization of larval Turku strain ze-
brafish, Puttonen et al. showed that the histaminergic neurons were morphologically
unaffected by short duration (10 or 30 minute) exposure to ethanol [355]. However,
in 7-day old fish, a 10-minute ethanol treatment of 0.75% and higher resulted in a sig-
nificant increase in the mRNA of histidine decarboxylase, but levels of the histamine
neurotransmitter in whole larvae were unchanged with the ethanol treatment [355].
We did note a significant change in imidazol-5-yl-pyruvate , which was
increased at some ethanol concentrations, is a histidine metabolism intermediate.
l-Histidine may be converted to hercynine and then ergothioneine. Ergothioneine
may then be enzymatically converted to thionurocanic acid. In our experiments,
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this metabolite was elevated at the 0.1% ethanol treatment level or higher. While
not present in our data set, its predecessor, the amino acid ergothioneine, has been
reported to have antioxidant effects, including prevention of copper-induced DNA
and protein damage [356]. Ergothioneine is not produced by animals, but has been
reported in marine organisms. However, the increase that occurs with ethanol may
indicate increased enzymatic activity that is converting more ergothionine to thiouro-
canic acid.
Additionally, some labs have shown that ergothioneine can prevent the oxidation
of hemoglobin and myoglobin, again in contrast to copper [357,358]. Real-time PCR
has demonstrated high levels of the ergothioneine transporter in fetal liver and cord
blood CD71+ cells [359,360]. Ergothourocanic acid has also been shown to provide an
anti-inflammatory effect. In cultured C2C12 mouse myoblasts, palmitic acid reduced
cell viability, p38 and JNK phosphorylation, and IL–6 mRNA expression were all
significantly improved with ergothioneine treatment [361]. Neuroprotection has also
been associated with ergothiourocanic acid. Injection of ergothiourocanic acid pro-
vided to has been shown to prevent toxic over-stimulation of NMDA receptors [359].
It has shown neuroprotective effects against the chemotherapeutic cisplatin in CBA
mice [362]. A reduction in β-amyloid-induced apoptosis in rat pheochromocytoma
(commonly used for neurobiological cell studies) by ergothiourocanic acid has also
been demonstrated [359].
The increase in the thiouroncanic acid may indicate that ergothioneine originally
present in the embryo has been utilized with the ethanol exposure. As only the
higher levels of ethanol exposure resulted in an increase in thiourocanic acid, this
may indicate that metabolism is being shunted away from other histidine metabolites.
Less would then be available in the ergothioneine form to provide protection from the
copper-related oxidative damage.
Methionine Metabolism 5-Methylthio-d-ribose, a metabolite in the methionine
metabolism pathway, was significantly decreased with mid- or high-doses of ethanol.
This is consistent with previous reports of methionine metabolism changes. Embryoid
bodies derived from 0.1% or 0.3% ethanol-cultured human embryonic stem cells show
significant decrease of the precursor of this metabolite, 5′-methylthioadenosine [79].
Both of these products are metabolites of S -adenosyl-methionine (SAM), and occur in
preparation for methionine salvage. Additionally, response to methionine treatment
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of ethanol-exposed mouse embryos has been mixed, showing rescue of only some
non-neural malformations [363].
Pyrrolysine, Vitamin B12, and Folate
Pyrrolysine , the 22nd amino acid, is genetically encoded in some
methanogenic archaea and bacteria, including some strains present in the human
gastrointestinal tract [364, 365]. In our experiments, pyrrolysine was increased at all
ethanol concentrations tested. In a brief review on the subject, Krzycki discusses
that pyrrolysine is an alternative amino acid and one of 300 non-canonical amino
acids that often arise as a result of post-translational modification of standard amino
acids [366]. Like selenocystein, pyrrolysine is introduced through what normally is a
stop codon by a transfer RNA. Lysine, commonly a limiting amino acid of protein
synthesis, is believed to be the source of pyrrolysine, formed from two lysines residues
in a S -adenosylmethionine dependent process [367, 368]. Unique among amino acids
due to it’s electrophilic imine bond, pyrrolysine may function in the activation, ori-
entation, and transfer of methylamines to corrinoids, proteins that bind corrinoid
cofactors containing cobalt [366,368].
Cobalt toxicity is associated with hematological, endocrine, neurologic, reproduc-
tive, and cardiac effects in humans [369]. In zebrafish, previous studies have shown
that elevations in cobalt concentrations are associated with increased apoptotic gene
expression; concentrations of >100 µg/L copper or higher are associated with abnor-
malities including decreased rates of survival, increased morphologic abnormalities,
bradycardia, and decreased growth [370]. Cobalt ions also “inhibit nucleotide excision
and DNA repair by the inhibition of incision and polymerization” [370]. Thus the
increase in l-pyrrolysine shown in our metabolome could relate to increased cobalt-
bound corinoids that cause copper-associated teratogenicity.
Vitamin B12 Essential vitamin B12 has the most complicated structure of all vi-
tamins. It consists of three components, including the corrinoid structure, dimethyl-
benzimidazole, and associated amides. The complex structure is because of the corrin
portion, which is maintained in all human cobalamin transporters [371]. While there
are several different forms of B12 that vary in charge, the main form in plasma is the
protein bound methylcob(II)alamine [372]. Contained within the corrin structure is
a cobalt atom. The carbon-cobalt bond is a central building block of complex vita-
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min B12 structure, also known as cyanocobalamine [371]. This carbon-metal bond is
considered unique in nature.
B12 is made only by bacteria and can be provided through dietary meat, dairy,
and some seafoods [372]. A complicated uptake and metabolism has evolved for the
handling of B12. First, it requires intrinsic factor (IF) from the stomach parietal
cells to be bound to B12 in the lumen of the distal ileum. Only then can the intrinsic
factor receptor recognize it and transport it into the enterocyte. Eventually lysosomes
target the IF-B12 complex and break B12 off. B12 is then bound to transcobalamin II
(TC-II), where it is released into the plasma [372].
Tissue uptake of B12 requires the TCII receptor for transport to the cytosol.
There lysosomes reduce cobalamin to eventually form methionine synthase. The
folate-dependent methionine synthase has several functions, notably the catalyzation
of nitrous oxide to nitrogen, which can result in the destruction of the polypeptide
back bone and inactivation of enzymes [372]. In the mitochondria, it is also reduced
using cofactors. Eventually methylmalonyl-CoA mutase is formed, which is converted
to succinyl-CoA. This is they utilized in amino acid carbons and propionyl CoA, both
of which are consumed in gluconeogenesis.
Methyl B12 (methylcobalamin) functions as a cofactor to aid methionine syn-
thetase in the conversion of 5-methyltetrahydrofolate and homocysteine to tetrahydro-
folate and methionine [373]. Pre- or co-treatment of hybrid motor neuron-neuroblastoma
cells (NSC–34D) with methylcobalamin (but not methyltetrahydrofolate) provided
neuroprotection or neurorescue to homocysteine induced caspase–3/7 mediated apop-
tosis [374]. Methyl vitamin B12 has also been reported to inhibit the homocysteine-
induced activation of caspases 3 and 7, thus preventing the associated apoptosis of
motor neurons [374]. Thus the increased pyrrolysine may indicate an increase in this
anti-apoptosis activity.
Amongst complications of low B12, spinal column demyelination, peripheral my-
opathy, memory loss, and altered moods such as depression and anxiety have all been
reported [375]. Biochemically this deficit can also be associated with increased levels
of serum methylmalonic acid and total homocysteine [375]. Due to the large size of
the B12 complex, it does not fall within the scope of our assay parameters.
Folate and 2-Hydroxymethylserine Vitamin B12 and folate function coopera-
tively. While it has long been understood that ethanol ingestion alters levels of folic
acid, some effects of ethanol exposure have been shown to be ameliorated by the com-
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bined treatment of folic acid and B12. Cultured Balb/c mouse embryos treated with
both folic acid and B12 did not show growth and gross developmental deficiencies when
treated with ethanol [376]. The “ethanol-resistant” CD–1 mouse strain is protected
from developmental toxicity when treated with folic acid and B12 [377]. Also, folic acid
supplementation suppresses changes in microRNA, target genes, and tearatogenesis
that occurs in fetal mouse brains after prenatal ethanol exposure [378]. In addition to
the well-associated neural tube defects, spontaneous abortions, and decreased weight
and length of offspring have been reported [375]. Further, folate insufficiency limits
methylation as well.
2-Hydroxymethylserine was significantly higher than controls at inter-
mediate ethanol concentrations. This non-proteinaceous metabolite stabilizes oligopep-
tide complexes with nickel(II) and copper(II) ions [379]. 2-Hydroxymethylserine,
when combined with tetrahydrofolate, can be reversibly converted to yield 5,10-
methylenetratrahydrofolate and d-serine by α-methyl serine hydroxymethyltransferase
[380]. (A complete review of folate metabolism is beyond the scope of this arti-
cle, however folate deficiency is associated with neural tube defects in development,
decreased DNA synthesis resulting in megaloblastic anemia, placental abruption,
congenital heart defects, spontaneous abortion, stillbirths, and fetal growth restric-
tion [381].) Since this reaction is reversible, it is unclear whether the increase in
2-hydroxymethylserine suggests increased conversion from 5,10-methylenetratrahy-
drofolate or an increased supply of 2-hydroxymethylserine for conversion to 5,10-
methylenetratrahydrofolate.
This reaction is dependent on pyridoxal-5′-phosphate (vitamin B6). In conjunc-
tion with acetylaldehyde formed by ethanol metabolism, in alcoholic subjects there
is a phosphatase-dependent degradation of phosphorylated vitamin B6 that occurs
in erythrocytes, which may relate to altered α-methyl serine hydroxymethyltrans-
ferase [382]. Cytosolic α-methyl serine hydroxymethyltransferase acts as a metabolic
control, preferentially regulating synthesis of deoxythymidine monophosphate over
SAM, the primary methylating agent in all cells [383]. SAM is consumed by phos-
phatidylethanolamine N -methyltransferase, which converts PE to PC. PE was un-
changed from controls, however many downstream metabolites of PC were signifi-
cantly decreased (see above). This supports the notion that deoxythymidine is being
preferentially produced to supply needs for DNA synthesis, since it is possible that
SAM is unavailable for PE conversion to PC.
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Hemizygosity for the cytosolic α-methyl serine hydroxymethyltransferase is associ-
ated with Smith-Magenis syndrome [384]. Smith-Magenis patients frequently display
a broad flat midface, broad nasal bridge, diminished growth, as well as hyperactivity,
and self-destructive behaviors [385]. In addition, in an analysis of human placental
villus explants, hydroxymethylserine was significantly increased in tissues from small
for gestational age individuals when hypoxic conditions were simulated by changing
the oxygen from 6% to 1% (p=0.0010) [205].
Once converted to a coenzyme, folate functions to donate or accept one-carbon
moieties reactions related to nucleotide metabolism, amino acid metabolism, or as a
regulatory compound. Mitochondria provide most of the single carbons for these re-
actions. However, cytosolic serine (generated from serine hydroxymethyl transferase)
as well as histidine and purines (from 5,10-methenyl-tetrahydrofolate) can provide
these carbons as well [381]. Purine was significantly increased with most ethanol
doses. The purines adenine and guanine function as nucleic acids in DNA and RNA.
Inosine 5′-monophosphate (IMP) was increased at mid-range ethanol doses. It is a
purine nucleotide involved in purine and histidine metabolism and secondary metabo-
lite biosynthesis. It is unclear whether the metabolite changes noted here are due to
an increased supply of one-carbon moieties for metabolism or decreased demand.
However, if we assume that deoxythymidine is increasing, and we see that purines are
increased, this may suggest a deficiency in the mechanisms of DNA synthesis.
Ngai and colleagues recently published a study of one-carbon metabolism in dams
and fetuses of Sprague Dawley® rats. Their work attributes alterations in one-carbon
metabolism and the (implied) long-term programming to genes in the hypothalamic-
pituitary-adrenal axis. More work is needed in this area, however, as pair-fed fetuses
were not significantly different from ethanol treated fetuses in serum methionine con-
centrations [386].
Folate interventions have been proposed to mediate FASD. Ethanol appears to
interfere with the transport of N -5 methyltetrahydrofolic acid from storage [387]. In
addition, measurements of serum folate in maternal blood and umbilical cord blood
in chronic drinkers demonstrate decreased ratio of fetal:maternal folate, suggesting
fetal supply may be shunted to the chronic alcohol-exposed mother [388]. However,
conclusive studies still need to be performed. Our evidence supports folate abnor-
malities in FASD, and that these changes occur in absence of decreased nucleic acids
for DNA and RNA synthesis.
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Mechanistic Relevance The changes noted in pyrrolysine levels in our metabolome
could implicate several different alterations under the alcohol-exposed condition. It
is interesting to note the significant change that occurs across the ethanol treatment
concentrations. One possible source of the increased pyrrolysine is an increase in the
amino acid lysine. This could be due to the degradation of protein tertiary struc-
ture present in the sample, which in turn allows for increased pyrrolysine production.
But, given the importance of pyrrolysine in the orientation and transfer of the critical
cobalt atom to corrinoid B12 structure, it is also possible that there is an increased
demand for the cobalt of vitamin B12. However, one might expect more of a dose
response in this instance. An exception to this is if the demands of even our very low
ethanol concentrations required increased pyrrolysine-supplied cobalt for B12. This
theory is supported by existing literature that demonstrates amelioration of mor-
phological abnormalities with folic acid and B12 supplementation as described above.
However, since we are unable to evaluate the quantity of folic acid or B12 moieties
with this protocol, we cannot currently determine whether there is an increased de-
mand remaining at the ethanol concentrations utilized. Further work is needed in this
area to determine the roles of each of these important players and to understand how
pyrrolysine changes that have been shown here resolve with B12 and the documented
folic acid changes in FASD.
2.4.8 Morphology
Abnormal craniofacial morphology and neuronal cell migration occur in FASD
[389]. At 0.01% ethanol and higher, β-aminopropionitrile was 4.90-fold or
more than of control levels. This metabolite is a naturally occurring, toxic amino acid
derivative used in the manufacture of polyurethane foam, β-alanine and pantothenic
acid. With maternal occupational exposure, it has reported in case studies as being
associated with rare Cantrell-sequence birth defects. In addition to other severe
morphological abnormalities, children with this genetic defect have “anterior thoraco-
abdominal wall defects with ectopia cordis, and diaphragm, sternum, pericardium,
and heart defects” [390]. In this case, the premature infant had aplasia of the right
foot and femur, “aplasia of the right kidney, cerebellar hypoplasia, and aplasia of the
cutis” [390]. Craniofacial abnormalities including short neck, low-set ears, and cleft
palate were also present in this infant, who died at 2 days postnatally [390].
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β-Aminopropionitrile irreversibly inhibits LOX, thereby preventing normal cova-
lent collagen, elastin, and bone cross-linking of lysine and hydroxylserine [267, 268,
391]. LOX is “a copper-dependent amine oxidase that initiates the covalent cross-
linking of collagen and elastin. LOX catalyses an oxidative de-amination of lysine
and hydroxylysine residues to peptidyl α-aminoadipic-δ-semialdehydes” [267]. Some
research has been published linking the copper-dependent enzyme LOX and changes
as a result of alcohol consumption, but to date we have found no reports associating
LOX and fetal alcohol syndrome.
Rats fed a low-protein ethanol diet showed increased collagen deposition in the
liver, which correlated strongly with increased LOX [392]. While this initially may ap-
pear to contrast our findings, this could indicate that β-aminopropionitrile is present
in the alcohol treated animals and as a result LOX is upregulated to compensate for
β-aminopropionitrile′s inhibitory effects.
In zebrafish, LOX morpholinos show “mildly undulated notochord, truncated
anterior-posterior axis, tail bending and smaller head”, “a complete disorganization
of muscle somites and neural defects”, and “pigment defects and pharyngeal arch
deformities consistent with neural crest dysfunction” [393]. LOX is detectable at 3
hpf in zebrafish embryos, with a peak expression at 90% epiboly stage, indicating it
is maternally and zygotically expressed [393]. By 48 hpf, Reynaud and co-authors
saw expression predominantly in the central nervous system, eyes, pectoral fin, and
muscles [393]. They also noted frequent pericardial edema at 48 hpf and beyond in
morpholinos [393].
2-Mercaptopyridine-N -oxide has demonstrable LOX inhibitory capabilities, which
result in abnormal zebrafish notochord morphogenesis resulting in visible undulations
in the embryo’s notochord [394]. These abnormal notochord result in zebrafish that
look similar to copper deficient zebrafish, having a wavy notochord [395]. While
review of our own morphological experiments with alcohol did not reveal similar
patterns, this could be due to the concentration of 2-mercaptopyridine-N -oxide or
β-aminopropionitrile used in these experiments, which result in an inhibition of LOX
to a much greater extent than that in our experiments (Chapter 4). β-Aminopro-
pionitrile can be formed by the reaction of 2-aminoproprionitrile and ammonia at
70 ◦C to 100 ◦C in the laboratory [396]. However, how this compound is formed under
biological conditions such as that in our experimental design is unclear and will need
further investigation.
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In addition, IPA identified dermatological disease as significant due to the presence
of the significantly changed polar metabolites urea, ifosfamide, and tretinoin as well as
tissue development due to increases in tretinoin and kynurenic acid and the decrease
in carnosine. Soft tissue morphological abnormalities have are a key marker in the
diagnosis of FASD. A flat mid face with smooth philtrum, abnormal nasolabial fold,
abnormal genital formation, and reduced subcutaneous fat, and abnormal palmer
creases [318]. (These features are based in soft tissue disorganization rather than
epidermal diseases.) In addition, a few laboratories have reported an association
of ethanol exposure prenatally with different dermatoglyphics. These included a
decrease in whorls, increased ulnar and radial loops, and ridges as well as increased
asymmetry [397,398].
Dimethyl trisulfide , a volatile organic compound, was significantly
decreased with ethanol exposure. This pungent, malodorous metabolite is commonly
associated with tissue decay and fungating lesions. It is present in human feces and
urine [399, 400]. However, it is unclear why this metabolite is present, but possibly
may be due to tissue decay with the ethanol treatment.
2.4.9 Cellular and Molecular Mechanisms
Glycosylation
We noted changes in several metabolites related to glycosylation, including N -
acetylglucosamine, isoprenoids, and 2-(α-d-mannosyl)-3-phosphoglycerate. With mid-
range to high ethanol doses, N -acetylglucosamine was significantly in-
creased. N -Acetylglucosamine is used in co-/post-translational glycosylation, mark-
ing a glycoprotein for transfer to a lysosome, a secretory granule, or the cell membrane.
This metabolite binds to the nitrogen atom of asparagine in the rough endoplasmic
reticulum. In addition to directing cellular proteins, glycosylation is essential for nor-
mal protein folding as well as normal protein secretion, which has been shown to be
disrupted with alcohol exposure [401]. N -Glycans affect the solubility and thermal
stability (physiochemical) properties of proteins [402]. Glycosylation can also be used
as an indicator of zebrafish egg quality. α-1,3-mannosyltransferase ALG2 mRNA is
differentially expressed with differences in fish egg quality [403].
Theory of glycosylation as mechanisms of FASD was specifically proposed in 2011
by Binkhorst, et al., and findings from previous reports support this notion [48].
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Binkhorst, et al., noted a newborn with a history of maternal alcohol abuse and mor-
phological features consistent with FASD, congenital disorders of glycosylation screen-
ing results were temporarily abnormal (assumed to be a false positive) [48]. Ethanol
decreases the secretion of the sugar moieties used to glycosylate proteins [404]. The
sugar moieties used in these structures vary from prenatal, postnatal, and adult
ages [405]. Lastly, with ethanol exposure, tubulin secretion has been shown to in-
crease as much as 33% in neonatal rat livers, while the polymerization of microtubules
is diminished [404]. This has been attributed to abnormal glycosylation.
Like the decreased 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one
we noted in our metabolome, other isoprenoids are known to decrease with prena-
tal ethanol exposure and lipoperoxidative ROS [48]. Dolichols, polyisoprenoids that
occur in all eukaryotic cell membranes, are essential for N -glyosylation of proteins
(asparagine residues) in the endoplasmic reticulum, which has been shown to be dis-
rupted with ethanol [406]. Dolichol in blood and urine was proposed as an indirect
marker for chronic or long-term alcohol use (in spite of referencing a study that
marginalized its biomarker value) [51, 407]. Dolichol, while increased in urine after
long-term and binge drinking in non-pregnant subjects, was not different in pregnant
mothers of infants displaying FASD compared to normal infants [407,408]. However,
its involvement in FASD may still be important, as sufficient dolichol is required for
glycosylation to begin. In addition, in hepatocytes from rats treated with 6 mg/kg
of ethanol for 12 hours, there was a “significant reduction of the de novo synthesis of
both dolichyl phosphate and free dolichol” [406]. Measurement of malondialdehyde
levels demonstrating the amount of lipoperoxidation, significantly decreased dolichyl
phosphate and free dolichol [48,406].
After leaving the endoplasmic reticulum, proteins are transported to the cis- side
of the Golgi apparatus in vesicles. When they emerge from the trans- side of the
Golgi complex, proteins are sorted to lysosomes, for secretion, or to the plasma mem-
brane. “Upon exposure to ethanol, developing L6 neurons manifest disruptions in
Golgi apparatus [(compactions)] and cytoskeletal elements which may in turn trig-
ger selective and significant perturbations to primary neurite formation and neuronal
polarity” [409].
The metabolite 2-(α-d-mannosyl)-3-phosphoglycerate was increased
by at least 4.81-fold with any ethanol treatment. Upstream of this metabolite is
mannose–6-phosphate (M6P). M6P is generated by the activation of N -acetyl-glu-
cosamine-1-transferase by cathepsin D and is the major lysosomal targeting tag for
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lysosomal enzymes, resulting the endocytosis of these enzymes. Dephosphorylation of
this metabolite generates α-d-mannosylglycerate, which has demonstrated protective
effects under extreme stresses, such as extreme heat or freezing. This metabolite also
has protective effects in neuroprotective effects in in vitro assays against fibrils that
form and are associated with Alzheimer’s disease [410].
Cathepsin D is an aspartic protease, involved in non-specific, acidic lysosomal
degradation, apoptosis, and postnatal tissue maintenance [411]. Although cathepsin
D is not required for embryonic development, developmental abnormalities have been
associated with cathepsin D [411]. Cathepsin D deficient mice demonstrate atrophy
of the intestinal mucosa, intestinal necrosis with thromboemboli, and loss of thymus
and spleen function two to three weeks after birth [412]. However, these animals do
appear to maintain lysosomal proteolysis, suggesting a redundancy of function [412].
As noted by Benes and references within, in Drosophila, a natural mutation in sheep,
and the American bulldog, inactivation of cathepsin D is associated with accumulation
of lipofuscinosis, which is associated with neruodegeneration and neural regression,
amongst other symptoms [411].
Zebrafish appears to be missing a domain of cathepsin D to activate phospho-
transferase; zebrafish appear to be N -glycosylated at Asn-134 only [413]. Zebrafish
experiments that knocked-down cathepsin D have demonstrated a profound morpho-
logic effect, not dissimilar to FASD. Normally present in eggs and developing em-
bryos, knock-down of cathepsin D results in shorter body length, impairment of yolk
sac absorption, microophtalmia, and other abnormal morphology [414]. Together, the
changes demonstrated in N -acetylglucosamines, isoprenoids, and 2-(α-d-mannosyl)-
3-phosphoglycerate suggest glycosylation is important in FASD.
Transcription Factors
Vitamin A Several transcription factors were noted to change in our metabolome,
including vitamins A and D. Vitamin A participates in a wide variety of essential bi-
ological processes, including vision, nervous system development and patterning, and
a variety of cellular functions. For placentates, maternal plasma is the main source
of retinol, while in oviparous species it is supplied by β-carotene in the yolk [415]. In
embryonic cells, retinol binds to retinol binding protein 4, which is then transferred
to a receptor protein that has been stimulated by retinoic acid 6. Retinol binds to cel-
lular retinol binding protein, and is then converted to retinaldehyde by retinaldehyde
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dehydrogenase 10 or ADH. β-Carotene is converted to retinaldehyde by β-carotene
oxygenase. Retinaldehyde is converted to retinoic acid by three retinaldehyde de-
hydrogenases. Retinoic acid can then participate in nuclear transcription regulation
or exit the cell [415]. During embryogenesis vitamin A controls homeobox genes re-
sponsible for anterior-posterior patterning and tetrapod digit specification [415]. A
gradient of morphogenic retinoic acid is established in conjunction with fibroblast
growth factor, retinaldehyde, and Cyp26A1, which designates anterior and posterior
patterning [416, 417]. In addition, vitamin A is required for normal cardiomyocyte
differentiation and heart patterning in the mouse [415,418].
Retinoid-related metabolism has long been studied as an importantly modified
mechanism in FASD. Enzymes required for catabolism of ethanol functionally over-
lap with those required to convert retinol to retinal and retinoate. For example, dur-
ing gastrulation in Xenopus embryos, ethanol competitively inhibits retinaldehyde
dehydrogenase [419]. Among its several functions, ADH3, along with the cofactor
NAD+, converts retinol to retinal, which is then able to be converted to retinoic
acid [84]. Due to mobilization of hepatic retinyl esters, some tissues are found to
have increased all-trans-retinoic acid with ethanol exposure [420–422]. Additionally,
cerebella of Long Evans pups postnatally (P7) exposed to ethanol (∼80 mM blood
alcohol concentration) show decreased expression of retinoic acid receptors α/γ and
increased expression of retinoic acid X receptors α/γ [423]. Interestingly, in genomic
interactome analysis of brains of offspring of c57BL/6J mice exposed at various times
to 2.5 g/kg ethanol, retinoate metabolism genes were underexpressed [130]. Because
of the multiple points of regulation and the extensive array of vitamin A functions,
pinpointing cause and effect of vitamin A abnormalities can be difficult [424].
Supplementation with retinoic acid during ethanol exposure has been shown to
reduce some ethanol-induced changes that occur in early gastrulation and somito-
genesis, including embryo length, ear circumference, and neural defects [423]. How-
ever, co-treatment with retinoic acid does not rescue microphthalmia in zebrafish,
but does appear to reduce optic nerve hypoplasia and photoreceptor differentiation
defects [425, 426]. Ocular developmental defects in FASD models may be due to
independent inhibition of retinoic acid and sonic hedgehog pathways [427].
We identified very large decreases of retinoate with low and mid-
high doses of ethanol, while 1′-hydroxy-γ-carotene glucoside increased
at any ethanol dose (Figure 2.9 and Chapter 3). γ-Carotene can be formed from
β-carotene [428]. γ-Carotene can also be converted in to retinol and subsequently
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form retinoids, a process that is believed to be blocked directly by ethanol [428].
It has been proposed that 1′-hydroxy-γ-carotene glucoside is formed γ-carotene by
the actions carotinoid 1,2-hydratase and glucosyl transferase [429]. The latter is
hypothesized to have increased antioxidant capacity because of the addition of the
hydroxyl group [429, 430]. Taken together, these may suggest that shunting of β-
carotene to γ-carotene may decrease supply for retinoids, suggesting altered function
of chembeta-carotene 15,15′-dioxygenase, the oxidoreductase which normally converts
β-carotene to all-trans-retinal in animals.
In addition, 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one was
present in our metabolome. This metabolite appears as a cleavage product, po-
tentially derived from 11-cisretinoate. This finding is significant, as it could be a
causative mechanism of aberrant vitamin A in FASD.
Relevant to the high number of lipid metabolites that were significantly changed
in our data set, retinoic acid does appear to influence lipid metabolism. De novo fatty
acid synthesis generates palmitate, which then undergoes processes of elongation and
desaturation to synthesize other fatty acids. Stearyl-CoA desaturase I (SCD1), which
desaturates saturated fatty acids, and to our knowledge has not previously been asso-
ciated with FASD, appears to be regulated by vitamin A [431]. In normal and vitamin
A deficient BALB/c mice, feeding 0.01 and 0.1% retinyl palmitate lead to induction of
SCD1 mRNA [432]. ∆-5Desaturase, required for synthesizing polyunsaturated fatty
acids like eicosapentaenoic and arachidonic acids, also appears to be regulated by
vitamin A [433, 434]. As discussed above, anandamide, derived from arachidonate,
was significantly decreased in our metabolome with all but the lowest ethanol dose
tested. The aberrant vitamin A metabolism might be important to explore for this
reason. Our data demonstrates a variety of responses of palmitate and the next larger
fatty acid stearate to ethanol treatment. Considered in conjunction with our findings
on retinoate and 1′-hydroxy-γ-carotene glucoside, vitamin A disruptions may explain
some of the changes we noted in fatty acids.
In conclusion, while the debate about the role of vitamin A disregulation in FASD
continues, we, not surprisingly, found significant changes in retinoate, 1′-hydroxy-
γ-carotene glucoside, and 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one. How-
ever, when taken in conjunction with abnormalities in fatty acids in our ethanol
model metabolome, SCD1 should be considered as a novel and interesting pathway

























Fig. 2.9. Zebrafish embryos were treated from 2–24 hpf to 0–3% ethanol.
Two vitamin A metabolites, 9,13-cis-Retinoate (Structure 4-8) and 1′-
hydroxy-γ-carotene glucoside (Structure 4-10), were identified in the po-
lar fraction. In the non-polar fraction, 1-(2,6,6-trimethyl-2-cyclohexen-
1-yl)-1-penten-3-one (Structure 4-9) is potentially a cleavage product of
retinoate. All metabolites were significantly changed, P < 0.05.
Vitamin D We detected several changes in vitamin D metabolites that may influ-
ence FASD etiology. Classical vitamin D molecules, such as cholecalciferol (D3), 25-
hydroxyvitamin D2, 25-hydroxycholecalciferol, 1,25-hydroxyvitamin D, 24,25-hydrox-
yvitamin D3, 25,26-hydroxyvitamin D3, or 7-dehydrocholesterol, were not present in
our data set. However, our data showed several other vitamin D analogs that changed
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with ethanol exposure. 1α,25-Dihydroxy-26,27-dimethyl-20,21-didehydro-23-oxavita-
min D3 and 1α-hydroxy-22-(3-methylphenyl)-23,24,25,26,27-pentanorvi-
tamin D3 were elevated up to 6.7-fold from controls at all tested ethanol
concentrations. Calcitroic acid (1α-hydroxy-24,25,26,27-tetranorvitamin D3 23-car-
boxylic acid) and 1α-hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid
changed modestly and inconsistently from controls. Because of vitamin
D’s ability to act as nuclear hormone receptor, alterations of vitamin D pathways are
important. In addition to critical role in serotonin metabolism and neural develop-
ment (discussed above), calcium homeostasis, bone building and maintenance, cell
cycle regulation, immune function, insulin secretion, cardiovascular regulation, and
muscle development [435].
Normal vitamin D metabolism begins via ingestion of vitamin D3 from food
sources or by generation of 7-dehydrocholesterol in the skin (derived from choles-
terol) when it is exposed to UVB radiation and heat. These conditions result in its
conversion to vitamin D3, also in the skin. Vitamin D3 then enters the blood, where
it binds with vitamin D binding protein (DBP) and is transported to the liver. In
the liver, it is converted by 25-hydroxylase and then stored in the form of 25-hydrox-
ylase. It can again circulate in the blood bound to DBP as 25-hydroxyvitamin D3,
where it can be transported to the kidney. Low levels of calcium in the blood stimu-
late the parathyroid gland to release parathyroid hormone, which acts on the kidney.
This stimulation by parathyroid hormone or low blood calcium causes increases the
conversion of 25-hydroxyvitamin D3 by extra-renal 1α-hydroxylase (Cyp27B1) into
1,25-dihydroxyvitamin D3 [436]. The DBP can the be recycled for transport of other
vitamin D molecules. From the kidney, the vitamin D once again travels through
the blood as 1,25-dihydroxyvitamin D3, bound to DBP in order to reach the target
tissues. In addition, 25-hydroxy vitamin D3 can be locally converted in some target
tissues by 1α-hydoxylase. In the target tissues, the 1,25-dihydroxyvitamin D functions
as an active metabolite at a vitamin D receptor (VDR) site, altering transcription.
Alternatively, it is converted to 1,24,25-trihydroxy vitamin D3 where it is degraded
by 24-hydroxylase (Cyp24) and then excreted [436]. 1α,25-Dihydroxyvitamin D2 can
also be oxidized by P450 into calcitroic acid.
Vitamin D3 acting at the VDR regulates transcription via as a nuclear recep-
tor. VDR plays an important role in intestinal calcium absorption, pancreatic β-cell
secretion, and growth and differentiation of a variety of tissues, such as cartilage,
smooth muscle, keratin, and bone [437]. It appears to also play an important role in
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brain cell differentiation, regulating calcium in neurons and preventing excitotoxicity,
protection from reactive oxygen species, and regulation of neurotophic factors [438].
VDR is initially expressed in the central nervous system in rodents at approximately
embryonic day 12 [129, 438]. During embryonic development, maternal vitamin D is
the only source available [438].
Like humans, fish require vitamin D, having diminished growth and lowered cal-
cium turnover under conditions of vitamin D deficient diet, as demonstrated in sea
bream (Sparus auratus) [439]. Both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin
D3 are present in the serum of fish [440,441]. At both 48 and 96 hpf, immunostaining
for VDR is positive in the ganglion cells of the developing eye, brain (diencephalon),
and epithelial cells lining the otic vesicle [441]. “VDR is widely expressed in tissues
of the adult male and female zebrafish, Danio rerio, specifically in epithelial cells of
gills, tubular cells of the kidney, and absorptive cells in the intestine,” as well as in
“skin, the olfactory organ, the retina, brain, and spinal cord. Sertoli cells of the testis,
oocytes, acinar cells of the pancreas, hepatocytes, and bile duct epithelial cells” [441].
Quantities of VDR in intestinal, but not gill, epithelial cells are responsive to admin-
istration of exogenous 1,25-dihydroxyvitamin D3 [441].
VDR expression in rats appears increased during times of decreased prolifera-
tion and programmed cell death [129, 442]. Given this, the metabolites identified in
our metabolome that can activate VDR may be inhibiting proliferation and increas-
ing apoptosis in FASD. “Analogs eliciting VDR activity must contain a 1α-hydroxyl
group and a side-chain that contains no aromatic substituents and most importantly
a hydroxyl at C24 or C25” [443]. 1α,25-Dihydroxy-26,27-dimethyl-20,21-didehydro-
23-oxavitamin D3 binds poorly to vitamin D binding protein and VDR, estimated to
be 33% that of 1α,25-dihydroxy vitamin D3 (as measured in pig intestine) [444]. How-
ever, 1α-hydroxy-22-(3-methylphenyl)-23,24,25,26,27-pentanorvitamin D3 , compared
to 1α,25-dihydroxy D3, can inhibit 96% of 1α-hydroxylase activity [444].
1α-Hydroxy-25,26,27-trinorvitamin D3 24-carboxylic acid is marginally higher with
ethanol treatment, staying nearly identical at 1.1-fold control with all ethanol doses.
Mizwicki noted that “to be effectively transported by DBP, [vitamin D analogs]
must contain a side-chain that is, for the most part, rotationally free and contains
a hydroxyl that is not sterically hindered by additional methyl groups at C25 and
C26” [443]. This suggests that while this metabolite may not react with VDR due
to the lack of a hydroxyl group at C24 or C25, but does bind to DBP, where it can
continue to be modified by the changed environment caused by ethanol exposure.
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It is possible this carboxyl group is a result of transcarboxylation with ethanol in
the system. The extent to which the carboxyl group substituted at C24 influences
these actions or the relationship to the similar 1α-hydroxy-24,25,26,27-tetranorvita-
min D3 23-carboxylic acid (calcitroic acid) in FASD is unclear and requires further
investigation.
1α-Hydroxy-24,25,26,27-tetranorvitamin D3 23-carboxylic acid (calcitroic acid) is
the renal catabolism product of 1,25-dihydroxy vitamin D3 and can be formed through
P450 oxidation. It mobilizes bone calcium and increases the transport of intestinal cal-
cium [444]. The inconsistent levels of calcitroic acid demonstrated in our metabolome
may suggest that calcium levels are in a state of flux over the ethanol concentration
curve tested.
In pregnancy, the maternal decidua of the placenta produces 1α-hydroxylase,
which is especially high in the first trimester [445, 446]. This has been hypothesized
to influence 1,25-dihydroxyvitamin D3’s role in suppressing the cytokines that trigger
maternal immune system, preventing induction of fetal rejection. In addition, vitamin
D status plays an important role in the regulation of metabolism. When vitamin D
levels are low, tryptophan 5-hydroxylase, also present in the placenta, is upregulated
to increase the conversion of tryptophan to 5-HT [158]. Tryptophan hydroxylase 2
on the vitamin D response element in the brain is also upregulated, allowing greater
conversion of tryptophan to serotonin [158]. Because of these alterations, there is less
tryptophan available for protein synthesis, which may result in decreased growth, such
as that demonstrated in FASD. In a comparison of offspring placenta of heterozygous
c57BL/6 VDR ablated mice, microarray of VDR null showed significant differences
in many genes, notably a 6.47-fold increase in Cyp24a1, In spite of the genetic differ-
ences, no functional differences in vitamin D were noted [447]. The relevance of the
above is questionable given that our model does not contain a placenta, and likely
all of the maternal vitamin D present is in the yolk sac, however this information is
important for understanding FASD.
Further, due to the positioning of the metabolite on the ligand binding domain,
vitamin D analogs bound to DBP in circulation remain “highly exposed to the ex-
ternal environment”, making DBP different than many of the other albumin related
proteins [443]. This may be important, especially in the context of pharmacological
models of FASD that utilize very high concentrations of ethanol, as these vitamin D
analogs would remain succeptible to modification by circulating ethanol.
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Previous works have demonstrated ethanol alters the vitamin D pathway. In one
study, pups from ethanol-fed Sprague Dawley® dams had reduced skeletal ossifica-
tion compared to pair-fed or control animals, in spite of there not being a difference
in calcium content between groups [448]. However, this experiment also noted that
the ethanol fed dams consumed less calcium and phosphorus, likely due to decreased
intake in these groups. In another study, cholecalciferol, the prehormone synthesized
from 7-dehydrocholesterol, given to Sprague Dawley® rats at 5 mg/kg significantly
reduced the number of perseverative-type errors demonstrated in a serial spatial dis-
crimination reversal task by 11.9% alcohol-exposed rats age postnatal day 49–52 [449].
However, cholecalciferol treatment did not improve the number of trials it took rats
to find the escape ladder in the trial. Alcohol treatment did not appear to reduce
vitamin D status, nor did vitamin D status appear to alter peak blood alcohol concen-
trations [449]. The authors hypothesize that cholecalciferol is providing a neuropro-
tective benefit to VDR containing regions of the brain, such as the cerebellum [449].
Pooled data from multiple ethanol exposure studies in developing c57Bl/6J showed
underexpression of the gene Cyp2R1 [130]. This gene encodes a Cyp liver enzyme
microsomal vitamin D3–25-hydroxylase, which converts cholecalciferol to 25-hydroxy
vitamin D3 [450]. Similarly, Cyp27B1, the P450 1α-hydroxylase responsible for con-
version of 25-hydroxy to 1α,25-dihydroxy vitamin D3, is underexpressed in ethanol
exposed pups, [130,450].
Other researchers investigating the liver metabolome of alcohol-dosed rodents have
discounted their own reports of 3-deoxyvitamin D3 ([(5(Z ),7(E ))-9,10-seco-5,7,10-
(19)cholestatriene (LMST03020618), instead determining the metabolite to be choles-
terol ((3)-cholest-5-en-3-ol; m/z 369.3516 [M H2O + H]+) to be more consistent
with analysis of their standards of this metabolite [451]. This, in conjunction with
our findings, suggest further investigation is warranted to explore these vitamin D
metabolome changes in FASD.
Nicotinamide
2,6-Dihydroxypseudooxynicotine was significantly changed in several
ethanol doses. In addition, cotinine methonium ion and nicotine glu-
curonide was increased with most ethanol doses. Both of these are gen-
erally recognized as a products of nicotine metabolism. Mugineic acid is





























pentanorvitamin D3 20,21-didehydro-23-oxavitamin D3
Fig. 2.10. Several vitamin D metabolites were identified in the polar
fraction.
in structure to nicotinamide, and was decreased in all but one of the ethanol treat-
ment groups [452]. Work in plants demonstrate mugineic acid antibodies also are
cross reactive with nicotinamide antibodies in assays. These changes suggest these
metabolites reflects changes in nicotinamide metabolism. Tryptophan is the precursor
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of nicotinic acid mononucleotide, which can eventually be converted to nicotinamide
adenine dinucleotide [183]. Tryptophan pathway abnormalities are well-established
in FASD (see above). Because of its critical function as a coenzyme in redox reac-
tions, changes in nicotinamide would have critical, far-reaching effects in FASD. This
represents a novel finding, and should be explored further as to the generality of this
effect.
2.4.10 Disease Resistance
N -(3-Oxo-octanoyl)-homoserine lactone was also elevated in the 0.1% or greater
ethanol treatments. Acylated homoserine lactones are common in the environment.
These are a type of quorum sensing molecule, which responds when a cell population
proliferates in a given volume to activate transcription. These molecules influence
a pathogen’s virulence, making them important for disease susceptibility, suggesting
a protective response by the embryo in generating N -(3-oxo-octanoyl)-homoserine
lactone [453,454].
2.4.11 Study Weaknesses
With all of the metabolites identified, several factors should be considered when
examining the overall trends present in our data set. First, the fact that these were
whole-embryo extracts must be considered. For some metabolites, it is likely that
our method underestimates important metabolite changes in some tissues, due to the
dilution from other tissues. A second concern is that, through the homogenization
of the whole embryo, we created interactions that would not naturally occur. Bio-
chemicals that may normally be compartmentalized from each other could be exposed
to what otherwise would appear as exogenous substances and result in some degree
of catabolism. Tissue compartmentalization and subcellular compartmentalization
confer too great of a functional difference on molecules to ignore these physiologi-
cal separations. Thus, it is a mistake to assume cells and zebrafish embryos always
respond in the same manner.
Further, some have suggested that generalized extraction methods, such as those
used here, can result in a loss of very polar lipids to the aqueous component dur-
ing extraction [455]. Thus, our values may underestimate the actual lipid modifica-
tions taking place during fetal ethanol exposure. Further, since the polar and non-
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polar metabolome were generated from separate experiments, it is possible that some
metabolites which are borderline polar/non-polar may be over- or underestimated by
being in both or neither fraction.
Hence, a follow-up investigation divided by tissue compartments for comparison
to these results may be warranted. This will be a difficult task, in no small part
due to the highly friable nature of the ethanol-cultured embryo. Conversely, metabo-
lites identified here may therefore be important in a wider-array of organ types than
previously anticipated by compartmentalized studies alone. Lastly, because of the de-
veloping nature of metabolomics databases and the relatively novel use of zebrafish in
such experiments, it is likely that some of the metabolites could have alternate iden-
tities. Periodic re-examination of metabolome databases could modify the findings
from work.
Why is FASD difficult to study?
Metabolomics offers a powerful method to gain insights in normal biochemistry
or disease processes. Metabolome changes are dynamic, especially during the rapid
evolution of development. Different developmental stages can be metabolomically
characterized, which has been demonstrated in the zebrafish [456].
In many biological contexts, an assumption can be made that changes in the
levels of a biochemical intermediate are due to changes in the rate of production or
the rate of degradation [153,189]. But, due to the protic solvent properties of ethanol,
alterations could occur at reaction precursors, intermediates, or products, in addition
to alterations in enzymes that normally alter metabolites. An additional complication
to describing mechanisms in FASD is that various enzymes have differential expression
during development, indicating that the normal metabolic and catabolic functions are
at less than maximal capacity.
Triage theory is the hypothesis that when nutrient availability is insufficient,
evolutionarily-conserved mechanisms are preserved over non-essential mechanisms
[457–459]. This theory has largely been applied to nutrient deficiencies that result
in disease, but it is logical to extend it to abnormalities caused in frank disease
of non-nutrient deficiency origin. By extension of triage theory, the developing em-
bryo self-preserves critical nutrient-utilizing processes acutely, disfavoring non-critical
evolutionary developmental processes. Thus, changes that occur in our model from
ethanol-exposure as compared to control are attributable to both the direct ethanol-
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induced biochemical changes as well as self-preservation triage of critical nutrient-
related in the embryo.
An additional difficulty in modeling FASD is the variety of tissue influences oc-
curring as a result of maternal, fetal, and placental metabolism of ethanol and its
products. Similarly, dosing of zebrafish in culture is not 100% efficient. Finding rel-
evant ethanol concentrations is important to creating useful models of FASD. Based
on blood alcohol content reported in a variety of studies, relevant ethanol concentra-
tions can range between 20 - 170 mM [460]. Ethanol is a teratogen, with an LC50 in
zebrafish of 338.5 mM after 48 hours or 280.5 mM after 24 hours of exposure [82].
Zebrafish embryos are even more sensitive to the metabolite acetylaldehyde (LC50
0.541 mM after 24 hours) [82].
The use of ethanol dosed in the water of zebrafish embryo medium is common.
The applied waterborne concentration and the embryonic dose is different, and ap-
pears at least partially dependent on the proportion of time the embryo is exposed
to ethanol during development. After 24 hours ethanol exposure for 100 mM wa-
terborne dosage, embryos contained 17.10±6.27 mM of ethanol, as determined by
enzymatic assay (alcohol dehydrogenase [ADH]), and with 200 mM dose waterborne
dose resulted in a 57.36±5.29 mM embryonic ethanol level (n=3) [82]. Others have
reported that ethanol applied at 167 mM between 24–27 hpf resulted in an embryonic
ethanol concentration of 51.7±5.6 mM (n=8–30 embryos per plate 100 mm plate), a
much higher embryonic exposure than previously reported [461]. But, it is clear that
waterborne doses are much greater than the embryonic exposure.
Multiple retention times
Due to the multiple retention times observed for some of the fatty acids, standards
of both palmitic and stearic acids were run (Appendix A). These standards eluted
at approximately 2.8 and 6 minutes, respectively. Mass spectra of peaks empirically
identified as palmitic and stearic acids were subjectively verified to ensure they were
similar to the standard. We hypothesize the differences in retention times of these
smaller fatty acids may be due to several factors. First, larger fatty acids and glyc-
erophospholipids separate in the column due to differing polarity based on their tail
lengths. Then, during MS, some of these larger chains may be fragmented, resulting
in the appearance of multiple metabolites with the same m/z values. Additionally,
given these were whole embryo extracts it is possible these fatty acids were associ-
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ated with atypical matrix components that impacted the elution times. In the future,
these could be examined by spiking standards into whole-embryo extracts to verify
differences in retention times or studying the metabolites in their native tissues.
Zebrafish Concerns
The embryonic yolk in zebrafish (and other model species) is an important con-
sideration when comparing human development. Prior to hatching, the entire supply
of nutrition comes from the yolk, which is largely made of the maternally-originating
lipoprotein vitellogenin [462]. Studies in multiple fish species have demonstrated that
in estrogen-stimulated fish vitellogenin is composed of 16–18% lipids, including gly-
coproteins, polyunsaturated fatty acids, and the [462]. The yolk components are also
the primary source of phosphorous (phosphovitin), calcium, protein, and lipids for the
embryo. Provided by the lipovitellin component of vitellogens, large protein droplets
form in the yolk, which provide amino acids for development. During the matura-
tion process, proteins become completely degraded, likely due to cathespsin-induced
proteolysis. Additional components present in the yolk include major receptor class
components, such as retinoids, retinoid binding protein, steroids, and thyroid hor-
mones. Also during this process, innate and adaptive immune responses are also
transferred to the egg [?].
At the early developmental stage of our experimental embryos, lipids would derive
only from the yolk, and not from ingestion of cholesterol and unsaturated fatty acids
obtained as adults from the diet [463]. On top of that, the gut is fairly undeveloped
until 60 hpf, making intestinal absorption of lipids of little importance in this model
[258]. Fish store lipids as triglycerides in visceral adipose, but visceral adipose does
not begin to accumulate until they begin eating [463]. Accordingly, more emphasis
may be needed on the role of yolk lipids (or maternal supply of lipids) with respect
to abnormal lipogenesis and lipolysis that appears to be occurring in this model of
FASD.
Oxygen Solubility
One possible problem in our experimental design, which immerses zebrafish em-
bryos in ethanol solution, is that in incubating the embryos for development at normal
laboratory protocol temperature of 28 ◦C likely alters the dissolved oxygen of the wa-
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ter. Baek, et al., proposed that higher dissolved oxygen concentrations in alcoholic
beverages decreased the time required for participant blood alcohol concentrations
to return to baseline [464]. It has long been known that even while using repeated
distilled ethanol, when placed in temperatures above 25 ◦C (up to 50 ◦C) results in
a decrease in oxygen gas solubility [465]. This is important in the interpretation
of changes that might involve ROS mechanisms, as our system would possibly min-
imze potential ROS effects. But, normal oxygen-requiring metabolism may also be
altered, especially in higher experiment ethanol concentrations. We did not examine
the effects of dissolved oxygen in our system, and that might be advisable in future
experiments. However, with the relatively small differences between alcohol concen-
trations we utilized in a normal laboratory incubator, the experiment must be well
designed to capture comparatively small differences experienced by the embryo. This
may also be important in the comparison of zebrafish data across laboratories, as
different laboratories may have different protocols regarding incubation environment,
which would greatly be affected by the use of recirculation of water as compared to
the standing water of many culture incubators.
Multiple assay methods
Two different detection modalities were used in these experiments, having different
levels of expert-established accuracies. However, the data presented in this work does
not weight these differences in this interpretation of the FASD model metabolome.
In the future, this should be addressed through development of a statistical or al-
gorithmic penalty to provide more emphasis on data derived from the Orbitrap. As
presented in this article, the differences in detection modalities are denoted by the
ppm difference, included in the associated tables, as well as indications to demonstrate
which fraction (and thus which detection modality is used).
2.4.12 Future Directions
Weinberg, et al. astutely point out that all of our understanding about ethanol-
related mechanisms can never be separated from absorption, dispersion, metabolism,
and excretion of nutrients [285]. For example, maternal nutritional status may be
impacted if she is a chronic drinker. In heavy drinkers alcohol interferes with thi-
amine absorption, a nutrient essential for normal energy metabolism and synthesis of
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lipids [466]. Gaining a better understanding of the metabolic changes is essential to
diagnosing and intervening in FASD.
Many studies targeting mechanisms of FASD in the brain focus specifically on
the hippocampus. This may be due to the behavioral changes noted in FASD in
conjunction with our current understanding of hippocampal functional modalities.
However, reactional changes induced with ethanol would be unlikely to specifically
target this single structure in the brain. The effects of ethanol are systemically
profound during development. Thus, in the future, we should either 1) work toward an
understanding of what makes hippocampal structure more susceptible to change than
other structures, or 2) refocus our interpretation of the FASD phenotype (including
behavior) to be more relevant to the global changes induced by ethanol.
Many of the abnormalities we have identified center at cholesterol metabolism.
From cholesterol is derived pregnenolone, progesterone, testosterone, estradiol, glu-
cocorticoids (like cortisol), vitamin D, and bile acids/salts. All of these metabolites
had significant changes in our analysis when exposed to ethanol. The question must
therefore be raised if 1) cholesterol regulation might be targeted and 2) our analysis
indirectly targets cholesterol-derived products biasing our findings.
In addition to differences noted in steroids related to sex hormones, we noted
metabolome differences relevant to metabolites reported by other scholars as hav-
ing a differential outcome in prenatally ethanol-exposed males and females. Females
display elevated ACTH stress responses, while males display higher levels of β-endor-
phins [285]. In addition, “normal testicular influences on HPA function are markedly
reduced in PAE males [285].” Further, male and female Sprague Dawley® rats
exposed to prenatal alcohol exhibit differential regulation of hypothalamic-pituitary-
adrenal (HPA), dopaminergic-adrenal (DA), and likely HPA-DA [467]. Due to the
sex-specific differences noted in the response of the brain to alcohol exposure, it will
be important to follow-up with work examining the correlation between sex of the
individual and metabolome differences in steroid hormones.
2.5 Conclusions
In conclusion, we found a vast array of significantly changed metabolites in our
zebrafish model of FASD. Pathways related to phospholipid structure and function,
cardiovascular development and functioning, oxidative stress, and vitamin A are some
of the interesting findings. Many were metabolites associated with established FASD
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mechanistic hypotheses. However, the novel metabolites we have identified may shift
our interpretation of many of these theories.
Acknowledgments
Funding for these experiments was provided by The Indiana Clinical and Trans-
lational Sciences Institute. The authors would like to thank Paul Collodi, PhD and
Abraham Fisseha Tesfamichael, who generously provided the zebrafish embryos.
148
3. COMPARATIVE MODELING OF FETAL ALCOHOL
SPECTRUM DISORDER: MORE IS NOT JUST MORE
3.1 Abstract
A comprehensive mechanistic profile of metabolite changes occurring in fetal al-
cohol spectrum disorder has yet to be developed. We used our well-established Mus
musculs (mouse) model to compare 0, 1, or 2 six-hour 400 mg/dL binge-type ethanol
exposures, and analyzed the whole-embryos at E10 extracts using a Thermo Fisher
LTQ Orbitrap coupled to an Agilent 1100 for liquid chromatography. From this data,
we generated a profile of significantly different metabolites resulting from ethanol
treatment, which included fatty acids, monoacylglycerides, glycerophospholipids, and
prenols. Many of the metabolite changes related to protein kinase C, as well as
lipid metabolism and lipid droplets. As a post hoc analysis, we also compared these
mouse model findings with our previously reported chronic ethanol exposure Danio
rerio (zebrafish) analysis, where embryos are exposed to 0—3% ethanol from 2—24
hours post-fertilization. Six significantly different, commonly-identified metabolites
were present, including fatty acids, phosphatidic acid, and sulfatide, which were an-
alyzed using a probabilistic principal components and covariates analysis. Interest-
ingly, metabolite responses in the two models diverged, suggesting that the chronic
ethanol exposure is not the same as more of the binge response. We also contextualize
these findings with a novel relativistic inter-specific timeline. These metabolite pro-
files provide a more comprehensive understanding of ethanol-induced changes during
development and may lead to better biomarker(s) identification or novel therapies for
FASD.
3.2 Introduction
3.2.1 FASD affects many, but alcohol is non-specific
Though it has been widely studied for decades, a comprehensive model for fetal
alcohol spectrum disorder (FASD) has yet to be determined. Ethanol acts as a sol-
vent, causing tissues to break apart. In addition to the alcohol itself, its constituent
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hydroxyl group, make excellent nucleophiles. In the laboratory, such reactions have
been shown to convert fatty acids into their ethyl esters via lipase catalyzation, with
a preference for short chain fatty acids in ethanol:fatty acid, especially in the presence
of CO2 [468]. With the evolution of our understanding about FASD, development of
new models, and improvement in technologies, many hypotheses have been advanced
regarding the primary drivers of this disease. These have included nitric oxide and
other reactive oxygen species, glutamate, vitamin A, serotonin signaling, lipids, glu-
cose regulation, adhesion molecules, and more [61, 62]. Yet, it is unclear how the
most important pathway changes caused by this far-reaching molecule of ethanol can
be discerned, targeted, and tracked as a biomarker(s). To that end, we conducted
a non-targeted, non-polar metabolomics analysis of our well-established Mus muscu-
lus binge alcohol model. We also compare and contrast findings of this experiment
with metabolomics results from previously reported experiments using a Danio rerio
chronic ethanol exposure model. A novel application of probabilistic principal com-
ponent and covariate analysis (PPCCA), applied interspecifically, was also utilized to
determine predominant underlying biological drivers in these differing FASD models.
Lastly, we contextualize the findings of these models by presenting a cross-species
relative timeline of these models.
3.2.2 Animal Modeling Considerations
Fetal alcohol spectrum disorder has been modeled in a variety of species and
modalities, ranging from rodents, to fish, to guinea pigs. Rodents dominate the field
of FASD research, due to their availability and well-published understanding of their
physiology and volume of work in the literature. Because of this, it is easy to put on
blinders with respect to the selection of the best model for a research question. But it
is important, in spite of the complexities of the process, that we prioritize models that
best captures the physiology or symptoms at hand [469]. Because we have relied so
heavily on rodent models, there remains a significant phylogenic separation between
knowledge of the effects of alcohol in humans and alternative models.
When selecting an animal model, several important considerations should be
made, but ultimately the goal is to mimic the human condition. Many factors influ-
ence the applicability of animals to understanding human dietary- or consumption-
induced toxicity and terratogenicity. These factors include genetics and physiology,
environment, diet and nutritional status, behavior, bioaccessibility, and bioavailabil-
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ity. Judgement of the success of an animal model can only be made by understanding
the overall context of the research question, physiology, environment, and experimen-
tal design.
Various techniques have been used to classify relationships betweens model organ-
isms and humans (or target species). Some use parsimony, trying to determine rela-
tionship with fewest possible point of evolutionary divergence and convergence [469].
Others prefer to rely on quantifiable differences (i.e. genetics) to construct basis to
create “maximum likelihood estimates” [469].When no longer considering a single ge-
netic modification from wild-type to knock-out, such as those used here for FASD,
genetics comparisons are based on ancestry [469]. Another consideration in compar-
ative modeling is cladistic relationships, wherein some species are necessarily nested
within each other [469].
The environment, behavior, and diet of a model organism should be considered as
well. The environment is an important driver of genetic, behavioral, and physiologic
differences. Also, animal models often perform insufficiently in modeling human be-
havior. (Human behavior is difficult for humans to predict, much less for an animal
model to predict.) While single behaviors may be mimicked in the laboratory, the
variety of human habits will likely always exceed that of what animals can model.
Additionally, diet is another extremely important factor. Humans in more developed
countries have a greatly varied diet. This is compared to a laboratory animal that
is fed routinely a single “complete” chow diet. Laboratory animals, while creating
a reductionist model of human nutrition, greatly simplify the impact of diet variety
(including sources) and nutritional status.
Finally, bioaccessibility and bioavailability are tremendously important, especially
in consideration of teratogenic studies. Bioaccessibility is defined as “the amount of
a chemical that is released from food into gastrointestinal tract fluid following a
simulated digestion and, as a result, is available for absorption by the intestinal mu-
cosa” [470]. This value is likely to vary between species, as the physiology of the gas-
trointestinal tract changes. This factor makes comparative modeling more difficult,
since the maturity and functioning of the digestive tract varies during development,
especially when compared between species like mice and zebrafish. Bioavailability is
“the extent to which the active ingredient of a drug dosage form becomes available at
the site of drug action or in a biological medium believed to reflect accessibility to a
site of action” [471]. This would be highly affected by any changes in the metabolism
of a substance between species, whether due to changes in development or just physio-
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logical differences. Bioaccessibility, bioavailability, genetics, physiology, environment,
and behavior must all be considered in establishing the merit and appropriate scope
of an animal model.
3.2.3 Utility of Zebrafish for FASD
Toxicology and developmental research has already demonstrated the usefulness of
fish, specifically zebrafish, as a model. This work is now being extended for research-
friendly intermediate scale screens of drugs at a stage between cell culture models and
mammalian models. The small size of the zebrafish may make sample collection more
difficult, but the ability to carry out larger experiments provides increased statistical
power. In general, zebrafish are much less expensive to maintain than other animal
models (however, do require vigilant monitoring of water quality). They reproduce
readily (typically laying 75–120 eggs) and rapidly in captivity [472]. Transparent
embryos make transgenesis easy. Their small size requires little space and husbandry
costs are much less than in rodent models [473]. Inducing the FAS zebrafish model
is also very simple compared to dosing a stressed pregnant rodent [472].
Though zebrafish seem to lack construct homology (e.g. living in water, fins in-
stead of arms), these vertebrates are highly conserved, providing genetic homology. As
such, a clear disadvantage of the zebrafish if that they require water for oxygen and not
air. As a result, any lung abnormalities that might appear in other animal models may
not be seen with the zebrafish. Use of the lower level phylogenic vertebrate supports
the reduce, refine, and replace objectives in animal research [472]. Relative to other
lower metazoans, zebrafish contain greater face validity, including more anatomic sim-
ilarities than others (Drosophila, Caenohabditis elegans, etc.), have comparable early
development, and general patterning similar to humans [389, 474, 475]. Importantly,
zebrafish demonstrate one-to-one face validity for human FASD. Zebrafish serve as
a predictive construct, as they develop decreased growth, craniofacial abnormalities,
spinal malformations, and damage to CNS, like humans [63, 472]. Other researchers
have demonstrated homology of heart malformations in the zebrafish FASD model
similar to humans [476]. In addition, zebrafish respond dose-dependently to alco-
hol [389]. The model is very fast, as the time required for alcohol exposure is limited
(24 hours at 2 hours post fertilization [hpf] or even just 2 hours at 24 hpf has been re-
ported) [477]. Furthermore, untreated zebrafish possess key mammalian (human, rat,
and mouse) liver regulatory factors for dyslipidemia. In terms of lipid metabolism,
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zebrafish show many similarities to humans [463, 475]. For example, zebrafish con-
serve the ability to store cytoplasmic lipid droplets [478]. These factors support the
construct validity of the zebrafish in FASD research.
Zebrafish have provided an important model for FASD, in no small part due to
the tremendous amount of work that has been done in zebrafish developmental biol-
ogy. Developmental norms are well-established and compare well with early human
development, which is important as “fetal cellular mechanisms often differ from adult
processes” [479]. However, it “fetal development is activity dependent” requiring pre-
vious stages to be successful prior to next [479]. This has important implications
on the long duration of ethanol exposure we use in the zebrafish model, since early
exposure effects surly compound later ones.
Zebrafish and humans share considerable genetic homoloy. Over 70% of human
genes contain at least one zebrafish ortholog [480]. There are a variety of genes for al-
cohol dehydrogenase (ADH), the enzyme that catabolizes ethanol to acetylaldehyde.
There are differences in the alcohol dehydrogenases present in zebrafish and mam-
mals. Both lineages contain ADH3, though it is hypothesized that the acquisition
of ADH1 occurred independently in these two genetic lineages. Further, the teleosts
whole-genome duplication event includes the genes encoding ADH. The result of these
changes created the ADH variants 1A1, 1A2, 3H, 3L, while humans have 1A, 1B, 1C,
2, 3, 4, 5. Mice and rats have H1, H2, H3, H4, H6A, H6B, with the variant H5ps
being present in mice and H5 occurring in rats [84]. ADH8A in zebrafish metabolizes
ethanol, and is not yet expressed at 24 hpf, but is at 36 hpf [82]. This has important
implications on our model, as it suggests the effects noted in our model are likely
impacted by this diminished ethanol-catabolizing capacity.
Beyond these advantages to using the zebrafish in FASD, there are some important
considerations including the lack of placenta, nutrient supply, the and tank environ-
ment. Zebrafish cannot support investigations in to the role of the placenta in FASD.
It is clear that the placenta is important in fetal programming [479]. But, the func-
tional similarities of the chorion membrane to the placenta is not [472]. Furthermore,
maternal interaction in zebrafish is completed at time of egg release; ethanol exposure
may likely not be a single event in humans, and the zebrafish model (as currently
implemented) does not mimic that very well [472]. But, zebrafish and the excised
mouse embryos both provide useful information as a negative and partial-negative
animal models, respectively.
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Zebrafish embryo nutrients are parentally derived, supplied in the yolk, which iso-
lates ongoing fetal-maternal nutrient interactions otherwise presented in embryonic
development. The composition of the zebrafish yolk is important in examining FASD
metabolic alterations. Vitellogenesis is the process of producing and accumulating
egg yolk proteins (vitellogens) from circulating precursors in the oocytes of non-
mammalians. Vitellogenins are largely composes of phospholipids and glycoproteins.
In teleosts, vitellogenins are composed of approximately 16–18% lipid, including the
polyunsaturated fatty acids phosphatidylcholine (PC), phosphatidylethanolamine,
and phosphatidylinsositol (PI) [462,481]. Additional fat is required for the oil droplets
that provide buoyancy for the egg [481]. Energy reserves for embryonic life come from
lipoproteins that are hydrolyzed [481]. Phosvitins, composed largely of phosphorous
bound to amino acid polyserine, provide vitellogenins much of the minerals required
for embryonic development [481]. Additionally, proteins are another important com-
ponent that are provided by the lipovitellin component of vitellogens. They form
large protein droplets in the yolk and provide amino acids for development.
The watery environment makes the zebrafish an easily induced FASD model, as
embryos take up the alcohol through immersion. This difference may influence the
uptake of alcohol, since the phenotype occurs at much higher concentrations than
what human effects occur. However, there is a significant (P < 0.0001) correlation
between alcohol concentrations in the media relative to alcohol inside of the egg [477].
The FASD phenotype response may be strain dependent, as some strains respond with
cyclopia only at higher ethanol concentrations (2.4%) relative to others (vs. 1.5%)
[63]. Given the method of ethanol exposure used in zebrafish, the use of circulating
water or still water has important implications on the dissolved oxygen of the water.
While this may be less of a concern for incubating embryos that have less exposure
to circulating water due to being at the bottom of a tank, it is certainly a factor for
hatched individuals. Further, it has been demonstrated that higher dissolved oxygen
concentrations in alcoholic beverages decreased the time required for participant blood
alcohol concentrations to return to 0.000% [464].
As research shifts to a better understanding of the genetic diversity in our world,
our potential for animal models also greatly expands. With the advancements in
bioinformatics, researchers are beginning to appreciate what genotypic, epigenetic,
protein, and metabolic changes between species means phenotypically and physio-
logically. The zebrafish model of FASD offers many benefits to researchers. These
benefits, must be weighed against the models downfalls to determine the hypothe-
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ses for which this model is most relevant. But, taken together, our well-established
c57BL/6J model of binge alcohol and our chrnoic zebrafish exposure can be beneficial.
3.2.4 Comparative Modeling
A potential method of assessing the strengths and weakness of an animal model is
through interspecific comparative modeling. Through the use of comparative study,
researchers can perform “the analysis of trait variation across rather than within
species, with the aim of testing hypotheses or generating new ones” [482]. Consid-
eration of phylogeny is important in comparative animal modeling, as understanding
relationships between disease related traits may alter the utility of a given animal
model. Some other important bases for model comparison include anatomy, physiol-
ogy, genetic variation, biomarkers, or evolutionarily (dendrologically). However, in-
terspecific comparisons of development are complicated by differences in the sequence
of development events as well as variations in the rates of these events. Further, over-
all development rates in general may vary between species as well as at different stages
during development.
In the field, the degree of genetic conservation and chromosomal synteny has long
been identified as a method to compare species [483]. Historically, we have identi-
fied models through characterization of the human disease, then finding a suitable
natural model or inducing one through genetic manipulation [484]. However, even
our workhouse lab rodents are known to have undergone a large amount of chro-
mosomal rearrangement, making this method difficult to use to align species maps,
much less draw conclusions [483]). Further, the strong reliance in the industry upon
highly inbred strains also removes a large degree of individual variation, which may
in turn be contribution to the reduction in statistical findings in trials in later non-
inbred species, including humans [485]. Two genetic comparison methods have been
used traditionally, including quantitative genetics and segregation and linkage analy-
sis [485].
Using the best animal models possible can reduce the number of animals in re-
search, refine our experiments to best answer the correct questions, replace the use
of phylogenically higher level animals with lower ones. However, we still lack qual-
ity quantitative methods to compare developmental staging interspecifically. To that
end, we present here a tool to compare development of multiple species across one
timeline.
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3.2.5 Comparison of PCA
An enormous limitation to our capabilities in translational medicine is the lack of
ability to quantitate the inter-specific differences observed in the laboratory. Principal
component analysis (PCA) is a method to take assumably linearly-related observa-
tions and transform them in to a data set with reduced dimensionality. “PCA asks:
Is there another basis, which is a linear combination of the original basis, that best
reexpresses our data set?” [486] First a linear function is identified to account for as
much of the variance as possible, and then they are orthogonally transformed. It is
commonly used in the analysis of complex data sets, such as -omics data, since it
puts the data “into lower dimensional space, revealing inherent data structure, and
providing a reduced dimensional representation of the original data ” [487]. It has
several limitations, however, including the lack of a probability component, does not
address other important underlying characteristics of the sample, and fails to address
missing data [487].
Since its inception decades ago, many iterations have been developed to address
these limitations, including the probabilistic PCA (PPCA), the probabilistic princi-
pal components and covariate analysis (PPCCA), and the mixtures of PPCA models
(MPPCA). “In contrast to the more conventional view of PCA which is a mapping
from the high dimensional data space to a low dimensional latent space, the PPCA
framework is based on a mapping from a latent space to the data space [487].” The
PPCCA extends upon the PPCA, incorporating covaritaes into the PPCA model.
These methods used the Expectation Maximization model, which uses an iterative
approach to find the Maximum Likelihood Estimates (selecting a parameter based
on maximizing the likelihood of obtaining the values observed) of a parameter [488].
Further, probabilistic models also offer the ability to determine the optimal number of
principal components, in MPPCA through the incorporation of a modified Bayesian
Information Criterion [487]. “This modified version of the BIC evaluates the like-
lihood at the maximum a posteriori (MAP) estimator instead of the MLE” [487].
Jackknife resampling refits the PPCA model with random observations removed, al-
lowing the “loadings of any probabilistic principal components based model [can] be
used to identify variables responsible for the structure in the data” and the associated
jackknife standard error can be used to compute confidence intervals for each of the
loadings [487].
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Notably, one weakness in selecting PCA, PPCA, or PPCCA for metabolomics
analysis is the underlying assumption of linearity in the latent variables. We demon-
strate many, but not all, metabolites having hormetic responses to ethanol, which
intuitively suggests non-linearity of latent variables, making validity of these meth-
ods questionable. MPPCA generates a collection PPCA models, which “can be
used to cluster subjects whilst facilitating dimensionality reduction of metabolomic
data” [487]. “Under the MPPCA model, in addition to the latent location vari-
able, the unobserved group membership of each observation is also viewed as a la-
tent variable [487].” However, MPPCA does not incorporate a covariate analysis.
Further work is needed in this area to explore better models for addressing this im-
portant weakness. Many machine learning models have been developed to address
such limitations, the use of kernel PCA, which utilizes a nonlinearity to transform
the data [486, 489]. It may be possible to apply such tools to metabolomics data to
improve the interpretation of such large and complex data sets.
In comparing only the metabolites present in both mouse and zebrafish metabolomes,
we lose important species differences in the reaction to ethanol-exposure. To examine
if species-specific differences can be identified posteriori in the MPPCA, in spite of
not being specified as a covariate, an additional analysis was run. It was anticipated
that this would also provided a statistical measure of the validity of this inter-specific
comparison. Using the MPPCA algorithm to analyze interestingly did not provide
an obvious identification of either the species differences nor the different ethanol
treatment concentrations (data not shown). Further research is needed to identify
weaknesses in the MPPCA method, or to explore optimization of the data entered
into to the model which would reveal the anticipated differences.
3.2.6 Findings
We used an un-biased metabolomics, to examine the non-polar small molecule
changes that occur in a binge model of FASD. We used liquid chromatography (LC)
with a Thermo Fisher LTQ Orbitrap mass spectrometer (MS/MS), which provides
a highly accurate identification of metabolites. We anticipated finding tryptophan
metabolites, as we have demonstrated decreased neuronal migration or differentiation
in 5-HT neurons originating in the midline raphe of the brainstem and projecting
to the dorsal and median raphe in the mouse embryos from alcohol-exposed dams
have [41]. These effects persist into adulthood of male offspring animals [40]. We also
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anticipated protein kinase C (PKC)-related metabolites to be significantly different,
based on similar findings in zebrafish. While we did not find the former, we indeed
identified significant differences in glycerophospholipids and sphingolipid changes that
are relevant to PKC. In addition, we identified metabolite related to abnormal lipid
metabolism and lipid droplets.
However, some have criticized rats and mice as models of prenatal ethanol ex-
posure, due to the majority of brain development occurring postnatally. Because of
this limitation, it is important to consider our findings in the context of our work
in zebrafish as well. Previously we reported our work in zebrafish from a similar
metabolomics study, where we saw nervous system related metabolite changes, in-
cluding myelination, tryptophan metabolism, and oxidative stress. In addition, we
saw cardiovascular related abnormalities, including significant differences in metabo-
lite related to myocyte contraction, vasculature, and coagulation. In addition, we
noted many changes in metabolites related to the endocrine system, including sex
hormones, and alterations in cellular and molecular function. Through comparing
and contrasting our non-polar mouse and zebrafish metabolomes, we have identified
many pathways that are differently altered in binge and chronic ethanol exposure
modalities. We further compare these findings through the use of a PPCCA and
contextualize them with a inter-specific development modeling tool.
3.2.7 Specific Aim and Study
The aim of this study is to develop an un-biased metabolome of ethanol-induced
changes in our binge-type mouse model. In addition, we compare similarities and
differences obtained from non-polar metabolomics analysis of mice and zebrafish using
PPCCA. In this work we will explore benefits and deficits of these model systems and
examine the translational impact when they are considered together in the context of
relativistic development. With this technique, we demonstrated both expected and
unexpected results of metabolite divergence between the two animal models, a finding
that suggests “more is not just more”.
3.3 Results
We utilized our well-established method of exposing excised c57BL/6J mouse em-
bryos to ethanol in a petri dish to examine the effects increased number of ethanol
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exposures on non-polar, whole-embryo metabolome changes. We identified a total of
32 metabolites that changed with ethanol exposure, including significant differences
in several fatty acids, glycerolipids, glycerophospholipids, ceramides, and retinoate.
A histogram of the one-way ANOVA P-value is included in Figure 3.9. Below we will
discuss in detail the metabolites we identified.
3.3.1 Fatty Acids
A total of ten fatty acids were identified in this metabolome (Table 3.3.1). Simi-
lar to our previously published zebrafish analysis, many of the fatty acid metabolites
eluted at multiple retention times. Dodecanoic acid eluted at three different retention
times, the earliest of which significantly differed from controls (Chapter 2). For mice
exposed to multiple ethanol doses, dodecanoic (lauric) acid was 6.423-fold higher than
untreated animals, significantly increased over the single-ethanol animals. Tetrade-
canoic (myristic) acid eluted at two retention times, the latter of which was signifi-
cantly different different. Hexadecanoic (palmitic) acid eluted at three separate re-
tention times, decreasing to –0.2-fold compared to controls with a single ethanol dose,
then increasing statistically significantly when in animals given two doses. Methyl
hexadecanoic acid changed significantly at the earlier of two elution times, decreas-
ing to –0.021-fold and then significantly increasing to as much as 0.027-fold controls
with two ethanol exposures. At the later elution time, a larger decrease to –0.535-
fold control was observed with a single dose, which then increased to –0.148-fold in
mice exposed to ethanol twice. (9Z )-Octadec-9-enoic acid differed significantly with
two ethanol exposures to 0.062-fold control level, but was not different with a sig-
nal ethanol exposure. Similarly, the earlier eluting octadecanoic (stearic) acid differed
significantly from controls in animals with two ethanol exposures 0.021-fold, while the
later eluting moiety significantly differed as well, being 0.043-fold greater than controls
with two ethanol exposures. This was statistically different from the –0.043-fold noted
in animals with a single ethanol dose. (5Z ,8Z ,11Z ,14Z )-Icosa-5,8,11,14-tetraenoic
(arachidonic) acid eluted at four retention times, changing statistically significantly
in two of them. Most retention times were associated with a significant increase in the
levels from singly and multiply dosed animals. 18-Methyl-(8Z ,11Z ,14Z )-nonadeca-
trienoic acid differed significantly with repeated ethanol doses, including relative to
singly dosed animals. Lastly, (8Z ,11Z ,14Z )-icosatrienoic acid did not vary signifi-
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cantly at its earlier retention time, but at the later retention time showed significant
increase in multiply dosed animals to as 0.327-fold.
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ID 6 h 6+6 h
Dodecanoic acid 1.17 ± 0.01*‡§ 1.784915 <0.01 0.000 6.423
HMDB00638 3.06 ± 0.12 1.779919 0.87 0.025 -0.184
5.10 ± 0.18 1.982239 0.38 -0.251 -0.030
Tetradecanoic acid 12.51 ± 0.29 0.955265 0.37 0.212 0.275
HMDB00806 22.70 ± 0.05* 1.209856 0.04 -0.682 0.617
Hexadecanoic acid 15.88 ± 0.22 0.845691 0.17 -0.348 -0.037
HMDB00220 16.60 ± 0.24§ 0.423041 0.37 -0.207 0.048
24.93 ± 0.12‡§ 0.384015 0.27 -0.236 0.057
Methyl hexadecanoic acid 18.00 ± 0.23*‡§ 0.657895 <0.01 -0.021 0.027
HMDB61859 25.83 ± 0.12‡§ 0.432183 0.62 -0.535 -0.148
(9Z )-Octadec-9-enoic acid 17.69 ± 0.25*‡§ 0.073338 <0.01 -0.001 0.062
HMDB00207
Octadecanoic acid 19.48 ± 0.17*‡§ -0.00985 0.02 -0.005 0.021
HMDB00827 26.62 ± 0.16*‡§ 0.468214 0.02 -0.043 0.043
(5Z ,8Z ,11Z ,14Z )-Icosa- 16.09 ± 0.26*‡§ -0.021693 0.02 0.023 0.137








ID 6 h 6+6 h
5,8,11,14-tetraenoic acid 24.02 ± 0.14§ 0.000000 0.07 -0.003 0.043
HMDB01043 31.84 ± 0.40*‡§ -0.061465 0.04 0.001 0.036
36.08 ± 0.45‡ -0.157113 0.13 -0.522 0.065
18-Methyl-(8Z ,11Z ,14Z-) 37.57 ± 0.45‡§ -0.295831 0.69 -0.233 -0.182
nonadeca-trienoic acid
LMFA01020221
(8Z ,11Z ,14Z )-Icosatrienoic acid 17.00 ± 0.19 0.02253 0.07 -0.552 0.379
LMFA01030158 24.75 ± 0.15‡§ 0.07706 0.10 -0.536 0.327
Fatty acid metabolites were identified in the non-polar fraction of ethanol-
exposed mouse embryos. The database identity of the metabolite is listed,
followed by the elution time, ppm difference, one-way ANOVA P-value, and
fold, relative to controls. *: P < 0.05 using ANOVA; † : P < 0.05 using
t-test, 6 h vs. control; ‡: P < 0.05 using t-test, 6+6 h vs. control; §:
P < 0.05 using t-test, 6 h vs. 6+6 h. Database ID abbreviations include
LMFA: LipidMaps and HMDB: Human Metabolome Database.
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3.3.2 Glycerolipids
Two glycerolipids were identified in the mouse metabolome (Table 3.2). Monoa-
cylglycerol (16:0/0:0/0:0) (MG) was significantly decreased from controls with a sin-
gle ethanol dose to –0.693, as well as significantly increased from controls with a
second ethanol dose to 0.395-fold (significantly different from singly dosed animals).
MG(18:0/0:0/0:0) differed similarly to –0.238-fold with a single ethanol dose and
0.060-fold with twice-dosed animals.
Table 3.2.
Two glycerolipid metabolites were identified in the ethanol-treated mouse
non-polar fraction, neither of which were significantly changed by one-
way ANOVA. The elution time of each metabolite is given, followed the
database identity of the metabolite, the ppm difference, ANOVA P-value,
and fold, relative to controls. ‡: P < 0.05 using t-test, 6+6 h vs. control;







ID 6 h 6+6 h
MG(16:0/0:0/0:0) 24.88 ± 0.12†‡§ 0.096888 0.21 -0.693 0.395
HMDB11564
MG(18:0/0:0/0:0) 26.60 ± 0.16‡§ -0.958393 0.26 -0.238 0.060
HMDB11131
3.3.3 Glycerophospholipids
Five glycerophospholipid metabolites were identified in the mouse FASD metabolome
(Table 3.3). Phosphatidic acid(18:0/18:2(9Z ,12Z )) (PA) was not different from con-
trol with a single ethanol dose, but after two doses was 6.213-fold higher than con-
trols. PC (O -22:2(13Z ,16Z )/22:3(10Z ,13Z ,16Z )) similarly significantly increased
to 6.371-fold higher than control animals in the 6+6 h group. Phosphatidylglu-
cose (12:0/19:0) (PG) was not significantly different with ethanol treatment. PG
(P -20:0/22:4(7Z ,10Z ,13Z ,16Z )) was significantly different, decreasing to –5.809-fold
with a single ethanol dose, then increasing to 1.011-fold in those dosed twice. Lastly,
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PS (20:1(11Z )/22:2(13Z ,16Z )) was significantly different with multiple ethanol ex-
posures, increasing to 6.291-fold.
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Table 3.3.
Glycerophospholipid metabolites were identified in the non-polar fraction of ethanol-exposed mouse embryos.
The database identity of each metabolite, elution time, ppm difference, one-way ANOVA P-value, and fold,
relative to controls are given. *: P < 0.05 using ANOVA; † : P < 0.05 using t-test, 6 h vs. control; ‡: P < 0.05
using t-test, 6+6 h vs. control; §: P < 0.05 using t-test, 6 h vs. 6+6 h. Metabolite abbreviations include
PA: phosphatidic acid; PC: phosphatidylcholine; PG: phosphoglycerol; PS: phosphatidylserine. Database ID






ID 6 h 6+6 h
PA(18:0/18:2(9Z ,12Z )) 32.44 ± 0.18*†‡§ -1.13561 <0.01 0.000 6.213
HMDB07861
PC(O -22:2(13Z,16Z)/ 38.73 ± 0.28*†‡§ 2.340455 <0.01 0.000 6.371
22:3(10Z ,13Z ,16Z ))
HMDB13456
PG(12:0/19:0) 36.09 ± 0.45 1.537769 0.18 0.003 0.037
LMGP04010057
PG(P -
20:0/22:4(7Z ,10Z ,13Z ,16Z ))-
33.73 ± 0.35*†§ 2.6191 <0.01 -5.809 1.011
LMGP04030085
PS-
(20:1(11Z )/22:2(13Z ,16Z ))-




Three prenol lipids were identified (Table 3.4). α-Bergamotenol was significantly
increased in the repeatedly dosed animals to 0.021-fold. Retinoate eluted at two
retention times. At the earlier retention time it was not significantly different, but
at the later retention time was, increasing to 0.032-fold control. 30-(2-(O -2Hydroxy-
ethane)-3-hydroxy-propane)-hopane was significantly increased to 6.339-fold in the
6+6 h treatment group.
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Table 3.4.
Prenol lipid metabolites identified in the non-polar fraction of ethanol-exposed mouse embryos.Three different
prenol metabolites were identified in the mouse non-polar fraction after ethanol treatment. The elution time of
each metabolite is given, followed by the calculated mass and the database identity of the metabolite, the ppm
difference, one-way ANOVA P-value, and fold, relative to controls. *: P < 0.05 using ANOVA; ‡: P < 0.05
using t-test, 6+6 h vs. control; §: P < 0.05 using t-test, 6 h vs. 6+6 h. Database ID abbreviations include C:






ID 6 h 6+6 h
α-Bergamotenol 22.65 ± 0.04‡ -0.482781 0.43 0.006 0.021
M91544
Retinoate 29.31 ± 0.20 0.151561 0.16 0.002 0.050
C00777 31.86 ± 0.39*‡§ 0.032644 0.04 -0.002 0.032





Six sphingolipids were identified in mouse treated once or twice with ethanol (Ta-
ble3.5). Ceramide (d18:1/16:0) (Cer) significantly differed, decreasing to –0.354-fold
with a single ethanol-exposure and increasing significantly to 0.992-fold in multiply-
exposed animals. Similarly, Cer(d18:1/22:0) decreased to –5.664-fold that of control
animals with a single ethanol dose, then increasing to 1.009-fold in multiply dosed an-
imals. Cer(d18:1/23:0) was significantly different, increasing to 6.358-fold only after
the second ethanol dose. Nervonic ceramide differed significantly as well, decreasing
to –0.626-fold with a single ethanol exposure, then increasing to 0.648-fold with two
exposures. N -Ligno-ceroyl-sphingosine increased in both treatment modalities. PI-
ceramide (d18:1/22:0) decreased to –0.238-fold in the 6 h group, but was significantly
increased from controls to 0.628-fold in the 6+6 h group. Lastly, C22 sulfatide was
significantly different because of the 6.381-fold levels in the twice-dosed group.
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Table 3.5.
Seven sphingolipid metabolites were identified in the ethanol-treated mouse non-polar fraction, many of which
changed significantly from untreated control animals. C22 Sulfatide, a glycerosphingolipid, is also included. The
database identity of each metabolite, elution time, the ppm difference, one-way ANOVA P value, and fold relative
to controls are given. *: P < 0.05; † : P < 0.05 using t-test, 6 h vs. control; ‡: P < 0.05 using t-test, 6+6 h vs.
control; §: P < 0.05 using t-test, 6 h vs. 6+6 h. Metabolite abbreviations include Cer: ceramide. Database ID






ID 6 h 6+6 h
Cer(d18:1/16:0) 32.37 ± 0.31*†§ -0.50157 0.03 -0.354 0.992
HMDB04949
Cer(d18:1/22:0) 39.62 ± 0.30*†§ -1.391557 <0.01 -5.664 1.009
HMDB04952
Cer(d18:1/23:0) 41.74 ± 0.28*‡§ -1.592142 <0.01 0.000 6.358
HMDB00950
Nervonic ceramide 39.78 ± 0.32*‡ -1.539479 0.04 -0.626 0.648
HMDB04953
N -Ligno-ceroyl-sphingosine 44.11 ± 0.34§ -1.671702 0.26 0.177 0.889
HMDB00831
Phosphatidylinositol-ceramide 33.97 ± 0.40‡ -2.466695 0.12 -0.238 0.628
(d18:1/22:0)
LMSP03030001




Four other metabolites were also identified in the mouse metabolome (Table ??).
1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one increased significantly with ei-
ther modality of ethanol-treatment. Dimethisterone was significantly different from
controls in the twice-dosed animals, decreasing to –0.199-fold. The peptide proline-
serine-argining decreased with singly-exposed animals, and increased in multiple-




Other metabolites identified in the non-polar fraction of ethanol-exposed mouse embryos.Five metabolites of
other types were identified in the mouse non-polar fraction. The database identity of each metabolite, elution
time, the ppm difference, ANOVA P-value, and fold relative to controls are given. ∗: P < 0.05 using one-way
ANOVA; †: P < 0.05 using t-test, 6 h vs. control; ‡: P < 0.05 using t-test, 6+6 h vs. control; §: P < 0.05 using







ID 6 H 6+6 H




Dimethi-sterone 22.60 ± 0.06‡ -0.220726 0.95 -0.182 -0.199
C07628
Proline-serine-arginine 21.58 ± 0.04 0.597437 0.36 -0.200 0.276
M15698
Lysine-histidine-methionine 15.58 ± 0.21 -2.250094 0.46 0.044 -0.517
M17238 16.86 ± 0.17§ -1.533058 0.11 -0.504 0.017
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3.3.7 Common Metabolites
Six significantly different metabolites common to both mouse and zebrafish FASD
models (Table 3.7). The m/z values were identified as 1-(2,6,6-trimethyl-2-cyclo-
hexen-1-yl)-1-penten-3-one, tetradecanoic acid, methyl hexadecanoic acid, octade-
canoic acid, PA(18:0/18:2(9Z,12Z)), and C22 sulfatide. In general the magnitude
of change was much greater for zebrafish than in mice. Changes with a single dose
of ethanol in the mouse model never exceeded 1-fold. However, with a second 6 h
ethanol exposure in the mouse model, PA(18:0/18:2(9Z,12Z)) and C22 sulfatide were
increased by more than 6.2-fold control levels. In the zebrafish, these metabolites
showed more than a 6-fold decrease with low ethanol concentrations, then increased to
levels similar to controls at moderate-ethanol doses. 1-(2,6,6-Trimethyl-2-cyclohexen-
1-yl)-1-penten-3-one increased marginally in the repeated mouse exposure model, but
was decreased at most ethanol doses in the zebrafish model, falling to as low as –7.059
with 0.1% ethanol. Tetradecanoic acid changed slightly in the mouse model, but was
increased more than 6-fold with all ethanol doses in the zebraifh model, except at
0.003% ethanol, where it was not different from controls. Methyl hexadecanoic acid
and octadecanoic acid both varied little from controls in the mouse model. In the ze-
brafish model methyl hexadecanoic acid increased slightly with 0.001% ethanol, then
decreased to –6.326-fold control levels at 0.3% ethanol and higher. Octadecanoic acid
similarly increased with 0.003% ethanol to 0.190-fold control levels, and then fell to
–0.825-fold control levels at 3% ethanol.
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Table 3.7.
Few significantly changed (one-way ANOVA within-species) metabolites were common to both the Danio rerio
and Mus musculus non-polar metabolomes. The database identity of each metabolite, as well as the fold, relative
to the same species controls are given. For the mouse treatments, embryos were excised and exposed to one (n=7)
or two (n=7) consecutive days for 6 h exposures of 400 mg/dL alcohol. Control mice (n=6.) were not exposed
to ethanol, but were incubated in culture medium. Zebrafish embryos (n=8 per group) were exposed from 2 –24
hpf to 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3% ethanol (v/v). Samples were then extracted and the non-polar
fraction was analyzed by LC-MS/MS (Orbitrap). Database ID abbreviations include C: KEGG; M: Metlin
Metabolite Fold Mus musculus Fold Danio rerio
ID 6 h 6+6 h 0.001 0.003 0.01 0.03 0.1 0.3 1 3




Tetradecanoic acid -0.682 0.617 6.557 0.000 6.186 6.745 7.193 6.745 6.745 6.473
HMDB00806
Methyl hexadecanoic acid -0.021 0.027 0.690 0.486 -0.001 -6.326 -6.326 -6.326 -6.326 -6.326
C16995
Octadecanoic acid -0.043 0.043 0.001 0.190 -0.031 -0.029 -0.001 -0.029 -0.029 -0.825
C01530
PA(18:0/18:2(9(Z ),12(Z ))) 0.000 6.213 -6.013 0.061 -6.013 0.086 0.103 0.086 0.086 0.753
LMGP10010036
C22 Sulfatide 0.000 6.381 -6.252 -6.252 -6.252 -0.169 -0.150 -0.169 -0.169 0.491
M41627
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3.3.8 Pobabilistic Principal Component and Covariates Analysis
Because we were comparing two different species with different modalities of
ethanol exposure, we pursued a PPCCA. This model is an extension on the prob-
abilistic principal component analysis, and allows for the incorporation of observed
covariates into the model. The MetabolAnalyze package was selected due to the need
to include the covariates (species and treatment) in the analysis. Standard principal
component analysis (PCA) does not accommodate this [487]. Further PPCCA also
accommodates missing variables using the “Expectation Maximum” algorithm.
The PPCCA was generated from the five common metabolites present in both
the mouse and zebrafish models that were significantly different. The Bayesian Infor-
mation Criterion plot indicated that the maximum number of principal components
(PrC), q, should be 4, and so subsequent models were generated using a maxq = 4
(Figure 3.10). Loadings plots were generated to examine the relationship between
each metabolite on the latent variable (Figure 3.2). The loadings plot demonstrated
the PrC1 was positively effected by the response of 1-(2,6,6-trimethyl-2-cyclohexen-
1-yl)-1-penten-3-one (the metabolite we believe to be a cleaved vitamin A moiety,
Cleaved A, based on their structural similarity [Figure 3.1, Structure ¡!–3-2]), methyl
hexadecanoic acid, and to a lesser extent octadecanoic acid to ethanol. Tetrade-
canoic acid and octadecanoic acid were the only metabolites that were negatively
loaded in PrC2. For PrC3, tetradecanoic acid, octadecanoic acid, PA(18:0/18:2),
and C22 sulfatide were positively loaded, while 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-
-1-penten-3-one and methyl hexadecanoic acid were negative. Lastly, all metabolites
except octadecanoic acid loaded negatively on PrC4. PA(18:0/18:2) and C22 sulfatide
always had the same directional loading on the latent variables. Scores plots demon-
strate the estimated score of each individual within the reduced PrC space (Figure
3.3). The increasing size of the circles, the 95% posterior set, indicate that PrC3
and PrC4 are less explanatory of our data than PrC1 and PrC2. The model was
refit using jackknife sampling to examine the uncertainty of the loadings estimates
(Figure ??). The loadings plot, which includes 95% confidence intervals calculated
from the standard error generated by recomputing the loadings, indicating which
loadings are significantly different from zero (Figure ??) [487]. 1-(2,6,6-Trimethyl-
2-cyclohexen-1-yl)-1-penten-3-one, methyl hexadecanoic acid, and octadecanoic acid

















Fig. 3.1. Zebrafish embryos were treated from 2–24 hpf to 0–3% ethanol.
Two of the vitamin A-related metabolites observed, included 9,13-cis-
Retinoate (Structure 3-1) and 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-pen-
ten-3-one (Structure 3-2), potentially a cleavage product of retinoate de-
gredation.
canoic acid, PA(18:0/18:2), and C22 sulfatide loaded significantly negatively on PrC1.
3.4 Discussion
FASD is caused by ethanol exposure during development. Because of the complex
nature of this syndrome, it has been difficult to determine biochemical effects common
to both binge and chronic alcohol exposure modalities. We have utilized our well-
established mouse model to generate an “unbiased” non-polar metabolome of FASD.
For mice, excised c57BL/6J E8.2 embryos were exposed to 400 mg/dL of ethanol
bursts on consecutive days for zero (control, n=6), one (6 h, n=7) or two 6 h (6+6
h, n=7). This model represents a binge ethanol effect. We compared these results to
our chronic ethanol exposure model, where zebrafish embryos are exposed from 2–24
hours post fertilization (hpf) to ethanol at concentrations from 0–3%.
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In the mouse metabolome, we noted differences in fatty acids (9), two glyc-
erolipids, several glycerophospholipids (5), three prenols, sphingolipids (7), and other
metabolies (4). These results echo similar findings in our chronic zebrafish FASD
model, however the magnitude of changes in the binge mouse metabolites was greatly
diminished (Chapter 2). In addition, our results demonstrate statistically signifi-
cant differences in the mouse metabolome between singly and doubly dosed animals,
suggesting a compounding effect of repeated binge exposure.
When we compared our previously reported zebrafish metabolome with the results
of the mouse metabolome, six common, significantly different metabolites were iden-
tified. These included 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one (Cleaved
A), tetradecanoic acid, methyl hexadecanoic acid, octadecanoic acid, PA(18:0/18:2),
and C22 sulfatide. We conduced a PPCCA of these models, to determine latent
similarities and differences of significantly different metabolites in these contrasting
exposure modalities and species. The PrC loadings of these models underscore the
importance of alterations of chemicals involved in neural structure formation, cell
death, and secondary cellular signaling in the etiology and pathogenesis of FASD.
The biochemical changes occurring in the non-polar FASD metabolome common to
both models, may represent a unifying approach to the dose and/or timing debate in
FASD research, and show that more is not just more.
3.4.1 Growth and Energy
Growth and energy metabolism changes are important in understanding FASD.
Animals consuming alcohol, generally reduce their intake of food [285]. This is gener-
ally addressed through the use of pair-fed dams. This might convey an overt advan-
tage to the zebrafish model, as they are not ingesting nutrients. However, we have
not examined whether or not there is a change in the uptake of nutrients sourced
from maternal yolk with ethanol. Also, Weinberg et al. perceptively point out that
mothers pair-fed to match the animals on the alcohol-based diet are therefore in a
restricted intake state, as the ethanol based-diets are formulated to be complete. In
their experiments, pair-fed animals appeared to be chronically hungry, consuming
their food much more rapidly than ad libitum fed animals. Therefore, the pair fed
animals are under an induced stressed by this limited diet [285]. These findings were
confirmed with post-adrenalectomy pair-fed animals showed increases in adrenocorti-
cotrophin and coricotrophin-relaeasing hormones, above that of control animals and
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similar to alcohol fed animals. However, even beyond these energy differences, we
noted changes that may influence lipid droplets and lipid uptake, which are likely to
alter growth and energy metabolism.
Hepatic Stellate Cells May Mobilize Lipid Droplets in Response to Retinoid
Metabolism Changes
Similar to our findings in zebrafish, we found many binge mouse metabolome
changes that impact the growth and energy. These included differences in fatty acids,
glycerophospholipids, and sphingolipids. PA, PC, and PS are all important in the ner-
vous system, but all three of these metabolites are also important in the structure and
function of lipid droplets [490]. Abnormal lipid droplets are associated with ethanol
consumption or prenatal ethanol exposure. Female UCh ethanol-preferring rats fed
ad libitum ethanol demonstrate unusual cytoplasmic lipid droplet accumulation in
the lining of the endometrium [491]. In addition, in prenatally ethanol exposed male
Wistar rats fed a high-fat diet after weaning, lipid droplets were abnormally accumu-
lated in the hypothalamus, pituitary, and liver [492]. In newborn offspring of Hartley
guinea pig dams fed 6 g ethanol/kg body weight for the second half of gestation,
electron micrographs of the gastrocnemius show enlarged lipid droplets [493].
In normal conditions, cytosolic lipid droplets in rat hepatic stellate cells (HSC)
contain “retinyl ester, triglyceride, cholesteryl ester, cholesterol, phospholipids, and
free fatty acids”, with retinyl esters and triglycerides making up the largest por-
tion of total lipids [494]. Lecithin:retinol acyltransferase is required for formation of
these lipid droplets [494]. In a distressed, diseased, or chronic alcohol-exposed state,
HSC become activated and lose these droplets, including the retinoid [494]. Recent
work in isolated HSC from Sprague Dawley® rats has demonstrated that vitamin
A and insulin are required to maintain HSC in their inactivated form [495]. Due to
mobilization of hepatic retinyl esters, some tissues are found to have an excess of
all-trans-retinoic acid with ethanol treatment [420–422].
Vitamin A has been well studies for its relationship to FASD. There is important
mechanistic overlap between alcohol catabolism and vitamin A metabolism. ADH3,
along with the cofactor NAD+, converts retinol to retinal, which is then able to be
converted to retinoic acid [84]. During gastrulation of Xenopus embryos, retinalde-
hyde dehydrogenase is competitively inhibited by ethanol [419]. There appears to be
a diminished effectiveness of vitamin A, as Long Evans pups postnatally exposed to
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ethanol (∼80 mM blood alcohol concentration) have decreased cerebellar expression
of retinoic acid receptors α/γ, but increased expression of retinoic acid X receptors
α/γ [423]. Further, genomic interactome analysis of the brains of c57BL/6J prena-
tally ethanol exposed mice (exposed at various times to 2.5 g/kg ethanol) showed
retinoate metabolism genes were underexpressed [130].
Vitamin A, significantly increased with ethanol treatment in our mouse model
and our previously reported zebrafish polar metabolome (Chapter 2). In addition, 1-
(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one significantly increased in the binge
mouse model, but was significantly decreased in the zebrafish. We hypothesize that
this metabolite, based on its structural similarity, is actually a cleaved form of vitamin
A. Vitamin A is an isoprenoid, a class of molecules noted to be perturbed in FASD [48].
Similarly, we found two other isoprenoids that differed in our model, one of which
increased 6.339-fold after two alcohol exposures.
Since we are examining whole-embryo extracts, simply mobilizing the lipid droplets
from the HSC would not result in a change in the metabolite levels detected. How-
ever, as retinyl esters and retinoate differ in mass, the increased vitamin A we detect
could be a result of increased mobilization and conversion to retinoate. Ethanol mo-
bilizes HSC lipid droplets in response to decreased function in vitamin A metabolism,
decreased retinoic acid receptors, and underexpressed genes, all caused by ethanol.
In addition, ethanol induces a cleavage of vitamin A, which likely further disrupts
function. With a single burst of ethanol, vitamin A metabolism is not different and
seemingly able to manage the insult. But, with an additional binge of ethanol, HSC
mobilize lipid droplets in compensation for the effects of ethanol. With the chronic
ethanol exposure of the zebrafish, the effects of ethanol result in vitamin A being
completely consumed, in spite of the lipid mobilization, and the cleavage product is
also broken down.
Lipid Metabolism
The non-polar extract metabolome of the ethanol-exposed embryo shows signifi-
cant differences in fatty acids. We noted significant alterations in dodecanoic, tetrade-
canoic, hexadecanoic, octadecanoic, (9Z )-octadec-9-enoic acid, amongst others. In
the zebrafish, we noted increased, decreased, and hormetic responses to ethanol treat-
ment in the significantly different fatty acids, which we believe are associated with
abnormal growth and development caused in part by aberrant fatty acid metabolism
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(Chapter 2). In the mouse model, significantly different metabolites were similar to
or marginally increased with a single ethanol dose, while a repeated dose increased
the fatty acid variation. From our data, it is unclear whether these increases are due
to decreased fatty acid utilization or increased synthesis.
MG can be generated via enzymatic alcoholysis [496]. Several lipases have aversion
to polyunsaturated fatty acids, resulting in a bias toward the reaction of saturated
and monounsaturated fatty acids being converted to ethyl esters [497]. 2-Monoa-
cylglycerol (2-MG) has also been shown to be produced in vitro by similar lipase
activities [498]. Particularly lipase D has been shown in vitro to result in high levels
of 2-MG, and can be deactivated by contact with ethanol, making a chronic drinking
mother exacerbate this lipase malfunction [496]. This ethanol-induced deactivation
of lipases could explain the decrease in MG noted in singly-dosed animals. Levels
of MG increased significantly between singly- and doubly-dosed animals, which may
suggest increased levels or function of lipase with repeated exposure.
Additionally, monoacylglycerol-acyltransferases (MGAT) and diacylglycerol (DAG)
acyltransferases are essential building blocks for triacylglycerol synthesis. MGAT
is localized in the endoplasmic reticulum, absorbing dietary lipids in the entero-
cyte [499]. It also mediates intracellular concentrations of MG and participates in
energy regulation and mediation of insulin sensitivity [499]. Monoacylglycerol-O -
acyltransferase 1 gene expression has been shown to increase 1.20-fold in Danio rerio
exposed to e − 7 M 17β-estradiol for three weeks [500]. In analysis of our polar
fraction metabolome in zebrafish, we noted that even with low ethanol doses 1α-hy-
droxyesterone increased significantly (Chapter 2). In addition, we found a significant
increase in 16-dehydroprogesterone and a significant decrease in a precursor-related
product 13-ethyl-16,17-dihydroxy-18,19-dinorpregna-4,9,11-trien-20-yn-3-one. (Inter-
estingly, others have reported no difference in 17β-estradiol in ethanol treated alcohol-
preferring or Wistar female rats [491, 501].) Taken together, these findings may sug-
gest that with ethanol exposure, increases in estrogen-related metabolites upregulate
MGAT, which in conjunction with inactivated lipase, causes changes in MG.
PPCCA and Lipids
Many researchers use PCA in order to analyze their data, but fewer go beyond and
look for the biological meaning behind them —the driver of the principal components.
Without a more in-depth exploration of interpretation of PCA, we are left in the realm
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of interesting coincidence rather than a meaningful research driver. Given the limited
amount of coinciding, significantly different metabolites in these species, it is difficult
to make the leap to interpretation. However, based on the PPCCA PrC1 loading
being positive for cleaved A, methyl hexadecanoic acid, and octadecanoic acid, the
latent variable may be representing the lipid metabolism changes noted above.
3.4.2 Nervous System
Glycerophospholipids
As in our previous work, we found many binge mouse metabolome changes that
impact the nervous system. Glycerophospholipid changes that occur with ethanol
exposure have important implications in the nervous system. With one exception,
the glycerophospholipids we identified were not different from control after a single
ethanol dose, but increased significantly after a second ethanol dose. PA, PS, and
PC increased the most, to more than 6.2-fold controls. These metabolites play an
important role in the nervous system. PC is converted by phospholipase D (PLD)
to PA. PA has a variety of functions, including in astroglial proliferation, neurite
outgrowth, function as a signaling molecule, or contribute to the phospholipid bilayer
of all cells [101,490].
Ethanol can shunt PLD to generate phosphatidylethanol instead of PA from PC
[99,115]. In addition, ceramide, which was generally decreased with one ethanol dose
and increased with two, can inhibit PLD [116]. With chronic ethanol exposure in the
zebrafish, there were a variety of differences in PA moieties, but PC moieties were
all significantly increased with ethanol treatment. In the binge mouse model, the PA
and PC detected significantly increased, but only after the second ethanol dose. It
is unclear whether these differences are due to decreased conversion of PC to PA by
PLD and/or decreased utilization of PA.
Sphingolipids
Ceramides have a variety of functions, including as precursor of the myelin com-
ponent sphingomyelin, as an activator of phosphatases and thereby cell death, and
also as a precursor to sphingosine [33]. It has been hypothesized that prenatal
ethanol exposure causes an increase of ceramide by increasing serine-palmitoyl trans-
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ferase activity. This results in de novo synthesis of ceramide, rather than conversion
from sphingomyelin via sphingomyelinase [33]. Others have proposed ethanol in-
creases ceramide sphingosine recycling in rat cerebellar granule cells [127]. During
all-trans-retinoic acid-induced neuron differentiation, SH-SY5Y neuroblastoma cells
have downregulated (mRNA, protein, and enzymatic activity) neutral ceramidase,
an enzyme critical for control of ceramide turnover [142]. This occurs without an
alteration in the level of sphingosine or sphingosine–1-phosphate [142]. In conjunc-
tion with the significant increase in retinoate and the established abnormalities in
retinoid metabolism that occurs with ethanol, our results may suggest that neutral
ceramidase is downregulated in FASD. However, we did note twice-dosed mice had
significantly increased N -ligno-ceroyl-sphingosine and ceramides than controls, so this
notion requires further investigation.
Many ceramides decreased significantly with a single ethanol dose, while others
increased significantly with two ethanol doses. The ceramide precursor octadecanoic
similarly decreased with one dose, but then significantly increased with two doses.
These differences are important as ceramide accumulation with ceramidase activity,
can lead to increases in sphingosine, and result in consequent toxicity to neurons [134].
PI-ceramide was present in both the zebrafish and mouse metabolomes. With
a single dose in the mouse or at the lowest chronic zebrafish dose, this metabolite
decreased. However, with higher zebrafish ethanol doses it was marginally increased,
and with a second ethanol dose in the mouse it was significantly increased from
controls. PI, which can be converted to the PKC activator DAG. Sphingosine and
ceramide accumulation are known to inhibit PKC [33, 135, 136]. Contrary to the
significant increase in PA and PC in twice-dosed animals, ceramides have been shown
to inhibit phospholipase D, preventing the conversion of PC to PA [116]. So, while
the decreases in PI in conjunction with increases in ceramides suggests decreased
PKC activation, the increases in PA and PC are confounding and require further
investigation.
Sulfatides
Sulfatides are a class of sulfoglycosphingolipid that participate in important phys-
iological functions such as the immune system responses, insulin secretion, hemosta-
sis, and thrombosis [143]. Studies of Sprague Dawley® show they compose ∼4.4%
of myelin [143, 144]. Sulfatides function as a negative regulator in oligodendrocyte
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differentiation, influence myelin stability, and a myelin-associated neurite outgrowth
inhibitor [143,145,146,148].
In the chronic zebrafish model, sulfatides were significantly decreased. However,
in the binge mouse model, a single ethanol dose did not modify sulfatide, but a
second dose increased it to 6.381-fold. It is possible that with minimal ethanol expo-
sure, sulfatides are unaffected. But, with repeated dosing, sulfatides are increased for
the purpose of myelin preservation. However, when alcohol exposure is chronic, the
decreased sulfatides represent destabilized myelin. Further study through examina-
tion of labelled sphingolipids may help clarify the exact relationship between ethanol
modalities and sulfatides.
PPCCA and the Nervous System
Based on the loadings of PrC2 and PrC3, the underlying latent variable of these
components is likely neural related. PPCCA PrC2 was positively loaded by cleaved A,
PA(18:0/18:2), and C22 sulfatide. PA(18:0/18:2) and C22 sulfatide. PPCCA PrC3
was positive for ocatdecanoic acid, PA(18:0/18:2), and C22 sulfatide, and to a lesser
extent tetradecanoic acid. It is clear that these metabolites are important in the
development and functioning of the nervous system. However, the exact mechanism
generating PrC2 and PrC3 requires further investigation.
3.4.3 Relativistic Inter-specific Development Model
An enormous limitation to our capabilities in translational medicine is the lack
of ability to quantitate the inter-specific differences seen in the laboratory. To be
effective as translational scientists we must develop methods to measure differences
in species to account for these not-so-nuanced differences. We have mainly focused
as a community on the use of biomarkers, but working toward quantitating model
differences will lead to better predictive models of human disease. To that end, we
have developed a novel application of the PPCCA, as discussed above. In addition,
to contextualize our metabolome findings, we have developed a tool for intra-specific
development comparison.
For over 100 years, even as early as Haekel’s artistic rendering of developmental
stages in the chick, the debate as to the similarity between species has continued.
While some find homology in the pattering of development stages, others find nu-
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ances that indicate clearly different developmental order, compartmentalization, and
modularity [502] Relative to mice and humans, many developmental systems are
conserved in zebrafish, such as the presence of somites, body axis patterning, and
central nervous system [469]. However, there are several important consideration.
Zebrafish demonstrate phylotypic variability, supporting the notion that “there is
no highly conserved embryonic stage in vertebrate embryos but rather a period of
general similarity” [502]. Further, vital to many experiments is breeding of fish. In-
dividual aquarium tanks require the manual insertion of breeding media (marbles or
mesh with plants over a collection vessel) into the tank for breeding. This results in
asynchronous breeding which has a great potential to influence embryonic or larval
temporal experiments.
There remains, however, appreciable utility in comparing and contrasting findings
from these exposure modalities, in spite of the species difference. An extremely
important consideration in the evaluation of any research model of development is the
asynchronous order or progression rate that occurs between species. For perspective,
an approximate timeline comparing human, mouse, and zebrafish development is
provided (Figure 3.6). The x-axis is lnproportion of days until reproductive maturity.
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Fig. 3.2. Principal component loadings barplots for the PPCCA model
generated from metabolites significantly changed in both the mouse and
zebrafish models of FASD, using species and ethanol exposure as covari-
ates. For the mouse treatments, embryos were excised and exposed to one
(n=7) or two (n=7) for 6 h exposures of 400 mg/dL alcohol on consec-
utive days. Control mice (n=6.) were not exposed to ethanol, but were
incubated in culture medium. Zebrafish embryos (n=8 per group) were
exposed from 2–24 hpf to 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3%
ethanol (v/v). Samples were then extracted and the non-polar fraction
was analyzed by LC-MS/MS (Orbitrap). The PPCCA model incorpo-
rates significantly changed (one-way within-species ANOVA, P < 0.05)
metabolites appearing in both species. Cleaved A: 1-(2,6,6-trimethyl-2-
cyclohexen-1-yl)-1-penten-3-one; PA: Phosphatiic Acid.
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Fig. 3.3. PPCCA scores plot of the individuals in each treatment group
with respect to the PC loading, demonstrating the estimated score of
each individual within the reduced PrC space. The increasing size of
the circles, the 95% posterior set, indicate that PrC3 and PrC4 are less
explanatory of our data than PrC1 and PrC2.The x- and y-axes represent
the relationship of one principal component to another. The filled circles
indicate mice and triangles indicate zebrafish. The color represents a
spectrum of ethanol exposure from zero (red) through 805.91 µ M (blue).
The grey circles represent 95% posterior sets, which are large, indicating
some degree of uncertainty. For the mouse treatments, embryos were
excised and exposed to one (n=7) or two (n=7) consecutive days for
6 h exposures of 400 mg/dL alcohol. Control mice (n=6.) were not
exposed to ethanol, but were incubated in culture medium. Zebrafish
embryos (n=8 per group) were exposed from 2–24 hpf to 0, 0.001, 0.003,
0.01, 0.03, 0.1, 0.3, 1, or 3% ethanol (v/v). Samples were then extracted
and the non-polar fraction was analyzed by LC-MS/MS (Orbitrap). The
PPCCA model incorporates significantly changed (one-way within-species
ANOVA, P < 0.05) metabolites appearing in both species.
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Fig. 3.4. Scatterplot of the PPCCA model loadings generated from
metabolites significantly changed in both the mouse and zebrafish models
of FASD, using species as a covariate.
The relationship of each metabolite in the principal components space is plotted. For the mouse
treatments, embryos were excised and exposed to one (n=7) or two (n=7) consecutive days for 6
h exposures of 400 mg/dL alcohol. Control mice (n=6.) were not exposed to ethanol, but were
incubated in culture medium. Zebrafish embryos (n=8 per group) were exposed from 2–24 hpf
to 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3% ethanol (v/v). Samples were then extracted and
the non-polar fraction was analyzed by LC-MS/MS (Orbitrap). The PPCCA model incorporates
significantly changed (one-way within-species ANOVA, P < 0.05) metabolites appearing in both
species. Cleaved A: 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one; PA: Phosphatiic Acid.
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Fig. 3.5. Barplot of the PPCCA model after Jackknife resampling, gen-
erated from metabolites significantly changed in both the mouse and ze-
brafish models of FASD, using species and ethanol exposure as covariates.
Cleaved A, methyl hexadecanoic acid, and octadecanoic acid loaded positively on Prin-
cipal Component 1, while tetradecanoic acid, PA(18:0/18:2), and C22 sulfatide loaded
negatively. Error bars representing 95% confidence interval show stearic acid is not
significantly loaded on PC1. For the mouse treatments, embryos were excised and
exposed to one (n=7) or two (n=7) consecutive days for 6 h exposures of 400 mg/dL
alcohol. Control mice (n=6.) were not exposed to ethanol, but were incubated in
culture medium. Zebrafish embryos (n=8 per group) were exposed from 2–24 hpf to 0,
0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3% ethanol (v/v). Samples were then extracted
and the non-polar fraction was analyzed by LC-MS/MS (Orbitrap). The PPCCA
model incorporates significantly changed (one-way within-species ANOVA, P < 0.05)
metabolites appearing in both species. Cleaved A: 1-(2,6,6-trimethyl-2-cyclohexen-1-
yl)-1-penten-3-one; PA: Phosphatiic Acid.
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Fig. 3.6. Developmental comparison of zebrafish and mouse FASD models
versus humans. In our experiment, zebrafish were exposed from 2–24 hpf
to 0–3% ethanol, indicated on the timeline as a blue horizontal bar. The
blue arrow indicates the time of zebrafish sacrifice. Mice were exposed
0, 1, or 2 times to 400 ng/dL of ethanol. Orange bars indicate mouse
ethanol exposure times. Orange arrow indicates the time when all mice
were sacrificed; Eye icon: lens vesicle complete; Open heart icon: begin-
ning of heart development; Filled and checked heart icon : completion of
heart development; A: initial development of arches; L: liver development
begins; M: beginning of meconium production; N: neural tube closure;
N*: neural rod cavitation completed; S: first somites appear
Based on this timeline, we note the magnitude of difference between the ethanol
exposures of the chronic and binge models is quite large. In addition, the ethanol
exposure for the binge mouse model occurs within the relative time-frame of the
zebrafish chronic exposure. At the time of sacrifice of the mice, they are approxi-
mately equivalent to Carnegie stage 15 humans. The time of zebrafish sacrifice would
approximate to early to mid 2nd trimester human development.
Due to the differences in rates of reproductive maturity in these species, the time-
line shows variation in key stages between species (i.e., each species has a different
point for fertilization). While there are limitations to this approach as a result, it can
still provide useful information regarding cross-species developmental comparisons in
animal modeling. For example, with this comparison of development, human and
zebrafish enter gastrulation relatively closely to one another, but mouse gastrulation
is later than these two. Zebrafish also differ in development during the early cleav-
age stage in that it has meroblastic discoidal clevage as opposed to mammals that
have equal holoblastic cleavage [503]. Also, development of the pharyngeal arches
in the zebrafish begins slightly after the human, but well before the mouse. (These
relative delays in mice are counterintuitive, as they are more precoccial at birth than
humans.) Gastrulation and pharyngeal arch development are during the time of the
ethanol exposure in the zebrafish model. However, in the mouse, this process occurs
after the time of sacrifice in our experiments.
Another potentially important difference is that heart development in the mouse
begins sooner than the zebrafish and later in the human, relatively. Heart develop-
ment completes in all three at a relatively similar time. This may have particular
relevance in the cardiovascular abnormalities that develop in FASD. In particular,
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this may include the effects surrounding PKC, as PI–3 kinase activation regulates
excitation-contraction in myocytes [254].
Zebrafish liver development begins after that of the human and before the mouse,
relatively. This is important in understanding how our models function in catabolism
of alcohol. However, based on this depiction of our model, liver development does
not begin until after our mouse binge exposures. This could explain why so many
metabolites relevant to the lipid droplet mobilization hypothesis discussed above are
significantly differed only after the second ethanol exposure. In the future, this could
be better controlled by not exposing the single-dose group to ethanol until the time
of the second dose of the twice-dosed group.
In terms of relative neural tube closure, humans begin much before mice. In ze-
brafish the completion of neural cavitation falls between these two, and is near the end
of the ethanol exposure window in this model. The implication of this is important, as
this suggests that nervous system-related changes noted in the mouse impact neural
development, more so than neural function. This distinction is important, as it can
help separate some of the complexities of development that inhibit our understanding
of neural defects in FASD.
While this method of relativistic developmental comparison is not without limits,
this information is still an important consideration. With such an approach, selecting
the most appropriate animal model for a development or aging-related disease or
pharmacology can be made easier. Further, for complicated diseases, such as FASD,
it can help explain differences in metabolism observed between different species, such
as what we have shown here with metabolomics. While no single animal model can
provide a comprehensive substitute for human research, intra-specific comparisons
between models such as zebrafish and mice provides tremendous power as FASD
research tool.
3.5 Conclusion
We have identified many mouse metabolites that appear to be significantly dif-
ferent only after a second dose of alcohol. We noted several changes that support
the hypothesis of abnormal lipid droplets in FASD, based on significant differences in
glycerophospholipids and vitamin A. In addition, we noted several changes in lipid-
related metabolites, that support the notion that FASD alters lipid metabolism, po-
tentially via ethanol’s inhibition of lipase and increased estrogen, resulting in MGAT
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inhibition. We also found ethanol-induced alterations that occurred with repeated
binges that may decrease PKC activation. These included changes in glycerophos-
pholipids, ceramides, and sphingolipids. Though we utilized post hoc analysis in the
comparison and contrasting of zebrafish and mouse models under differing exposure
modalities, we have observed interesting differences between our models of binge and
chronic alcohol-induced FASD. In addition, we have contextualize the metabolome
differences between these models with respect to their relative development.
3.6 Materials and Methods
3.6.1 Animal Husbandry and Ethanol Exposure
Animal experiments using Danio rerio were performed in accord with Purdue
Animal Care and Use policies at Purdue University (West Lafayette, Indiana, USA)
using approved protocol 1111000275. Extensive details of the Danio rerio ethanol
exposure are available in our previous publication (Chapter 2). In brief, healthy
adult AB strain zebrafish, were housed in 15-gallon glass aquaria with approximately
twenty-four mixed male and female. Light timing was used to induce spawning.
To collect fertilized eggs, mesh topped pyrex dishes were placed in aquaria at 0925
AM. After confirming eggs were fertilized via visual microscope examination, they
were incubated in E3 media (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33
mM MgSO4 in distilled water) [63]. At 2 hours post-fertilization (hpf), embryos
were randomized in to ethanol treatment groups (n=8 per group) and transferred
in to 6-well plates with the appropriate ethanol concentration in each well. Ethanol
treatment groups included 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3% v/v. Embryos
were incubated in covered plates at 28 ◦C (18 hours (h) light, 6 h dark) until 24 hpf.
Embryos were washed with E3 media twice and further incubated until 48 hpf, at
which time they were flash frozen in liquid nitrogen and stored at −80 ◦C until time
of sample processing.
Animal experiments for Mus musculus were performed in accord with Indiana
University School of Medicine (Indianapolis, Indiana, USA) Animal Care and Use
policies using approved protocol 000000 ethanol exposure was achieved using our
previously reported protocol. In brief, c57BL/6J mouse embryos were excised from
the dam at noon on E8.2. Culture of the embryos began an hour later in petri dishes



























































































































































































































































Fig. 3.7. Experimental design for c57BL/6J Mus musculus embryos
cultured in ethanol.
Mouse embryos were excised from the dam at noon on E8.2, with culture of the embryos beginning
an hour later in petri dishes with medium (control embryos, n=6). Ethanol-treated animals were
exposed once (6 hour, n=7) or twice (6+6 hour, n=7) to ethanol 400 mg/dL for six hour increments.
Alcohol was added from 1:00–7:00 PM, and then the media was changed. On the second day, the
media was again changed at 3:00 PM for all animals. For the 6+6 hour group, alcohol was again
added from 9:00 AM–3:00 PM. All embryos were harvested the following day at 10:00 AM, at which
time the embryos were dissected with the yolk-sac removed and snap frozen.
and 6+6 h (n=7) groups, 400 mg/dL alcohol was added from 1:00–7:00 PM, at which
time the media was changed. On the second day, the media was again changed at
3:00 PM. For the 6+6 h group, alcohol at 400 mg/mL was again added from 9:00
AM to 3:00 PM. All embryos were harvested the following day at 10:00 AM, at which
time the embryos were dissected with the yolk sac removed and snap frozen. Embryos




Sample preparation was conducted as previously reported (Chapter 2). In brief,
samples were thawed at 4 ◦C, extracted in 2:1 methanol:water, homogenized, ex-
tracted in cold chloroform, centrifuged and concentrated. The non-polar fraction was
dissolved in 50% double-distilled water, 25% methanol, 25% acetonitrile.
The samples were analyzed using Thermo Fisher LTQ Orbitrap (Waltham, MA
USA) mass spectrometer (MS) coupled to an Agilent 1100 series Liquid Chromatog-
raphy (LC) (Agilent Technologies, Santa Clara, CA, USA), using an Eclipse XDB-C8
column (Agilent Technologies, Santa Clara, CA, USA). Solvent A was water + 0.1%
piperidine and solvent B was acetonitrile:methanol (50:50 v/v) + 0.1% piperidine [64].
Extensive details on the separation settings have also been previously reported (Chap-
ter 2). The mass spectrometry (MS) analysis used negative polarity electrospray ion-
ization. A mass range of 100–1200 atomic mass units was used for full scan analysis
and XCalibur software (v.2.1.0) was used for analysis.
3.6.3 Data Processing
Results for the non-polar metabolites from each species were processed separately.
Using the Purdue Bindley Bioscience Center Omics Discovery Pipeline Software, re-
tention time, m/z, and peak intensity data from each data set were separately decon-
voluted with a m/z variation setting of 0.07, an LC peak width of 10, and a minimum
noise-to-signal ratio of 0.5 [65]. Alignment across non-polar samples required an m/z
variation of 0.015 and a retention time variation across samples of less than 0.7 min-
utes. The peak frequency cutoff was 60. Normalization required the detected peak to
occur in 60% of the samples of at least one treatment group, and 35% species-wide.
As previously reported, metabolites with identical m/z appeared in the data and
when the retention times were within 1 minute, metabolites were combined, but
those with a larger difference in retention time were retained as separate metabolites.
Metabolites were identified and classified using the Human Metabolome Database
(HMDB), the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa Labo-
ratories), LipidMaps, METLIN, or the PubChem Substance and Compound database
[66–72]. Identified metabolites from both species were filtered based on being within
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3 parts per million (ppm) difference of the exact mass of the metabolite, with ppm
difference defined as
ppm difference ==
(observed mass − theoretical mass)
(theoretical mass)
× 1, 000, 000
Data were excluded as noise if it failed to have a minimum signal intensity across a
species’s samples of e10 or greater or were likely misidentified (such as drug metabo-
lites only appearing in one sample concentration). Data for samples that were frac-
tionated on differently aligned peaks were manually combined for each species if
entire groups were split between metabolites identified as the same entity. Treatment
groups for each metabolite were compared using a within-species one-way ANOVA
with metabolites considered significant at P < 0.05. The differences between repeated
exposures of ethanol in the mouse were also compared using a t-test. The fold for




where ī is the average of the intensity values for the group of interest and c̄ is the
average of the intensity values for the control group.
3.6.4 Statistical Analysis
After the data processing, significantly different (P < 0.05) metabolites identified
in both species were assembled. Since very few of the metabolites were identified
in both data sets and having similar retention times, lots of data appears “missing”
data in the combined set are treated as “0.1”, since some analytical tools cannot
handle null values. PPCCA is designed to handle missing values, but for internal
consistency the choice was made to maintain them as “0.1”. In addition, since the
PPCCA we are using is a post hoc analysis and the ethanol exposure concentrations
and modalities differed between species, ethanol exposure values, multiplying the
ethanol concentration and the proportion of development time the embryos were
exposed to ethanol.
We used the MeabolAnalyze package for R to generate a PPCCA [487]. R Studio
(R Studio, Boston, Massachusetts, USA), Version 0.99.902, and R (The R Founda-
tion for Statistical Computing, Vienna, Austria), Version 3.2.2, were used for this
analysis. Spectral data for metabolites common to both species and having one-way
194
ANOVA P < 0.05 were entered in the model in addition to the species and relative
ethanol exposure values. (Note: this is a different P-value limit than used for our
previously published zebrafish analysis.) Where metabolites with multiple retention
times existed, the maximum signal intensity for a defined metabolite was used for
each sample. Functions for plots provided in the package were modified to generate
color plots with appropriate axes labels and to run on Diagrid.org (Purdue University,
West Lafayette, Indiana, USA) cluster computers unmonitored.
In order to compare the two species, an estimation of the average ethanol ex-
posure both the zebrafish and mouse models (Table 3.8).The ethanol concentrations
used to treat the zebrafish and mice were converted to mol/L. To compare the mod-
els, given their different ethanol treatment concentrations, durations, and stages of
development, a modified ethanol dose was calculated as follows:
RelativeExposure(nM) ==
[(tout1 − tin1)Ethanol1(nM)] + [(tout2 − tin2)Ethanol2(nM)]
tReproductiveMaturity
where toutn − tinn is the duration of each exposure, Ethanoln is the ethanol concen-
tration given in nM. tReproductiveMaturity was approximated from c57BL/6J mice for
“Weeks at first mating” as 7.7 weeks, and for zebrafish as 57 dpf [504,505].
Fig. 3.8. This adjustment accounted for the development age during the
ethanol exposure(s) and the proportion of development captured during
the exposure. For the mouse treatments, embryos were excised and ex-
posed to one (n=7) or two (n=7) consecutive days for 6 h exposures of 400
mg/dL alcohol. Control mice (n=6.) were not exposed to ethanol, but
were incubated in culture medium. Zebrafish embryos (n=8 per group)
were exposed from 2–24 hpf to 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or
3% ethanol (v/v).
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Concentration Given Species Exposure Time Relative Ethanol
(mM) (h) Exposure (mM)
0.00 Mouse, Fish 0 0
(control)
0.17 Fish 22 2.76
0.51 Fish 22 8.27
1.71 Fish 22 27.56
5.14 Fish 22 82.68
8.68 Mouse 6 403.04
8.68 Mouse 6 + 6 805.91
17.1 Fish 22 275.59
51.41 Fish 22 826.76
171.37 Fish 22 2755.88
514.10 Fish 22 8267.65
The developmental landmarks for calculations and on the timeline were derived
from publications describing the typical time of these events for zebrafish, mice
(c57BL/6J, when available), and humans [258, 506–515]. Additional reference im-
ages used for drawing the human figures [516].
3.6.5 Data Management Plan
Raw data sets from the metabolite analysis are available for viewing at https://
purr.purdue.edu/publications/1398 or doi:10.xxxxxxxx.
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Fig. 3.9. Histogram of the p-values obtained from the ANOVA for the
FASD mouse model non-polar metabolome
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Fig. 3.10. Bayesian Information Criterion plot for the PPCCA model.
The plot indicates that the optimal number of principal components, q,
for our PPCCA model is four. For the mouse treatments, embryos were
excised and exposed to one (n=7) or two (n=7) consecutive days for 6 h
exposures of 400 mg/dL alcohol. Control mice (n=6.) were not exposed to
ethanol, but were incubated in culture medium. Zebrafish embryos (n=8
per group) were exposed from 2–24 hpf to 0, 0.001, 0.003, 0.01, 0.03,
0.1, 0.3, 1, or 3% ethanol (v/v). Samples were then extracted and the
non-polar fraction was analyzed by LC-MS/MS (Orbitrap). The PPCCA
model incorporates metabolites that appeared in the metabolomes of both
species and were significantly changed, one-way within-species ANOVA,
P < 0.05.
199
4. BIOMARKERS OF FETAL ALCOHOL SPECTRUM
DISORDER: THE DIFFERENCE YOU CAN’T SEE
Although fetal alcohol spectrum disorder (FASD) has been clinically identifiable after
birth by the medical community for decades, a comprehensive and robust biomarker(s)
has yet to be established to allow for early diagnosis and intervention. To that end we
previously characterized the ethanol-induced changes in the zebrafish model of chronic
ethanol and the binge mouse model exposures. We examined the morphologic fea-
tures of zebrafish embryos exposed to the same treatments, finding little evidence of
significant difference as a whole. We were able to replicate radical morphologic ab-
normalities of other laboratories by modifying ethanol dose and timing.) In spite of
this lack of statistical difference in morphologic measurements, our previous work has
demonstrated there are statistically significant metabolite differences, demonstrating
that ethanol alters embryonic physiology even at concentrations of ethanol where
statistically significant morphologic differences are absent. Here we exam many of
the commonly proposed biomarkers for FASD, many of which were absent in our
metabolomes. We also examine the possibility of biomarkers suggested from statisti-
cally significantly different metabolites common to our mouse and zebrafish models.
This striking contrast between significantly different metabolites in the absence of
morphologic of statistically significant visible changes reiterates the need for more
robust biomarkers to diagnose and characterize FASD.
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4.1 Introduction
Several factors contribute to the missed diagnosis of FASD, including subtle or
absent facial dysmorphology, unreliable reports of maternal drinking history, and
insufficiently robust biomarkers. Thus, intervention is difficult, whether through be-
havioral therapy, or potential pharmacological treatment [51,517]. A wide variety of
embryonic metabolites are altered by alcohol exposure, which offer the possibility of
novel biomarker(s) identification. However, broad metabolite screens have not been
fully assessed for their biomarker(s) potential in whole vertebrate embryos exposed
to ethanol.
Several teratogenic pathways (nitric oxide and other reactive oxygen species,
glutamate, vitamin A, serotonin signaling, lipids, glucose regulation, and adhesion
molecules) are altered after embryonic ethanol exposure. This has resulted in a wide
range of theoretical models as potential causative agents of FASD [61,62], and many
metabolites have been proposed as biomarkers of ethanol exposure. Sampling of meco-
nium has shown the presence of fatty acid ethyl esters (FAEEs) correlating with ma-
ternal alcohol consumption [518,519]. While offering the benefit of not being invasive,
meconial FAEE biomarkers have been reported in children of non-ethanol consum-
ing mothers, potentially limiting their robustness as population screening biomark-
ers [54,55]. FAEEs have also been reported in hair, which, while also a useful medium
for noninvasive biomarker testing, has shown changes in some FAEEs corresponding
with use of hair cosmetics [59]. Further, animal studies of dizygotic twins have shown
differing FAEE levels in the offspring, indicating that equivalent maternal ethanol
doses do not result in equivalent FAEE levels or possibly even equivalent ethanol
exposures [520]. Thus, while widely studied, FAEEs still face limitations in clinical
diagnostic use. Therefore, we sought to measure FAEEs via metabolomics and also
to identify novel biomarkers of FASD.
Zebrafish have become a widely utilized species in the laboratory, especially for
FASD and craniofacial abnormality studies [521, 522]. In our previous publications,
we examined the metabolome generated from zebrafish embryos to 0–3% ethanol
from 2–24 hours post fertilization (hpf). In addition, we have examined the non-
polar extracts from a binge ethanol exposures to embryonic mice. After extrac-
tion of the whole embryo from each species, we used metabolomics via liquid chro-
matography with mass spectrometry detection (Orbitrap or Time of Flight). We
found changes in metabolites associated with lipid metabolism, molecular transport,
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and small molecule biochemistry. Significant differences occurred in glycerophospho-
lipids and sphingolipids, which are consistent with previously proposed mechanisms
in FASD neuronal and cardiac abnormalities (Chapter 3).
Here, we examined the morphologic differences occurring with these treatments
in zebrafish. Surprisingly, in spite of many individuals with abnormal features, we
found few morphologic measurements that were significantly different from controls.
This highlights the startling impact ethanol has on embryonic metabolites, even in
the absence statistical differences in morphology.
The aims of this study are to examine the utility of biomarkers suggested in our
previous work, as discovered through hypotheses supported by our metabolomics
studies, comparative species Probabilistic Principal Component and Covariate Anal-
ysis (PPCCA), and Ingenuity Pathway Analysis® (IPA) biomarker suggestions. We
will do this in the context of biomarkers already suggested in the literature, as well
as suggest new metabolites that may be useful in the identification, assessment, or
treatment of FASD. Our evidence underscores the need for robust biomarkers, as
biochemical changes are occurring even in the absence of clinical features used to
diagnose FASD. From this work we conclude that a biomarker panel may be a more
reliable strategy for characterizing risk to offspring of maternal drinking, exposure
patterns, and severity of FASD.
4.2 Results
4.2.1 Mortality and Morphology
To examine the correlation between shortened lifespans and metabolites, we mea-
sured the mortality/teratology and morphometry of embryos at each ethanol concen-
tration tested. We treated zebrafish embryos from 2–24 hpf with ethanol concentra-
tions of 0 (n = 10), 0.001 (n = 8), 0.003 (n = 8), 0.01 (n = 9), 0.03 (n = 7), 0.1
(n = 8), 0.3 (n = 8), 1 (n = 7), and 3% (n = 7) (vol/vol). As shown in Figure
4.1, 49 of 72 total embryos (eight of the ten controls) survived to hatch. For several
ethanol concentrations, the Kaplan-Meier estimates of the median survival could not
be generated because the mortalities at the end of the observation period did not
exceed 50%. Thus, the reported bound of the upper confidence intervals are listed
as not applicable (NA). These concentrations included the control, 0.001%, 0.003%,
0.01%, and 0.3%. The median survival time for the 0.03% and 0.1% treatment group
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(n = 8) was 40.0 hpf (95% CI = 38.5 to NA) and 40.1 hpf (95% CI = 40.1 to NA),
respectively. For the 1% (n = 7) and 3% (n = 7) treatment groups the median sur-
vival times were 40.2 (95% CI = 39.1 to NA) and 39.0 (95% CI = 33 to NA) hpf.
The log-rank test did not demonstrate a statistically significant difference between
the survival rates (χ2 = 14.9, df = 8, P = 0.061). Nevertheless, the log-rank test
for trend showed a significant trend for mortalities with increasing concentrations of
ethanol (χ2 = 11.0, df = 1, P < 0.001). The Cox Proportional Hazards model
h(t,X) = h0(t)e
Σp(i=1)βiXi
for the ethanol concentration was
h(time, [Ethanol]) = (time)eΣ
p
(i=1)0.506× [Ethanol] + 0.164
where z = 3.08 and p = 0.002. The likelihood ratio was 7.59 (df = 1, n =
72, number of events = 23, P = 0.006).
Zebrafish larvae were measured to assess ethanol’s effects on morphology, as shown
in boxplots of the morphological measurements (Figure 4.2). Measurements included
the total length (Figure 4.2A), head circumference (Figure 4.2B), distance from the
outer boarders of each eye (Figure 4.2C), and the area of the eye (Figure 4.2D), as il-
lustrated in Figure 4.2L. Q-Q plots and Shapiro-Wilk test (P < 0.05) values indicated
most measurements within each group were normally distributed (Figures 4.3, 4.4,
4.5, 4.6, 4.7, and Table 4.1). At the 3% concentration only one individual survived,
prohibiting inclusion of this treatment group. By ANOVA, ethanol treatment failed
to result in a significant differences between treatment groups and controls for length
(F1,29 = 0.590, P = 0.449), head circumference (F1,29 = 2.753, P = 0.108), eye to
eye distance (F1,29 = 2.693, P = 0.112), or eye area (F1,29 = 2.693, P = 0.112).
Similar results were obtained through MANOVA, treating ethanol as a factor for the
combined dependent variables of length, head circumference, eye to eye distance, and
eye area (Wilks− Lambda F8,36 = 1.281, P = 0.170).
Qualitative evaluations of zebrafish larvae were made according to the procedure
described by Panzica-Kelly, et al., utilizing a detailed morphological scoring system.
This system uses a scale from 0–5, with 5 indicating the “Anatomical structure is
entirely normal for developmental stage”. [523] Of the qualitative evaluations, body
shape (χ2 = 17.7, df = 8, P = 0.023) and yolk sack edema (χ2 = 15.8, df = 8, P =
0.046) were the only categories that significantly differed, as shown in Figures 4.2F
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Fig. 4.1. Kaplan-Meier survival curve demonstrating zebrafish embryos
exposed to increasing concentrations of ethanol were less likely to sur-
vive to hatch. Only 1/8 of those exposed to 3.0% ethanol hatched at
48 hpf as opposed to untreated embryos, where 8/10 survived. The
Cox Proportional Hazards model for the ethanol concentration was
h (time,Ethanol) = (time) eΣ
p
(i=1)0.506×Ethanol+0.164, where z = 3.08,
Ethanol = Ethanol Concentration, and p = 0.002. The likelihood ratio
was 7.59 (df = 1, n = 72, number of events = 23, P = 0.006).
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Fig. 4.2. Boxplots of qualitative and quantitative morphometric evaluations. Ethanol
exposed zebrafish larvae were imaged at time of hatching and subsequently digitally
measured. Significant differences were seen only in the qualitative measure of body
shape and yolk sack edema. Distances are shown in µm. (∗ : P < 0.05, ANOVA) (A)
Average Length, (B) Head Circumference, (C) Distance Between Exterior Boarders
of the Eyes, (D) Eye Area, (E) Eye Area/Average Length, (F) Body Shape, (G) Tail
Shape, (H) Pericardial Edema, (I)Yolk Sack Edema, (J) Head (Brain) Space, (K) Otic-





























































































































































































































































































































































































































































Fig. 4.3. Q-Q plots of quantitative morphometric length to examine for
normal distribution. Measurements were generally normally distributed.
Each plot represents the distribution of the zebrafish for a given ethanol
concentration from 0 –3% ethanol.
and 4.2I, respectively. Both measures were significantly different from control with
the 0.003% treatment (P < 0.05). The mean score for body shape was 4, indicating
“Slight variation in morphology suggestive of a developmental delay or anomaly that
is potentially recoverable.” [523] Yolk sack edema was also significantly different from
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Fig. 4.4. Q-Q plots of quantitative head circumference to examine for
normal distribution. Measurements were generally normally distributed.
Each plot represents the distribution of the zebrafish for a given ethanol
concentration from 0 –3% ethanol.
controls in the 0.01% and 0.3% treatments, with the means of these groups being
4. Tail shape (χ2 = 12.0, df = 8, P = 0.153, Figure 4.2G), pericardial edema
(χ2 = 9.1, df = 8, P = 0.334, Figure 4.2H), head (brain) shape (χ2 = 10.7, df =
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Fig. 4.5. Q-Q plots of the distance between external portions of the eyes to
examine for normal distribution. Measurements were generally normally
distributed. Each plot represents the distribution of the zebrafish for a
given ethanol concentration from 0 –3% ethanol.
8, P = 0.218, Figure 4.2J), and otic-optic space (OOS, χ2 = 9.9, df = 8, P = 0.282,
Figure 4.2K) were not different from control.
Ethanol treatment resulted in one or more individuals per group with abnormal
morphology, as qualitatively graded (Figure 4.8). Atypical tissue extending from the
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Fig. 4.6. Q-Q plots of eye area to examine for normal distribution. Mea-
surements were generally normally distributed. Each plot represents the
distribution of the zebrafish for a given ethanol concentration from 0 –3%
ethanol.
eye (blue arrows) was seen in individuals in several treatment groups (0.001, 0.01, 0.03,
0.3% lateral views). Abnormal tails were seen in many individuals across treatment
groups (0.003, 0.3, and 1% in lateral views). Moderate pericardial edema was seen in
3/8 individuals in the control group as well as in individuals in all ethanol exposure
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Fig. 4.7. Q-Q plots of the ration of eye area to length in order to ex-
amine for normal distribution. Measurements were generally normally
distributed. Each plot represents the distribution of the zebrafish for a
given ethanol concentration from 0 –3% ethanol.
groups except 3%. Moderate yolk sack edema at was observed in a few individuals
across the treatment groups (0.003 and 0.1%). These individuals are shown in Figure
4.8 in the lateral view. Individuals with moderately abnormal head morphology were
present in several treatment groups, including 0.003 (2/6) and 0.3% (1/6), appearing
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to have a shortened forebrain segment. Moderate narrowing of the OOS was observed
in a single individual in the control, 0.003, 0.03, and 0.1% groups.
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Fig. 4.8. Ethanol treatment resulted in one or more individuals per
group with abnormal morphology, as qualitatively graded. Atypical tis-
sue extending from the eye (blue arrows) was seen in individuals in several
treatment groups (0.001, 0.01, 0.03, 0.3% lateral views). Abnormal tails
were seen in many individuals across treatment groups (0.003, 0.3, and
1% in lateral views). Moderate pericardial edema was seen in 3/8 individ-
uals in the control group as well as in individuals in all ethanol exposure
groups except 3%. Moderate yolk sack edema at was observed in a few
individuals across the treatment groups (0.003 and 0.1%). These individ-
uals are shown in the lateral view. Individuals with moderately abnormal
head morphology were present in several treatment groups, including 0.003
(2/6) and 0.3% (1/6), appearing to have a shortened forebrain segment.
Moderate narrowing of the OOS was seen in a single individual in the
control, 0.003, 0.03, and 0.1% groups.
To confirm the lack of startical difference in morphology was not part of a sys-
temic protocol problem, a subsequent study included 1.5 and 2.4% ethanol in the
concentration curve. Also, a time variable of when the alcohol was added was in-
cluded, having a set at 2 hpf and a set at 4 hpf. Embryos from the 1.5 and 2.4%
exposures at both time points elicited several aberrant morphological changes and re-
sembled those reported from other laboratories [63,524,525]. Abnormalities included
individuals missing tails and/or faces in the 2 hpf group, and narrowing of the eye
to eye distance, missing faces, microophthalmia, cyclopia, bent tails, and generalized
apparent disruption of cellular patterning in the 4 hpf group (Figure 4.8). Pericardial
edema, yolk sack edema, and tail and craniofacial abnormalities were also present in
individuals in the 1.5 and 2.4% ethanol treatments.
4.2.2 IPA Biomarkers
IPA was utilized to identify relevant molecules pathways modified with the ethanol
exposure. Using the biomarker analysis tool within IPA, biomarkers for each ethanol
concentration tested in the zebrafish were identified. The greatest number of identi-
fied biomarkers occurred with the 0.03% ethanol data set. A few of these metabo-
lites were excluded as mis-identifications (drug-related metabolites) by the metabo-
lite databases, including butabarbital, ecgonine, fasoracetam, and harmaline. The
metabolites identified with the biomarker filter for the non-polar data set included
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1-(1(Z )-hexadecenyl)-sn-glycero-3-phosphoethanolamine, 2-oxostearic acid, 3-acetyl-
tropine, cyclic 2,3-bisphospho-d-glycerate, d-desthiobiotin, methyl palmitate, tetrade-
canoic acid, palmitic acid, pentadecanoic acid, and stearic acid. The metabolites
identified with the biomarker filter for the non-polar data set included creatinine and
urea, which were both significantly different in the zebrafish metabolome. Creatinine
applications included diagnosis, efficacy, prognosis, safety and unspecified application.
Urea applications included diagnosis, efficacy, prognosis, and safety.
In addition to the work conduced in zebrafish, we examined the IPA biomarkers
suggested from our established mouse model of binge prenatal ethanol exposure. For
this dataset, only the metabolite arachidonic acid was identified for both the single
and doubly exposed mouse embryos with a biomarker application of efficacy.
4.3 Discussion
4.3.1 The Need for Biomarkers
Several factors contribute to the missed diagnosis of fetal alcohol spectrum dis-
orders (FASD), including subtle or absent facial dysmorphology, unreliable reports
of maternal drinking history, and insufficiently robust biomarkers. Thus, interven-
tion is difficult, whether through behavioral therapy, or potential pharmacological
treatment [51, 517]. A wide variety of embryonic metabolites are altered by alcohol
exposure, offering the possibility of identifying novel biomarkers. However, broad
metabolite screens have not been pursued in whole vertebrate embryos exposed to
ethanol for the purpose of biomarker(s) identification.
Diagnostic techniques such as ultrasound and 3-D facial analysis have been pro-
posed as FASD identification tools. In prenatal ultrasounds of the midline shape
of the corpus callosum, a “hook”-shaped structure (splenium angel greater than 90
degrees) was strongly associated with ethanol exposure during pregnancy, even with
confounders such as gestation al age, birth weight, sex, ultrasound age. Analysts were
able to successfully identify this structure 12 of 23 ethanol-exposed infants and a one
false positive among the 21 unexposed or “lightly”-exposed controls [49].
A newer tool has been developed to help diagnose children lacking classical dys-
morphology but did have a history of heavy prenatal ethanol exposure. Using a
3-D facial photograph, this tool agreed significantly agreed with classical criteria
(0.90–.92, depending on view), even correctly identifying those classified as having
214
partial FASD [526]. However, as we demonstrate here, offspring biochemistry is al-
tered even in the absence of dysmorphology. Further, based on the specific metabolites
identified as significantly different in the chronic zebrafish and binge mouse ethanol
exposure models, biochemical changes are of physiological importance with long-term
implications.
Based on the 2001 Biomarker Definitions Working Group, a biomarker is “A
characteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a therapeu-
tic intervention”. [527] For FASD, biomarkers predominantly are aimed at serving as
an indicator of the disease, for the “prediction and monitoring of clinical response to
an intervention”, as a clinical endpoint that “reflects how a patient feels, functions,
or survives”, or a surrogate endpoint, which is “a biomarker that is intended to sub-
stitute for a clinical endpoint expected to predict clinical benefit (or harm or lack
of benefit or harm) based on epidemiologic, therapeutic, pathophysiologic, or other
scientific evidence”. [527]
Many factors effect biomarker utility, including physical factors such as tissue
accessibility and biomarker stability and reliability over time [528]. Sampling of
biomarkers for FASD requires consideration of developmental stage, ease of tissue ac-
cess, be it maternal or offspring, or sampling after birth or during childhood. Meco-
nium has often been proposed as a tissue for assessment for FASD, in part for its ease
of sampling. However, this matrix does not allow for prenatal intervention. In this
discussion, we will not focus on biological matrices appropriate for biomarkers, as our
metabolites reflect whole embryos and therefore cannot address these differences.
4.3.2 Mortality and Morphology
The log-rank test for trend was significantly different between groups ordinated
by ethanol concentration, but the Kaplan-Meier log rank test failed to show a signif-
icant difference in survival between ethanol concentration groups. This indicates the
survival observations should be extended, which would also allow generation of the
median survival statistics. Further, the morphological differences may be attributed
to the natural variation that occurs in hatching of a clutch of eggs [502]. Neverthe-
less, the lack of Kaplan-Meier statistical difference further supports the notion that
physiologically important metabolite changes are occurring, even in the absence of
survival effects.
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Morphological differences were not significant by ANOVA, but zebrafish embryos
exposed to ethanol responded with alterations in normal development. Morphological
abnormalities were noted with ethanol treatments, as well as qualitative differences
in body shape. The lack of statistical findings may be due to the small number of
survivors in the high dose groups or that the original concentrations tested missed
the critical 1.5 and 2.4% ethanol. These doses have been shown to elicit significant
abnormalties in morphology in zebrafish [63, 524, 525]. In non-survivors, tissue de-
graded rapidly and therefore did not provide reliable samples for imaging. In spite
of the lack of statistically significant morphologic outcomes, changes did occur in our
original concentration curve, underscoring the relevance of the metabolite changes at
low ethanol doses.
Another potential reason for the lack of significance in morphologic findings may
be related to the developmental modularity of the zebrafish. Others have reported
that during the phenotypic stage, only during less than optimal conditions (temper-
ature, oxygen, and salinity) does modularity become important [529]. That is to
say that intra-group developmental consistency is favored over individual variation in
morphology as a result of the strain induced by suboptimal environmental conditions.
Thus, in our experiments, we would expect the variation of the untreated groups to
be larger than the variation in ethanol treated groups. As shown in Q-Q plots of the
morphometric values (Figures 4.3, 4.4, 4.4, 4.5, and 4.7), there is a tendency for the
trend lines to become flatter in slope as the ethanol concentration increases.
4.3.3 Existing Biomarkers
A variety of biomarkers have been proposed for FASD, and have been extensively
reviewed [51,53,530]. The objective of this discussion is to review commonly proposed
metabolite biomarkers for FASD that are detectable with our metabolomics methods.
This includes reviewing common biomarkers that were absent in our metabolome as
well as proposing additional biomarker strategies.
Direct Biomarkers
Oxidative Ethanol Metabolism Several FASD biomarkers reported in the liter-
ature of FASD were not identified in our analyses. For instance, products of alcohol
catabolism were not identified in the metabolome, as our Orbitrap assay method
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accurately detects molecules with a m/z of 100–1200. Ethanol (46.0421866 g/mol),
acetaldehyde (44.05300 g/mol), and acetate (60.05200 g/mol) are beyond the limit of
detection.
Acetylaldehyde, a metabolite of ethanol via Cyp450, has been explored as a di-
rect biomarker particularly for moderate to high levels of drinking [51]. But, it is
detectable in blood for only a very short time after ingestion [530]. We did not detect
acetylaldehyde in our zebrafish non-polar or polar metabolomes, however did detect
similar metabolites, such as butanal and acetamimde (Chapter 2). Acetylaldehyde
protein adducts have also been considered as potential biomarkers, however these
products are much too large for our metabolite detection strategy [51].
Increased excretion of acetoacetate has been detected with proton nuclear mag-
netic resonance spectroscopy in a zebrafish disease model of alcoholic fatty liver [531].
We found a significant decrease in acetoacetic acid at mid-range and higher ethanol
doses. In addition, betaine excretion decreased in the alcoholic fatty liver model, and
crotono-betaine was similarly decreased at mid-range and higher ethanol doses in our
experiments [531].
Non-oxidative Ethanol Metabolism
Fatty Acid Ethyl Esters Based on the literature, we examined our metabolome
for FAEEs. Formed from the esterification of alcohol and fatty acids or acyl-CoA/
fatty acids, FAEEs have been proposed as a biomarker of in utero ethanol exposure,
and can be measured in meconium where it correlates with maternal alcohol consump-
tion [30, 51, 518, 532–538]. While offering the benefit of not being invasive, meconial
FAEEs have been reported in children of non-ethanol consuming mothers, poten-
tially limiting their robustness as population screening biomarkers [54–56]. FAEEs
have also been reported in hair, which, while also a useful medium for noninvasive
biomarker testing, has shown changes in some FAEEs corresponding with use of hair
cosmetics [59]. Further, animal studies of dizygotic twins have shown differing FAEEs
levels in the offspring, indicating that equivalent maternal ethanol doses do not result
in equivalent FAEE levels or possibly even equivalent ethanol exposures [520]. FAEEs
have been demonstrated in serum as well [539]. Thus, while widely studied, FAEEs
still face limitations in clinical diagnostic use. These metabolites are believed to be
produced by the ethanol-exposed fetus, making it a direct biomarker for ethanol expo-
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sure [540]. Ethyl linoleate, a FAEE, has been proposed as a negative biomarker from
meconium, indicating “infants not exposed in utero to high levels of alcohol”. [532]
Given the emphasis placed in the literature on FAEEs as FASD biomarkers, we
compared metabolites identified in our analysis with those FAEEs reported by Burd
and Hofer in their meta-analysis of FAEEs as biomarkers for fetal alcohol expo-
sures [53]. In this analysis, ethyl esters of palmitate, stearate, oleate, linoleate, and
arachidonate were identified as potential biomarkers [53, 54, 518, 532, 535, 537, 541].
None of these nine FAEEs were identified in our study, including when the peak scan
width was narrowed to 5, rather than the 10 used to identify the other metabolites.
This is in contrast to the findings of by Loftus et al., who detected several FAEEs
using LC-MS in the liver of rats and mice exposed to ethanol [451]. We believe this
is due to their use of acetonitrile to stabilize of the FAEEs, which we did not do.
Ethyl arachidonate has been proposed as a FAEE biomarker [542]. Gas chromatog-
raphy of umbilical cord vessel fatty acids from self-reported alcohol-consuming black
women demonstrated that alcohol consumption positively correlated with arterial ves-
sel wall docosahexaenoic acid and arachidonic acid [543]. Similar findings are associ-
ated with periconceptional ethanol intake and neonatal cord blood serum [32]. In the
mouse metabolome, arachidonic acid ((5Z ,8Z ,11Z ,14Z )-icosa-5,8,11,14-tetraenoic)
was significantly increased, especially after the second ethanol binge-dose. In our
zebrafish metabolome, its precursor, anandamide, significantly decreased at all but
the lowest ethanol dose. This suggests either an increase in enzymatic function pro-
ducing ((5Z ,8Z ,11Z ,14Z )-icosa-5,8,11,14-tetraenoic), shift in the demand of it, or
decrease in its utilization. However, it is important to note this is not the only route
to anandamide, as it can also be a product of multiple pathways [344,544].
Phosphatidylethanol Phosphatidylethanol (PEth) is another proposed direct
biomarker of ethanol [51, 545]. It can be measured in dried blood spots, with high
specificity, relative other FASD biomarkers [546]. We anticipated finding PEth in our
metabolome, as it is generated by phospholipase D conversion from phosphatidyl-
choline [547]. We found many PLD-related metabolites altered in the zebrafish
metabolome, including phosphtidic acids, phosphatidylcholines, and phosphtidylethanolamine,
which were all significantly different. However, we did not identify metabolites with
m/z corresponding to PEth.
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Ethyl glucuronide and ethyl sulfate Ethyl sulfate and ethyl glucuronide are
direct non-oxidized, minor metabolites. Sulfotransferase can form ethyl sulfate from
ethanol. Ethyl glucuronide is generated by glucuronidation by uridine diphosphate-
glucuronosyltransferase, for the purpose of excreting toxic substances. Ethyl glu-
curonide and ethyl sulfate show correlation with specific but not total FAEEs in meco-
nium [51,548]. However several weaknesses have been presented for these metabolites.
For ethyl glucuronide non-consumers and those consuming small amounts of alcohol
may present this biomarker at levels below the limit of quantification [51]. We did
not identify metabolites with masses corresponding to ethyl glucuronide and ethyl
sulfate in our whole embryo extracts. However, we did note palmitoyl glucuronide
was significantly decreased and nicotine glucuronide was significantly increased.
Indirect Biomarkers
Many of the biomarkers proposed for FASD are enzymes, such as cytochrome
P450, γ-glutamyltransferase, aspartate aminotransferase, and alanine aminotrans-
ferase [50, 51]. These are too large to be detected by our method. In addition, large
protein biomarkers, such as carbohydrate deficient transferrine, are also too large for
our detection method [51]. Assessment of mean corpuscular volume of erythrocytes,
also a proposed biomarker for FASD, is not directly detectable via our metabolomics
method [51]. However, glycosylation- and tryptophan-related metabolites may have
utility as biomarkers.
Glycosylation Biomarkers Dolichols and sialic acid have been proposed as biomark-
ers relevant to glycosylation. Based on a case study of a newborn with maternal his-
tory of alcohol abuse in comorbid with morphological abnormalities similar to FASD,
some have suggested changes in glycosylation as an important factor in FASD [48].
In this individual, glycosylation screening was transiently abnormal. In addition,
ethanol is known to decrease secretion of the sugars use to glycosylate proteins [404].
Excretion of urinary dolichols has been demonstrated in newborns of alcoholic
mothers, however has also been described by Halmesmki as “a poor indicator of abu-
sive drinking” in pregnant alcohol abusers [407, 530, 549]. Ethanol is also known to
disrupt dolichols, polyisoprenoids that occur in all eukaryotic cell membranes, which
are essential for N -glyosylation of proteins (asparagine residues) in the endoplasmic
reticulum [406]. In our whole embryo extracts, none of our metabolites were identified
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as dolichol, but we did detect other isoprenoids, such as 1-(2,6,6-trimethyl-2-cyclo-
hexen-1-yl)-1-penten-3-one, which decreased significantly with ethanol exposure in
the chronic zebrafish model and increased significantly in the binge mouse model.
Sialic acid, “the name for a series of acyl-derivatives of neuraminic acids that occur
as nonreducing terminal residues of glycoproteins or glycolipids in biological fluids and
cell membranes”, has been proposed as a biomarker for alcohol abuse [530,550]. Like
most of the other proposed biomarkers, we did not identify this in the zebrafish or
mouse metabolomes. But we did identify other indicators of glycosylation malfunction
in the zebrafish metabolome. N -Acetylglucosamine, which marks a glycoprotein for
transfer to the lysosome, was significantly increased at mid-range ethanol doses and
higher.
We did find 2-(α-d-mannosyl)-3-phosphoglycerate, which was significantly increased
at any ethanol dose tested in our zebrafish model. This metabolite is downstream
of mannose-6-phosphate, a tag for lysosomal degradation that is generated via acti-
vation of N -acetyl-glucosamine-1-transferase by cathepsin D. Zebrafish knockouts for
cathepsin D demonstrate abnormal morphology, including shorter body length and
microophtalmia, similar to reports by others of FASD, although inconsistent with our
morphologic findings [414]. Based on this evidence, in spite of not identifying sialic
acid metabolites in our datasets, glycosylation-based biomarkers are likely a useful
tool in profiling FASD.
Tryptophan Metabolites 5-Hydroxytryptophol and 5-hydroxyindolylacetic acid
are both serotonin metabolites, a pathway known to be modified with prenatal ethanol
exposure [551]. 5-Hydroxytryptophol and the ratio of 5-hydroxytryptophol/5-hydrox-
yindolylacetic acid (5-HTOL/5-HIAA) have been proposed as indirect biomarkers of
recent moderate to high levels of drinking [51, 552]. However, there remain no pub-
lished studies in pregnant women.
In addition, embryonic stem cell-derived embryoid bodies and neural cells cultured
with 0.1 or 0.3% ethanol for four days have demonstrated features suggestive of other
potential biomarkers [79]. Four confirmed l-thyroxine, 5-methylthioadenosine, and
the tryptophan metabolites, l-kynurenine and indoleacetaldehyde. While we did
not identify any of these exact metabolites in the zebrafish or mouse metabolomes,
we did identify many tryptophan-related metabolites, including oxindole, kynurenic
acid, 7-chlorokynurenic acid, and uncaric acid. Taken together, further investigation
220
of tryptophan-related metabolites may result in identifying robust biomarkers for
FASD.
4.3.4 Biomarkers Suggestioned from Metabolomics
Biomarkers Suggested the Zebrafish Metabolome
Previously we have reported on a comprehensive metabolome from whole-embryo
extracts taken from zebrafish exposed to 0–3% ethanol from 2–24 hpf. In that pub-
lication, we cite numerous pathways that are significantly different. These path-
ways provide an interesting framework from which to find multi-metabolite profiles,
which could be used as a biomarker for FASD. Such pathways include changes re-
lated to the nervous system, cardiovascular system, and growth and energy. Ner-
vous system-related metabolite changes included molecules involved in myelination,
tryptophan metabolism, and oxidative stress. Metabolites related to vascularization,
myocyte contraction, and coagulation were modified, which affect the cardiovascular
system. Growth and energy are modified in part through altered fatty acid and amino
acid metabolism. Together, these profiles provide a characteristic dynamic profile of
changes occurring in FASD.
Non-polar Comparative Animal PPCCA
We have previously reported a cross-species Probabilistic Principal Component
and Covariate Analysis (PPCCA), which highlighted several changes in metabolites
potentially relevant as FASD biomarkers (Chapter 3). Six metabolites were com-
mon to the chronic zebrafish and binge mouse ethanol exposure models. These in-
cluded 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one, which we believe could
be a cleaved molecule of vitamin A, tetradecanoic acid, methyl hexadecanoic acid,
octadecanoic acid, PA(18:0/18:2(9(Z ),12(Z ))), and C22 sulfatide (Table 3.7). Several
of these metabolites had responses to ethanol that diverged between species, where
the metabolite varied positively in the mouse binge exposure model but negatively
in the chronic zebrafish model. It is unclear if these differences are rooted in differ-
ences in species’ responses to the ethanol treatment, an effect of exposure duration,
or likely a combination of both. Further, several of the metabolites decreased in the
binge mouse model with a single dose, but increased with a second dose. These in-
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cluded tetradecanoic acid, methyl hexadecanoic acid, and octadecanoic acid. Due to
the simultaneous treatment of all test mice with the first dose of ethanol, it is unclear
whether the change noted after the second dose reflects direct effects of alcohol, rem-
nants of a compensating response to the first ethanol dose, or a biological variation
in the response that occurs after a second ethanol exposure.
Many of the relationships of these metabolites to alcohol in the zebrafish did not
appear dose responsive. This may indicate the need for examination of intermediary
doses within the curve. However, C22 sulfatide was decreased in zebrafish with low
ethanol concentrations and trended to slightly increase with the highest ethanol dose.
Singly dosed mice did not differ in C22 sulfatide, but doubly-dosed mice significantly
increased. PA(18:0/18:2(9(Z ),12(Z ))) similarly responded. Therefore, these may be
relevant to investigate as potential biomarkers. They are both important to neural
changes occurring in FASD (Chapter 3).
Lastly, tetradecanoic acid increased significantly in doubly dosed mice and in
nearly all ethanol doses in the zebrafish, which may suggest another potential biomarker.
While none of the metabolites that were significantly different and common to both
FASD models appear to be presumptive biomarkers of FASD, several of these metabo-
lites may provide an important tool for characterizing the type of ethanol exposure
(binge or chronic) and the severity of FASD.
IPA
The biomarkers identified via the Biomarker Filter in IPA demonstrate some weak-
nesses, and would likely not be robust for use in FASD. The biomarkers IPA identified
were vague and not specific for development, zebrafish, or alcohol metabolism, and
were disproportionally for drugs or exogenous chemicals that were unlikely to be in
our system. For example, fatty acid differences on their own are too vague of a change
to pinpoint a biological abnormality. Further development of metabolite databases
and pathway analysis tools is needed before such automated strategies can suggest
biologically relevant and robust biomarkers.
An alternative to the single compound biomarkers that
An alternative to the single compound biomarkers that have often been proposed
is the use of a metabolome profile, where differences of several metabolites that would
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individually be insufficient as a biomarker are considered together to generate a dis-
ease profile. We propose this as a method to capture the vast biochemical changes
that are occurring in FASD. Metabolomics analysis can be performed for a relatively
low-cost. However, further examination and optimization, possibly through artificial
intelligence strategies, is required.
To determine the exact composition of this profile would need to be conducted.
But, it would likely involve some of the cardiovascular and nervous system related
metabolites we have previously identified. It may also involve vitamin A related
metabolites, which were identified previously in our binge mouse and chronic zebrafish
exposure models.
4.4 Conclusion
Our findings of significantly different metabolites in zebrafish model conjunction
with a lack of statistical difference in most morphologic measures suggest current rec-
ommended limits for ethanol consumption during pregnancy need to be reexamined.
With our previous reliance on dysmorphology for diagnoses, it is likely there has been
a gross underestimation of the effects of ethanol on the fetus. Based on that variety
of changes in many different classes of metabolites, we observe a significant difference
even with low levels of chronic ethanol exposure. Repeated exposure to ethanol under
binge-type conditions in mice shows different effects than singly-dosed, which is an
important consideration in the allowable dose recommended by health professionals.
Further work is needed in these models to determine metabolome changes in even
lower doses and shorter durations in the zebrafish model show similar modifications.
However, we can effectively determine that in spite of unseen morphologic statisti-
cal differences, the metabolome is changed with embryonic ethanol exposure in the
zebrafish.
4.5 Materials and Methods
4.5.1 Study Design
Animal experiments using Danio rerio were performed in accord with Purdue
Animal Care and Use policies at Purdue University (West Lafayette, Indiana, USA)
using approved protocol 1111000275. Details of our study design for the zebrafish and
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mouse have been reported previously. In brief, healthy AB zebrafish embryos (n = 8)
were exposed from 2–to 0, 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, 1, or 3% ethanol from 2–24
hpf. At 48 hpf, whole embryo extracts were snap frozen and stored at −80 ◦C. The
same experimental design was used for morphometric and survival analysis, except
the embryos remained in E3 media until hatching (∼48 hours) and then were imaged.
A follow-up experiment was also conducted using the above protocol with the addition
of 1.5 and 2.4% ethanol concentrations. Additionally, ethanol treatments beginning
at 4 hpf in addition to the 2 hpf were added.
Animal experiments for the binge Mus musculus model were performed in accord
with Indiana University School of Medicine (Indianapolis, Indiana, USA) Animal
Care and Use policies using approved protocol 000000. Excised E8.2 c57BL/6J mouse
embryos were cultured in a dish with medium (controls, n=6). Treated animals were
exposed on one (n=7) or two (n=7) days to 400 mg/dL of ethanol for six hours, being
washed and incubated with medium between exposures. The embryos were harvested
the next day and dissected, removing the yolk sac, snap frozen, and stored at −80 ◦C
until shipment to the processing lab at Purdue University (West Lafayette, Indiana,
USA).
Samples for metabolomics from both species were thawed at 4 ◦C, extracted in
2:1 methanol:water, homogenized, extracted in cold chloroform, centrifuged and con-
centrated. The non-polar fraction was dissolved in 50% double-distilled water, 25%
methanol, 25% acetonitrile. The samples were analyzed using Thermo Fisher LTQ
Orbitrap (Waltham, MA USA) mass spectrometer (MS) coupled to an Agilent 1100
series Liquid Chromatography (LC) (Agilent Technologies, Santa Clara, CA, USA),
using an Eclipse XDB-C8 column (Agilent Technologies, Santa Clara, CA, USA). Sol-
vent A was water + 0.1% piperidine and solvent B was acetonitrile:methanol (50:50
v/v) + 0.1% piperidine [64]. Extensive details on the separation settings have also
been previously reported (Chapter 2). The mass spectrometry (MS) analysis used
negative polarity electrospray ionization. A mass range of 100–1200 atomic mass
units was used for full scan analysis and XCalibur software (v.2.1.0) was used for
analysis.
The zebrafish polar fraction was dissolved in 20% acetonitrile, 80% water with
0.1% formic acid. Polar samples were then analyzed by LC-MS (Time of Flight).
Data processing was conducted as previously reported (Chapters 2 and 3).
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4.5.2 Imaging and Morphometry
Using a Nikon NIS Elements System, ice-water sedated larvae were imaged twice
—first with the right pectoral, then dorsal fin upwards. Individuals without a visible
heartbeat were designated as mortalities. Subsequently, larval images were measured
digitally for total length (averaged from both views), head circumference (dorsal
view), area of the eye (right pectoral view), and distance between outside portions of
the eyes (usually from dorsal view), as shown in Figure 3L. White-balance adjusted
images (Photoshop v.11.0.2, 2010) were subjectively evaluated for morphologic abnor-
malities in body shape, tail shape, pericardial edema, yolk sack edema, head (brain)
shape, and the otic-optic space (OOS) according to guidelines published by Panzica-
Kelly et al. [523]. The evaluators were blinded to the treatment groups.
4.5.3 Ingenuity Pathway Analysis ®
Ingenuity Pathway Analysis® (IPA) (Ingenuity Systems, Redwood, CA) was used
for additional metabolome network analysis, as previously reported. Metabolites
were required to have at least one concentration with a 0.001-fold or greater to be
considered in the subsequent IPA analysis. The Biomarker Filter was applied using
the default settings in IPA, selecting all for Species, Tissue and Cell Lines, Node
Types, Diseases, Biofluids, and Biomarker Applications and Diseases. Separate filters
were generated for the polar and non-polar zebrafish data sets and the mouse data
set.
4.5.4 Statistical Analysis
Survival proportions were calculated using the Kaplan-Meier method in R Studio
version 3© 2007. Individuals surviving until the time of hatching were censored. The
survdiff function of the Survival CRAN package was used, which weighted deaths
using the Peto-Peto modification of Gehan-Wilcoxon to detect early differences in
survival (Version 2.37–4). Additionally, a logrank test for trend was used to compare
the Kaplan-Meier survival curves over all concentrations as well as Cox proportional
hazard ratio model (coxph) [553].
Analysis of morphometry measures began with analysis of the distributions using
Q-Q plots and Shapiro Wilk testing by ethanol concentration groups. Non-parametric
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analysis of the morphological variables was conducted on each measurement type us-
ing the a one-way ANOVA. Individuals that were dead prior to hatching were not




FASD is resultant of a wide-array of biochemical pathway modifications, in no
small part due to the polar protic nature of ethanol. Ethanol is a solvent and can
function in acid-base modification, ester formation, halogenation, haloform reactions,
dehydration, oxidation, and chlorination. These reactions can have a devastating
effect on offspring of ethanol-consuming mothers, generating life-long disease. The
estimated prevalence of FASD in the United States is 33.5 per 1,000 live births [1].
Currently, there are no robust biomarkers or effective interventions for FASD, due to
the lack of comprehensive understanding of the mechanisms of FASD.
This dissertation explores the mechanisms involved in FASD. The first aim of this
work is to investigate the mechanisms, as a whole, that are changed in an animal
model (zebrafish) of FASD, with the use of metabolomics (Chapter 2). The second
aim is to compare and contrast metabolite findings in two different, well-established
models of FASD, the zebrafish and excised embryonic mouse (Chapter 3). Finally,
the third specific aim is to identify and characterize potential biomarkers from these
models of FASD (Chapter 4).
Our results demonstrated that a vast array of biochemical pathways are modified
in the chronic ethanol exposure zebrafish model of FASD (Chapter 2). Many of
these pathways confirmed earlier literature, but the comprehensive nature of this
study expands upon many of these pathways, and links several that were previously
considered in isolation as mediators of FASD. In addition, examination of the non-
polar excised embryonic mouse demonstrates a significant difference between a single
binge dose of ethanol and a two binge doses (Chapter 3). Similar metabolites to the
zebrafish are identified in this model, though the degree and direction of change is
not always consistent. These findings suggest that more ethanol does not necessarily
result in an amplified, same-direction response, and that longer duration exposures do
not always change metabolites the same way binge exposures do. In addition, a novel
application of the probabilistic principal component and covariate analysis (PPCCA)
to examine latent variables suggested by the combined models. Lastly, we examine
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biomarkers suggested from the mouse and zebrafish model metabolomes, the PPCCA,
and Ingenuity Pathway Analysis® (Chapter 4). We consider these biomarkers with
a morphometric analysis of the zebrafish, where few significant differences are noted.
Together, these observations suggest that in spite of a lack of morphologic changes,
biochemistry of the prenatally exposed individual is significantly changed.
This dissertation contributes to the understanding of FASD, by examining mech-
anistic changes in a non-specific manner. Rather than simply presenting classes of
metabolites significantly differed with the chronic ethanol exposure model, it con-
textualizes the metabolites within the altered biochemical pathways. This reduces
publication bias, allows for the expansion of suggested mechanisms, and identifies
novel pathways. This dissertation also examines differences in models of chronic and
binge-type ethanol consumption. It contributes to comparative animal modeling by
exploring mathematical means to compare interspecific data. Lastly, it advances the
field of FASD biomarkers, suggesting that a panel of biomarkers may be more suitable
for FASD than a single entity.
5.2 Major Findings
5.2.1 Developing the Big Picture of Fetal Alcohol Spectrum Disorder: A
Proposed Mechanism of Metabolite Changes (Chapter 2)
1. A total of 647 non-polar fraction metabolites were identified. Of these, 94 were
unique from each other with less than a 3 ppm difference from the theoretical
mass of their associated identified metabolite. Eighty-two metabolites signifi-
cantly differed as a function of the ethanol concentrations tested (P < 0.001,
ANOVA).
2. Several metabolites that are related to ethanol catabolism were identified.
3. Many metabolites that significantly differed are implicated in the development,
structure, and function of the nervous system.
(a) Glycerophospholipids, including phosphatidylserine, phosphatidic acid, phos-
phatidylethanol, and phosphatidylinositol, are modified with ethanol ex-
posure and showed a variety of changes in our model. Many of these
metabolites are associated with abnormalities in phospholipase D func-
tioning.
228
(b) Sphingolipid moieties tended to be significantly higher at either mid-range
ethanol doses or with all concentrations tested. These metabolites have
important roles in the nervous system, which impact astroglial migration,
neurite outgrowth, myelin structure, and cell membranes.
(c) Metabolites associated with myelin structure and function were signifi-
cantly different, including sulfatides, lignoceric ceramide, and metabolites
related to vitamins A, D, and K.
(d) Many metabolites identified were related to tryptophan metabolism. These
included differences in the serotonergic, oxindole, and kynurenine arms of
tryptophan pathways.
(e) Oxidative stress abnormalities were associated based on the metabolites
acetylaldehyde, butanal, carnosine, aspidospermine, anandamide, and tryp-
tophan. Some antioxidants were also significantly different, indicating an
altered capacity to manage oxidative insult.
(f) Alterations in metabolites related to anandamide and protein kinase C
were also identified.
4. Metabolite changes suggested alteration of the cardiovascular system, including
metabolites related to myocyte contraction, vasculature, and coagulation.
5. Several important components of the endocrine system were modified in our
metabolome, including sex hormones, the hypothalamic-pituitary-adrenal (HPA)
axis, and icosanoids.
6. Renal system functioning via (12S )-hydroxy-16-heptadecynoic acid was identi-
fied.
7. Many participants in pathways related to growth and energy were modified.
(a) Metabolites related to glycolysis and gluconeogenesis were modified.
(b) Fatty acid metabolism appears highly altered in this model of FASD.
Metabolites related to β-oxidation, fatty acid synthesis, energy and bile
acids, and other cholesterol derivatives were identified.
(c) Modified amino acid metabolism was indicated by differences in histidine
metabolites and methionine.
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(d) Metabolites associated with pyrrolysine (functions in the activation, ori-
entation, and transfer of methylamines to proteins that bind corrinoid
cofactors containing cobalt), vitamin B12, and folate were identified.
(e) Metabolites associated with abnormal morphology were significantly dif-
ferent in the metabolome.
8. Metabolites known to participate in normal cellular and molecular mechanisms
were significantly different, including the glycosylation pathway and the tran-
scription factors vitamins A and D.
9. The cofactor nicotinamide, a tryptophan derivative, is related to several signif-
icantly different metabolites. This may suggest a novel FASD mechanism.
5.2.2 Comparative Modeling of Fetal Alcohol Spectrum Disorder: More
is Not Just More (Chapter 3)
1. We identified a total of 32 metabolites that changed with ethanol exposure, in-
cluding significant differences in several fatty acids, glycerolipids, glycerophos-
pholipids, ceramides, and retinoate.
2. Several metabolites were related to FASD-associated changes in growth and
energy.
(a) Based on our findings of phosphatidic acid, phosphatidylcholine, phos-
phatidylserine, and vitamin A, hepatic stellate cells may mobilize lipid
droplets in response to retinoid metabolism changes induced by ethanol.
(b) The non-polar extract metabolome of the ethanol-exposed embryo shows
significant differences in fatty acids. In conjunction with results from
the zebrafish model, these findings may suggest that with ethanol expo-
sure, increases in estrogen-related metabolites upregulate monoacylglycerol
transferase, which in conjunction with inactivated lipase, causes changes
in monoacylglycerol.
(c) Based on the PPCCA Principal Component (PrC) 1 loading being posi-
tive for a possible vitamin A cleavage product, methyl hexadecanoic acid,
and octadecanoic acid, the latent variable may be representing the lipid
metabolism changes noted above.
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3. Other metabolites were related to nervous system changes.
(a) Several glycerophospholipid changes support the theory of abnormal func-
tion of phospholipase D.
(b) Ceramide alterations have implications in the nervous system, as this
metabolite functions as a precursor of the myelin component sphingomyelin,
as an activator of phosphatases and thereby cell death, and also as a pre-
cursor to sphingosine.
(c) Sulfatide differences were also noted in the mouse binge model.
(d) Based on the loadings of PrC2 and PrC3, the underlying latent variable of
these components are likely neural related. PPCCA PrC2 was positively
loaded by cleaved A, PA(18:0/18:2), and C22 sulfatide. PA(18:0/18:2) and
C22 sulfatide.
5.2.3 Biomarkers of Fetal Alcohol Spectrum Disorder: The Difference
You Can’t See (Chapter 4)
1. In examining the mortality of ethanol treated embryos, the log-rank test for
trend was significantly different between groups ordinated by ethanol concen-
tration, but the Kaplan-Meier log rank test failed to show a significant difference
in survival between ethanol concentration groups.
2. Morphological differences were not significant by ANOVA for measurements of
head circumference, eye size, eye-to-eye distance, total length, but zebrafish
embryos exposed to ethanol did responded with alterations in normal develop-
ment.
3. A single metabolite biomarker was not identified.
(a) None of the highly cited proposed biomarkers were present in metabolome.
Many biomarkers are too large for detection with our method (proteins and
enzymes). For fatty acid ethyl esters, our method was likely insufficient to
stabilize these metabolites.
(b) Six significantly different metabolites were common to the chronic ze-
brafish and binge mouse ethanol exposure models. These included 1-(2,6,6-
trimethyl-2-cyclohexen-1-yl)-1-penten-3-one, which we believe could be a
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cleaved molecule of vitamin A, tetradecanoic acid, methyl hexadecanoic
acid, octadecanoic acid, PA(18:0/18:2(9(Z ),12(Z ))), and C22 sulfatide.
Several of these metabolites had responses to ethanol that diverged be-
tween species, where the metabolite differed positively in the mouse binge
exposure model but negatively in the chronic zebrafish model. It is un-
clear if these differences are rooted in differences in species’ responses to the
ethanol treatment, an effect of exposure duration, or likely a combination
of both.
(c) The biomarkers IPA identified were vague and not specific for development,
zebrafish, or alcohol metabolism, and were disproportionally for drugs or
exogenous chemicals that were unlikely to be in our system.
5.3 Limitations
This dissertation provides a comprehensive model of metabolites changed in FASD.
With this information, hypotheses of several novel mechanisms have been generated,
including nicotinamide metabolism changes and altered vitamin A. Several products
of nicotine metabolism were significantly different, which may suggest a changes in
nicotinamide metabolism are involved in FASD. Nicotinamide is the amide of vitamin
B3. Tryptophan is the precursor of nicotinic acid mononucleotide, which can eventu-
ally be converted to nicotinamide adenine dinucleotide. This represents a novel find-
ing, and should be explored further as to the generality of this effect. Modifications
to this pathway have implications for redox reactions and post-translational modifi-
cation of proteins. 1-(2,6,6-Trimethyl-2-cyclohexen-1-yl)-1-penten-3-one was present
in both our mouse and zebrafish metabolomes. This metabolite is structurally similar
to vitamin A, and could potentially be a cleavage product from 11-cisretinoate. This
finding is significant, as it could be a causative mechanism of aberrant vitamin A in
FASD. This dissertation also provides additional evidence about some of the hypoth-
esized mechanisms of FASD, such as alterations of several branches of tryptophan
metabolism.
5.3.1 Morphology
There are several limitations of this work. The morphologic analysis revealed little
difference in the zebrafish. As a result, an additional study was conducted at ethanol
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concentrations (1.5 and 2.4%) published by other laboratories that demonstrated a
difference in morphology. These additional concentrations confirmed instances of
cyclopia in the offspring, demonstrating the anticipated effects on craniofacial mor-
phology. We conclude that these are critical doses for these phenotypes, although at
unrealistically high doses for relevance in humans. Our concentration curve, which
extends from 0–3% ethanol is sufficient to capture metabolomic change, including a
higher dose than the often reported 1.5 and 2.4%.
5.3.2 Metabolomics
Metabolomics provides, at best, a snapshot of a system under a given condi-
tion. The difficulties in understanding FASD lie not only in the solvent nature of
ethanol, but also in the capturing ethanol’s modifications to the unique conditions
of development. Measuring the metabolome of a system can be a good monitor of
the homeostatic state of that system. However, development cannot be considered
as an extension of the normal homeostatic condition. It must be considered a unique
process. Add to this the solvent nature of ethanol, and the disturbing nature of FASD
become even more difficult to understand. So, while the metabolomics method does
give us an unbiased estimation of changes in our system under ethanol exposure, it
cannot capture the dynamic changes occurring in the system.
Because of the previous knowledge gained through centuries of biochemical explo-
ration of enzymatic reactions and their substrates and products, we have a basis for
understanding dynamic changes that occur in normal metabolism and homeostasis.
The dynamics of development make understanding these changes even more difficult.
While life sciences has gone far in understanding gene expression, protein regula-
tion, etc., its considerations of these processes is still largely static. When we use a
metabolomics, we are creating a static image of changes in the system, but because of
the dynamic nature of development and homeostatic processes, these snapshots are
still only a best guess at understanding changes in a system. We must work toward
understanding these changes in a dynamic (think three-dimensional) environment.
Changes to a system in disease cannot be considered singularly, but rather must be
examined as part of that system as a whole. Thus our quantitative explanations of a
disease must also.
The field of metabolomics is still a very young one. In such, often during the
analysis of m/z values from the MS, metabolites that were quite illogical would appear
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in the metabolome. This may reflect the immature nature of the database content.
Secondly, this may also be a bias of the investment that pharmaceutical research
has already put into developing rich metabolomics databases of their research. Over
time, the database quality limitation will likely become less of an issue. Further,
our output data can be archived and reanalyzed as these resources become further
developed. New findings may come from this. Further, as more is known about
the relationship between different genes, proteins, and metabolites, the vast research
literature on FASD can be incorporate in to the comprehensive model of the ethanol-
induced changes occurring in FASD. Likely, this global modeling of FASD mechanisms
will rely heavily on bioinformatics tools, which are being developed at a rapid pace.
In the metabolomics study, the metabolite detection method used is not sensitive
for metabolites which are very small (below 200 Daltons). Therefore, we were unable
to examine changes in alcohol metabolism itself, such as the changing concentrations
of acetylaldehyde. Similarly, many of the commonly proposed biomarkers are very
large (proteins or enzymes) and therefore are not detectable with our methodology.
Secondary analysis tools also have limitation. Data entered in the IPA software is
limited by the identification of metabolites by the software designers. IPA does not
include metabolites listed in databases that more comprehensively catalog lipids, such
as LipidMaps and Metlin. Further, many of the metabolites identified as relevant to
the metabolome changes were exogenous compounds, more likely misidentified by the
existing databses.
5.3.3 Mouse Study
One weakness in the mouse study is that the singly dosed animals were dosed
at the same time of as the first ethanol dose in the doubly dosed animals. This
makes the interpretation of the data more difficult, because it is unclear whether the
differences in response to ethanol are a compounding effect of the second dose or an
effect of a longer wash-out time before metabolomics. In the future, this could easily
be corrected by dosing the singly-dosed animals only when the doubly-dosed animals
were given their second dose.
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5.3.4 Comparative Study
Finally, another limitation of this work is in the comparative modeling approach.
This study examines the effects of chronic and binge ethanol exposures in two different
species. Since it was a post-hoc analysis, study design could not be altered to address
the compound nature of the study design differences, ethanol exposure type and
species. In the future, a binge-type ethanol exposure could be explored in the zebrafish
to examine the similarities and differences to the mouse response.
5.4 Future Directions
Several follow-up studies are suggested by these findings. In our morphologic
analysis, we noted few statistically significant differences in common developmental
parameters. This was surprising due to the significant difference in many metabolites
observed in the zebrafish model. In the future, it would be important to measure
the long-term effects of these ethanol doses, to determine the degree to which the
individual could compensate metabolically.
Another strategy would be to use a radiolabeled ethanol and then examine the
metabolome changes [554, 555]. Repeating the experiment would show where the
metabolites are created through destruction of the embryo versus incorporation of
ethanol into the embryo. However, analysis of metabolites may be difficult based on
the current content of metabolite databases.
To further unique contributions, work is needed to confirm the identify and for-
mation of 1-(2,6,6-trimethyl-2-cyclohexen-1-yl)-1-penten-3-one, as well as whether it
is truly a cleaved molecule of vitamin A. Similarly, based on the importance of nicoti-
namide in redox reactions, post-translational modification of proteins, and as an
enzymatic co-factor, further investigation is warranted of metabolites related to these
pathways, including 2,6-dihydroxypseudooxynicotine, cotinine methonium ion, and
mugineic acid.
Lastly, because of the established limitations in existing proposed biomarkers for
FASD, it is important to use new, unbiased methodologies like metabolomics to
identify potential novel biomarkers. Most of the existing proposed biomarkers for
FASD were not present in our metabolomes or were not appropriate to assess with
metabolomics. While we did identify many metabolites that were significantly dif-
ferent in the zebrafish metabolome and a handful that were significantly different
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in both the zebrafish and mouse models, a clear biomarker was still not identified.
However, with the use of artificial intelligence computing strategies, in the future it
may be possible to identify a panel of biomarkers that produces a characteristic FASD
profile. To achieve this, further comparative modeling work is needed, to tease out
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[84] R Gonzàlez-Duarte and R Albalat. Merging protein, gene and genomic data:
the evolution of the MDR-ADH family. Heredity, 95(3):184–197, September
2005.
[85] H Deng, J F Schindler, K B Berst, B V Plapp, and R Callender. A Ra-
man spectroscopic characterization of bonding in the complex of horse liver
alcohol dehydrogenase with NADH and N-cyclohexylformamide. Biochemistry,
37(40):14267–14278, October 1998.
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M L Zeneroli, and F Moroni. Tryptophan metabolism and hepatic encephalopa-
thy. Studies on the sedative properties of oxindole. Advances in Experimental
Medicine and Biology, 467:155–167, 1999.
[169] J C Vederas, E Schleicher, M D Tsai, and H G Floss. Stereochemistry and mech-
anism of reactions catalyzed by tryptophanase Escherichia coli. The Journal of
Biological Chemistry, 253(15):5350–5354, August 1978.
[170] Guido Mannaioni, Raffaella Carpenedo, and Flavio Moroni. 5-hydroxyindole
causes convulsions and increases transmitter release in the CA1 region of the
rat hippocampus. British Journal of Pharmacology, 138(1):245–253, January
2003.
[171] M Grilli, L Raiteri, L Patti, M Parodi, F Robino, M Raiteri, and M Marchi.
Modulation of the function of presynaptic alpha7 and non-alpha7 nicotinic
receptors by the tryptophan metabolites, 5-hydroxyindole and kynurenate in
mouse brain. British Journal of Pharmacology, 149(6):724–732, November 2006.
[172] Trevor W Stone. Neuropharmacology of quinolinic and kynurenic acids. Phar-
macological Reviews, 45(3):309–379, September 1993.
[173] Osamu Takikawa. Biochemical and medical aspects of the indoleamine 2,3-
dioxygenase-initiated l-tryptophan metabolism. Integrative Glycobiology and
Future Perspectives, 338(1):12–19, December 2005.
[174] Mary J Druse, Alison Kuo, and Nuzhath Tajuddin. Effects of in Utero Ethanol
Exposure on the Developing Serotonergic System. Alcoholism: Clinical and
Experimental Research, 15(4):678–684, August 1991.
[175] S E Maier, W J Chen, and James R West. Prenatal binge-like alcohol exposure
alters neurochemical profiles in fetal rat brain. The psychopharmacology of
feeding, obesity and body weight regulation, 55(4):521–529, December 1996.
[176] Youssef Sari, Loubna A Hammad, Marwa M Saleh, George V Rebec, and Yehia
Mechref. Alteration of selective neurotransmitters in fetal brains of prenatally
alcohol-treated C57BL/6 mice: quantitative analysis using liquid chromatogra-
phy/tandem mass spectrometry. International Journal of Developmental Neu-
roscience, 28(3):263–269, May 2010.
[177] Susanne Kuehnl, Sebastian Schroecksnadel, Veronika Temml, Johanna M Gost-
ner, Harald Schennach, Daniela Schuster, Stefan Schwaiger, Judith M Rollinger,
Dietmar Fuchs, and Hermann Stuppner. Lignans from Carthamus tincto-
rius suppress tryptophan breakdown via indoleamine 2,3-dioxygenase. Phy-
tomedicine : international journal of phytotherapy and phytopharmacology,
20(13):1190–1195, October 2013.
251
[178] Joanne Kwak-Kim, Kwang Moon Yang, and Alice Gilman-Sachs. Recurrent
pregnancy loss: a disease of inflammation and coagulation. The Journal of
Obstetrics and Gynaecology Research, 35(4):609–622, August 2009.
[179] Flavio Moroni. Tryptophan metabolism and brain function: focus on kynure-
nine and other indole metabolites. European Journal of Pharmacology,
375(1–3):87–100, June 1999.
[180] Trevor W Stone and L Gail Darlington. Endogenous kynurenines as targets for
drug discovery and development. Nature Reviews Drug Discovery, 1(8):609–620,
August 2002.
[181] Y Dang, W E Dale, and O R Brown. Comparative effects of oxygen on in-
doleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine
pathway. Free Radical Biology and Medicine, 28(4):615–624, February 2000.
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[407] E Halmesmäki, R Roine, and M Salaspuro. Gamma-Glutamyltransferase, As-
partate and Alanine Aminotransferases and Their Ratio, Mean Cell Volume and
Urinary Dolichol in Pregnant Alcohol Abusers. British journal of obstetrics and
gynaecology, 99(4):287–291, April 1992.
[408] Risto P Roine. Effects of Moderate Drinking and Alcohol Abstinence on Urinary
Dolichol Levels. Alcohol, 5(3):229–231, May 1988.
[409] Teresa A Powrozek and Eric C Olson. Ethanol-induced disruption of Golgi
apparatus morphology, primary neurite number and cellular orientation in de-
veloping cortical neurons. Alcohol, 46(7):619–627, November 2012.
[410] Jungki Ryu, Mathumai Kanapathipillai, Georg Lentzen, and Chan Beum Park.
Inhibition of Beta-Amyloid Peptide Aggregation and Neurotoxicity by Alpha-
D-Mannosylglycerate, a Natural Extremolyte. Peptides, 29(4):578–584, April
2008.
[411] Petr Benes, Vaclav Vetvicka, and Martin Fusek. Cathepsin D—Many Functions
of One Aspartic Protease. Critical Reviews in Oncology Hematology, 68(1):12–
28, October 2008.
[412] P Saftig, M Hetman, W Schmahl, K Weber, L Heine, H Mossmann, A Köster,
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Yi Zhou, Yong Gu, Jennifer Yen, Jan-Hinnerk Vogel, Tina Eyre, Seth Red-
mond, Ruby Banerjee, Jianxiang Chi, Beiyuan Fu, Elizabeth Langley, Sean F
Maguire, Gavin K Laird, David Lloyd, Emma Kenyon, Sarah Donaldson, Har-
minder Sehra, Jeff Almeida-King, Jane Loveland, Stephen Trevanion, Matt
Jones, Mike Quail, Dave Willey, Adrienne Hunt, John Burton, Sarah Sims,
Kirsten McLay, Bob Plumb, Joy Davis, Chris Clee, Karen Oliver, Richard
Clark, Clare Riddle, David Eliott, Glen Threadgold, Glenn Harden, Darren
Ware, Beverly Mortimer, Giselle Kerry, Paul Heath, Benjamin Phillimore, Alan
Tracey, Nicole Corby, Matthew Dunn, Christopher Johnson, Jonathan Wood,
Susan Clark, Sarah Pelan, Guy Griffiths, Michelle Smith, Rebecca Glithero,
Philip Howden, Nicholas Barker, Christopher Stevens, Joanna Harley, Karen
Holt, Georgios Panagiotidis, Jamieson Lovell, Helen Beasley, Carl Hender-
son, Daria Gordon, Katherine Auger, Deborah Wright, Joanna Collins, Claire
Raisen, Lauren Dyer, Kenric Leung, Lauren Robertson, Kirsty Ambridge,
Daniel Leongamornlert, Sarah McGuire, Ruth Gilderthorp, Coline Griffiths,
Deepa Manthravadi, Sarah Nichol, Gary Barker, Siobhan Whitehead, Michael
Kay, Jacqueline Brown, Clare Murnane, Emma Gray, Matthew Humphries,
Neil Sycamore, Darren Barker, David Saunders, Justene Wallis, Anne Bab-
bage, Sian Hammond, Maryam Mashreghi-Mohammadi, Lucy Barr, Sancha
Martin, Paul Wray, Andrew Ellington, Nicholas Matthews, Matthew Ellwood,
Rebecca Woodmansey, Graham Clark, James Cooper, Anthony Tromans, Dar-
ren Grafham, Carl Skuce, Richard Pandian, Robert Andrews, Elliot Harrison,
Andrew Kimberley, Jane Garnett, Nigel Fosker, Rebekah Hall, Patrick Gar-
ner, Daniel Kelly, Christine Bird, Sophie Palmer, Ines Gehring, Andrea Berger,
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[496] Maŕıa del Mar Muñ́ıo, Alfonso Robles, Luis Esteban, Pedro A González, and
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[498] Luis Esteban, Maŕıa del Mar Muñ́ıo, Alfonso Robles, Estrella Hita, Maŕıa J
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